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Abstract 
Foot-and-mouth disease (FMD) is endemic in Kenya where serotypes A, O, SAT1 and SAT2 are 
frequently encountered. Despite the importance of the dairy industry and the frequent 
reporting of disease, the epidemiology of FMD and field-based vaccine effectiveness has been 
poorly described in these endemic settings. Additionally, the disease impact has been 
inadequately characterised, despite the importance of such information when allocating scarce 
resources for animal health in national disease control strategies. The objectives of this 
doctoral thesis were to gain field experience of FMD in endemic settings and to use 
appropriate outbreaks to assess the vaccine effectiveness, gather evidence to optimise the use 
of vaccines and inform national policy, and to estimate disease impact. 
 
Outbreaks on two large-scale dairy farms located within Nakuru County, Kenya, were 
investigated and detailed descriptions of the outbreaks are presented. Both farms regularly 
used locally produced, aqueous adjuvanted, non-NSP purified quadrivalent (A, O, SAT1, SAT2) 
vaccine every 4-6 months. The first attended outbreak was caused by serotype SAT2 and 
evidence was found of limited or no vaccine effectiveness. At the second outbreak, due to 
serotype O, there was evidence of increasing protection with increasing number of doses. The 
reasons behind the vaccine poor effectiveness are discussed and are likely to include poor 
match with the field strain and inappropriate schedules in youngstock. Virus neutralisation test 
data were made available from the vaccine manufacturer who sample animals on farms using 
routine prophylactic vaccination. The influence of maternally derived antibody on the response 
to vaccination was investigated with these data and recommendations on vaccine schedules 
and future research priorities are made based on the evidence presented. 
 
On the farm that had SAT2, analysis of the disease impact was performed using individual 
animal data. Longitudinal analysis of individual milk yields utilising generalised estimating 
equations and an autoregressive variance structure to account for the correlation of yields for 
individual animals was performed. Predictions of 305-day milk yields were made based on 
previous lactations in the same herd. Despite a clear herd level impact, no difference was 
found between recorded clinical FMD cases and non-cases. More detailed analysis revealed 
significant reductions among older animals in earlier stages of lactation but younger cows 
were able to recover sufficiently so that no overall impact was seen. The impact of clinical 
disease on the rate of clinical mastitis and culling was analysed utilising a historical cohort 
approach with survival analysis over a 12-month period after the commencement of the 
5 
 
outbreak. Hazard ratios (HR) were generated using Cox regression accounting for non-
proportional hazards by inclusion of time-varying effects. There was good evidence of an 
increased rate of mastitis in the first month after the onset of the outbreak (HR=2.9, 95%CI 
0.97-8.9, P=0.057) although the effect on culling was less clear. The implications of these 
findings for policy and further research are discussed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6 
 
Contents 
CHAPTER 1. INTRODUCTION .................................................................................. 16 
1.1 FOOT-AND-MOUTH DISEASE – THE VIRUS, THE DISEASE AND ITS IMPACT ................................... 16 
1.2 FMD CONTROL POLICIES ................................................................................................... 19 
1.3 FMD VACCINES .............................................................................................................. 22 
1.4 FMD IN KENYA ............................................................................................................... 25 
1.4.1 Agricultural background ....................................................................................................... 25 
1.4.2 FMD occurrence and control ................................................................................................ 26 
1.4.3 FMD research in Kenya ......................................................................................................... 29 
1.4.3.1 Phylogenetics ............................................................................................................... 29 
1.4.3.2 Serosurveys .................................................................................................................. 30 
1.4.3.3 Economics .................................................................................................................... 33 
1.4.3.4 FMD vaccination in Kenya ........................................................................................... 33 
1.5 VACCINE EFFECTIVENESS ................................................................................................... 35 
1.6 OVERALL AIM OF THESIS .................................................................................................... 36 
1.7 STRUCTURE OF THE THESIS ................................................................................................ 37 
CHAPTER 2. LITERATURE REVIEW 1 – FMD VACCINE EVALUATION ......................... 38 
2.1 POTENCY TESTS ............................................................................................................... 38 
2.2 SEROLOGICAL ASSESSMENTS .............................................................................................. 42 
2.2.1 Surrogates and correlates of protection .............................................................................. 42 
2.2.2 Methods used in establishing correlates .............................................................................. 43 
2.2.3 Correlates of protection and FMD ....................................................................................... 44 
2.3 VACCINE MATCHING ......................................................................................................... 47 
2.4 FIELD EVALUATIONS ......................................................................................................... 52 
2.5 SIMULATION MODELS ....................................................................................................... 54 
2.6 CONCLUSION .................................................................................................................. 59 
CHAPTER 3. RESEARCH QUESTIONS AND FIELD WORK ........................................... 63 
3.1 RESEARCH AIMS .............................................................................................................. 63 
3.2 FIELD WORK AND FUNDING ............................................................................................... 63 
3.3 RESEARCH OBJECTIVES ...................................................................................................... 65 
PART A – EPIDEMIOLOGY ........................................................................................ 69 
CHAPTER 4. FARM 1 – OUTBREAK DESCRIPTION AND VACCINE EVALUATION 
(RESEARCH PAPER 1)............................................................................................... 70 
4.1 ABSTRACT ...................................................................................................................... 72 
4.2 INTRODUCTION ............................................................................................................... 73 
4.3 MATERIALS AND METHODS................................................................................................ 75 
4.3.1 Farm background ................................................................................................................. 75 
4.3.2 Study population .................................................................................................................. 76 
4.3.3 FMD history and outbreak ................................................................................................... 80 
4.3.4 Data analysis ......................................................................................................................... 80 
4.4 RESULTS ......................................................................................................................... 81 
4.4.1 Demography ......................................................................................................................... 81 
7 
 
4.4.2 FMD outbreak description.................................................................................................... 82 
4.4.3 Farm response to FMD outbreak ......................................................................................... 85 
4.4.4 Patterns by age, parity, lactation and breed ........................................................................ 86 
4.4.5 Patterns by lifetime vaccine doses received ........................................................................ 88 
4.5 DISCUSSION .................................................................................................................... 88 
4.6 CONCLUSION .................................................................................................................. 93 
4.7 ACKNOWLEDGEMENTS ..................................................................................................... 93 
CHAPTER 5. IMPACT OF FMD ON MASTITIS AND CULLING (RESEARCH PAPER 2) ..... 99 
5.1 ABSTRACT .................................................................................................................... 101 
5.2 INTRODUCTION ............................................................................................................. 101 
5.3 MATERIALS AND METHODS ............................................................................................. 103 
5.3.1 Study area and population ................................................................................................. 103 
5.3.2 FMD outbreak..................................................................................................................... 104 
5.3.3 Study design ....................................................................................................................... 105 
5.3.4 Statistical analysis ............................................................................................................... 105 
5.4 RESULTS ....................................................................................................................... 106 
5.5 DISCUSSION .................................................................................................................. 117 
5.6 COMPETING INTERESTS ................................................................................................... 120 
5.7 AUTHORS’ CONTRIBUTIONS ............................................................................................. 120 
5.8 ACKNOWLEDGEMENTS ................................................................................................... 120 
CHAPTER 6. IMPACT OF FMD ON MILK YIELD (RESEARCH PAPER 3) ...................... 126 
6.1 ABSTRACT .................................................................................................................... 127 
6.2 INTRODUCTION ............................................................................................................. 128 
6.3 MATERIALS AND METHODS.............................................................................................. 132 
6.3.1 Study population ................................................................................................................ 132 
6.3.2 FMD outbreak summary ..................................................................................................... 132 
6.3.3 Milk yield recording ............................................................................................................ 132 
6.3.4 Statistical analysis ............................................................................................................... 133 
6.4 RESULTS ....................................................................................................................... 134 
6.5 DISCUSSION .................................................................................................................. 141 
6.6 ACKNOWLEDGEMENTS ................................................................................................... 144 
CHAPTER 7. FARM 2 – OUTBREAK DESCRIPTION AND VACCINE EVALUATION ....... 146 
7.1 INTRODUCTION ............................................................................................................. 146 
7.2 MATERIALS AND METHODS.............................................................................................. 146 
7.2.1 Farm background ............................................................................................................... 146 
7.2.2 Study population ................................................................................................................ 147 
7.2.3 FMD history and current outbreak ..................................................................................... 147 
7.2.4 Data analysis ....................................................................................................................... 148 
7.3 RESULTS ....................................................................................................................... 149 
7.3.1 Demography ....................................................................................................................... 149 
7.3.2 FMD outbreak description.................................................................................................. 151 
7.3.3 Farm response to FMD outbreak ....................................................................................... 155 
7.3.4 Patterns by age, sex, parity, lactation, breed and previous disease status ........................ 155 
7.3.5 Patterns by lifetime vaccine doses received ...................................................................... 158 
8 
 
7.3.5.1 Estimation of relative vaccine effectiveness .............................................................. 159 
7.4 DISCUSSION .................................................................................................................. 160 
CHAPTER 8. DISCUSSION OF THE FMD OUTBREAKS ON FARM 1 AND FARM 2 ...... 165 
8.1 FARM BACKGROUNDS ..................................................................................................... 165 
8.2 FARM DEMOGRAPHICS ................................................................................................... 165 
8.3 OUTBREAK DESCRIPTIONS ............................................................................................... 168 
8.4 VACCINE USE, EFFECTIVENESS AND SCHEDULE MODIFICATION ................................................ 173 
PART B – SEROLOGY ............................................................................................. 178 
CHAPTER 9. LITERATURE REVIEW 2 - DECAY OF MATERNALLY DERIVED ANTIBODY IN 
THE CALF AND THE INFLUENCE ON RESPONSE TO FMDV VACCINATION ................. 179 
9.1 DECLINE OF MATERNALLY DERIVED ANTIBODY FOR FMD IN CALVES ........................................ 179 
9.1.1 Discussion ........................................................................................................................... 182 
9.2 INFLUENCE OF MATERNALLY DERIVED ANTIBODY ON THE RESPONSE TO COMMERCIALLY AVAILABLE 
FMD VACCINES IN CALVES .......................................................................................................... 185 
9.2.1 Early studies with formalin inactivated vaccines................................................................ 185 
9.2.2 Aqueous versus oil adjuvanted vaccines ............................................................................ 186 
9.2.3 Evaluation using non-VNT serology .................................................................................... 188 
9.2.4 Evidence from the field ...................................................................................................... 190 
9.2.5 Alternative strains .............................................................................................................. 191 
9.2.6 Reviews and unpublished data ........................................................................................... 192 
9.2.7 Discussion ........................................................................................................................... 193 
9.2.7.1 Response to the first dose .......................................................................................... 193 
9.2.7.2 Response to repeated doses ...................................................................................... 194 
9.2.8 Conclusion .......................................................................................................................... 195 
CHAPTER 10. DECLINE OF MATERNAL ANTIBODIES AND THE IMPACT ON 
VACCINATION RESPONSE ...................................................................................... 202 
10.1 INTRODUCTION ............................................................................................................. 202 
10.2 METHODS .................................................................................................................... 203 
10.2.1 Farm background ........................................................................................................... 203 
10.2.2 Vaccination and sampling .............................................................................................. 203 
10.2.3 Laboratory tests ............................................................................................................. 203 
10.2.4 Data analysis .................................................................................................................. 204 
10.3 RESULTS ....................................................................................................................... 204 
10.4 DISCUSSION .................................................................................................................. 215 
10.4.1 Maternally derived antibody ......................................................................................... 215 
10.4.2 Response to first dose of vaccine ................................................................................... 216 
10.4.3 Titre trends with repeated vaccination .......................................................................... 216 
CHAPTER 11. DISCUSSION ..................................................................................... 220 
11.1 KEY FINDINGS ................................................................................................................ 220 
11.2 IMPLICATIONS ............................................................................................................... 221 
11.2.1 FMD outbreaks on large-scale dairy farms in Kenya ...................................................... 221 
11.2.2 FMD vaccination ............................................................................................................ 222 
11.2.3 FMD economics.............................................................................................................. 225 
9 
 
11.3 STRENGTHS AND LIMITATIONS ......................................................................................... 226 
11.3.1 External validity of study results .................................................................................... 226 
11.3.2 Vaccine effectiveness estimate ...................................................................................... 229 
11.3.3 Accuracy of the case definition and lack of serological data from outbreaks ............... 229 
11.3.4 Vaccine matching ........................................................................................................... 230 
11.3.5 “Outbreak bias” ............................................................................................................. 231 
11.3.6 Vaccination reducing disease impact ............................................................................. 232 
11.3.7 Follow-up period ............................................................................................................ 232 
11.3.8 Source of VNT data ........................................................................................................ 232 
11.4 RECOMMENDATIONS ..................................................................................................... 233 
11.4.1 Farm contingency plans ................................................................................................. 233 
11.4.2 Surveillance .................................................................................................................... 237 
11.4.3 Vaccine and impact evaluation ...................................................................................... 238 
11.4.4 National policy implications ........................................................................................... 240 
11.4.5 Further research priorities ............................................................................................. 245 
11.5 DISSEMINATION OF RESULTS ............................................................................................ 246 
11.6 CONCLUSION ................................................................................................................ 246 
CHAPTER 12. REFERENCES ..................................................................................... 248 
CHAPTER 13. APPENDICES ..................................................................................... 265 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
List of Tables 
Table 1.1. Countries with zones classified as FMD free either with or without vaccination 
according to the OIE.................................................................................................................... 20 
Table 1.2. Summary of recent serosurveys in Kenya analysing seroprevalence by age category 
in cattle ....................................................................................................................................... 32 
Table 2.1. Summary of potency tests as recommended by the OIE (OIE, 2009). ....................... 39 
Table 2.2. Association between antibody titres measured by LPBE and VNT and clinical 
protection for serotypes A, O and C. Adapted from Van Maanen and Terpstra (1989). ........... 45 
Table 2.3. Summary of challenge results for homologous and heterologous viruses compared 
to the vaccine matching r1 value. Adapted from Brehm et al. (2008) ....................................... 49 
Table 2.4. Comparison of PPG tests and EPP estimates from four cross protection trials. 
Adapted from Robiolo et al. (2010) ............................................................................................ 50 
Table 2.5. Analysis of sensitivity and specificity obtained by different assays for predicting the 
protective status against a heterologous strain of FMDV. Adapted from Brito et al. (2014). .... 52 
Table 2.6.  Logistic regression output comparing the time since vaccination and the odds of 
having a transmission coefficient above the median value for the outbreak based on 1221 
outbreaks (representing 51% of outbreak farms). Modified from Brito et al. (2011). ............... 59 
Table 2.7. Comparison of the issues related to experimental and field based methods for 
evaluating FMD vaccines. ........................................................................................................... 62 
Table 3.1 Research objectives, research questions, hypotheses and methodological approaches 
used to address the study aims. ................................................................................................. 66 
Table 4.1. Descriptive data and FMD incidence rate by management group during the FMD 
outbreak on Farm 1 .................................................................................................................... 78 
Table 4.2. Descriptive analysis evaluating associations between various risk factors and being a 
case of FMD on Farm 1. .............................................................................................................. 87 
Table 5.1. Reasons for exit and culling after a foot-and-mouth disease outbreak on Farm 1. 108 
Table 5.2. Clinical mastitis - characteristics of the study population (n=409) and univariable 
analysis for Farm 1 .................................................................................................................... 111 
Table 5.3. Culling - characteristics of the study population (n=644) and univariable analysis for 
Farm 1 ....................................................................................................................................... 113 
Table 5.4. Final multivariate Cox-regression model examining the association of FMD with 
clinical mastitis and culling on Farm 1 ...................................................................................... 115 
Table 6.1 Summary of studies reporting the impact of FMD on milk yield in cattle. ............... 130 
11 
 
Table 6.2. Description of study population for analysing the impact of FMD on milk yields on a 
large-scale dairy farm in Nakuru County, Kenya. ...................................................................... 135 
Table 6.3. Summary of management groups containing lactating cattle for analysing the impact 
of FMD on milk yield on a large-scale dairy farm ..................................................................... 135 
Table 6.4. Results of a generalised estimating equation (GEE) model comparing milk yields of 
reported clinical FMD cases and non-cases .............................................................................. 137 
Table 6.5. Results of a multiple linear regression model comparing the actual and predicted 
milk yields for cows lactating during an outbreak of foot-and-mouth disease ........................ 139 
Table 7.1. Descriptive data on animals present and FMD incidence by management group 
during the FMD outbreak on Farm 2 ........................................................................................ 150 
Table 7.2. Descriptive risk factor analysis evaluating associations with being a case of FMD on 
Farm 2 ....................................................................................................................................... 157 
Table 8.1. Summary of Farm 1 and Farm 2 outbreak characteristics. ...................................... 166 
Table 9.1. Regression and correlation coefficients and associated half-lives for different strains 
of FMD virus (Adapted from Spath et al, 1995) ........................................................................ 182 
Table 9.2. Summary of studies examining the decline of maternal antibodies in calves receiving 
colostrum from dams vaccinated for FMD. .............................................................................. 184 
Table 9.3. Summary of studies examining the antibody titre response to the first and second 
vaccine dose according to the age and adjuvant type used ..................................................... 197 
Table 9.4. Summary of a selection of commercially available FMD vaccines and suggested 
schedules in cattle .................................................................................................................... 200 
Table 10.1. Dates of vaccination, batch number(s) of vaccine used and the number of animals 
sampled ..................................................................................................................................... 205 
Table 10.2. Number of animals responding to first vaccination by the level of maternally 
derived antibody (MDA) for each serotype. ............................................................................. 210 
Table 10.3. Repeated doses of vaccine – titres at vaccination and 21 days later. ................... 212 
 
List of Figures 
Figure 1.1. Geographical distribution of FMD and location of serotype pools. Source: Di Nardo 
et al. (2011) ................................................................................................................................. 18 
Figure 1.2. Stage progression in the Progressive Control Pathway (PCP). Source: FAO (2011) . 22 
Figure 1.3. Dairy cow density in Kenya. Source: Omore et al., (1999)........................................ 26 
Figure 1.4. Population of different FMD susceptible species in Kenya created from the 2009 
agricultural census. Source: https://www.opendata.go.ke/. Accessed 2nd October 2014. ........ 27 
12 
 
Figure 1.5. Trends in FMD serotypes detected in Kenyan outbreaks from 2003 to 2013 
inclusive. ..................................................................................................................................... 28 
Figure 1.6. Epidemic curve and cumulative incidence over time, taken from the data presented 
by Gakuya et al. (2011) ............................................................................................................... 34 
Figure 2.1. Percentage protection (with 95%CI) with different PD50 levels of vaccine collated for 
serotypes O, A and C based on the data presented by Vianna Filho et al. (1993) ..................... 39 
Figure 2.2. Relationship between the percentage of animals protected from clinical disease 
(with 95%CI) and serological titre category measured by neutralisation tests for all animals and 
for virus strains from serotypes O, A and C. Produced from data presented in Sutmoller et al 
(1980) .......................................................................................................................................... 46 
Figure 3.1. Map showing the location of Nakuru County within Kenya ..................................... 64 
Figure 4.1. Overall map of farm and locations of livestock groups on the first day of the FMD 
outbreak on Farm 1 .................................................................................................................... 76 
Figure 4.2. Epidemic curve and cumulative incidence of FMD for all management groups 
combined on Farm 1 ................................................................................................................... 83 
Figure 4.3. Dates and location of FMD onset and movements of groups subsequent to 
becoming affected on Farm 1. .................................................................................................... 84 
Figure 4.4. Incidence risk (with 95% confidence intervals) of FMD by the lifetime number of 
FMD vaccine doses given to all animals present on Farm 1 during the outbreak period .......... 88 
Figure 5.1. Unadjusted Kaplan-Meier survival curve for FMD cases and non-cases related to 
developing clinical mastitis on Farm 1 ...................................................................................... 109 
Figure 5.2. Unadjusted Kaplan-Meier survival curves for FMD cases and non-cases related to 
culling on Farm 1. ...................................................................................................................... 109 
Figure 5.3. Variation in hazard ratio over time for cases of FMD developing clinical mastitis on 
Farm 1 ....................................................................................................................................... 116 
Figure 6.1 Weekly calculated mean daily milk yields for cattle that were lactating during an 
outbreak of foot-and-mouth disease (FMD) on a large-scale dairy farm ................................. 136 
Figure 6.2. Frequency distribution of actual yields produced from the beginning of the 
outbreak to the end of the animal’s lactation for all cows present during an outbreak of foot-
and-mouth disease ................................................................................................................... 138 
Figure 6.3. Mean difference (with 95% CI) between actual and predicted milk yields for 
different combinations of predictors based on a multiple linear regression model for cows 
lactating during an outbreak of foot-and-mouth disease ........................................................ 140 
13 
 
Figure 7.1. Epidemic curve and cumulative incidence of FMD for all management groups 
combined on Farm 2 ................................................................................................................. 152 
Figure 7.2. Schematic outline of contacts between different management groups during the 
outbreak period on Farm 2 ....................................................................................................... 153 
Figure 7.3. Outline of Farm 2 showing paddock and group locations during outbreak ........... 154 
Figure 7.4. Incidence risk (with 95% confidence intervals) of FMD by the lifetime number of 
FMD vaccine doses given to all animals present on Farm 2 during the outbreak period ........ 158 
Figure 7.5. Relative vaccine effectiveness by the number of lifetime doses of vaccine received 
with 95% confidence intervals for Farm 2. ............................................................................... 159 
Figure 8.1. Population pyramid and age specific incidence for Farm 1/SAT2 and Farm 2/O. .. 167 
Figure 8.2. Epidemic curves for Farm 1/SAT2 and Farm 2/O with solid arrows showing the 
onset of cases in each affected group. ..................................................................................... 171 
Figure 8.3. Incidence of FMD by age category for Farm 1/SAT2 and Farm 2/O with 95% 
confidence intervals. ................................................................................................................. 172 
Figure 8.4. Mean number of doses of vaccine received by age category of Farm 1/SAT2 and 
Farm 2/O with different vaccine schedules .............................................................................. 176 
Figure 8.5. Incidence of FMD by number of doses of vaccine received for Farms 1/SAT2 and 
Farm 2/O with 95% confidence intervals. ................................................................................. 177 
Figure 10.1. Frequency distribution of neutralising antibody titres for different FMDV serotypes 
at the time of first vaccination. ................................................................................................. 207 
Figure 10.2. Scatter plot of neutralising titres of calves blood sampled at the time of first 
vaccination versus age with regression line ............................................................................. 208 
Figure 10.3. Box plot representing the distribution of neutralising titres for 22 dams of calves in 
the study population for each serotype. .................................................................................. 209 
Figure 10.4. Proportion of animals seroconverting to the first dose of vaccine by the level of 
MDA present at vaccination ..................................................................................................... 211 
Figure 10.5. Response to the first five doses of quadrivalent vaccine reflected by an increase in 
neutralising titre to the homologous virus strain. .................................................................... 213 
Figure 10.6. Proportion of animals with a “protective titre” (greater than 1.36) by the number 
of doses of vaccine. ................................................................................................................... 214 
Figure 11.1. Comparison of the incidence by the number of doses for Farm 1/SAT2 and Farm 
2/O and the pattern of neutralising titres with repeated doses of vaccine for respective 
serotype .................................................................................................................................... 224 
Figure 11.2. Photograph of a smallholder farm on the outskirts of Nakuru ............................ 228 
14 
 
Figure 11.3. Photograph of a Co-operative society based in Esageri, Baringo County ............. 228 
Figure 11.4. Photograph of wheel bath present on Farm 1/SAT2. ........................................... 236 
Figure 11.5. Photograph of government-subsidised reactive vaccination campaign in Ngata, 
Nakuru County, January 2012 ................................................................................................... 241 
Figure 11.6. Vaccination card used by the Kenyan Veterinary Association for regular campaigns 
carried out in what was the Central Province (now Nyeri County). ......................................... 243 
Figure 11.7. Photograph taken inside of cool box during government subsidised vaccination 
campaign in Ngata, Nakuru County, January 2013. .................................................................. 244 
 
List of Supplementary material 
Supplementary material 4.1. Cattle group locations and movements during the outbreak on 
Farm 1 ......................................................................................................................................... 95 
Supplementary material 4.2. Epidemic curves for management groups with putative point 
exposures to FMDV on Farm 1.................................................................................................... 96 
Supplementary material 4.3. Epidemic curves for management groups with putative exposure 
to FMDV through the introduction of an incubating animal on Farm 1. .................................... 97 
Supplementary material 4.4. Photograph showing the movement of animals along the road on 
Farm 1 ......................................................................................................................................... 98 
Supplementary material 5.1. Culling – univariable associations with other diseases on Farm 1
 .................................................................................................................................................. 121 
Supplementary material 5.2. Clinical mastitis - univariable associations with other diseases on 
Farm 1. ...................................................................................................................................... 123 
Supplementary material 5.3. Schoenfeld residual tests for non-proportionality of each 
indicator variable prior to model backward fitting. .................................................................. 125 
Supplementary material 6.1. Mean daily milk production per group on Farm 1 ..................... 145 
Supplementary material 7.1. Epidemic curves for each group on Farm 2 ............................... 163 
 
 
 
 
 
 
 
 
15 
 
List of abbreviations and acronyms 
AHA Animal Health Assistant 
BVS Bovine Vaccinal Serum 
CFT Complement Fixation Test 
DPC Days Post Challenge 
DPV Days Post Vaccination 
DVO District (Sub-County) Veterinary Officer 
DVS Department of Veterinary Services 
EP European Pharmacopoeia 
EPP Expected Percentage of Protection 
EuFMD European Commission for the Control of Foot-and-Mouth Disease 
FAO Food and Agriculture Organisation of the United Nations 
FMD Foot-and-Mouth Disease 
FMDV Foot-and-Mouth Disease Virus 
GEE Generalised Estimating Equations 
GLM Generalised Linear Model 
HF Holstein-Friesian 
IDL Intradermolingual 
KEVEVAPI Kenya Veterinary Vaccines Production Institute 
KVA Kenya Veterinary Association 
LPBE Liquid Phase Blocking ELISA 
MDA Maternal Derived Antibody 
NSP Non-Structural Protein 
OIE Office International des Epizooties (World Organisation for Animal Health) 
PCP Progressive Control Pathway 
PD50 50% Protective Dose 
PPG Protection from Podal Generalisation 
SAT Southern African Territories 
SP Structural Proteins 
SPBE Solid Phase Blocking ELISA 
SPCE Solid Phase Competition ELISA 
TAD Transboundary Animal Disease 
VM Vaccine Matching 
VNT Virus Neutralisation Test 
16 
 
Chapter 1. Introduction 
1.1 Foot-and-mouth disease – the virus, the disease and its impact 
Foot-and-mouth-disease (FMD) is caused by a non-enveloped single stranded RNA picornavirus 
within the Aphthovirus genus. It has the ability to infect all species of the order Artiodactyla 
(i.e. animals with cloven/even-toed hooves) including cattle, pigs, sheep and goats. Camelids 
are not considered to have an important role in transmission although they may be infected in 
certain circumstances  (Wernery and Kaaden, 2004) . Several species of wildlife are known to 
be susceptible to FMD virus (FMDV) infection and the African buffalo (Syncerus caffer) has 
been implicated as a maintenance host (Thomson et al., 1992).  
Disease is most apparent in cattle and pigs, varying from subclinical to malaise, pyrexia and 
vesicular lesions on the tongue, dental pad, interdigital space and teats. A drop in milk yield is 
often apparent in lactating cattle (Kitching, 2002). The characteristic appearance of the lesions 
over time means their age may be estimated which is helpful in epidemiological investigations 
(DEFRA, 2005). Mortality rates are generally reported as less than 5%, with deaths mostly 
occurring in youngstock subsequent to acute myocarditis (Alexandersen et al., 2003). In severe 
cases, adults may die secondary to starvation. Reports of a “heat intolerance and hair 
overgrowth syndrome” after FMD has been reported in East Africa, that may be associated 
with viral induced changes to the pituitary gland (Catley et al., 2004; Sutmoller et al., 2003). 
Small ruminants (i.e. sheep and goats) tend to have milder clinical signs that often go 
unnoticed.  
FMDV is considered to be highly transmissible and spreads predominantly through aerosol or 
ingestion (Alexandersen et al., 2003). Virus is shed in all excretions and secretions of an 
infected animal and transmission through contact with contaminated fomites is also possible. 
FMDV is one of very few infections that have been reported to be spread over long distances 
by wind. This has been considered as the most likely route of infection to the Isle of Wight 
from Brittany in 1981 (Garland and Donaldson, 1990) and distances up to 16 km were 
speculated in the UK 2001 epidemic based on field investigations and meteorological analysis 
(Gloster et al., 2005). This method of transmission is particularly favoured in cold and humid 
conditions (Donaldson, 1972). Ruminants tend to be more susceptible to FMDV through 
aerosol spread than pigs although the latter tend to produce more aerosolised virus (Kitching 
et al., 2005). Transmission may also occur through animal products including milk, meat or 
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offal. Pigs are considered particularly prone to infection by ingestion of virus. The feeding of 
illegally imported non-heat-treated swill to pigs is considered the likely route of introduction to 
the UK in 2001 (Paton et al., 2009). Typically the post-mortem decrease in carcase pH will 
inactivate the virus although this does not extend to lymph nodes, bone marrow and some 
offal, so deboned meat may be traded internationally in some circumstances (Alexandersen et 
al., 2003). 
The published incubation period range is 2-14 days. Animals are usually infectious before the 
onset of clinical signs with milk and semen having been reported to have virus up to four days 
before. Acute clinical signs typically resolve within two weeks although secondary infections 
can lead to protracted disease and milk yields may not recover in the current lactation 
(Kitching, 2002). Up to 50% of animals may harbour virus in the pharynx more than 28 days 
after clinical recovery, the period that defines an animal as a virus “carrier” (Salt et al., 1996). 
This may occur in vaccinated animals without the presence of clinical signs (Cox et al., 2005). 
Carrier status has not been demonstrated in pigs. The role of carriers in subsequent 
transmission is unclear and controversial. Whereas there is some evidence from the field that 
transmission may occur between carrier African buffalo and cattle, in an experimental setting 
Dawe et al., (1994a, 1994b) were unable to demonstrate this. Moreover, when data in the 
literature from experimental transmission studies in cattle were used to parameterise a 
mathematical model, an estimated average of 0.026 (95%CI 0.008-0.059) animals were 
infected by a FMDV carrier for each month it was present (Tenzin et al., 2008). Field evidence 
for the transmission of FMDV from carrier to susceptible cattle is old and anecdotal (Sutmoller 
et al., 2003). Despite this, the possibility of carriers has large implications for control policy and 
trade in countries free of disease. 
FMD is endemic in many regions of the world including parts of South America and across 
most of Africa, the Middle East and Asia (Figure 1.1). The whole of sub-Saharan Africa is 
endemic except for parts of South Africa near the Kruger National Park where infection 
appears to be maintained in the African buffalo population.  
There are seven serotypes of FMDV, denoted A, C, O, South African Territories (SAT) 1, 2, 3 and 
Asia-1. The serotypes are grouped into pools depending on their geographical distribution with 
serotype O being the most widespread (Figure 1.1). Serotypes are further subdivided into 
topotypes based on a 15-20% difference in the genetic sequence of the virus protein 1 (VP1) 
region that follows broad geographical regions (Samuel and Knowles, 2001). The antigenic 
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diversity varies between serotypes, with A and SAT2 being particularly diverse (Bastos et al., 
2003; Upadhyaya et al., 2014). 
 
 
Figure 1.1. Geographical distribution of FMD and location of serotype pools. Source: Di Nardo 
et al. (2011) 
 
Immunity is considered to be serotype specific, though there is evidence for cross-protection 
under certain circumstances. For example infection with multiple serotypes may decrease the 
severity of signs when exposed to other serotypes (Doel, 1996). As is common with RNA 
viruses, the genome replication is error-prone resulting in a highly mutable virus such that 
animals which have recovered from one infection may be susceptible to infection with a 
different strain of the same serotype, hindering control efforts (Domingo et al., 2002; 
Grubman and Baxt, 2004). 
The annual global economic impact of FMD has been estimated as US$11 billion (90% range 
6.5-20) in endemic regions alone although this is a likely underestimate because it only 
considers the costs from decreased production and vaccination (Knight-Jones and Rushton, 
2013). Field data on economic impact are limited particularly in endemic settings and 
estimates are often based on expert opinion and assumptions (James and Rushton, 2002). Viral 
incursions into countries free of infection can have devastating economic consequences. The 
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UK 2001 outbreak is estimated to have cost between 12.3 and 13.9 billion USD through control 
measures, subsidising farmers, prohibited international trade and effects on tourism 
(Thompson et al., 2002).  
The distribution of countries with endemic infection tends to parallel regions of low household 
income. Within these countries, there is limited opportunity for international trade since trade 
is only allowed with other FMD endemic countries. For the individual farmer, the disease has 
direct economic impact through decreased milk production, reduced growth rates, loss in 
draught power, increased perinatal mortality, increased associated disease (e.g. mastitis), 
poorer fertility (including abortion) and increased culling from prolonged lameness (Doel, 
2003). A recent estimation of the cost of disease among smallholder cattle farmers in 
Cambodia revealed the average cost to be between 216 and 371 USD per affected animal 
(Young et al., 2012). Although FMD is often considered a disease of particular importance to 
wealthier countries that wish to remain free of disease, its control is also likely to have a role in 
poverty reduction in poorer countries with endemic disease (Perry and Rich, 2007). 
1.2 FMD control policies 
FMD control policies vary depending on the epidemiology and available resources. “Stamping-
out” policies whereby susceptible animals on infected farms are culled along with “dangerous 
contacts” (animals on farms at high risk of infection) implicated through outbreak 
investigations has formed the basis of control measures in many FMD-free countries. This 
approach is typically combined with movement controls, surveillance strategies, appropriate 
carcase disposal and cleaning and disinfection of affected farms. In the UK 2001 outbreak, the 
highly controversial “contiguous cull” strategy involved the slaughtering of neighbouring farms 
irrespective of clinical signs or other risk factors for the introduction of infection, as this was 
suggested by mathematical models to be the most effective control method (Ferguson et al., 
2001). This policy, and the models it was based on, were later subjected to extensive criticism 
and described as “seriously flawed” and with inherent biases (Mansley et al., 2011).  
Vaccination has been used in FMD-free settings in response to introduced infection, combined 
with other measures outlined above. Recent examples include outbreaks in the Netherlands 
(2001), Argentina (2001), South Korea (2010) and Uruguay (2001). In the Netherlands, 
vaccination was limited to a particular zone whereas in the other examples nationwide 
vaccination was performed. Vaccine may also be applied as a permanent buffer zone as is the 
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case in western Turkey to reduce the chances of spread into the EU, and in Botswana to 
prevent spread to a FMD-free zone. Vaccine policy has been heavily influenced by trade 
implications (Sutmoller et al., 2003). This comes from the theoretical possibility that 
vaccinated animals may become virus carriers and the difficulties in distinguishing between 
infected and vaccinated animals. Vaccination in free settings may be either “protective” or 
“suppressive”. Both are aimed at decreasing the likelihood of transmission but “suppressive” 
vaccination is combined with the culling of infected animals to hasten the re-establishment of 
a FMD-free status. This was the strategy used by the Netherlands in 2001 (Bouma et al., 2003). 
According to the World Organisation for Animal Health (Office International des Epizooties, 
OIE), whole countries or zones within may be classified as “free with vaccination” or “free 
without vaccination” with this status affecting the ability to trade with other counties. The 
countries free without vaccination are represented in Figure 1.1. Currently, Uruguay and the 
Republic of Korea are recognised by the OIE as FMD-free with vaccination. Countries that have 
FMD free zones are shown in Table 1.1. 
 
Table 1.1. Countries with zones classified as FMD free either with or without vaccination 
according to the OIE (source: http://www.oie.int/animal-health-in-the-world/official-disease-
status/fmd/list-of-fmd-free-members/, accessed 1/10/2014)  
FMD free zone (no vaccination) FMD free zone (with vaccination) 
Argentina Argentina 
Bolivia Bolivia 
Botswana Brazil 
Brazil Colombia 
Colombia Paraguay 
Malaysia Peru 
Moldova Turkey 
Namibia  
Peru  
Philippines  
South Africa  
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In endemic areas, culling is not usually considered a viable control option due to the associated 
costs and stakeholder resistance. Therefore, FMD is generally controlled through a 
combination of movement controls and vaccination. Countries with sufficient resources may 
opt for mass vaccination as in parts of South America, India and Israel. This strategy was 
successful in eliminating disease from Europe, which ceased vaccinating in 1991. In some 
circumstances, as in Europe before 1991 and Uruguay, only cattle were vaccinated as impact is 
usually greatest in this species. This strategy appeared to be effective in eliminating infection 
from other susceptible species in these countries. Where resources are limited, which tends to 
be the case in endemic areas (Rweyemamu et al., 2008), vaccination may be strategically 
applied for example using “ring vaccination” in a pre-defined area surrounding an outbreak as 
an attempt to limit spread. Vaccine may be whole or part subsidised by the government or 
alternatively farmers may have to pay full vaccine costs themselves. 
FMD is classified as a transboundary animal disease (TAD) with control efforts seen as an 
international public good. Sustainable control in endemic areas has been advocated as a global 
necessity not only to reduce the impact in these settings but also to reduce the source of 
infection to free countries (Rweyemamu et al., 2008). In 2012, a joint FAO/OIE Global 
Conference on FMD control in Bangkok formally embraced the “Progressive Control Pathway” 
(PCP) for FMD control (FAO, 2011). This strategy, initially developed by the European 
Commission for the Control of Foot-and-Mouth Disease (EuFMD) within the FAO, was designed 
to assist endemic areas to progressively reduce disease impact and virus circulation so that 
countries could eventually apply for official OIE endorsement of their control plan and then 
achieve freedom from disease either with or without vaccination. There are five stages (Figure 
1.2): understanding the epidemiology and developing a risk based control plan (Stage 1); 
implementing control measures to reduce disease impact (Stage 2); reducing virus circulation 
(Stage 3); achieving OIE recognised stages as free-with-vaccination (Stage 4) and ultimately to 
free-without-vaccination (Stage 5). Countries need to provide evidence for their progression 
and are aided by FMD experts. This process may also apply to zones within a country. 
Vaccination is an integral part of the PCP process in reducing disease impact and virus 
circulation but is just one component of many that should be utilised for effective FMD control 
(Rweyemamu et al., 2008). The PCP process is described as “outcome based” acknowledging 
that control strategies are likely to vary between different regions such that a prescriptive 
strategy is not appropriate. This is also likely to be the case for vaccination strategies. 
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Figure 1.2. Stage progression in the Progressive Control Pathway (PCP). Source: FAO (2011) 
 
1.3 FMD Vaccines 
FMD vaccines have been produced on a large-scale since the 1940s (Barteling, 2002). The 
pioneering “Frenkel” method involved culturing virus in bovine tongue epithelium cells which 
was then inactivated with formaldehyde and adjuvanted with aluminium hydroxide. This was 
later replaced by the more efficient baby hamster kidney (BHK) cell line and inactivation with 
binary ethylenimine (BEI) due to reports of incomplete inactivation seen with formaldehyde 
leading to vaccine associated outbreaks. Saponin was added to aluminium hydroxide as an 
additional adjuvant, and oil-based vaccines became available with claims that they were more 
effective in pigs, induced more persistent titres and were better able to circumvent 
interference from maternally derived antibody (Cloete et al., 2008; Gomes, 1984; Gomes et al., 
1980). 
FMDV vaccines are now produced by at least 56 commercial and governmental institutions 
around the world (Mezzer, O., Vallée SA, Personal communication, 2014). All contain 
killed/inactivated virus or virus antigen with either aluminium hydroxide/saponin (known as 
“aqueous”) or oil adjuvant. The latter have been extensively used in South America. Most 
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companies use BEI inactivation although a minority continue to use formaldehyde. Various 
types of oil adjuvants are used including a double oil emulsion (otherwise known as a water-in-
oil-in-water emulsion) (Barnett and Carabin, 2002). When used prophylactically in endemic 
settings, vaccines are often given twice in a primary course 4-6 weeks apart followed by 
boosters every 4-12 months depending on the species and epidemiological situation (Parida, 
2009). 
Vaccines often contain strains from more than one serotype or multiple strains within a 
serotype. As well as the epidemiological situation, the selection of a strain will also depend on 
its ability to grow in cultures, stability and antigenicity (Barteling, 2002). The 146S particle of 
the VP1 protein has been found to be the most important for antigenicity. Payloads of 
between 1 and 10μg per strain are usually used in each dose, although there is some variation 
between serotypes (Doel, 1996, 2003).  
All FMD vaccines are purified to some extent to remove cellular debris that may cause adverse 
reactions and also to concentrate the vaccine. The latter is part of the process in producing 
“high potency vaccines” since potency is generally related to the antigen concentration. The 
OIE and European Pharmacopeia prescribe official vaccine potency tests (described and 
discussed in detail in Chapter 2) that are based on virus challenge into the tongue of 
experimentally vaccinated and non-vaccinated cattle. Serological correlates (also described in 
Chapter 2) are also extensively used particularly for licensing vaccines in South America in 
circumstances in which a correlation with protection has been demonstrated. A protocol has 
been adopted for pigs but no equivalent tests have been described for small ruminants or 
buffalo (Parida, 2009). The potency of a vaccine may be influenced by several factors including 
the antigen quantity, antigen quality, the particular strain used, adjuvant and vaccine schedule 
(Paton et al., 2005). High potency vaccines have been associated with a more rapid onset of 
protective immunity and a greater capacity for cross-topotypic protection compared to low 
potency vaccines (Brehm et al., 2008; Doel et al., 1994). 
Vaccines may be further purified by removing non-structural proteins (NSP). Animals given a 
NSP-purified vaccine will usually not have antibodies present to these proteins unless they 
have been exposed to infection. This allows the use of NSP serology to distinguish vaccinated 
and exposed animals. Unlike the structural protein (SP) equivalents, for which serological tests 
are also available, NSP antigens are conserved across viral serotypes so NSP antibodies do not 
distinguish between serotypes. However, animals receiving many doses of a NSP-purified 
vaccine may still seroconvert to NSP. Therefore NSP serology is particularly useful in FMD-free 
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settings where typically only one or two doses of a NSP-purified vaccine are used. This may 
also be helpful for the detection of carriers since vaccinated animals may be infected and 
become a carrier without showing clinical signs although vaccines can decrease the risk of 
becoming a carrier particular in high antigen doses (Cox et al., 2005; Parida, 2009; Paton et al., 
2006). However, where a non-NSP purified vaccine is used, multiple doses may be required in 
order to induce an increase in NSP titres (Sutmoller et al., 2003). NSP antibodies are measured 
through a blocking ELISA, whilst serotype specific SP antibodies are generally measured 
through virus neutralisation tests (VNT), liquid-phase blocking ELISA (LPBE), solid-phase 
competition ELISA (SPCE), or solid-phase blocking ELISA (SPBE). 
Several problems with current FMD vaccines limit their effective use and warrant the 
evaluation of their effectiveness in the field. Close match of vaccine virus to that in the field is 
important to ensure effectiveness. Serological vaccine matching studies may be performed 
which can indicate likely effectiveness of a vaccine against a particular strain, but there are 
several limitations to this approach including uncertainty over the identity of the precise 
vaccine strain and standardisation of vaccine derived sera (Paton et al., 2005). Recently the 
sensitivity of conventional vaccine matching tests has also been questioned (Brito et al., 2014, 
discussed in Chapter 2). Effectiveness is also limited by the short duration of protection, 
estimated as only six months after an initial two dose regimen (Doel, 2003) although duration 
may be longer with a high potency oil adjuvanted vaccine (Cox et al., 2010). Given the high 
transmissibility of the virus, high levels of coverage are required for herd immunity (Paton et 
al., 2009). Passive maternally-derived antibody (MDA), passed to the neonatal calf through 
immunoglobulin-rich colostrum, is known to interfere with the vaccine response (Kitching and 
Salt, 1995). The half-life for FMD antibodies in the calf is estimated at around 22 days with 
“significant titres” persisting for up to six months in endemic settings (Nicholls et al., 1984). A 
“window of susceptibility” (otherwise known as an “immunity gap”) therefore exists between 
waning passive immunity and the ability to respond to the vaccine (Doel, 2003). Vaccine 
antigens degrade at temperatures above 8°C and the cold chain is often difficult to maintain in 
resource poor countries where FMD is endemic (Garland, 1999). There is also evidence that 
the antibody response post vaccination varies with breed with one recent study showing lower 
responses in Jersey sires’ offspring compared to Holstein (Di Giacomo et al., 2013). 
Despite these problems, vaccines are used extensively to control FMD. It is estimated that over 
two billion doses of vaccine are used globally each year mainly in China, South America, India 
and the Middle East (Paton et al., 2009). This includes government subsidised mass vaccination 
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as part of national control strategies, “ring” (or “reactive”) vaccination in response to 
outbreaks to reduce impact and spread, and use by individual farmers as prophylaxis in case of 
exposure. With the considerable use of a problematic vaccine, rigorous evaluation is needed. 
1.4 FMD in Kenya 
1.4.1 Agricultural background 
Like most of East Africa, Kenya’s economy is dominated by the agricultural sector. According to 
the World Bank in 2012 the value added % of GDP for agriculture was 30% (Source: 
http://data.worldbank.org/, accessed 2nd October 2014). Milk is the most important livestock 
product, representing around 70% of the total gross value of livestock’s contribution to the 
agriculture sector and four times more important than meat on a GDP basis. National milk 
output from cattle has been estimated to be 5.8 billion litres per year (Behnke and Muthami, 
2011). Most of the dairy cattle population is in the western part of Kenya, in the southern part 
of the Rift Valley (Figure 1.3). Smallholder farmers are estimated to produce over 70% of the 
national milk supply. These farmers are generally based on 1.2-2.0 hectare plots of land, own 
2-5 cattle and yield around 5kg milk per cow per day (Muriuki, 2011). The remaining is supplied 
by large-scale farms that - although they contribute relatively less milk nationally - are less 
prone to seasonal fluctuations in production mainly due to the greater capacity for storage of 
fodder. It is estimated that 70% of national milk output is produced from “grade” cattle (i.e. 
pure-breed European dairy cattle or their crosses with indigenous breeds) making up almost all 
marketed milk (Muriuki, 2011).   
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Figure 1.3. Dairy cow density in Kenya. Source: Omore et al., (1999)  
http://ilri.org/infoserv/Webpub/fulldocs/InvestingInDairy/DOX/, accessed 2nd October 2014.  
 
1.4.2 FMD occurrence and control 
FMD is endemic in Kenya with O, SAT1 and SAT2 serotypes in apparent constant circulation 
with occasional outbreaks of serotype A. Serotype C was last isolated in 2004 (Sangula et al., 
2011). The FMD susceptible population is mainly small ruminants although a large number of 
cattle are also present (Figure 1.4). Surveillance is mainly passive with reports made from 
farmers to local animal health assistants (private or government-employed), private veterinary 
practitioners, or local government veterinary officers. The farm is then visited by a government 
veterinary officer to confirm that the suspicion is consistent with FMD and a sample is taken 
and submitted to the National FMD Laboratory in Embakasi, for diagnosis and serotype testing 
by antigen (Ag)-ELISA. A recent review of laboratory capacities for FMD in East Africa shows 
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Kenya as being the best equipped in the region having the ability to do Ag-ELISA, Complement 
Fixation Tests (CFT), PCR and virus isolation and to serve as a laboratory to several other East 
African countries. Available serological assays include VNT, LPBE and NSP-ELISA (Namatovu et 
al., 2013a).  
Figure 1.5 shows the number of confirmed FMD outbreaks and the serotype detected by the 
national FMD laboratory over a ten year period. This does not include the number of 
unconfirmed outbreaks and as surveillance is mainly passive, there is likely to be 
underreporting. However, the relative numbers of different serotypes is likely to reflect actual 
patterns. FMD is considered to be associated with the dry seasons (normally January-March 
and July-September) coinciding with increased movements of pastoralist cattle searching for 
grazing. Information gleaned from veterinarians working in Kenya suggests FMD is present at 
all times of the year with a higher incidence during the dry seasons. 
 
 
Figure 1.4. Population of different FMD susceptible species in Kenya created from the 2009 
agricultural census. Source: https://www.opendata.go.ke/. Accessed 2nd October 2014. 
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Figure 1.5. Trends in FMD serotypes detected in Kenyan outbreaks from 2003 to 2013 
inclusive. Serotype C not included (one report only from 2004). Source: Kenyan FMD 
laboratory, Department of Veterinary Services.  
 
FMD is a notifiable disease in Kenya and so control is driven by the government through the 
Department of Veterinary Services (DVS). In 1967/1968, a plan for disease-free zones in 
Nakuru and Laikipia was created and successfully implemented. Through the regular use of 
mass vaccination and strict movement controls, meat exports to Europe were possible in the 
1970s. A lack of resources and higher demand for meat within Kenya led to this export status 
being eventually lost and it has not since been regained (Rweyemamu, 1984a). Current 
methods employed in Kenya include movement restrictions, market closures and ring 
vaccination (Namatovu et al., 2013a). The only licensed FMD vaccines in Kenya are produced 
by the government owned Kenya Veterinary Vaccines Production Institute (KEVEVAPI) and 
include quadrivalent (O, A, SAT1, SAT2), trivalent (O, SAT1, SAT2 or O, A, SAT2) and 
monovalent vaccines. The current vaccine is aqueous adjuvanted (aluminium hydroxide and 
saponin) and not NSP-purified. According to government sources, KEVEVAPI produces around 
15 million monoequivalent doses of vaccine annually, with around 7 million used in Kenya. 
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Evaluation is through the PD50 assay as recommended by the European Pharmacopeia and OIE 
(OIE, 2009).  
Among smallholders, vaccination is typically limited to government-subsidised ring vaccination 
in response to a confirmed outbreak. This involves offering farmers a single dose of subsidised 
vaccine per animal to areas surrounding a confirmed outbreak after a period of publicising the 
dates and locations. Vaccination usually takes place at a communal handling facility such as a 
cattle dip or on a farm that has a working crush. Alternatively vaccination teams will move 
from farm to farm offering vaccine. Usually only cattle are included in these campaigns. Data 
on vaccination use is relayed back to the central DVS where estimates on coverage are made 
based on the doses used and the 2009 animal census figures for the area. This vaccination 
policy is dependent on vaccine and finance availability and consequently vaccine coverage is 
typically low estimated by veterinary officers at around 10%. Larger commercial farms often 
employ prophylactic vaccination, which may be supplied through the government at a 
subsidised rate, but often is sourced directly from the manufacturer at an unsubsidised cost. 
This is in part because of a lack of certainty over vaccine availability through the local 
government and distrust of government cold chain practices.  
In some parts of Kenya, in particular the Central province, the Kenyan Veterinary Association 
(KVA) has organised vaccination campaigns passing discounts associated with bulk vaccine 
purchase on to the farmer. However, in these campaigns FMD is considered alongside other 
diseases including Lumpy Skin Disease (LSD) and Clostridial disease, meaning FMD vaccine is 
not included in all areas. Records of vaccinations are not routinely kept at the individual animal 
level. 
As part of a government campaign, “Kenya Vision 2030”, there are now plans to set up five 
disease free zones to enable export of animal products to disease free countries (Source: 
http://www.vision2030.go.ke). FMD is one of the target diseases and the campaign specifies 
improvements in vaccination as an important strategy. FMD vaccine evaluation is therefore 
timely for Kenya. 
1.4.3 FMD research in Kenya 
1.4.3.1 Phylogenetics 
Several research studies have been carried out and published related to FMD in Kenya. The 
majority of studies focus on the phylogenetic analysis and characterisation of isolated virus 
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strains with possible implications for vaccination.  Two studies looking at serotype O isolates 
from 1964 to 2011 revealed four topotypes to have been present in Kenya during this time 
(East Africa [EA]-1, EA-2, EA-3 and EA-4). The vaccine strain is based on an EA-1 topotype 
strain. Of the 66 viruses sequenced in these two studies, a EA-1 topotype has only been 
detected on one occasion (in 2007) since the year 2000 raising concerns over the potential for 
the vaccine to be effective in the field  (Sheila N. Balinda et al., 2010; Wekesa et al., 2013). A 
recent analysis of 38 serotype A strains collected between 1964 and 2013 showed five lineages 
within the African topotype (two of which now appear extinct) all having a countrywide 
distribution (Wekesa et al., 2014b). This study also raised concerns over the similarity of more 
recent isolates with the vaccine strain currently in use having an average difference in VP1 
sequence of 13% for viruses isolated between 2003 and 2013. One study of serotype C 
suggested that given the limited nucleotide diversity of samples taken over 40 years it is 
possible that re-introductions of improperly inactivated vaccine strains may have been 
responsible for the outbreaks (Sangula et al., 2011).   
A study of SAT1 isolates from East Africa suggested that of two independent groups of strains 
introduced from South Africa  those seen in Kenya and Tanzania were similar enough to 
suggest transboundary exchanges of virus from movements of livestock or wildlife (Sangula et 
al., 2010a). Several studies have analysed sequences of SAT2 throughout sub-Saharan Africa. 
One of these focussed on isolates from Kenya and found two distinct lineages to be present 
between 1957 and 2007 (Sangula et al., 2010b). Again there have been concerns over the 
vaccine since only one SAT2 strain from one of these lineages is present in the vaccine with 
unknown cross protection capacity. 
Di Nardo et al. (2011) related the virus topotype distributions to livestock movements and 
concluded that the diversity in ecosystems and the adaptation of pastoralists to seasonal 
trends in climate and grazing are important determinants in the distribution of the viruses and 
may bring cattle into contact with susceptible wildlife. Cross-border movements of animals are 
also important for FMD circulation with large numbers of animals moving from neighbouring 
Tanzania and Ethiopia to Nairobi, where higher prices can be obtained. 
1.4.3.2 Serosurveys 
Several serosurveys have been published on different species in Africa. A report by Paling et al. 
(1979) described clinical signs and positive neutralising titres in domesticated eland 
(Taurotragus oryx) on a large ranch in south east Kenya, likely due to SAT2 as this was isolated 
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from clinically affected cattle on the same ranch at the same time. Virus could still be isolated 
from the cattle 10 months after the outbreak but not from buffalo (Syncerus caffer) and eland, 
although for the latter two species low numbers of samples were taken. 
A later study by Bronsvoort et al. (2008) determined the seroprevalence of NSP and SP 
antibodies in wildlife that had contact with livestock populations in parts of Eastern and 
Central Africa (including Kenya). Sera were collected from 27 different species between 1994 
and 2002 as part of Rinderpest surveillance. Of the 731 samples taken, 483 were from African 
buffalo (Syncerus caffer). VNT for SP antibodies were measured in these sera for all three SAT 
serotypes. 327/483 (67.7%) of the buffalo were positive to NSP antibodies compared to 
11/248 (4.4%) in the non-buffalo species demonstrating the relative importance of buffalo. 
Age stratification of the results from the buffalo indicated over 60% seroconversion by the age 
of nine months indicating early lifetime exposure. The age distribution was closely matched by 
the VNT result for SAT2. 
A serosurvey in the “Somali Eco-System” was performed utilising 499 samples collected from 
cattle over a two year period beginning in January 2007 (Chepkwony et al., 2012). These had 
been collected as part of the final evaluation of the Rinderpest eradication programme. VNT 
for SP antibodies were performed to five serotypes (O, A, C, SAT1, SAT2). 226/499 (45.3%, 
95%CI 41.0, 49.7) samples were seropositive to one or more serotypes with serotype O being 
the most common (in 118/499 [23.6%] of samples). Similar prevalences were found for 
serotypes A, SAT1 and SAT2 at around 15% each although it was significantly lower for C at 
1.6%. Seropositivity was significantly different for age categories and appeared to show a 
linear increase (Table 1.2). There was no significant difference in seropositivity between sexes. 
No vaccination campaigns had been recorded as having taken place in this region.  
A nationwide cross sectional study of cattle was performed in 2010 by Kibore et al. (2013). 
They tested 3,709 samples from 39/47 counties taken over a two month period for NSP 
antibodies. Overall 1947/3709 (52.5%) were positive similar to that reported by Chepkwony et 
al (2012) although NSP seroprevalence by age was not presented (Table 1.2). A sub-selection 
of NSP-positive samples (n=738) was analysed by LPBE on which a risk factor analysis was 
based (Table 1.2). In this latter analysis, animals were defined as positive if seropositive to one 
or more serotypes by LPBE. Limited inference can be made from this analysis because only NSP 
positive samples were chosen and no trend was analysed between the number of serotypes to 
which each age category was positive (only zero or ≥1). Risk factor analysis of NSP 
seropositivity would have been more appropriate but was not possible from the data 
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presented. Additionally, insufficient data and details on study design were presented to 
understand the geographical distribution of seropositivity and the implications of using a non-
purified vaccine were not discussed. An opportunistic NSP serosurvey of pigs was also 
conducted alongside this cattle serosurvey (pigs only being sampled if found at the randomly 
selected cattle sites) which revealed 101/191 (53%) to be positive despite no history of clinical 
disease (Wekesa et al., 2014a). Those positive for NSP antibodies were also tested for serotype 
specific antibodies using SPBE and VNT which revealed SAT1 to be the causative serotype that 
was also prevalent during cattle at the time. Some of the pigs had been vaccinated but a 
history of vaccination was not associated with seropositivity consistent with the consensus 
that aqueous based vaccines are ineffective in this species. 
 
Table 1.2. Summary of recent serosurveys in Kenya analysing seroprevalence by age category 
in cattle.  
Study Test Age 
category 
Seropositive Total Percentage 
(95% CI) 
P-value 
Chepkwony et al, 
2012 
VNT 1-2 years 111 290 38.3 (32.7-
43.9) 
<0.001 
  2-3 years 107 199 53.8 (46.8-
60.7) 
 
  3-4 years 8 10 80.0 (51.2-
98.5) 
 
  Total 226 499 45.3 (41.0-
49.7) 
 
Kibore et al, 
2013 
NSP All 
animals 
1947 3705 52.5 (50.0-
55.0) 
 
 LPBEa <1 year 181 227 79.7  
  1-2 years 157 203 77.3  
  >2 years 253 308 82.1  
  Total 591 738 80.1  
Note: For VNT and LPBE, animals were defined as seropositive if positive to one or more 
serotypes. The survey by Chepkwony et al (2012) was performed in the Somali Eco-System 
whereas the study by Kibore et al (2013) was nationwide. a LPBE were performed on a subset 
of NSP positive samples.  
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1.4.3.3 Economics 
Two papers have presented case reports on the economic impact of FMD on large-scale dairy 
herds in Kenya (Kimani et al., 2005; Mulei et al., 2001). Using participatory methodology 
among pastoralists in Narok, Onono et al. (2013) scored East-Coast Fever (ECF) and FMD to be 
the highest ranking diseases in terms of impacts on production. FMD was reported to be the 
disease most frequently encountered in cattle of those discussed. These studies are 
considered in more detail in Chapter 5 and Chapter 6.  
1.4.3.4 FMD vaccination in Kenya 
Immune response to the locally available quadrivalent vaccine was assessed by Berger et al. 
(1975). In two different field trials they investigated whether there was a difference in the 
response to SAT serotypes if included in polyvalent vaccines. In the first trial, 46 Friesian or 
Ayrshire cattle aged between 20 and 36 months were vaccinated at zero, three and 27 weeks. 
In the second, six groups of 20 Boran steers were given a single dose of vaccine containing 
different serotype combinations. In both trials, animals were periodically blood sampled and 
tested by VNT to the vaccine strains and mean titres over time were presented. They 
concluded that polyvalent vaccines with SAT serotypes produced satisfactory levels of 
immunity, although three doses were needed for the SAT1 vaccine and there was some 
evidence that a better response is seen to SAT2 when used in monovalent form. The SAT1 
strain is the only one that is still included in the current vaccine. 
Evidence for field effectiveness of FMD vaccines in Kenya is limited. In the aforementioned 
study by Paling et al. (1979) (section 1.4.3.2), an outbreak of SAT2 occurred among cattle 
despite biannual vaccination although no details were given to sufficiently appraise the vaccine 
effectiveness. Ndiritu et al. (1983) later published the results of vaccine matching tests which 
compared nine SAT2 field isolates to four vaccine viruses to identify the vaccine strain with the 
broadest serological spectrum for inclusion in the vaccine.  
Anderson et al (1974) compared the prevalence of carrier cattle in vaccinated and non 
vaccinated areas with no recent outbreak history. The former were sampled at slaughter in the 
abattoir whilst for the latter probangs were performed on live animals. The prevalence of 3.3% 
in the non vaccinated area (n=2,219) and 0.49% in vaccinated areas (n=1,231) led the authors 
to conclude that carrier cattle were not a significant risk to virus elimination in routinely 
vaccinated areas. 
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Although primarily focussed on the treatment of affected animals, one study did report an 
outbreak on a cattle dairy farm that affected 95/166 (57.2%) of animals over a 21 day period 
despite using prophylactic vaccination three times a year (Gakuya et al., 2011). The most 
recent vaccination had occurred four days before the outbreak began and was the locally 
produced quadrivalent vaccine (A, O, SAT1, SAT2). Ag-ELISA revealed the serotype to be SAT1 
and VP1 sequencing at the World Reference Laboratory (WRL), Pirbright, showed it was 
10.56% different to the vaccine strain. There were no results of any vaccine matching tests. 
Data on the number of animals affected per day and the age category they belonged to (>2 
years, 1-2 years and <1 year) were presented, but no denominators were presented; thus it is 
not possible to calculate incidence by age or number of vaccine doses received. However, most 
of the cases were in animals over two years of age (66/95, 69.5%). An epidemic curve created 
from these data is shown in Figure 1.6. Given the dissimilar VP1 sequences, it is unlikely that 
the vaccine was the source of the virus but this study does present evidence of a lack of 
vaccine effectiveness for the SAT1 serotype. 
 
 
Figure 1.6. Epidemic curve and cumulative incidence over time, taken from the data presented 
by Gakuya et al. (2011) on a farm that had an outbreak of FMD due to SAT1 four days post 
vaccination.  
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Similarly a study by Mulei et al. (2001), that focussed on the economics of a FMD outbreak on 
a commercial dairy farm in Kenya, reported an outbreak due to serotype O affecting 123/207 
(59.4%) of cattle despite vaccinating 104 days earlier. Vaccine schedules and animal ages were 
not given, but from the outbreak description, the incidence tended to be higher in adults 
affecting 20.8% of lactating cows compared to less than 5% in weaned and suckling calves. 
1.5 Vaccine effectiveness 
Vaccines may have direct and indirect protective effects. Direct protection refers to effects in 
vaccinated animals themselves. Indirect protection is a population level effect whereby 
vaccination reduces transmission and risk of exposure (and therefore infection or disease) 
irrespective of whether an individual has been vaccinated or not. Vaccines may also protect 
against infection, infectiousness or disease. Different study designs can be utilised to compare 
different populations or subpopulations depending on the specific aspects of protection that 
are being analysed (Halloran et al., 1999, 1997).  
Vaccine efficacy is defined as “1-RR” where RR is the risk or rate ratio which is the incidence in 
the vaccinated divided by the incidence in the (similarly exposed) unvaccinated populations. 
This is measured under controlled trial conditions to ensure equal exposure of the vaccinated 
and unvaccinated groups. Other assumptions include random administration of the vaccine 
and a homogenous population with all individuals equally susceptible to infection. These 
studies are typically done through randomised controlled trials (Smith et al., 1984). 
Vaccine effectiveness has an identical calculation but is measured in field conditions and is 
therefore more reflective of “real-life” conditions. Vaccine efficacy studies are usually carefully 
performed and can be considered performance under “ideal” conditions that are unlikely to be 
possible in routine programme conditions. Alternatively, the vaccine effectiveness estimate 
reflects the effectiveness of a vaccine programme at a farm, regional and/or national level. 
Vaccine effectiveness therefore has important implications for policy. The study population is 
heterogeneous and therefore calculations usually need to be adjusted for potential 
confounders such as age, sex and previous exposure. These studies are typically observational 
using a cohort or case-control approach (Smith et al., 1984), although cluster randomised trials 
may also be used whereby the herd immunity effects of vaccination can be assessed (Clemens 
et al., 2011). Effectiveness studies are an essential component of post-licensure monitoring in 
human vaccines. 
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In human vaccinology, these evaluation issues are widely accepted but among veterinary 
vaccines these terms have not been standardised (Knight-Jones et al., 2014b). Vaccines in 
veterinary species are extensively used, including for FMD, and in many different species. 
Despite this, vaccine effectiveness studies are rarely performed for veterinary vaccines, and 
vaccine evaluation tends to rely on experimental challenge or seroconversion. These 
assessments do not account for the heterogeneity of field conditions and therefore 
extrapolating their outcomes to a wider population is uncertain. Additionally, there is a 
tendency for veterinary vaccine manufacturers to not publish fully the results of their trials 
which for ethical reasons are made available to national control agencies such as the National 
Institute for Biological Standards and Control (NIBSC) in the UK or Food and Drug 
Administration (FDA) in the USA for human vaccines. As a result, there is a great need to carry 
out rigorous field based evaluations of veterinary vaccines, especially when public money 
subsidises their use and where diseases have implications for human health, household 
income and animal welfare. This is particularly pertinent in developing countries where 
agriculture is so important. 
Despite the importance of FMD to Kenya and the East African region and the not-insignificant 
investment in vaccination, no studies evaluating the field performance of the vaccines have 
ever been published.  
1.6 Overall aim of thesis 
The overall aim of this thesis is to gain a greater understanding of FMD field epidemiology, 
evaluate the performance of FMD vaccination in Kenya, and to measure the impact of disease 
among Kenyan dairy cattle. 
Objectives:- 
1. To conduct a review of the literature on current FMD evaluation methods 
2. To gain experience of FMD in the field and gather data on its epidemiology 
3. To find outbreaks of disease that have occurred on farms that have used recent 
vaccination and perform vaccine effectiveness studies 
4. To use farm records on production parameters to estimate the impact of disease 
5. To use recent post-vaccination serological data from the vaccine manufacturer to 
complement the epidemiological studies 
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1.7 Structure of the thesis 
This thesis is a research paper style thesis that has three complete papers (Chapter 4, Chapter 
5, Chapter 6), and two additional non-published results chapters (Chapter 7 and Chapter 10). 
For consistency in style, the latter two have also been written in the style of research papers. 
Chapter 2 is a literature review on FMD vaccine evaluation which leads onto Chapter 3 which 
gives details of the research questions and specific objectives of the thesis including the field 
work activity.  
There are two parts to the thesis. Part A is on epidemiology, and Part B is on serology. 
Part A presents the analyses of two outbreaks of FMD on large-scale dairy farms that used 
routine prophylactic vaccination. The first outbreak is described in Chapter 4 which includes an 
evaluation of the vaccine and has been accepted for publication in Acta Tropica. Chapter 5 and 
Chapter 6 use this same outbreak to describe the impact on clinical mastitis, culling and milk 
yield and include separate literature reviews on these subjects. Both of these chapters have 
been submitted for publication. The second outbreak is similarly described in Chapter 7, and a 
separate discussion comparing the two outbreaks is presented in Chapter 8.  
Part B of the thesis evaluates serological data made available from the vaccine manufacturer in 
the light of the epidemiological findings presented in Part A. A review on the impact of 
maternally derived antibody on the response to vaccination is presented in Chapter 9 followed 
by the analysis in Chapter 10. 
An overall discussion of both parts of this thesis is presented in Chapter 11. 
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Chapter 2. Literature review 1 – FMD vaccine evaluation 
The objective of this review is to provide a comprehensive background on FMD vaccine 
evaluation methods. Only commercially available vaccines and their application in cattle were 
considered. A search of the literature in the English language was performed in 
Pubmed/Medline and Web of Science using the search terms: (fmd OR foot-and-mouth) AND 
(bovine OR cattle OR cow) AND (vaccine OR vaccination). Of the 241 articles initially found, a 
screen based on the titles and abstract refined these to 62 articles that were found relating to 
the evaluation of vaccines in individual or populations of cattle. The OIE Terrestrial Manual was 
also included. On the basis of these results, the following areas were reviewed: potency 
testing, vaccine matching, serological assessments, field evaluations and mathematical 
modelling. 
2.1 Potency tests 
Evaluation of FMD vaccines is performed mainly through experimentally infecting vaccinated 
animals in a controlled setting in the context of a “potency test”. Two types of potency test are 
outlined in the OIE Terrestrial Manual (OIE, 2009). The first of these is also the recommended 
European Pharmacopeia (EP) test that provides a 50% protective dose (PD50) value. Naïve or 
vaccinated cattle over six months of age are challenged by intradermolingual (IDL) virus 
inoculation, 21 or 28 days (for aqueous- or oil-based respectively) post vaccination with the 
homologous strain. Groups of five animals are vaccinated with either a full dose of vaccine, 1/4 
dose or 1/10 dose to determine the PD50 value. Animals are observed and examined for eight 
days with protection defined as no observable foot lesions. At least two statistical methods are 
employed for calculating the PD50 value. The EP suggests maximum likelihood methods (probit 
analysis and logistic regression) while the OIE prefer the Spearman-Kӓrber statistic in assessing 
the dose response relationship (Reeve et al., 2011). Vaccines are recommended to contain at 
least 3 PD50 per dose when used “for routine prophylactic use”, although 6 PD50 is preferred 
(OIE, 2009). The other OIE approved test is the “Protection from Podal Generalisation” (PPG) 
which is commonly used in South America. A full dose of vaccine is given to 16 cattle that are 
IDL-challenged at least four weeks post-vaccination. A minimum of 12 animals must show 
protection for the vaccine to be approved for field use. In both tests, summarised in Table 2.1, 
two unvaccinated control animals must show generalised disease for the test to be declared 
valid. Vianna Filho et al. (1993) collated data from two different laboratories in Brazil and 
Argentina for three serotype (O, A, C) comparing the percentage of protection with the PD50 of 
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the vaccine as measured by potency tests. These data are represented in Figure 2.1. Although 
still based on challenge studies, this graph does demonstrate the expected increase in clinical 
protection with increasing PD50 value which appears to be a repeatable trend based on the 
small confidence intervals and using data from more than one laboratory. 
 
Table 2.1. Summary of potency tests as recommended by the OIE (OIE, 2009). 
Potency test Number of 
animals
a
 
Dose Challenge (dpv
b
) Follow up 
(dpc
c
) 
Pass-mark 
50% protective dose 
(PD50) 
17  1/10, 1/4, full 
dose (5 animals 
per dose) 
21 (aqueous-), 28 
(oil-adjuvanted) 
8 days post 
challenge 
≥3.0  
Protection from 
Podal Generalisation 
(PPG) 
18  Full dose 30 8 days post 
challenge 
12/16 
protected 
a includes two unvaccinated control animals. bdpv = days post vaccination cdpc = days post 
challenge 
 
 
Figure 2.1. Percentage protection (with 95%CI) with different PD50 levels of vaccine collated for 
serotypes O, A and C based on the data presented by Vianna Filho et al. (1993), Table 5.  
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A major limitation of potency tests is the small number of animals used leading to high degrees 
of statistical uncertainty. Computer simulations of potency tests have explored this uncertainty 
and indicated that the PPG test provides a more reliable estimate of potency than PD50 
calculations.  A particular problem noted by Sutmoller (1986) with the PD50 calculation is that 
the standard error becomes unacceptably high where the dose-response curve is flat. Using 
their PPG test simulation models, they found that if a vaccine actually protects 90% of 
recipients, a PPG “pass-mark” of 12/16 will approve 99% of vaccine batches. If the vaccine 
actually protects 70% of recipients, using this same pass-mark would approve 55% of batches. 
The authors note that there is a compromise between producing vaccines acceptable to the 
livestock industry and the cost of the tests to the manufacturers.  
A more recent study reported computer simulations using archived data from 1,644 
challenged individuals (Reeve et al., 2011). Based on their findings, they suggested modifying 
the potency tests to two groups of six animals, one receiving a 1/3 of the usual full dose of the 
vaccine and the other 1/6 of the dose, combined with two unvaccinated controls. They found 
that this regime performed better than the EP recommended PD50 test at determining if a 
vaccine was above the 3PD50 or 6PD50 threshold. It was also comparable to the OIE tests for 
both PD50 and PPG calculations despite using fewer animals (16) compared to the usual 17 or 
18 with benefits to cost and animal welfare. The same study also suggested that the OIE 
preferred statistical method was superior to those suggested by the EP. 
The issue of poor precision in the PD50 calculation was assessed by Goris et al. (2007) who 
analysed data from 10 potency tests with the same vaccine for the O1 Manisa strain. When 
combining the animals from all tests together, the overall PD50 value was 10.0 (95%CI 7.5-
13.3). However the results of the individual trials varied from 4.6 to 24.3. To put this in 
context, two of the vaccine trials had a PD50 result of 6.0 but with 95% confidence intervals of 
2.8-15.5 and 3.1-13.7 reflecting the uncertainty in the point estimate. They also showed that 
there was a 32.4% (95%CI 27.9, 36.8) probability that two animals in the same trial receiving 
the same dose of vaccine would have different protection level (defined as “vaccine 
accordance”). The between-test variability was higher with a 58.8% (95%CI 54.8-63.1) 
probability that animals receiving the same dose would have the same result in a different trial 
(defined as “vaccine concordance”). 
The same research group later assessed the precision of the PPG test, analysing the results of 
six identical trials using a serotype A stain vaccine challenged with homologous virus (Goris et 
al., 2008a). Combining the results, overall 88.5% (95%CI 80.7-93.5) of vaccine recipients were 
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clinically protected ranging from 75 to 100% between tests. The vaccine accordance and 
concordance levels (using the same definitions as in the preceding paragraph) were 75.9% 
(95%CI 64.9-86.2) and 73.7% (95%CI 62.1-84.3) respectively. Although the results of a single 
PPG test was more reliable than a single PD50 test, only one of the six PPG trials had a lower 
limit of the confidence interval above the 75% cut-off, this being where all 16 animals were 
protected. The authors suggested that the number of animals should be increased to provide 
greater statistical evidence although they considered that this might be “unfeasible and 
unethical from an animal welfare point of view”. Therefore they suggested that because PPG 
retrials were required for vaccine authorisation in Argentina, these PPG results should be 
combined to narrow the confidence intervals of the estimates. 
Large numbers of potency test results may be combined to give a more complete account of 
the expected protection from a vaccine when cattle are experimentally challenged. Vianna 
Filho et al. (1993) combined the analysis of 658 PD50 tests for serotypes A, C or O from two 
different institutes in Argentina and Brazil using a hydroxide-saponin adjuvanted vaccine. 
Analysis of the percentage of animals protected from clinical disease revealed a strong 
association with the PD50 value (P<0.001). In the groups receiving the undiluted (i.e. full) dose, 
78% (95%CI 76-80) and 91% (90-93) of individuals were clinically protected for vaccines of 3.0 
and 6.0 PD50 respectively (Figure 2.1). However, they failed to find a “satisfactory” dose-
response relationship in 145 (22%) of the potency tests performed meaning a reliable estimate 
could not be made, highlighting the limitations of relying on one test in evaluating a vaccine. 
The same study presented data from 65 PPG tests for three batches of hydroxide-saponin 
(n=17, n=8, n=13) and two batches of oil-based (n=20, n=7) vaccine. Except for one of the 
aqueous adjuvanted batches that had one test markedly different from the others (11/15 
protected versus all protected in the twelve other tests), they found all results were 
significantly associated (P<0.05) and on this basis recommended the PPG test for evaluating 
FMD vaccines due to greater reproducibility of the results and the absence of a dose-response 
requirement as with the PD50 calculation (Sutmoller, 1986). 
Jamal et al. (2008) combined the results of 297 potency tests performed from 1965 to 2006 to 
determine the relationship between the PD50 level and the percentage of animals clinically 
protected when challenged with homologous virus. A variety of strains were used covering 
four FMDV serotypes (A, C, O, Asia-1). Aluminium hydroxide, aluminium hydroxide with 
saponin, and double oil emulsion adjuvanted vaccines were also compared.  They found that 
there were differences seen in the relationship depending on the serotype and the adjuvant 
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used and that “no common level of protection can be assigned to all FMD vaccines with the 
same amount of PD50 per dose” and so advocated alternative tests for evaluating FMD 
vaccines. 
A meta-analysis of challenge studies was performed by Halasa et al. (2011) looking at clinical 
and virological protection defined as not seroconverting to NSP from IDL challenge or exposure 
to an infected animal in an experimental setting. Animals had been vaccinated once with a 
NSP-purified, high potency (>6.0 PD50) vaccine as recommended to be used in an emergency 
setting. Serotypes O, A and Asia-1 were included. The pooled relative risk for clinical FMD 
comparing vaccinated and non-vaccinated individuals was 0.13 (95%CI 0.09-0.18) whilst for 
FMD infection it was 0.71 (0.59-0.85). No difference was seen between serotypes. 
2.2 Serological assessments 
The inherent variability of potency tests due to the low numbers of animals used, costs, 
compromised animal welfare and risks associated with facilities using live virus, have led to the 
search for alternative correlates so that serological tests can be used to evaluate vaccines in 
line with the “Replacement, Reduction and Refinement” principles of animal experimentation 
(Flecknell, 2002).  
2.2.1 Surrogates and correlates of protection 
Specific immune markers have been used for many diseases to reflect the level of protection 
to clinical disease when exposed to infection. Such a marker may have a direct role in 
conferring immunity or have no specific role but be indirectly correlated. The former is known 
as a “surrogate” of protection whilst the latter is a “correlate” of protection according to WHO 
terminology (Nguipdop Djomo et al., 2012), although only the latter term is generally used for 
FMD.  
When considering a surrogate or correlate of protection induced by vaccine, correlations are 
typically sought between the use of vaccine and the marker as well as the marker with clinical 
protection. The overall protective effect of the vaccine may then be assessed by bypassing the 
marker phase. Vaccine-induced markers may have different relationships to protection 
compared to natural infection due to stimulating different immunological pathways. 
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2.2.2 Methods used in establishing correlates 
The aforementioned relationships between vaccination, immune markers, and clinical 
protection have been assessed through a variety of methods that may be experimental or field 
based. The “Prentice criteria” have been used to assist validation of surrogates in human 
vaccine studies (Prentice, 1989). These include showing significant associations:  
a) between administration of a vaccine and clinical protection,  
b) between the surrogate and receiving the vaccine,  
c) between clinical protection and the surrogate, and  
d) showing that the surrogate lies on the sole causal pathway such that adjusting for 
the level of surrogate removes the association between receiving the vaccine and 
clinical protection.  
Surrogates or correlates of protection have been extensive studied for a variety of human 
diseases. Randomised controlled trials offer a powerful method of assessment due to their 
ability to control confounding variables. Vaccine efficacy trials can provide such data if 
participants are sampled at appropriate time points post vaccination. For example, (Black et 
al., 2011) sampled a subset enrolled into an influenza vaccine trial measuring 
haemagglutination inhibition (HI) titres 50 days post placebo or one of two types of vaccine. 
Two doses were given 30 days apart and active surveillance with rtPCR confirmation used to 
define cases. The study related various HI titre cut-offs to clinical protection revealing the 1:40 
cut-off was associated with 50% clinical protection in adults but with 22% protection in 
children.  
Observational studies can also provide valuable insights into these relationships. An 
opportunistic cohort study of a measles outbreak among university students after a recent pre-
exposure blood drive gave evidence that a plaque reduction neutralisation level of 120 was 
associated with protection from classical signs of disease (Chen et al., 1990). Of those with 
levels below this cut-off, 8/9 individuals developed disease compared to 0/71 with levels 
above. 
Challenge studies have also been used in humans. Buisman et al., (2008) looked at circulating 
serotype specific poliovirus IgA levels in elderly people challenged with either serotype 1 or 
serotype 3 monovalent oral poliovirus vaccine. Inverse linear regression revealed a correlation 
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between pre-existing serotype specific circulating IgA and faecal virus titres for both serotypes 
(serotype 1, r=0.57; serotype 3, r=-0.61; P<0.0001).  
2.2.3 Correlates of protection and FMD 
Several homologous challenge experiments, including results from potency tests, provide 
evidence for an association between antibody titres and protection from clinical FMD. Martin 
& Chapman (1961) found all animals to be clinically protected above a neutralisation antibody 
cut-off of 1/32, representing around 60% of the 137 animals challenged, although some 
animals with lower levels also appeared to be protected. Van Bekkum et al. (1969) found that 
424 cattle exposed to serotype C virus two weeks post vaccination were more resistant than 
92 animals with similar antibody titres exposed at 9-49 months post vaccination implying 
vaccine-induced protection decreased over time, independent of the immunological measure. 
Hamblin et al. (1987) challenged four groups of 24 cattle intradermolingually with different 
FMD strains after receiving different dilutions of vaccine and found overlapping titres in the 
protected and non-protected groups for VNT but not LPBE. Low numbers of animals in non-
protected groups make interpretation difficult, but a protective cut-off of 2 logs to the base 10 
was generally consistent with protection for LPBE. For serotype C, there were no non-
protected animals making comparison impossible. Van Maanen and Terpstra (1989) found VNT 
and LPBE results to be highly correlated with each other for the serotype strains assessed 
(correlation coefficients A=0.84, O=0.75, C=0.74; P-values <0.0005). They found serum titres 
and percentage protection (probits) to be significantly associated for both tests (P<0.01) with 
the regression coefficients shown in Table 2.2 (no confidence intervals were presented). The 
greater reproducibility seen in LPBE results led the authors to conclude that this test provides a 
more reliable correlate of protection. Both of these studies reported relatively higher titres for 
protection when using LPBE compared to VNT in agreement with the later study by Goris et al. 
(2008b).  
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Table 2.2. Association between antibody titres measured by LPBE and VNT and clinical 
protection for serotypes A, O and C. Adapted from Van Maanen and Terpstra (1989). 
  LPBE VNT 
Serotype Number challenged PA50 Regression coefficient PA50 Regression coefficient 
A10 105 0.90 4.3 0.42 3.9 
O1 79 1.23 3.4 0.99 2.7 
C1 67 1.18 2.9 0.48 4.7 
Note: PA50 = log antibody titre that provides 50% clinical protection. LPBE = liquid phase 
blocking ELISA, VNT=virus neutralisation test. 
 
Attempts have been made to establish the expected percentage of protection (EPP) relative to 
titres based on data collected from a large number of PPG tests and the generation of 
correlation tables (OIE, 2009). These are used extensively in South America for licensing of 
vaccines. Periolo et al. (1993) evaluated PPG potency tests from 1,634 animals on 102 batches 
of quadrivalent vaccine for serotypes A, C and O. Animals were IDL challenged at 90 days post 
vaccination (dpv). A close correlation between the LPBE titres and protection was observed 
with percentages of protection ranging between 87 and 100% for different serotypes when 
titres were >2.1 logs to the base 10. Although a trend was evident between the titres and 
protection, there were no statistical analyses or regression coefficients presented and they 
could not be calculated from the data shown. Based on the results of ten PPG tests with serum 
samples taken at 30 dpv and measured with VNT and LPBE, Robiolo et al. (2010) found the 
estimated EPP to have “excellent repeatability, reproducibility and concordance with PPG for 
vaccine potency”.  
Sutmoller et al. (1980) used data from routine PPG potency tests using oil and aqueous based 
vaccines and were able to correlate neutralising titres at 3-4 weeks post vaccination with the 
expected protection. Results from 532 cattle for serotypes A, C and O found that higher titres 
were needed to protect cattle from the latter serotype (slope O=0.73 [SE=0.29]; slope 
A&C=1.402 [SE=0.096]). The overall relationship between titres and clinical protection is 
shown in Figure 2.2. Several other studies have demonstrated this variation between 
serotypes in the level of titres required for protection and also variation in protective levels 
from different laboratories.  Van Maanen and Terpstra (1989) measured PA50 (the log antibody 
titre that provides 50% clinical protection) values which differed between serotypes for both 
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VNT and LPBE assays (Table 2.2). This difference between serotypes was not seen by Barnett et 
al. (2003), although they found highly significant differences in protective antibody levels 
between laboratories, in agreement with Sutmoller and Vieira (1980) and Goris et al. (2008b) 
but in contrast to Maradei et al. (2008). In the study by Goris et al. (2008b), several serological 
tests were analysed including VNT, LPBE, SPCE, serotype O ELISA and NSP ELISA using the 
results of ten repeated PD50 trials. They found that the accuracy of the different tests in 
predicting protection also depended on the laboratory performing that test. This effect was 
also seen by Willems et al. (2012) when analysing the results of five PD50 trials for a serotype A 
strain. 
 
 
Figure 2.2. Relationship between the percentage of animals protected from clinical disease 
(with 95%CI) and serological titre category measured by neutralisation tests for all animals and 
for virus strains from serotypes O, A and C. Produced from data presented in Sutmoller et al 
(1980) , Table 2.  
 
The evidence for associating antibody levels and clinical protection for FMD is based 
predominantly on the results of experimental potency tests. Many of the studies show a 
significant correlation between antibody levels and clinical protection and an EPP has been 
validated in South America based on the PPG test for vaccine licensure. However, small 
numbers of animals may be used which gives uncertainty to these estimates and there may be 
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variation in the protective level between the serotypes, laboratory and serological assay. 
Additionally, with the experimental challenge methods used, it is difficult to extrapolate 
protective titres to clinical protection of animals exposed in the field with differing vaccine 
doses, animal ages and production systems. Whereas laboratory data are required for licensing 
vaccines, there is a need for data on correlates in field conditions to allow serological 
validation of FMD vaccines that will guide vaccine strategy. 
2.3 Vaccine matching 
As an RNA virus, one of the characteristics of the FMD virus is that rapid mutations result from 
errors in RNA replication (Domingo et al., 2002). These genetic mutations may lead to 
antigenic changes so that the antibody induced by a particular vaccine strain is less effective 
for protecting against a mutated field strain. Although genetic sequencing may be useful in 
monitoring the emergence of these strains, the relationship between specific nucleotide 
changes on antigenicity is complex and poorly characterised (Paton et al., 2005). 
Close match of vaccine virus to that in the field is important to ensure effectiveness. In vitro 
serological vaccine matching studies may be performed which can indicate likely effectiveness 
of a vaccine against a particular strain. These tests are performed by a relatively small number 
of laboratories around the world. Sera from cattle (known as “Bovine Vaccinal Serum” or BVS) 
vaccinated 21 days previously are pooled and the reactivity compared between the vaccine 
and field strain. A one way comparative relationship (“r1”) value is calculated by dividing the 
titre against the field isolate to that against the vaccine stain. This reactivity is usually 
measured by VNT or ELISA and occasionally CFT. With VNT, based on field experience a value 
>0.3 is considered to be indicative of sufficient match between the strains for the vaccine to 
confer protection against the field strain. When ELISA is used, values over 0.4 indicate a close 
relationship while for CFT a 0.25 cut-off is recommended (Paton et al., 2005; Rweyemamu, 
1984b). Mattion et al. (2009) found VNT to be a more reliable method for estimating the r1 
values due to more reproducible inter-laboratory results compared to LPBE. There are several 
limitations to this in vitro approach including uncertainty over the identity of the precise 
vaccine strain and standardisation of vaccine-derived sera (Paton et al., 2005). However, the 
usefulness of vaccine matching tests has been demonstrated in the field. Maradei et al. (2011) 
were able to show a temporal decrease in r1-value and EPP with the emergence of a new 
serotype A strain consistent with PPG tests alongside an observed increase in FMD epidemics 
in areas using vaccination.  
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There have been several studies based on challenge experiments that show that if high enough 
neutralising titres are induced (for example by using a high potency or antigen payload 
vaccine) this can lead to cross-protection against heterologous strains of the same serotype. 
Nagendrakumar et al. (2011) compared responses to experimental challenge with either O1 
Campos or O1 Manisa virus after administration of different payloads of O1 Manisa vaccine. 
When comparing the neutralising antibody titres to O1 Manisa for challenge with O1 Campos or 
O1 Manisa, the PA50 were 1.8 (95%CI 0.44-7.7) and 0.95 (95%CI 0.19-3.5) respectively 
demonstrating the higher protective titre required for heterologous protection although from 
the confidence intervals this difference does not appear statistically significant.  The cross-
protective effect of high potency vaccines was also demonstrated by Brehm et al. (2008) who 
performed three homologous and eight heterologous PD50 potency tests for a strain of 
serotype A (Table 2.3). Animals were vaccinated with a double oil emulsion vaccine containing 
4-10μg of antigen per dose. All animals in the homologous potency tests were protected 
irrespective of dose. The r1 values for the heterologous strains were all <0.3 (range 0.04 to 
0.23) based on comparative VNT titres. The calculated PD50 values for the heterologous 
challenge varied from 2 to 18, although only in two experiments was it below 6.0. Protection 
was associated with high neutralising titres to the challenge virus. These results indicate that 
protection may occur despite a poor vaccine match if the potency is sufficiently high.  
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Table 2.3. Summary of challenge results for homologous and heterologous viruses compared 
to the vaccine matching r1 value. Adapted from Brehm et al. (2008).  
Vaccine stain Challenge strain Challenge type PD50 r1-value 
A22 Iraq A22 Iraq Homologous 32  
A22 Iraq A Iran 96 Heterologous 6.06 0.09 
A22 Iraq A Egypt 06 Heterologous 10.56 0.12 
A22 Iraq A Iran 99 Heterologous 3.84 0.04 
A Iran 99 A Iran 99 Homologous 32  
A Iran 99 A 22 Iraq Heterologous 13.93 0.10 
A Iran 99 A Iran 96 Heterologous 18.38 0.23 
A Iran 96 A Iran 96 Homologous 32  
A Iran 96 A Iran 99 Heterologous 10.56 0.12 
A Iran 96 A22 Iraq Heterologous 2.0 N/A 
A Iran 96 A22 Iraq Heterologous 8.0 0.10 
Note: PD50 values were determined by OIE/EP recommended methods. r1 values were 
determined through virus neutralisation tests. 
 
The EPP method (described in section 2.2) can also be used to estimate the expected 
protection against heterologous field strains. Tables of correlation between titres and clinical 
protection are formulated from multiple PPG test results using logistic regression models. The 
expected protection can be estimated against a field strain by measuring titres to that strain 
using serum from animals vaccinated with an alternative strain. Sera are taken from 16 or 30 
18-24 month old cattle at 30 days post vaccination and again at 30 days post-revaccination 
with titres measured through VNT or LPBE. The EPP is calculated by comparing the titres to the 
correlation tables and calculating the proportion of animals one would expect to be protected. 
Using sera from the revaccinated animals, an EPP <75% (for a sera panel of 16 animals) or 
<70% (for a panel of 30 animals) indicates low expected protection against the field strain (OIE, 
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2009). Based on the results of four cross-protection trials, Robiolo et al. (2010) found the mean 
EPP to be closely correlated with the mean PPG percentage particularly when assessed 
through VNT (Table 2.4). 
 
Table 2.4. Comparison of PPG tests and EPP estimates from four cross protection trials. 
Adapted from Robiolo et al. (2010).  
Trial PPG                
(%, 95%CI) 
LPBE   VNT  
  Mean titre EPP          
(%, 95%CI)a 
EPP                   
(%, 95%CI)b 
Mean titre EPP                
(%, 95%CI)c 
3 56.3                 
(33.2-76.6) 
2.01 57.9           
(46.7-69.1) 
76.4              
(70.3-82.6) 
1.17 50.6         
(34.9-66.2) 
4 25.0                 
(10.5-50.0) 
1.74 41.9            
(30.8-53.0) 
66.0              
(58.3-73.8) 
0.97 29.1         
(18.5-39.7) 
5 12.5                  
(3.8-36.4) 
2.15 61.9           
(48.0-75.8) 
78.3              
(70.5-86.0) 
0.85 19.8        
(19.8-19.8)d 
6 12.5                   
(3.9-36.6) 
2.09 63.3           
(50.7-75.9) 
78.9             
(70.5-86.0) 
0.85 19.8        
(19.8-19.8)d 
Note: The vaccine strain was A24 Cruzeiro. Challenge strain for PPG and the LPBE/VNT titres 
was A/Arg/01. Titres are the mean of the 16 animals used in the PPG potency trial. Trial 
numbers are identical to that used in the published study.                
a based on SENASA’s curve for A/Arg/01. b based in SENASA’s curve for A24. c based on 
PANAFTOSA’s curve for A24. d Confidence intervals reported in original manuscript. 
 
Brito et al. (2014) evaluated the sensitivity and specificity of the r1 value and other serological 
measures of cross-protection (including VNT, IgG1 and IgG1/IgG2 ratio) through the generation 
of Receiver Operator Characteristic (ROC) curves. The gold standard was clinical protection 
through a PPG test with samples taken 30 days post vaccination. Heterologous serotype A 
strains were used for vaccination (A24/Cruzeiro) and challenge (A/Arg/01). The r1 was 
calculated using VNT, and all the other tests were done for both the vaccine and challenge 
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strains. Sixty-four animals were included in the analysis. All results were significantly different 
between protected and non-protected based on a P-value being <0.05 although the evidence 
was less for the r1 value at P=0.13. Using the recommended 0.3 cut-off, a sensitivity and 
specificity of 0.41 (95%CI 0.22-0.64) and 0.81 (95%CI 0.67-0.90) respectively were found. For 
the other tests, greater specificity was achievable but the confidence intervals for the 
sensitivity all tended to overlap (Table 2.5). Compared to the r1 value, the other tests tended 
to have greater accuracy with the most accurate test being the VNT level to the heterologous 
strain. Interestingly the optimal cut-off for r1 was 0.45 based on the ROC curve analysis which 
had a sensitivity and specificity of 0.12 and 1.00 respectively. The authors suggested that a 
combination of tests be used rather than relying on a single measure of expected cross-
protection. This study is limited in just considering individual animal values, when pooled sera 
are more often used in vaccine matching studies. 
Tekleghiorghis et al. (2014) also used a ROC curve analytical approach, but instead used 10 
different serotype A strains with five cattle vaccinated per strain. Blood samples were taken 21 
days post vaccination and tested for VNT, neutralization index test and LPBE from which r1 
values were calculated. The gold standard for ROC curve analysis was a measure of the 
difference in amino acid sequence in the VP1 region of the genome rather than clinical 
protection. They found r1 values from LPBE tests to be most consistent in determining genetic 
differences. However, since r1 values do not reflect the magnitude of the titres needed for 
protection, it is recommended that vaccines should be selected based on the levels of titre 
induced against the field virus rather than the r1 value alone. 
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Table 2.5. Analysis of sensitivity and specificity obtained by different assays for predicting the 
protective status against a heterologous strain of FMDV. Adapted from Brito et al. (2014).  
Assay Cut-off value Sensitivity (95%CI) Specificity (95%CI) Accuracy 
r1 VNT 0.30 0.41 (0.22, 0.64) 0.81 (0.67, 0.90) 0.70 
r1 VNT 0.45 0.12 (0.02, 0.36) 1.00 (0.91, 1.00) 0.78 
IgG1/IgG2 (A24) 19.92 0.29 (0.10, 0.56) 0.96( 0.85, 0.99) 0.79 
IgG1 (A24) 2000.00 0.47 (0.23, 0.72) 0.94 (0.82, 0.99) 0.69 
VNT (A24) 2.16 0.41 (0.18, 0.67) 1.00 (0.92, 1.00) 0.84 
VNT (A/Arg/01) 1009 0.47 (0.26, 0.69) 1.00 (0.91, 1.00) 0.86 
IgG1 (A/Arg/01) 314.33 0.53 (0.31, 0.74) 0.96 (0.85, 1.00) 0.84 
IgG1/IgG2 (A/Arg/01) 9.28 0.71 (0.47, 0.87) 0.98 (0.88, 1.00) 0.91 
Note: Animals were vaccinated with A24/Cruzerio with blood samples taken 30 days later. The 
heterologous stain under consideration was A/Arg/01. Gold standard is based on clinical 
protection after intradermolingual challenge at 30 days post vaccination. Optimal cut-offs 
established through Receiver operator characteristic (ROC) curve analysis. Accuracy is defined 
by the sum of the true positive and true negatives divided by the total number of samples. 
 
2.4 Field evaluations 
Although field-effectiveness studies are an essential part of ongoing evaluation of human 
vaccines, they are rarely conducted for veterinary vaccines, including FMD. In Israel, an 
outbreak on a feedlot and neighbouring dairy farm that were using non-structural protein 
(NSP) purified vaccines, allowed comparison of morbidity estimates and NSP seropositivity of 
groups with different vaccine histories. The investigators found that, despite a good vaccine 
match (r1=0.37 compared to the recommended >0.3 for neutralising vaccine matching tests) 
and potency (PD50=>6.0): a) cattle were not protected from infection seven months post 
vaccination regardless of the lifetime number of doses received (100% NSP antibody positive, 
18% clinically affected); b) two doses of vaccine with the second dose three months before 
challenge did not provide protection for all animals from infection or clinical disease (96% NSP 
antibody positive, 50% clinically affected) and c) vaccination two weeks prior to the outbreak 
with one dose of vaccine was sufficient to protect all from clinical disease with minimal NSP 
antibody positive animals in these groups (Elnekave et al., 2013). In Turkey, post-outbreak 
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investigations among smallholders revealed poor effectiveness of the Asia-1 Shamir vaccine 
consistent with a poor vaccine match. Higher vaccine effectiveness estimates of 69% and 63% 
were calculated for protection from disease and infection respectively using the alternative 
Sindh-08 vaccine strain (Knight-Jones et al., 2014a). Both of these studies provided information 
which would not have been possible to obtain through experimental studies, and both have 
important implications for vaccine policy.  
As part of a wider study looking at the impact of maternal immunity on response to 
vaccination, Nicholls et al. (1984) conducted a field study on four large farms in Brazil where 
FMD was endemic, comparing the incidence of FMD among calves given two different 
schedules. The traditional vaccine schedule (dosed every four months irrespective of age) was 
used on half the calves on three farms and on all the animals on the remaining farm (n=9,056 
calves). A different schedule was used on all remaining animals (n=7,951 calves), delaying the 
first dose to 5-6 months old with a second dose given one month later. The clinical disease 
incidence was monitored for a 12 month period after implementing the change. Among calves, 
the incidence on the farms using the traditional schedule was 11.0% compared to 0.09% with 
the revised schedule, a difference unlikely due to chance (χ2= 741, P<0.01). Combined with the 
other findings in the paper, they recommended that vaccination should be delayed in calves 
until 5-6 months of age. Although it is encouraging to see field data provided to support a 
modification to the vaccine schedule, there are several limitations to this study including: a) 
“calves” and “adults” not being clearly defined; b) no explanation on the likelihood of exposure 
of all the groups (the authors assume “the possibility of an FMD outbreak was equal in all 
vaccination groups”); c) no comparison groups on the one farm which just received the 
traditional schedule d) numbers of cases and animals were not provided at the individual farm 
level. No vaccine effectiveness estimate was attempted by the authors in this study and given 
these methodological problems it cannot be calculated from the data presented. 
Another study examined the use of vaccination over a ten year period in Uganda, where ring 
vaccination in response to outbreaks is government policy for FMD control (Muleme et al., 
2012). Vaccine was procured from a manufacturer in neighbouring Kenya, and it was 
estimated that an average of 10.3% of cattle were vaccinated per year although this varied 
between regions and was related to the reported number of outbreaks. The reported mean 
time between outbreak notification and commencement of vaccination was 7.5 weeks, ranging 
from 1 to 40 weeks which they claimed to be too long to allow control the outbreak 
particularly with the low coverage. This study suggests that ring vaccination was ineffective in 
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this setting due to the lack of resources, delayed vaccine procurement and other constraints 
such as regional conflicts. The authors also highlight the lack of vaccine matching data. No 
individual animal data or effectiveness estimates were presented in this study. 
A meta-analysis performed by Cai et al. (2014) analysed the results of 28 Chinese language 
papers looking at field-based seroconversion post-vaccination in order to evaluate the 
“efficacy” of routine vaccination in China. Seventy-three studies were included in these papers, 
covering serotypes O and Asia-1, and included pigs, cattle, sheep and goats. Samples were 
tested either with LPBE or indirect haemagglutination assay (IGA). Among cattle, the overall 
median with “protective immunity” was 81% (90%CI 62-96%) based on a predefined protective 
titre. No references or data were provided to indicate the source and accuracy of the 
protection cut-offs used. The analysis does not consider the effect of multiple doses or 
previous exposure limiting its usefulness. Despite the title and objectives of this study, the 
efficacy or effectiveness of vaccination was not covered in this analysis based on conventional 
use of this terminology.  
2.5 Simulation models 
The potential effectiveness of vaccination as an intervention in FMD control, either alone or in 
combination with other measures, has also been explored with the use of mathematical 
models. These are mainly used by FMD-free counties to inform decision makers on control 
measures in the event of a disease incursion as part of a national contingency plan. Typically, 
various aspects of ring-vaccination have been assessed. It is outside the scope of the thesis to 
do a detailed appraisal of all aspects of these simulation models, but a review focussing on 
how models are parameterised in relation to vaccine effectiveness is worthwhile in order to 
highlight the limitations of using models in vaccine evaluation and reveal areas where relevant 
data are lacking. 
Most modelling studies make assumptions that a vaccine becomes protective, either partially 
or completely, at three (Ferguson et al., 2001; Thornley and France, 2009), four (Bates et al., 
2003; Halasa et al., 2014; Porphyre et al., 2013; Tildesley et al., 2006; Traulsen et al., 2011; 
Ward et al., 2009), seven (Hayama et al., 2013; Keeling et al., 2001; Morris et al., 2001), 11 
(Backer et al., 2012), 14 (Dürr et al., 2014), or 21 (Martínez-López et al., 2010) days after a 
single dose of vaccine. Roche et al. (2014) incorporated uncertainty into this onset of immunity 
by having a probability distribution (triangular (4, 5, 6)) although no references were provided 
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to support this assumption. Boklund et al. (2013) incorporated the time to onset of immunity 
in their sensitivity analysis and the infectivity after vaccination was based on expert opinion. 
Within all these studies there are also various assumptions on vaccine efficacy and the effect 
of vaccination on infectiousness often at the farm level. This protection is typically assumed to 
be 80 to 100% after the assumed onset of immunity. Fewer studies consider vaccine efficacy at 
the individual animal level. Porphyre et al. (2013) assumed 90% of cattle were totally 
protected on vaccinated farms leaving the remaining 10% totally susceptible to infection and 
onward transmission. They varied the efficacy from 50 to 98% in a sensitivity analysis. Tildesley 
et al. (2006) similarly varied the vaccine efficacy from 50 to 100%. Some more recent models 
(Boklund et al., 2013; Halasa et al., 2014) based their assumptions on vaccine efficacy on the 
output of meta-analysis by Halasa et al. (2011) which considers protection only in an 
experimental setting as described previously.  
The studies typically referenced for the assumptions (if given) are all based on experimental 
challenge studies. To appreciate the models they are informing, an understanding of those 
studies that are commonly cited is necessary. Doel et al. (1994) challenged groups of 2-3 cattle 
at different times after vaccination (4, 8, 12, 16 and 21 days) with either an aqueous or oil-
based high potency (i.e. >6.0PD50) serotype O or C vaccine. Cattle were challenged by being 
exposed for one hour to an experimentally inoculated pig in the acute stages of infection. Of 
the four animals challenged four days after vaccination (two for oil and two for aqueous), all 
appeared to be protected from clinical disease for both serotypes. The two non-vaccinated 
control animals showed generalised clinical disease. Those cattle that were tested for the 
serotype O strain were the subjects for later experiments with the serotype C stain but with an 
alternative adjuvant. This crossover design was also used for those initially challenged with the 
serotype C strain. Similar experiments were performed by Golde et al., (2005) using a double 
oil emulsion vaccine for serotype O with a PD50 of 3.0. Two trials using groups of either three 
or five cattle were IDL challenged at four and seven days post vaccination and compared to 
two unvaccinated controls. In the group of three, all showed clinical disease at 4 dpv but none 
showed disease at 7 dpv. For the group of five, those challenged at 4 dpv had reduced disease 
severity compared to controls. Again those at 7 dpv appeared to be protected. Cox et al. 
(2005) tested a high potency oil-adjuvanted serotype O vaccine by vaccinating 20 cattle and 
having five unvaccinated controls. Challenge was at 21 dpv by exposure to five inoculated 
cattle for a five day period. A different strain of serotype O was used for challenge. All animals 
were protected except the five unvaccinated controls. They showed that 45% of vaccinated 
cattle that had been exposed were PCR positive 28 days after challenge but live virus could not 
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be isolated so were considered low risk for transmission on this basis. A later similarly 
designed study by the same research group showed apparent protection at ten days post 
challenge for both single and 10x antigen concentration vaccine compared to unvaccinated 
controls although there was no significant difference between the vaccinated groups (Cox et 
al., 2007) . This latter study also introduced five vaccinated “sentinel” cattle to those 
vaccinated cattle that were challenged and demonstrated viral RNA to be present in three 
sentinels indicating possible transmission. However, due to the lack of clinical disease or NSP-
seroconversion the risk they pose for onward transmission should be considered negligible. 
Orsel et al. (2005) did experiments using 24 calves that were divided into six groups of four. 
Three groups were vaccinated with a high potency oil-adjuvanted serotype O vaccine while the 
other three groups were not vaccinated. Two calves from each group were intranasally 
inoculated with a heterologous strain 14 days after vaccination. Disease in the two non-
inoculated calves was monitored and average number of transmissions (“reproduction 
numbers”) were calculated for those vaccinated and non-vaccinated. The reproduction 
numbers were significantly different among the two groups (0.18 [95%CI 0.01-1.2] vs 2.52 
[95%CI 1.13-52.1]) with the values being significantly below and above 1.0 for the respective 
groups based on a one sided statistical test. On this basis the authors conclude that 
vaccination may reduce virus transmission. A similar approach with similar conclusions was 
later published using adult cattle (Orsel et al., 2007).  
Three modelling studies were found that used field data on vaccines to parameterise models 
that then evaluated their effectiveness. Cleland et al. (1994) used data from 60 villages in 
Thailand to parameterise a state-transition model of a village herd. This was combined with 
the results of serological monitoring of cattle and buffalo1 from 21 villages performed over 
four six-monthly vaccination rounds.  Neutralising titres were measured for serotypes A, O and 
Asia-1. Animals were sampled at vaccination and one month later. It was assumed that a 
neutralisation titre of 1/32 (or 1.5 logs to the base 10) was associated with protection. 
Immunity was assumed to only come from vaccination and not natural exposure. “Vaccine 
efficacy” was used inappropriately to describe seroconversion to vaccination rather than 
protection. Animals that had antibody levels <1.2 at first sampling for all three serotypes were 
used in the “efficacy” estimate which assumed protection if increasing in titre to over 1.5 after 
vaccination. Probabilities were calculated for animals being able to maintain their immunity at 
protective levels between rounds of vaccination which was then used to parameterise the 
model. The model concluded that “six-monthly vaccination with an approximate 70% coverage 
                                                          
1
 Species not stated but presumably Water buffalo, Bubalus bubalis 
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would never achieve the minimum acceptable level of herd immunity”. Comparatively 
“Increasing the coverage to 90% resulted in periods of several months where more than 80% 
of animals were immune alternating with periods immediately prior to revaccination where 
the level of herd immunity dropped below an acceptable level”. Although interesting, this does 
not evaluate the vaccine in terms of its effectiveness at preventing infection or clinical disease. 
Woolhouse et al. (1996) used data from two vaccine trials and outbreak data from four Saudi 
Arabian dairy farms to parameterise a mathematical model. Data from two vaccine trials 
(n=30, n=18) with periodic sampling up to 110 days post a single dose of vaccine were used 
and the proportion of animals with antibody titres above an assumed protective threshold (2 
logs to the base 10, measured by LPBE) was modelled over time and parameterised with these 
trial data. This was combined with detailed outbreak data from five outbreaks on four large 
(1,750-2,850 cattle) dairy farms over a five year period that were used to construct a 
Susceptible, Latent, Infectious, Recovered (SLIR) model.  The conclusion of this paper was that 
currently available vaccines cannot prevent outbreaks on large-scale dairy herds due to the 
short duration of protection, antigenic differences between viruses and high FMDV 
transmissibility. A number of assumptions in this model bring these conclusions into doubt 
including:- 
a) The protective threshold used was based upon experimental challenge with IDL virus 
(Hamblin et al., 1987; Periolo et al., 1993). The variation in the protective threshold 
was acknowledged but not incorporated into the model. 
b) Previous vaccinations were assumed to not affect the response to vaccination 
c) Animals below the age of six months were not considered because “outbreaks among 
calves are delayed, typically by 20-25 days, and affect relatively few animals, typically 
2-3%, and so have little or no impact on the initial course of an outbreak”. 
d) Antibody titres after vaccination are independent of the number of previous doses and 
the time since the previous dose “consistent with available information” although the 
citation given was not consistent with this assumption 
e) Entry into the herd balances the loss due to mortality, although the number of doses 
of animals exiting the herd was likely to be much higher than an animal entering a 
herd (animal entering herd has 1-2 doses, 5 year old animals exiting herd would have 
received up to 15 doses if vaccinated every four months). 
A different approach to investigating these outbreaks is required in order to more thoroughly 
establish the reason for vaccine ineffectiveness and suggest modifications to current practices. 
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Brito et al. (2011) used data from an outbreak of serotype A in Argentina to parameterise an 
infectious disease model and evaluate the effectiveness of vaccination.  Records were available 
from 1,349 herds with clinically affected animals (representing 56.4% of those affected in the 
outbreak). The within-herd transmission coefficient (β, defined as the “average number of 
individuals that are newly infected from an infectious individual per unit time) was estimated 
for each herd using the standard mass action assumption:- 
  
   
  
 
Where N is the number of animals in the herd, Ca the number of cases caused by a single 
infected animal per day (defined as the total number of cases on the farm divided by the 
duration of the outbreak in days), I the number of animals infected at the time of the outbreak 
detection and S the number of susceptible animals at the beginning of the outbreak (S=N-I). 
Cases and control herds were defined by having a β over and below the median β value. 
Multivariate logistic regression was used to associate putative risk factors including vaccination 
status and time since vaccination. The results of the model for the different vaccination 
categories are shown in Table 2.6. The authors conclude that “the protective effect of the 
vaccine was evidenced by the association between vaccination and low rate of within-herd 
transmission...suggesting that emergency vaccination has a protective impact on disease 
transmission and that there is a decreased transmission rate within the herd even if the 
vaccine is applied soon before or even [a] few days after initial infection in the herd”. As can be 
seen in Table 2.6, the P-value with herds vaccinated 0-4 days after the estimate date of first 
infection was 0.218, making this aspect of their conclusion questionable.  
The approach used by Brito et al. (2011) is also open to a number of biases:  
a) Although cattle had been previously vaccinated with a strain of virus that had poor 
match with the field strain, the authors assumed it would have no protective effect 
and did not consider previous disease exposure. 
b) Homogenous mixing was assumed on the farm which is unlikely particularly during an 
outbreak when farms often instigate control measures. 
c) “I” is based on the number of animals affected at outbreak detection. This is likely to 
vary between farms as certain types of farm may be expected to detect cases earlier in 
the outbreak. 
d) Lesion ageing was used to establish the estimated date of FMDV introduction into the 
herd. There are well known limitations with lesion ageing particularly when older 
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lesions are found but there is no indication in the study of the lesion ages seen with 
this uncertainty incorporated into the statistical model. 
Overall the modelling component seems unnecessary in this study. A more useful (and simpler) 
approach that would have more effectively evaluated the vaccine, would have been to look at 
the association between the individual incidence and vaccination status that could have been 
adjusted for other farm-level factors such as age distribution.  
 
 Table 2.6.  Logistic regression output comparing the time since vaccination and the odds of 
having a transmission coefficient above the median value for the outbreak based on 1221 
outbreaks (representing 51% of outbreak farms). Modified from Brito et al. (2011).  Model is 
also adjusted for report date and days to detection based on lesion ageing.  
Variable Category n Odds ratio 95% confidence intervals P-value 
Vaccination Non-vaccinated 823 Baseline - - 
 0-4 days aftera 25 0.60  (0.26, 1.36)  0.218 
 1-7 days before 105 0.49  (0.32, 0.75)  0.001 
 8-14 days beforea 56 0.61  (0.35, 1.07)  0.085 
 15-28 days beforea 57 0.79  (0.45, 1.36)  0.391 
 >28 days beforea 156 0.69 (0.47, 1.01) 0.056 
a Days in relation to the estimated day of first infection in the herd 
 
2.6 Conclusion  
Evidence from potency tests show that the PPG provides a more reliable estimate than the 
PD50 test in evaluating the vaccine’s ability to protect experimentally inoculated animals. 
Although these potency tests are well established and extensively studied, they are all based 
on artificially inoculated animals in controlled settings making their relevance to conditions of 
field exposure uncertain. Although often used, serological correlates of protection also have 
their limitations with differences seen between tests, serotypes and laboratories. Like potency 
tests, they are also primarily based on experimental conditions that have questionable 
relevance to the field. Although useful to give an indication of likely protection, vaccine 
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matching also has several limitations and has not been thoroughly validated in the field being 
again mainly based on experimental evidence or anecdote. 
Mathematical models are important to policy makers as they can rapidly, and cheaply, explore 
the potential impact of putative control strategies. This is particularly important for FMD in 
free countries where outbreaks are devastating in naïve populations and so they are 
extensively used and published in the literature. A review of the assumptions used on 
vaccination has revealed that the data used to parameterise them are typically based on 
challenge experiments. Extrapolating the results of these experiments to a broader “real-life” 
population is likely to be highly inaccurate due to the contrast in conditions and heterogeneity 
in individuals present in a typical animal population. Unfortunately those models that do use 
field data make a number of other assumptions that limit their ability to inform policy. The 
dangerous limitations that models have was highlighted in reviews after the devastating UK 
2001 outbreak when “severely flawed” models supported the contiguous cull policy that used 
“highly improbable biological assumptions” with a “culling policy driven by unvalidated 
predictive models” (Kitching et al., 2006; Mansley et al., 2011). James and Rushton (2002) 
highlighted the lack of available published data to inform a ring vaccination policy so that its 
effect cannot be satisfactorily predicted and an economic model cannot be formulated with 
confidence envisaged. These experiences should highlight the need for collection of field data 
to improve the accuracy of these models. However, this has not been the case and even 
models published this year tend to use the same limited experimental studies to inform their 
parameters. Although most countries that published these models are FMD-free and field trials 
are inappropriate, several other countries have used vaccination to control disease incursions 
and lessons can be learnt (or appropriate studies may be financially or logistically supported) in 
endemic countries that use a ring vaccination policy. 
In recent years, field data have begun being published relating to vaccine effectiveness 
although this is still relatively minor compared to the literature on experimental studies. The 
bias towards the latter is likely for a number of reasons including the greater level of control in 
experimental studies that makes their conclusions appear to be more scientifically rigorous 
and do not suffer from such issues as confounding to the same extent. Additionally, such 
experiments are easier to justify on ethical grounds compared to challenge studies in humans 
which are comparatively rare and so observational studies have been more typical. The 
advantages and disadvantages of experimental and field approaches are summarised in Table 
2.7. Challenge models based on serological correlates or through measurement of direct 
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clinical protection are the norms for assessment of veterinary vaccines prior to licensure 
including for FMD. These approaches are limited as they do not account for such issues as 
vaccine coverage, cold chain problems, multiple doses, differing schedules and maternal 
immunity. They also don’t account for field level exposure to a pathogen which may be very 
different to that used in the experimental model. However, for human vaccines field based 
evaluation is an essential part of the licensure process with well validated epidemiological 
methods that should be applied equally to veterinary vaccine evaluation. 
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Table 2.7. Comparison of the issues related to experimental and field based methods for evaluating FMD vaccines. 
Issue Experimental Field 
Population Homogenous ages and breeds Mixed ages and breeds 
Precision Small numbers lead to statistical uncertainty. Larger numbers possible 
Cost Expensive due to facilities needed Relatively cheap. Prospective studies can be expensive. 
Location Only at bio-secure facilities Anywhere with endemic disease using vaccination 
Comparability Controlled conditions facilitate comparisons 
between tests and laboratories 
Each evaluation may be specific to particular setting 
Confounding Homogenous population and randomisation means 
this is less of a problem 
Needs to be adjusted for if observational study. Field trials can use 
randomisation. 
Bias Homogenous sample makes it difficult to apply the 
results to a heterogeneous population 
Selection bias (e.g. farms with vaccine failures may not be representative 
“outbreak bias”) 
Recall bias in retrospective studies 
Loss to follow-up in cohort studies 
Ethics Ethical issues with experimenting on animals Making use of animals infected in field means no experimental inoculations 
needed. Ethical issues if using non-vaccinated controls or placebos. 
Data availability Detailed data collection on individuals possible May be lack of data on affected population (e.g. vaccination histories) 
Length of follow up Usually short Can be long term 
Experience Long and established. Have been used successfully 
in past as part of control programmes 
Limited experience in veterinary field. Lots of experience with human 
vaccines. 
Virus exposure Un-natural exposure route and uncertainty over 
which route is most representative of the field 
Real-life, variable exposure 
In prospective cohort studies, animals may not be exposed to virus 
Strain selection Can control Less control 
Policy relevance Greater for FMD-free settings Greater for FMD endemic settings, or FMD free with vaccination. 
Vaccine selection Can choose specific vaccine May not have ability to choose. May have problems interpreting serology if 
using a non-NSP purified vaccine. 
Vaccine delivery Can control how vaccine is given and timing Limited control over how vaccine is delivered and can’t predict timing 
Resources available More resources due to mainly being used by richer, 
FMD-free countries 
Limited resources in endemic settings to perform studies 
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Chapter 3. Research questions and field work 
3.1 Research aims 
The literature on FMD vaccine evaluation demonstrates the global lack of field-based 
evaluations of these vaccines and the propensity for relying upon experimental methods. The 
heavy reliance on mathematical models based upon questionable assumptions further 
highlights the need for the collection and analysis of field data of vaccine effectiveness. As 
later detailed in the introduction sections of the research papers in Chapter 5 and Chapter 6, 
there is also a dearth of information related to the impact of disease in endemic settings.  
The aim of this thesis is to address these shortfalls through the collection of relevant data from 
a FMD endemic country. As shown in the introduction to the thesis, there is also a lack of data 
on FMD epidemiology among Kenyan dairy farms which limits the capacity to offer advice to 
these farms relating to prevention, containment and reducing the impact of FMD outbreaks. 
3.2 Field work and funding 
Through the European Commission for the Control of Foot-and-Mouth disease (EuFMD) based 
at the Food and Agriculture Organisation (FAO), Kenya was suggested as a suitable location for 
these studies, in particular the area surrounding Nakuru in what was then the Rift Valley 
Province, now known as Nakuru County (Figure 3.1). There were several reasons for this 
recommendation:- 
1. FMD is endemic in Kenya with many outbreaks occurring each year 
2. Kenya produces its own FMD vaccine which is used in its control strategy 
3. Kenya is looking to move forward with disease control for FMD under the “Kenya 2030 
vision” and is supportive of relevant research to meet these aims 
4. The area surrounding Nakuru has a large population of FMD susceptible species 
evidenced by the 2009 national census, including a large number of dairy farms and 
European breeds of cattle appropriate for studies on FMD 
5. Ongoing EuFMD training courses in Nakuru provide opportunities for access to the 
field, to attend ongoing FMD outbreaks on a variety of farm types, and to provide local 
contacts to assist with data collection  
6. There are good transport links in and out of Nakuru for attending outbreaks of disease 
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Figure 3.1. Map showing the location of Nakuru County within Kenya. Nakuru County is circled 
in red (Source: Google Maps, accessed 22/10/2014).  
 
Over the initial 12 months of the PhD, several field trips were made to Kenya, facilitated by 
EuFMD. During this time, field experience of FMD was gained and opportunities to explore the 
feasibility of various research projects were taken. Through contacts made, two outbreaks on 
large-scale dairy farms were attended that provided the data for Part A of this thesis. Both of 
these outbreaks were used by EuFMD as part of their training courses. The first outbreak was 
in August-September 2012 (“Farm 1”) whilst the second was in October-December 2013 
(“Farm 2”). Both farms were willing to share their data for the purposes of this research and 
signed a consent form (Appendix A). The data from Farm 1 were available electronically and 
with an appropriate follow-up time within the time-frame of the thesis to make a disease 
impact assessment possible. 
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A meeting was held with KEVEVAPI in February 2012, which revealed the existence of four 
quality assurance (QA) farms. Vaccines are supplied to these farms for free in exchange for 
KEVEVAPI being allowed to take blood samples at vaccination and 21 days later. Data collected 
over 20 years were available for one farm of which several were available electronically. 
KEVEVAPI agreed to share these data for analysis and this farm was conveniently located to 
allow further data collection on the animals present. This analysis forms Part B of the thesis, 
with specific aims and objectives informed by Part A.  
A Memorandum of Understanding was signed between the FAO and the Department of 
Veterinary Services (DVS) which formed the basis of a research permit application to study 
FMD epidemiology, disease impact and vaccine effectiveness (Appendix B).  
Funding for field work was from a combination of sources including EuFMD, the Royal 
Veterinary College and MSD Animal Health. A Bloomsbury Scholarship provided the stipend 
and tuition fees for a three year period. All field work was led by myself (Nick Lyons). I was 
assisted by veterinary officers at the National FMD Laboratory, Embakasi, in particular Drs 
Abraham Sangula, Eunice Chepkwony, and Kenneth Ketter as well as regional government staff 
(veterinary officers or animal health assistants) initially under the authority of the Provincial 
Director of Veterinary Services for Rift Valley Province, Dr Nathan Songok, and later the County 
Director of Veterinary Services, Dr Cleophas Kogo. Centrally, field work was supported by the 
Deputy Director of Veterinary Services, Dr Thomas Dulu working under the authority of the 
Director of Veterinary Services for Kenya. Data were made available from KEVEVAPI under the 
authority of the Managing Director, Dr Geoffrey Muttai assisted by the QA manager, Mr 
Stephen Njeu. 
3.3 Research objectives 
This thesis addresses the shortage of field evidence supporting vaccine effectiveness for FMD 
and the lack of evidence behind the impact of disease on large-scale dairy farms in Kenya. The 
research is presented in two parts, based on the epidemiological evidence gathered (Part A) 
and the serological evidence as provided by the vaccine manufacturer (Part B). The specific 
objectives are presented in Table 3.1. 
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Table 3.1 Research objectives, research questions, hypotheses and methodological approaches used to address the study aims. The chapters denote where 
in the thesis the different sections are addressed. Continued on next page.  
Research Objective Research question Hypothesis Methodological approach Chapters 
Understand how FMD 
vaccines are currently 
evaluated. 
How are vaccines for FMD currently 
evaluated? What are the limitations of 
these approaches? 
Current methods for the evaluation of FMD vaccines 
are inadequate and a greater emphasis on field 
evaluation is needed. 
Comprehensive literature review 2 
Part A – Epidemiology 
Understand typical 
outbreaks of FMD on 
large-scale dairy farms 
in Kenya. 
How do typical outbreaks on large-
scale dairy farms develop, and what 
are some of the potential routes of 
introduction and intra-farm spread? 
Detailed outbreak investigations increase our 
understanding of FMD in these settings and can 
inform the development of generic and farm-
specific contingency plans for large-scale dairy 
farms in Kenya. 
Outbreak investigation, cohort 
study with univariable analysis and 
spatial representation methods 
(Farms 1 and 2) 
4, 7, 8, 
11 
What are the risk indicators for FMD in 
individual cattle on large-scale dairy 
farms in Kenya? 
What control measures may reduce 
the intra-farm spread and subsequent 
disease impact? 
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Table 3.1. Continued from previous page. 
Research Objective Research question Hypothesis Methodological 
approach 
Chapters 
Part A- Epidemiology 
Evaluate the effectiveness of FMD vaccines on 
large-scale dairy farms using regular 
prophylactic vaccination. 
What is the effectiveness of 
routine vaccination on large-
scale farms? 
Patterns of the incidence by the number of 
doses received indicate vaccine 
effectiveness. 
Cohort study  4, 7, 8 
Quantify the impact of FMD on clinical 
mastitis, culling and milk yield. 
What is the impact of FMD on 
the rate of clinical mastitis? 
Animals with FMD are at a risk of developing 
clinical mastitis. 
Survival analysis (Farm 1) 5 
What is the impact of FMD on 
culling rate? 
Animals with FMD are at risk of culling during 
and for a period of time after the outbreak 
period. 
Survival analysis (Farm 1) 5 
What is the impact of FMD on 
milk yield? 
Animals with FMD produce a significantly 
lower amount of milk compared to non-
diseased individuals. 
Generalised Estimating 
Equations (Farm 1) 
6 
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Table 3.1. Continued from previous page.  
Research Objective Research question Hypothesis Methodological approach Chapters 
Part B – Serology* 
Understand the decay of 
maternally derived antibody and 
the impact this has on the 
response to vaccination.  
What is the published evidence for the half life 
in the decline of maternal antibodies for FMD? 
Published half lives are mainly based on 
experiments and are comparable with 
the literature for antibodies to other 
diseases. 
Comprehensive literature 
review 
9 
What published evidence supports the 
interference of maternally derived antibody 
with response to FMD vaccines and how may 
this be circumvented? 
Limited field evidence exists behind this 
reputed interference. 
What are the half-lives for SP antibodies of the 
four serotypes present in the Kenyan FMD 
vaccine? 
Half-lives for these titres are consistent 
with the evidence in the literature. 
Tobit regression, correlating 
VNTs with age at the first 
dose of vaccine 
10 
How does the titre at first dose affect the 
response to vaccination? 
Higher titres at first vaccination are 
associated with a reduced increase in 
titre as measured 21 days later.  
Linear regression 10 
*The analysis of Part B was informed by the vaccine evaluations performed in Part A of the thesis. 
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Part A – 
Epidemiology  
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Chapter 4. Farm 1 – Outbreak description and vaccine evaluation 
(Research Paper 1) 
In September 2012 whilst on location in Kenya, a notification was received directly from a 
farmer of an outbreak of FMD that had begun a few days before. The farmer was asked to 
record the date and identification number of each animal as they became affected. Although a 
sample had already been taken by an animal health assistant (AHA) representing the local 
government veterinary officer, a further visit was made to the farm shortly afterwards with a 
veterinarian from the National FMD laboratory to confirm the presence of disease and to 
discuss data availability for research purposes.  
Due to other commitments and the possibility of infection spreading to other farms, it was not 
possible to remain on the farm for the full duration of the outbreak period. Therefore farm 
staff assisted with data collection as described in section 4.3.3 of this chapter. The farm was 
visited on several occasions during and after the outbreak for data collection purposes and 
interviewing the farm owner and staff. 
This chapter gives a detailed account of the outbreak and evaluation of the vaccine 
performance. It includes necessary background for the impact analysis presented in Chapter 5 
and Chapter 6. It has been accepted for publication by Acta Tropica in September 2014 (DOI: 
10.1016/j.actatropica.2014.09.010). Supplementary materials are presented at the end of this 
chapter. The formatting of this paper has been adapted so that it is compatible with the rest of 
this thesis. Further details on data management are in Appendix C and photographs of clinical 
cases can be found in Appendix E. 
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4.1 Abstract 
During August-September 2012, an outbreak of Foot-and-mouth Disease (FMD) due to 
serotype Southern African Territories-2 (SAT2) occurred on a large, extensively grazed dairy 
farm in Nakuru County, Kenya. Over 29 days, 400/644 (62.1%) cattle were recorded as 
displaying clinical signs consistent with FMD. Out of the 18 management groups present, 17 
had clinical cases (weighted mean incidence rate 3.5 per 100 cattle-days, 95% CI 2.4, 5.1; range 
0.064 to 10.9). Transmission may have been encouraged when an infected group was moved 
to a designated isolation paddock. A four to five day minimum incubation period was apparent 
in five groups for which a point source exposure was evident. Further transmission was 
associated with the movement of individual animals incubating infection, use of a common dip 
and milking parlour, and grazing of susceptible groups in paddocks neighbouring to infectious 
cases. Animals over 18 months old appeared to be at highest risk of disease possibly due to 
milder clinical signs seen among younger animals resulting in reduced transmission or cases 
not being recorded. Cows with a breeding pedigree containing a greater proportion of zebu 
appeared to be at lower risk of disease. The outbreak occurred despite regular vaccination 
(three times per year) last performed approximately three months before the index case. 
Incidence risk by the lifetime number of doses received indicated limited or no vaccine 
effectiveness against clinical disease. Reasons for poor vaccine effectiveness are discussed with 
antigenic diversity of the SAT2 serotype and poor match between the field and vaccine strain 
as a likely explanation. Detailed field-derived epidemiological data based on individual animals 
are rarely presented in the literature for FMD, particularly in East-Africa and with the SAT2 
serotype. This study provides a detailed account and therefore provides a greater 
understanding of FMD outbreaks in this setting. Additionally, this is the first study to provide 
field-derived evidence of poor vaccine effectiveness using a SAT2 vaccine. Further field-based 
measures of vaccine effectiveness in line with evaluation of human vaccines are needed to 
inform FMD control policy which has previously relied heavily upon experimental data and 
anecdotal experience. 
Keywords: foot-and-mouth disease; vaccine effectiveness; Kenya; outbreak; cattle; dairy; 
epidemiology 
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4.2 Introduction 
Foot-and-mouth disease (FMD) is a highly contagious infectious disease of cloven-hooved 
animals caused by a Picornavirus of the genus Aphthovirus. Seven distinct serotypes with 
limited immunological cross protection exist, all of which are known to be highly transmissible 
and with devastating impacts when introduced into FMD-free countries. Transmission of FMD 
virus (FMDV) occurs mostly by direct contact or aerosol droplets although indirect 
transmission through animal products, fomites and wind is also possible (Alexandersen et al., 
2003). Different viral strains may differ in terms of excretion levels, virulence and 
transmissibility (Alexandersen et al., 2003). 
In recent years, outbreaks have been described in several previously FMD-free countries 
including the UK (Gibbens and Wilesmith, 2002; Gibbens et al., 2001), the Netherlands (Bouma 
et al., 2003), Japan (Muroga et al., 2012) and South Korea (Park et al., 2013). These 
descriptions and subsequent risk factor studies have focussed primarily on farm-to-farm level 
transmission, since control policies have emphasised preventing the virus moving to non-
infected holdings (Ellis-Iversen et al., 2011; Muroga et al., 2013; Wilesmith et al., 2003). In 
endemic countries like those in sub-Saharan Africa, studies of FMD have tended to focus on 
genetic sequencing with phylogenetic tree construction (Sheila N Balinda et al., 2010; Sahle et 
al., 2007; Sangula et al., 2010a; Wekesa et al., 2013), ecological studies on spatiotemporal 
distribution of reported outbreaks (Allepuz et al., 2013; Ayelet et al., 2012), seroprevalence 
(Bayissa et al., 2011; Kibore et al., 2013), and the role of wildlife (Caron et al., 2013).  
In both FMD-free and endemic settings, few field data are available at the individual animal 
level. In “FMD-free” settings, culling is likely to begin immediately, preventing the observation 
of all cases and related data collection. Data are limited from endemic settings due to a 
combination of under-reporting, lack of resources and poor farm records. Hutber and Kitching 
(2000) described the temporospatial spread of FMD due to serotype O between livestock 
groups on a large-scale dairy farm in Saudi Arabia. This analysis indicated that physical barriers 
between pens slowed transmission and that direct contact was the main reason for spread. In 
Thailand, an outbreak of FMD serotype A on two related dairy units also indicated the 
importance of direct animal contact, with virus not spreading to susceptible cattle 20 metres 
away from an infected group (Gleeson et al., 1995).  
Much of our knowledge on virus transmission has been based upon animal experiments 
(Charleston et al., 2011; Mardones et al., 2010; Orsel et al., 2009, 2007).  These experiments 
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cannot fully account for the heterogeneity of conditions in the field. Additionally, due to high 
cost, a small number of animals are often used leading to large degrees of statistical 
uncertainty (Alexandersen et al., 2003). Caution should be taken when extrapolating 
experimental results to mathematical models at a local, national or wider regional level (e.g. 
East Africa). There is therefore a need for data from real outbreaks to be reported to increase 
our understanding of FMDV behaviour in a variety of field settings. 
Data are particularly lacking for the field evaluation of vaccines. The OIE-approved test for 
vaccine potency involves intradermolingual challenge of immunologically naive cattle after 
receiving varying doses of vaccine of the homologous strain (OIE, 2009). Subsequent disease 
monitoring allows the calculation of a dose that protects 50% of recipients (PD50). A PD50 value 
over 3.0 is considered acceptable for use in a routine prophylactic setting though a value over 
6.0 is preferred (OIE, 2009). Low repeatability and low reproducibility of this test have been 
reported and large confidence intervals exist due to small numbers of animals used (Goris et 
al., 2007; Jamal et al., 2008). Various alternative approaches have been advocated, based 
primarily on serological correlates (Barnett et al., 2003; Goris et al., 2008b). In the field, there 
are many determinants of vaccine effectiveness in addition to potency, including vaccine 
coverage, cold chain quality and vaccination schedules. In-vitro vaccine matching tests based 
on the reaction of serum from vaccinated animals to field and homologous vaccine strains 
provides an “r-value” (r1) that indicates antigenic similarity and expected protection but does 
not necessarily correlate with field performance because of the many other factors that can 
limit vaccine effectiveness (Paton et al., 2005). For example a study from Thailand reported 
disease among animals that had been vaccinated 2-3 months before despite a r1 value of 0.61  
(Gleeson et al., 1995), a value that indicates a close relationship between the field and vaccine 
strains and expected cross-protection (Paton et al., 2005).Therefore detailed evaluation of 
FMD vaccines through collection and analysis of field data is essential to understand 
performance and limiting factors. The latter will help inform policy on FMD control using 
vaccination which is particularly important in regions committed to the Progressive Control 
Pathway (PCP) (Sumption, 2012).  
Although field effectiveness studies are an essential part of ongoing evaluation of human 
vaccines, they are rarely conducted for veterinary vaccines, including FMD. In Israel, an 
outbreak on a feedlot and neighbouring dairy farm was analysed. Comparison of morbidity 
estimates and non-structural protein (NSP) seropositivity of groups with different vaccine 
histories revealed that despite a good vaccine match (r1=0.37 compared to the recommended 
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>0.3 for neutralising vaccine matching tests) and potency (PD50=>6.0): a) cattle were poorly 
protected from infection seven months post vaccination regardless of the lifetime number of 
doses received; b) two doses of vaccine with the second dose three months before challenge 
provided poor protection from infection or clinical disease and c) vaccination two weeks prior 
to the outbreak with one dose of vaccine was sufficient to provide some protection from 
clinical disease (Elnekave et al., 2013). In Turkey, post-outbreak investigations among 
smallholders revealed poor effectiveness of the Asia-1 Shamir vaccine consistent with a poor 
vaccine match. Higher vaccine effectiveness estimates of 69% and 63% were calculated for 
protection from disease and infection respectively using the alternative Sindh-08 vaccine strain 
(Knight-Jones et al., 2014a). Both of these studies provided information which would not have 
been possible to obtain through experimental studies, and both have important implications 
for vaccine policy.  
The objectives of this study were to conduct a detailed descriptive analysis of an FMD 
outbreak using individual animal data in an endemic setting and to quantify risk indicators for 
disease including an assessment of vaccine performance. The broader aim is to use field-
derived data to inform FMD control at the national and East Africa regional level in particular 
where vaccination is used and indicate areas for further evaluation. The analysis of this 
outbreak will also provide a background for further studies on FMD impact during the same 
outbreak. 
4.3 Materials and methods 
4.3.1 Farm background  
The outbreak occurred at a 1,600 hectare mixed arable and large-scale commercial cattle dairy 
farm located in Rongai subcounty of Nakuru County. An estimated 25% of the total farm area 
was used for livestock. Several residential properties and other businesses unrelated to the 
dairy herd were present on the farm with around 150 employees coming onto the farm each 
day. Of these, approximately 25 people had direct contact with livestock. Apart from 
segregation from neighbouring farms, the presence of a perimeter fence, and a policy of not 
purchasing replacement stock, there were no specific biosecurity measures in place. Dairy 
farm income was mainly through milk sales and selling in-calf or freshly calved heifers to other 
dairy farms. Milk was also purchased from local small-holders for onward sale to a dairy.  
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4.3.2 Study population 
Numbers of FMD susceptible livestock kept on the farm were approximately 600 cattle, 100 
sheep and 300 goats. Small ruminants were kept in separate grazing areas a few kilometres 
from the cattle, preventing direct contact between them (Figure 4.1). No pigs were owned and 
minimal wildlife was present due to low numbers in the local area and the presence of 
perimeter fencing. 
 
 
Figure 4.1. Overall map of farm and locations of livestock groups on the first day of the FMD 
outbreak on Farm 1 (31st August 2012). The arrow indicates the movement of the group 
containing the index case to the isolation paddock.  
 
Cattle were managed in 18 different groups based on age, weight, production and pregnancy 
status (Table 4.1) and kept in separate paddocks. All groups were kept outside and supervised 
24 hours a day by at least one stockman for purposes of security and to monitor animal health 
and oestrus events. As soon as possible after birth, each calf was placed into an individual 
hutch up to the age of around eight weeks when they were weaned. After receiving four litres 
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of pooled colostrum, calves were fed fermented milk known locally as “maziwa lala”. There 
were five separately grazed lactating cow groups including three that tended to contain cows 
of lower parity. All cattle were uniquely identified with a number visible on an ear tag which 
was placed shortly after birth. The location of animal groups was recorded and movement 
between paddocks was by within-farm roads and cross-paddock movements as appropriate 
(Figure 4.1). 
Calving occurred all year round and all breeding was through artificial insemination utilising 
sexed semen. The breeds were predominantly European pedigree (Holstein-Friesian, Ayrshire 
and Jersey), with a variable genetic contribution from zebu breeds (predominantly Boran). No 
bulls were present on the farm, and any male calves were sold within a few days of birth. Cows 
were milked twice daily through a single mobile milking parlour which had a semi-fixed 
location depending on the paddocks grazed by the lactating cow groups. During milking, the 
lactating animals were fed at common feed troughs. Over the 12 month period prior to the 
outbreak, the average number of lactating cows was 183 resulting in an average daily milk 
yield of 17.0kg. All cattle were dipped once a week through a single permanent dip located 
centrally in the farm. Dip and parlour locations at the start of the outbreak are shown in Figure 
4.1. 
 
 
 
 
 
 
 
 
 
78 
 
Table 4.1. Descriptive data and FMD incidence rate by management group during the FMD outbreak on Farm 1  (31st August-28th September 2012). Age and parity 
at start of outbreak. Table continued on following page.  
Group ID Cattle-
days  
N 
a 
Age b (mean, 
range) 
Parity (mean, 
range) 
Lifetime vaccine doses (mean, median, 
range) c 
Incidence rate  
per 100 cattle-days (95% 
CI) 
Onset 
date 
Youngstock 1 (Y1) 
 
1569 69 
 
17.4 (-28, 121) - 0.01 (0, 0-1) 0.064 (0.0090-0.45) 19/9/12 
Youngstock 2 (Y2) 
 
517 19 93.3 (69, 168) - 0.26 (0, 0-1) 0.19 (0.027-1.4) 13/9/12 
Youngstock 3 (Y3) 
 
242 9 137.4 (110, 204) - 1 (1, -) 0 - 
Youngstock 4 (Y4) 
 
901 38 216.6 (161, 515) - 1.1 (1, 1-3) 1.0 (0.52-1.9) 6/9/12 
Youngstock 5 (Y5) 
 
55 6 530.3 (469-608) - 3.2 (3, 3-4) 10.9 (0.49-24.3) 7/9/12 
Youngstock 6 (Y6) 
 
380 32 328.2 (227-401) - 2.2 (2, 1-3) 4.2 (2.6-6.9) 7/9/12 
Youngstock 7 (Y7) 
 
407 27 309.8 (227-572) - 2.0 (2, 1-3) 2.5 (1.3-4.6) 5/9/12 
Youngstock 8 (Y8) 
 
574 47 463.1 (311-628) - 3.0 (3, 2-4) 5.9 (4.2-8.3) 31/8/12 
Youngstock 9 (Y9) 
 
947 50 598.0 (404-913) - 3.6 (3, 3-6) 2.9 (2.0-4.2) 6/9/12 
Youngstock 10 
(Y10) 
 
1147 67 785.4 (568-1431) - 5.0 (5, 3-9) 4.1 (3.1-5.5) 5/9/12 
a For groups, total number of individual cattle that were in the group at some stage of the outbreak. b Days for youngstock and “All groups”, years for other groups.    
c Full vaccine histories not available for all cattle (Dry cows =27, Close-up dry cows=31, Lactating 4=52, Lactating 5=52) 
79 
 
Table 4.1. Continued from previous page. 
Group ID Cattle-
days  
N a Age b (mean, 
range) 
Parity (mean, 
range) 
Lifetime vaccine doses (mean, median, 
range) c 
Incidence rate  
per 100 cattle-days 
(95% CI) 
Onset 
date 
In-calf heifers (H) 
 
467 55 2.4 (1.6-3.7) - 5.7 (6, 3-9) 9.2 (6.8-12.4) 5/9/12 
Dry cows (D) 
 
421 29 4.4 (1.0-8.1) 1.6 (0-4) 9.1 (9, 2-13) 3.6 (2.1-5.9) 6/9/12 
Close-up dry cows 
(C) 
379 32 3.7 (2.3-9.0) 1.1 (0-5) 7.8( 7, 5-13) 3.7 (2.2-6.2) 5/9/12 
Lactating 1 (L1) 
 
578 38 3.3 (2.6-4.3) 1.1 (0-2) 7.7 (7, 6-10) 5.2 (3.6-7.4) 7/9/12 
Lactating 2 (L2) 
 
592 30 3.2 (2.4-4.5) 1.1 (1-2) 7.5 (7, 6-10) 3.4 (2.2-5.2) 6/9/12 
Lactating 3 (L3) 
 
672 36 3.3 (2.6-5.6) 1.1  (1-3) 7.7 (7.5, 6-11) 4.0 (2.8-5.9) 11/9/12 
Lactating 4 (L4) 
 
917 56 5.0 (3.4-9.4) 2.6 (1-6) 10.1 (10, 8-13) 5.5 (4.1-7.2) 12/9/12 
Lactating 5 (L5) 
 
983 55 4.7 (3.4-9.7) 2.5 (1-6) 9.8 (10, 8-13) 5.0 (3.8-6.6) 6/9/12 
All groups 11748 644 850.5 (-28-3543) 1.7 (1-6) 5.0 (5, 0-13) 3.4 (3.1-3.7) 31/8/12 
a For groups, total number of individual cattle that were in the group at some stage of the outbreak. b Days for youngstock and “All groups”, years for other groups.    
c Full vaccine histories not available for all cattle (Dry cows =27, Close-up dry cows=31, Lactating 4=52, Lactating 5=52) 
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4.3.3  FMD history and outbreak 
The last recorded outbreak on the farm occurred in July 2004 although the sample submitted 
to the Kenyan National FMD Laboratory was negative on antigen detection ELISA. Only five 
animals present during the outbreak described here were on the farm in July 2004, and no 
detailed records were available from the earlier outbreak. 
The recent FMD outbreak began in late August 2012. On 7th September, four epithelium 
samples were taken from four affected animals in the isolation paddock and sent to the 
National FMD Laboratory in Embakasi, Kenya. On 10th September, FMD virus was confirmed by 
antigen detection ELISA as due to serotype SAT2 in all four samples. This was subsequently 
confirmed by the World Reference Laboratory (WRL), Pirbright, UK as SAT2 topotype IV from 
VP1 sequencing (WRL batch number 2013/00019; sample KEN/4/2012). Daily recording of 
FMD cases was made by the livestock manager in consultation with individual group stockmen 
using lists of cattle ear tag identification numbers for each group. FMD cases were defined by 
the presence of hyperptyalism with at least one other clinical sign consistent with FMDV 
infection (decreased milk yield, decreased feed intake, oral lesions, interdigital lesions, 
pyrexia), although not all cases received a physical examination by farm staff due to the large 
numbers affected and limited resources. No clinical cases of FMD were seen among small 
ruminants. This recording system resulted in the number of cattle in the following categories: 
clinical cases, non-clinical cases in affected group, non-affected group. 
Prior to the outbreak, the farm routinely vaccinated cattle against FMDV with an aqueous 
quadrivalent vaccine (O, A, SAT1, SAT2) approximately every four months. All animals present 
on the allotted date were vaccinated irrespective of age. No additional doses were given to 
those after receiving their first dose as part of a primary course. The date of the last 
vaccination was 22nd May 2012. Sheep and goats were not vaccinated.   
4.3.4 Data analysis 
All data pertaining to animal details, health events, breeding, individual animal movements, 
and farm exit were recorded using InterHerd software (InterAgri, School of Agriculture, 
Reading, UK) using the animal’s unique ear tag identification number. Due to the large number 
of cases of FMD, they were not individually entered into InterHerd but instead manually 
recorded on paper before being entered into MS Excel and imported to Stata 12.0 where they 
were merged with appropriate data from InterHerd/Microsoft Access 2007. 
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A map of the farm was created by identifying fields and generating polygons using Google 
Earth 7.1 in consultation with the farm owner and livestock managers prior to being imported 
into ArcGIS 10.2 (ESRI, Redlands, California, USA). Putative exposure dates at the group level 
were made based on group locations, group movements and individual animal movements. 
For descriptive analysis, a cohort study approach was utilised. The case definition was based 
on observations conducted and recorded by farm staff. Due to the complexities of genetic 
backgrounds, breeds were classified according to the proportion of the pedigree ascribed to 
zebu breeds based on breeding history (100% exotic, <25% zebu, 25-49% zebu, ≥50% zebu). 
Days in milk for lactating cows was defined as early (0-100 days), mid (101-250 days) and late 
(>250 days). Those calving during the outbreak were included in the “early” category. A mixed 
effects Poisson regression model was utilised to generate rate ratios, incorporating group ID as 
random effect to account for the correlation within groups. Likelihood ratio tests were used to 
assess model fit including variables as linear or categorical. 
4.4 Results 
4.4.1 Demography 
A total of 644 cattle were present on the farm during the outbreak period (31st August – 28th 
September) totalling 11,748 cattle-days at risk (Table 4.1). Twenty-seven cows calved during 
the outbreak period producing 26 live calves of which one was male; one cow had a stillbirth 
and no twins were recorded. Of all female cattle on the farm, most were nulliparous when the 
outbreak began (380/643, 59.1%) with the majority of non-nulliparous cows being primiparous 
(138/263, 52.5%). Of those cows calving during the outbreak, eight were calving for the first 
time and for those lactating during the outbreak, most were in the early lactation period (0-
100 days in milk; 107/271; 39.5%). Eleven cows were dried-off during the outbreak whilst 42 
were dry for the entire outbreak period. 
Most cows (551/644, 85.6%) were of a European pedigree with the predominant breed being 
Holstein-Friesian (HF): 237/644 (36.8%) were purebred HF and 248/644 (38.5%) had HF make 
up more than half of the animals pedigree. Other European breeds used include Ayrshire, 
Guernsey, Simmental and Jersey. The zebu breeds present were Boran and Sahiwal. 
Four animals exited the herd during the outbreak. The male calf that was born was sold to 
another farm at nine days of age. Two female calves died at five and six days of age during the 
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outbreak with no clinical signs of disease having been recorded. Both were 100% European 
pedigree. One purebred Holstein-Friesian 3.5 year old cow died six days after being recorded 
as a case of FMD. This represents an overall mortality rate of 3/644 (0.47%). No specific 
reasons for any deaths were recorded nor post-mortem examinations conducted. Two further 
deaths occurred in the two week period after the outbreak (one yearling heifer and one 12 day 
old calf) although neither had been recorded as clinically affected with FMD. 
4.4.2 FMD outbreak description 
The outbreak occurred over a 29-day period with the first case recorded on 31st August and 
the last on the 29th September 2012 with an overall attack rate of (400/644) 62.1%. Only one 
management group had no recorded cases (Y3). The index case was an 18-month old Holstein-
Friesian cross Guernsey heifer located in group Y8. After the index case, three successive 
generations of cases can be seen as the outbreak spread around the farm (Figure 4.2). Within 
affected management groups, the weighted mean incidence rate was 3.5 per 100 cattle-days 
(95% CI 2.4, 5.1) varying from 0.064 to 10.9 (Table 4.1). 
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Figure 4.2. Epidemic curve and cumulative incidence of FMD for all management groups 
combined on Farm 1. Arrows indicate the dates of FMD onset within each group. The 
denominator for the cumulative incidence is the mean daily number of cattle present on the 
farm over the outbreak period (31st August-28th September).  
 
The location of the index case was in the centre of the farm (Figure 4.1). The origin of infection 
was unknown, but FMD was present in the local area making introduction by workers who 
keep their own susceptible livestock the most likely pathway of introduction. No small 
ruminants were recently purchased prior to the outbreak and their distance from the cattle 
makes it very unlikely that they were the source of infection. Although milk was purchased by 
the farm, it did not enter animal holding areas with the milk tank being located remotely from 
the mobile parlour. The one bull calf that was born during the outbreak was sold to another 
farm and did not contact any other groups on the study farm.  The affected group was moved 
to the designated isolation paddock the day after the index case was identified together with 
another youngstock group (both termed Y8, Supplementary material 4.1).  The latter had not 
had any recorded cases at the time of the mixing and the reason for their mixing was not 
recorded and therefore likely to have been an error. The dry cow group (“D”) was moved into 
the paddock that the index case was in directly afterwards, presumably due to a lack of 
awareness of the potential transmissibility of infection, and developed its first cases five days 
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later. Cases also appeared in the following days along the road down which the group with the 
index case moved (Groups Y7, Y10, H and C, Figure 4.3). Local spread was apparent around the 
initial location of the index case, whilst simultaneously appearing in the south west corner of 
the farm (groups L2 and L5) which appeared to be then spread in a northerly direction (Figure 
4.3). Both foci continued their spread towards the centre of the farm (Figure 4.3). 
 
 
Figure 4.3. Dates and location of FMD onset and movements of groups subsequent to 
becoming affected on Farm 1. Movement of group Y3 which had no cases is also shown. The 
group with the index case is shown in the isolation paddock after being moved on 1st 
September (see Figure 4.1 & Supplementary material 4.1). The milking parlour was moved 
from location 1 to location 2 on 1st September.  
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Most likely exposure dates and routes were established for each group. In five groups, a point 
exposure is likely (Supplementary material 4.2). In groups Y4, Y7, Y9, C and L2 it is thought to 
be related to the movement of the infected group to the isolation paddock along the road on 
1st September. The time from exposure to the first case was 4 or 5 days consistent with field 
derived incubation periods (Hugh-Jones and Tinline, 1976). For groups L1 and L5 exposure can 
be ascribed to a single freshly calved animal having been moved from the close-up group 
which had cases two days after the move. In both cases the animal that was moved was the 
index case in the new group and was believed to have been incubating virus when moved. The 
time from this animal becoming a case to other cases seen in the group was 4 and 3 days for 
groups L1 and L5 respectively (Supplementary material 4.3). The remaining groups appear to 
have been affected due to spread from neighbouring paddocks or possibly to exposure at the 
milking parlour or dip.  
4.4.3 Farm response to FMD outbreak 
On seeing the first suspected case of FMD on the 31st August 2012 the local government 
district veterinary officer was notified and an appropriate sample subsequently taken. The 
farm management responded the following day by isolating the affected group and moving the 
lactating cow groups and mobile parlour to another part of the farm in an attempt to protect 
the milking herd (Supplementary material 4.1). Individual animals were subsequently added to 
the isolation groups as they became clinically affected in an attempt to limit spread and so 
individual treatment could be efficiently delivered. On day 14 of the outbreak, isolation was 
stopped due to widespread disease and practical difficulties. The farm took no other specific 
biosecurity measures although stockmen were assigned to a single group for the outbreak 
period. 
Affected cattle were treated with an oral application of sodium carbonate powder. This alkali is 
a commonly used treatment in this region that is believed to kill the virus through an increased 
pH in the oral cavity. Where deemed appropriate by the livestock managers, cattle were also 
treated with intramuscular antibiotics and topical antibiotic spray to the inter-digital areas. 
Those with teat lesions may have had teat cannulas used to allow milk let down due to the 
lesions preventing effective milking. No reactive vaccination took place. 
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4.4.4 Patterns by age, parity, lactation and breed 
Examination of incidence risk by age showed a dramatic increase in FMD risk by age category 
appearing to plateau by 12-18 months of age (Table 4.2). No effect was seen when looking at 
parity or lactation stage although of lactating groups, those in mid-lactation (101-250 days) 
had the highest incidence risk (Table 4.2). When considering the effect of zebu genetics on the 
risk of FMD, there was a negative correlation between FMD risk and the percentage of zebu 
breeding pedigree (Table 4.2). 
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Table 4.2. Descriptive analysis evaluating associations between various risk factors and being a 
case of FMD on Farm 1.  
Variable N  FMD cases (row %) Rate ratio (95% CI) P-value a 
Age category (n=644)     
Born during outbreak 26 1 (3.8) 0.061 (0.0078, 0.48) 0.008 
<6 months 78 4 (5.1) 0.040 (0.014, 0.47) <0.0001 
6m-<1y 57 18 (31.6) 0.26 (0.14, 0.48) <0.0001 
1-<1.5y 79 58 (73.4) 1.0 (0.66, 1.6) 0.92 
1.5-<2y 75 49 (65.3) 0.79 (0.54, 1.1) 0.22 
2-<3y 120 93 (77.5) Baselineb - 
3-<4y 111 97 (87.4) 1.1 (0.76, 1.5) 0.76 
4-<5y 55 47 (85.5) 0.82 (0.53, 1.3) 0.36 
5-<6y 22 17 (77.3) 0.73 (0.41, 1.3) 0.29 
6-<7y 9 6 (66.7) 0.61 (0.26, 1.4) 0.26 
7-<8y 6 6 (100) 1.2 (0.50, 2.8) 0.71 
8-<9y 3 2 (66.7) 0.59 (0.14, 2.5) 0.47 
9-<10y 3 2 (66.7) 0.65 (0.16, 2.7) 0.56 
     
Parity (n=643)     
    0 380  184 (48.3) 
0.89 (0.74, 1.1) 0.18 
    1 138  110 (79.7) 
    2 77 67 (87.0) 
    3 29 22 (75.9) 
    ≥4 19 17 (89.5) 
     
Lactation stage (n=271)     
    Early-lactation (<0-100d) 101 83 (82.2) 
1.0 (0.89, 1.1) 0.99 
    Mid-lactation (101-250d) 85 75 (88.2) 
    Late-lactation (>250d) 43 34 (79.1) 
    Dry 42 29 (69.1) 
     
Breed (n=644)     
    100% Exotic breed 551 356 (64.6) 
0.79 (0.66, 0.95) 0.011 
    <25% Zebu 53 24 (45.3) 
    25-49% Zebu 28 12 (42.9) 
    ≥50% Zebu 12 8 (66.7) 
Note: For age and breed, n=644. For other risk indicators n=643 as the male calf born during 
the outbreak was excluded from the analysis. Rate ratios are generated from Poisson 
regression incorporating the group ID as a random effect. Parity, breed and lactation stage 
were included as linear variables based on the result of likelihood ratio tests comparing 
categorical and linear models.                   
a Wald test. b Baseline category assigned to group with highest number of individuals. 
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4.4.5 Patterns by lifetime vaccine doses received 
The risk of FMD appeared to increase with increasing total lifetime doses of vaccine (Figure 
4.4). The point estimates plateau from 5 doses onwards although the confidence intervals 
overlap for all groups with 3 doses or more. This represents a very similar pattern to the 
incidence risk by age due to the routine administration of vaccine every approximately 4 
months to all animals on the farm leading to strong collinearity between these variables.  
 
Figure 4.4. Incidence risk (with 95% confidence intervals) of FMD by the lifetime number of 
FMD vaccine doses given to all animals present on Farm 1 during the outbreak period  (31st 
August-28th September).  
 
4.5 Discussion 
This study provides a detailed analysis of an FMD outbreak due to SAT2 on a large-scale dairy 
farm in an endemic setting. The outbreak appeared to spread through the movement of 
incubating animals, the movement of an infected group along a road, the use of a single 
milking parlour and dip, and through neighbouring paddocks. Key findings include the low 
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incidence rate seen among younger animals and the apparent lack of vaccine effectiveness. 
Animals with a zebu pedigree tended to be at lower risk of disease.  
In an attempt to limit the spread of the outbreak, the farmer moved the group with the index 
case (the “index group”) to an isolation paddock towards the west side of the farm, whilst the 
lactating cow groups were moved to the eastern part. This action likely led to exposure of 
other groups particularly since the distance between animals on the road and neighbouring 
paddocks is short (Supplementary material 4.4). Moving a dry cow group to a pasture in which 
clinically affected animals had been present earlier the same day was also likely to cause 
exposure in this group.  An alternative isolation and group movement strategy may have led to 
a more restricted outbreak and prevented exposure of the lactating groups although it is likely 
that extended biosecurity measures would also have been required. The latter is important 
since the extensive use of shared equipment among lactating groups led to widespread 
exposure and negatively impacted milk production and short-term farm income. All large-scale 
farms should have individual contingency plans developed with their veterinary surgeon for 
actions to be taken when FMDV and other infectious disease incursions occur. Such plans 
should pre-identify isolation paddock locations based on the possible location of the index 
case and also should restrict the movements of workers between groups.  
The incidence risk among youngstock was low in comparison to older animals. This is surprising 
since these animals had not left the farm so had not been exposed elsewhere, and they had 
received fewer doses of vaccine. Immunity is passed to calves solely through colostrum and it 
thought to wane by approximately 4-5 months of age (Nicholls et al., 1984). The last outbreak 
of FMD was in 2004 and only five animals on the farm were still present in 2012; passive 
immunity would not be expected to have a great impact even if the same strain had been 
present in 2004. All youngstock groups except one (Y3) had at least one clinical case. One 
explanation is that this one group was not exposed to virus. Although the group had no 
neighbouring paddocks with clinically affected animals up until day 20 of the outbreak (group 
L3 was located on the other side of a river and wooded area), on day 20 it moved past 
paddocks with clinically affected animals. In addition the weekly dipping increased the 
probability that this group was also exposed to infection. All youngstock groups except Y1 
were in free grazing paddocks and therefore any infection would be expected to spread once 
in a group. In group Y1, the calves were in individual hutches in rows of three. Infection would 
be expected to spread more slowly as there is little direct contact, although given the relatively 
close proximity of the hutches combined with the communal use of feeding equipment and 
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movement of personnel, it seems likely that most calves would still have been exposed to 
significant quantities of virus. Despite this, only one case was seen in this group. 
As all groups were likely to be exposed to infection, the low incidence risk among younger 
animals needs explanation. It is possible that records were poorly kept among the youngstock 
as they are less regularly inspected. However, every group was permanently supervised by 
individuals who liaised with the livestock manager each day and reported any sick animals. The 
farm manager does not believe youngstock were less observed or reported compared to other 
groups during the outbreak.  Alternatively it is possible that the severity of disease was less in 
calves, or there was some innate immune mechanism in place that reduced their susceptibility 
to infection. This hypothesis could not be formally tested as the severity of clinical signs were 
not recorded in this outbreak to support this theory. The lower risk among cows with zebu 
genetics has also been reported elsewhere and is consistent with anecdotal reports (Singh et 
al., 1981). 
It is interesting that an outbreak of FMD was reported in the Netherlands in 2001 which was 
traced to a group of calves that passed through an infected location in France connected to the 
serotype O outbreak in the UK (Bouma et al., 2003). In the farm that had the index case, calves 
were housed together but in individual pens restricting direct contact. Limited transmissibility 
was demonstrated based on NSP seroconversion and no clinical disease observed despite their 
being immunologically naïve. Experiments later performed on 4-9 week calves with the same 
strain supported these findings (Bouma et al., 2004). Additionally severe clinical signs were 
seen in adult cows (Orsel et al., 2010). In the outbreak reported here, a similar clinical pattern 
indicates that clinical signs of FMD may be relatively mild among youngstock in different 
settings and serotypes and therefore less readily detected in passive surveillance. No physical 
examinations of the animals were performed so it is possible mild signs were present but not 
detected. Follow up serological investigations might have provided further information but 
with the regular use of a non NSP-purified vaccine, the results would have been difficult to 
interpret due to the presence of maternal antibodies that may contain anti-NSP antibodies and 
calves receiving their first dose at less than 4 months of age. There is a need to evaluate the 
NSP antibody induction with the Kenyan vaccine so that serosurveys can be interpreted more 
effectively in the evaluation of vaccine effectiveness. 
An absolute estimate of vaccine effectiveness was not possible in this investigation because of 
the lack of appropriate comparison groups. Vaccine effectiveness is defined as 1 minus the 
relative risk of disease comparing vaccinated and unvaccinated groups, measured in the field 
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(rather than in controlled conditions) and assuming equal exposure (Halloran et al., 1997). The 
situation on this farm is complicated by all animals having been vaccinated at the same time 
meaning there is an absolute correlation between the number of doses and age so that age 
cannot be adjusted for when investigating incidence by the number of doses received. Despite 
being unable to produce an estimate, the vaccine appeared to have had limited or no effect in 
reducing the risk of clinical disease in this outbreak evidenced by the high risk in 
multivaccinated animals.  
There are a variety of reasons why the vaccine may not have worked in this outbreak, including 
low potency, inability to maintain the cold chain, poor match between the field and vaccine 
stain, and waning immunity since the last dose. In the field, reasons for poor effectiveness can 
be complex and multifactorial so specific reasons may not necessarily be elucidated. Vaccines 
for SAT2 are known to be difficult to produce and a higher concentration of antigen per dose is 
usually required, possibly because the immunogenic antigen is less stable (Parida, 2009). For 
the vaccines used in this farm, the manufacturer performs vaccine potency tests according to 
the OIE guidelines and only markets vaccines with a PD50 over 6.0 per dose according to OIE 
recommendations for routine prophylactic use (OIE, 2009). In this outbreak, the last 
vaccination was just over three months before the index case. Generally, FMD vaccines are 
expected to provide immunity to the homologous strain for six months after an initial two dose 
regimen (Doel, 2003) although in the author’s (NL) experience most large-scale farms in Kenya 
use the vaccine every four months. No second dose was included in the primary course 
although this is often recommended for FMD vaccines. However, the absence of a second 
boosting dose is unlikely to have been responsible for the high incidence risk in this outbreak 
as animals that had received several doses also had high risk of disease. Problems with the cold 
chain cannot be ruled out in this outbreak, but are considered unlikely as many animals had 
received a large number of doses with no evidence of cumulative protection observed. Also, 
repeated problems with the cold chain on this farm are considered unlikely given the farm’s 
vaccination practices. SAT2 virus is known to have a high sequence variability and therefore 
likely antigenic diversity (Sahle et al., 2007; Vosloo et al., 2009). Two distinct lineages were 
observed to be circulating in Kenya during the same time period (Sangula et al., 2010b). 
Furthermore the VP1 sequencing performed at the WRL found the strain to be topotype IV 
which although the same as the vaccine strain (Hall et al., 2013; Sangula et al., 2010b) had a 
13% difference in the nucleotide sequence (Knowles, N., personal communication, 2014) 
suggesting possible issues with the matching of these strains. Vaccine matching test results for 
the strain isolated from this outbreak are not available but it is clear that with such known 
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diversity, such testing should be regularly performed particularly for SAT2 strains. The 
inclusion of multiple strains in the vaccine may also be necessary for field effectiveness.  
Care must be taken when generalising the results of this single outbreak to other scenarios 
where FMD vaccines are used, as the effectiveness may differ. From a broader perspective, 
endemic countries that use vaccination should develop standard protocols to investigate 
apparent vaccine failures. Part of this includes notification of the vaccine manufacturer, 
though for transparency independent epidemiologists should perform subsequent 
investigations. When outbreaks occur on large-scale farms, farmers should be encouraged to 
record the date and identification of animals affected. This information should be 
supplemented by individual animal data to include a minimum of age, sex, and number of 
doses of vaccine received. Where resources allow, specific clinical signs should be individually 
recorded to indicate disease severity as this may be reduced by vaccination. A standard clinical 
case definition should be utilised such as the one in this study and information on how the cold 
chain is maintained should be collected. Where outbreaks occur in multiple farms such as in 
smallholder dairy areas, clinical data on individual animals are less likely to be available so farm 
level data may be more appropriate. In both scenarios, where comparison groups are 
available, for example if different groups received the latest dose at different times, these 
groups should be compared. Additionally, where a NSP purified vaccine is used, these studies 
may be supplemented by performing a structured post-outbreak serosurvey to identify 
infected animals. Vaccine matching may also be used alongside these analyses although the 
accuracy of vaccine matching may be low (Brito et al., 2014). As demonstrated in this study 
useful data can still be collected without this information.  
In summary, this study is the first to describe an outbreak of FMD due to serotype SAT2 at the 
individual animal level in a field setting. More effective internal control measures might have 
limited the spread of infection and it is recommended that all large-scale farms should develop 
individual contingency plans with their veterinarian.  Evidence is presented that indicates poor 
vaccine effectiveness and suggests further investigations should be conducted to elucidate the 
reasons behind the poor performance. This study demonstrates that field evaluations can 
reveal circumstances in which the vaccine may be underperforming despite being associated 
with a high PD50. National control strategies in FMD endemic countries where vaccination is 
used should have routine field evaluations as part of their control policy and standardised 
practices to investigate apparent vaccine failures including notification of the vaccine 
manufacturer. Such evaluation is even more essential where government subsidised vaccines 
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are used so that cost-effectiveness of the control programme can be ensured. Given that 
outbreaks of FMD due to SAT2 have been reported outside of sub-Saharan Africa in recent 
years, the evidence presented in this study have broad implications for FMD control at an 
international level where SAT2 vaccines may be used and indicate how vaccine evaluations 
may be performed. 
4.6 Conclusion 
Detailed accounts of FMD are rarely presented in the literature from endemic settings and this 
is the first known account for serotype SAT2. The findings have implications for FMD control in 
a national and broader regional context. Problems were found with the field performance of 
the SAT2 vaccine. This has been suspected based on molecular studies and experience from 
potency tests, but has not to date been reported in detail in the field. The lower incidence or 
milder clinical signs among youngstock has implications for surveillance as it may take longer 
for infection to be detected in these groups leading to further onward spread. This 
phenomenon has not previously been reported with a SAT serotype but is similar to that seen 
with a serotype O strain in the Netherlands. Although the reason for poor vaccine 
effectiveness was not determined, and care must be taken with generalising the results from 
only one outbreak, this study does indicate the potential and procedure for analysis of field 
data to reveal problems with FMD vaccination in endemic settings. This approach should be 
applied to similar scenarios worldwide and is useful even where advanced laboratory 
techniques like vaccine matching are not available. It is suggested that such evaluations be 
encouraged in similar and different settings to build up a more complete picture of actual 
vaccine effectiveness. 
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Supplementary material 4.1. Cattle group locations and movements during the outbreak on Farm 1 up to the date that the last group became affected.   a) Day 1 
locations and day 2 group movements b) Day 2 locations and subsequent group movements during outbreak (see arrow legend). The circle represents the area 
enlarged below. In “a” Groups Y9 and Y10 were moved to the more centrally located paddock each evening before returning the following morning. After 1st 
September, this was only done for group Y9.  
a)         b) 
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Supplementary material 4.2. Epidemic curves for management groups with putative point exposures to FMDV on Farm 1. The arrows indicate dates when 
exposure is likely to have occurred due to the group with the index case having been walked along the road neighbouring paddock.  
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Supplementary material 4.3. Epidemic curves for management groups with putative exposure to FMDV through the introduction of an incubating animal on Farm 
1. Arrows indicate the dates of introduction and the date of onset for the index case in that group. In both groups, the introduced animal was also the index case 
in that group.  
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Supplementary material 4.4. Photograph showing the movement of animals along the road on Farm 1 demonstrating the fencing used and proximity to the fields 
containing other livestock groups.  
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Chapter 5. Impact of FMD on mastitis and culling (Research Paper 2) 
The data recorded on Farm 1 provided the opportunity to do an analysis of the impact of FMD 
on clinical mastitis, culling and milk yield using individual animal records. As of August 2013, 12 
months of data were available allowing data extraction, cleaning and analysis to begin. Data 
were routinely backed-up every day by the farm to a Dropbox account to which access was 
permitted. Further details on data management are in Appendix C. 
The first analysis looks at clinical mastitis and culling for which a survival analysis approach was 
utilised. This paper has been submitted to the journal “Veterinary Research”. Supplementary 
materials are included at the end of this chapter.  
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5.1 Abstract 
Foot and mouth disease (FMD) is a highly transmissible viral infection of cloven hooved 
animals associated with severe economic losses when introduced into FMD-free countries. 
Information on the impact of the disease in FMDV-endemic countries is poorly characterised 
yet essential for the prioritisation of scarce resources for disease control programmes. A FMD 
(virus serotype SAT2) outbreak on a large-scale dairy farm in Nakuru County, Kenya provided 
an opportunity to evaluate of the impact of FMD on clinical mastitis and culling rate. A 
historical cohort approach followed animals over a 12-month period after the commencement 
of the outbreak. For culling, all animals were included; for mastitis, those over 18 months of 
age. FMD was recorded in 400/644 cattle over a 29-day period. During the follow-up period 74 
animals were culled or died whilst in the over 18 month old cohort 63 developed clinical 
mastitis. Hazard ratios (HR) were generated using Cox regression accounting for non-
proportional hazards by inclusion of time-varying effects. Univariable analysis showed FMD 
cases were culled sooner but there was no effect on clinical mastitis. After adjusting for 
possible confounders and inclusion of time-varying effects there was weak evidence to support 
the effect of FMD on culling (HR=1.7, 95% confidence intervals [CI] 0.90-3.4, P=0.10). 
Conversely for mastitis, there was stronger evidence of an increased rate in the first month 
after the onset of the outbreak (HR=2.9, 95%CI 0.97-8.9, P=0.057).  
Keywords: foot-and-mouth disease; Kenya; cattle; dairy; epidemiology; economics; mastitis; 
culling 
5.2 Introduction 
Any disease among livestock creates inefficiency in a production system with negative 
economic impact to farmers. This impact can be divided into direct and indirect losses 
(Rushton, 2009). Direct losses are associated with an animal having a disease whose 
consequences may be immediately visible (e.g. death, abortion) or latent (e.g. reduced 
fertility). Indirect losses can be divided into additional costs, such as through the use of 
vaccines for disease prevention, or lost revenue which may occur if a farm is under quarantine, 
restricting access to local markets (Rushton, 2009). For many animal diseases an accurate 
estimation of disease impact is difficult due to a lack of available data and the variability of 
production systems seen around the world.  
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Foot and mouth disease (FMD) is a viral condition of ruminants characterised by initial pyrexia 
followed by the development of vesicles on the tongue, hard palate, coronary band and 
interdigital region. Lesions are also commonly seen on the teats in lactating cows and a sudden 
milk drop is typically seen (Kitching, 2002). Sudden death may also occur in young calves 
secondary to an acute myocarditis (Alexandersen et al., 2003). FMD virus is well known for 
being highly transmissible, made evident by widespread outbreaks seen when introduced to 
disease-free susceptible populations (Gibbens and Wilesmith, 2002; Muroga et al., 2012; Yang 
et al., 1999); the virus is prevalent to varying degrees throughout Africa, South America and 
Asia (Sumption et al., 2008).  
The annual global economic impact of FMD has recently been estimated at US$11 billion (90% 
range US$6.5-21 billion) in endemic settings and an additional minimum of US$1.5 billion has 
been ascribed to virus incursions into FMD-free countries (Knight-Jones and Rushton, 2013). 
The latter impact may be considerably more, given for example that in the UK in 2001, where 
the outbreak has been estimated to have cost $US9 billion (Thompson et al., 2002). Moreover, 
the direct impact due to production loss in endemic areas is likely to be considerably 
underestimated as this is based on data from studies only considering losses through deaths, 
decreases in weight gain, milk production and draught power (Barasa et al., 2008; Ferrari et al., 
2013; Şentürk and Yalçin, 2008; Shankar et al., 2012). A study from Turkey also considered 
fertility and culling related losses, but was based on an economic model utilising evidence 
gained through a survey of expert opinion rather than objective data (Şentürk and Yalçin, 
2008, 2005). A Kenyan field study of a SAT1 outbreak on four commercial dairy farms in 1999 
did consider a broader range of direct and indirect impacts and estimated these losses to total 
around US$468,000 (range 15,000-225,000) (Kimani et al., 2005). This study is limited by only 
considering losses occurring during the outbreak period, analysing herd level losses 
retrospectively though a post-outbreak survey and not considering background levels of 
disease and culling. Ultimately, poor characterisation of these effects and a lack of available 
data preclude a more accurate estimate of economic impact in endemic areas. It is important 
that data from real outbreaks in the field are collected to gain a more accurate depiction of 
FMD impact and so inform resource allocation by governments and individual farmers. This is 
particularly necessary in endemic settings where many infectious diseases are present and 
competing for resources to implement control. 
In developed countries, mastitis is frequently referred to as the most economically important 
disease in dairy herds (Seegers et al., 2003) and is also reported as a major cause of morbidity 
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among smallholders in Eastern and Southern Africa (Phiri et al., 2010). Farm profitability is 
reduced through decreased milk production, increase in milk discard, treatment costs, and 
associated culling. In animals affected with FMD, viral infection and replication within the 
udder may occur and teat lesions are likely to increase the risk of bacterial infection leading to 
clinical and subclinical mastitis (Wellenberg et al., 2002). Mastitis is one of many factors 
important in determining herd culling or replacement rate which have major implications for 
herd profitability (Gröhn et al., 2003; Lehenbauer and Oltjen, 1998). 
Kenya has the largest population of dairy cattle in East Africa (Thorpe et al., 2000) and is 
endemic for four serotypes of FMD virus (A, O, SAT1, SAT2) (Namatovu et al., 2013b). Although 
smallholder dairies are estimated to supply over 70% of the marketable milk in Kenya (Muriuki, 
2011), large-scale farms are still an important part of the Kenyan dairy industry tending to be 
more resistant to seasonal changes in milk production due to adoption of fodder storage 
technologies (Karanja, 2003). Despite the clear impacts of mastitis and culling on dairy herd 
profitability, these parameters are poorly characterised among farms affected with FMD in 
endemic settings, and this may lead to underestimation of disease impact. 
In August and September 2012, an outbreak of FMD occurred on a large-scale dairy farm in 
Nakuru County, Kenya (Lyons et al., 2015). The aim of this study was to use the data from this 
outbreak to estimate the impact of being a case of FMD on risk of developing clinical mastitis 
and of subsequent culling, utilising survival analysis methods to provide objective evidence for 
these parameters in an endemic setting.  
5.3 Materials and Methods 
5.3.1 Study area and population 
The study area and population have been described in detail elsewhere (Lyons et al., 2015). In 
brief, the data were from a 1600 hectare mixed arable and large-scale commercial cattle dairy 
farm. Normal numbers of FMD susceptible livestock on the farm are approximately 600 cattle, 
100 sheep and 300 goats. The farm had no pigs, and perimeter fencing ensured minimal 
wildlife. Small ruminants were kept in separate paddocks a few kilometres from the cattle 
preventing direct contact between them. Cattle were all extensively grazed in 18 different 
groups based on age, weight, production and pregnancy status. As soon as possible after birth, 
the calf is placed into an individual hutch up to the age of around eight weeks. There are five 
separately grazed lactating cow groups including three that tend to contain cows of lower 
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parity. All groups are supervised 24 hours a day by at least one stockman for purposes of 
security and to monitor animal health and oestrus events. All cattle are uniquely identified 
with a number visible on an ear tag which is placed shortly after birth. 
Dairy farm income is mainly through milk sales and selling in-calf or freshly calved heifers to 
other dairy farms. Cattle give birth all year around and all breeding is through artificial 
insemination utilising sexed semen. No bulls are present on the farm, and any male calves are 
sold within a few days of birth. All data pertaining to health events, breeding, and farm exit are 
recorded using InterHerd software (InterAgri, School of Agriculture, Reading, UK).  
5.3.2 FMD outbreak 
The outbreak of FMD on this farm has been described in detail elsewhere (Lyons et al., 2015). 
In brief, serotype SAT2 was detected by antigen ELISA by the National FMD Laboratory in 
Embakasi, Kenya. This was subsequently confirmed by the World Reference Laboratory, 
Pirbright, UK. The index case was reported on the 31st August 2012. FMD cases were defined 
by demonstrating hyperptyalism with at least one other clinical sign consistent with FMDV 
infection (decreased milk yield, decreased feed intake, oral lesions, interdigital lesions, 
pyrexia), although not all recorded cases received a physical examination by farm staff due to 
the large numbers affected. Daily recording of FMD cases was made by the livestock manager 
in consultation with individual group stockmen using lists of cattle ear tag identification 
numbers for each group. No clinical cases of FMD were seen among small ruminants.  
The last recorded case in the study outbreak had onset on the 28th September 2012. The last 
previous outbreak on the farm occurred in July 2004 although the sample submitted on that 
occasion to the Kenyan National FMD Laboratory failed to detect any viral antigen. Only five 
animals present during the current outbreak were on the farm in July 2004 but no detailed 
records were available from the earlier outbreak. 
All cattle on the farm were vaccinated with the locally available quadrivalent vaccine (O, A, 
SAT1, SAT2) approximately every four months. The date of the last vaccination was 22nd May 
2012. Sheep and goats were not vaccinated.  Previous analysis found very limited or no vaccine 
effectiveness in preventing clinical disease (Lyons et al., 2015).  
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5.3.3 Study design 
In this historical cohort study of disease impact, the primary risk factor under consideration 
was being a clinical case of FMD. The primary outcomes were whether a cow developed 
clinical mastitis (defined by having a swollen quarter or the presence of visible changes in the 
milk) or were culled (defined by leaving the herd due to any disease or death). The study 
population was all cattle present on the farm at some point during the outbreak period (31st 
August – 28th September 2012). The date of the index case (31st August 2012) was the date of 
entry into the study unless animals were born during the outbreak in which case the date of 
birth was used. All animals were followed until exit from the herd or the end of the study 
period (22nd August 2013). Reasons for herd exit are routinely recorded by the farm including 
the primary disease responsible for culling. If an animal was sold for breeding or meat with no 
associated health reason for exit, it was censored at the date of herd exit. For the clinical 
mastitis analysis, the study population was restricted to animals over the age of 18 months at 
the start of the outbreak, considered the age when clinical mastitis becomes a possibility, and 
animals exited the cohort at their first clinical episode of clinical mastitis and did not re-enter 
the cohort. 
Potential confounders for the association between being a case of FMD and culling or 
developing clinical mastitis included age, parity, stage of lactation, breed, and suffering 
another disease in the 12 months prior to the beginning of the outbreak. Several breeds and 
cross-breeds are present on the farm. Breed classification was based on the proportion of 
pedigree from indigenous breeds compared to non-indigenous exotic varieties. Binary 
variables were created for whether an animal was recorded as being affected with a previous 
disease in the last 12 months. Although the farm vaccinates against FMD, previous analysis 
demonstrated limited or no effectiveness against clinical disease and the schedule used means 
this is highly co-linear with age so vaccination was not considered as a separate variable in the 
analysis. Age was categorised according to quintiles, and the number of days in milk was 
classified at the start of the outbreak as pre-lactation, early-lactation (<0-100 days), mid-
lactation (101-250 days), late-lactation (251+ days) and dry. Cows calving during the outbreak 
were included in the early lactation category (<0-100days). 
5.3.4 Statistical analysis 
Hazard ratios were generated through Cox proportional hazard regression models to estimate 
the effect of being a case of FMD on the primary outcomes. Assessment of confounders was 
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made through their association with the risk factor (being a case of FMD) and outcome (culling 
or developing clinical mastitis), changes in the hazard ratio when added to the multivariable 
Cox regression model as well as not being present on any putative causal pathway. 
Associations between variables and being a case of FMD were assessed through chi-square 
tests whilst association with subsequent culling and developing clinical mastitis was through 
calculation of rate ratios and likelihood ratio tests. Associations with P-values of <0.1 were 
retained for multivariable model building using a backward fitting approach. Age was included 
in all models as an a priori confounder. Prior to model building, likelihood ratio tests were used 
to assess for linear trends of risk factor variables where appropriate. The proportional hazards 
assumption was assessed through examination of a combination of Nelson-Aelen plots and 
global Schoenfeld residual tests. Where evidence for non-proportional hazards was observed, 
Schoenfeld residuals for each indicator variable were generated alongside scaled Schoenfeld 
residuals plots to explore the non-proportionality. Based on these observations, variables were 
incorporated as time-varying effects with a choice of multiplier function based on the 
observed plots and Akaike information criterion (AIC) values. Repeated examination of 
Schoenfeld residuals and scaled residual plots were conducted to ensure the time varying 
effect was accounted for in the model incorporating the time-varying effect. Interaction 
between terms in the final model were tested through likelihood ratio tests. 
All data were extracted from Interherd through Microsoft Access and imported into Stata 13.0 
(Statacorp, Texas, USA) for analysis. 
5.4 Results 
A total of 644 cattle were present at some point during the outbreak including 26 born during 
this period of which one was male. Four hundred and nine animals were at least 18 months of 
age at the start of the outbreak period and hence included in the mastitis analysis. Of all cattle 
present during the outbreak, 400 (62.1%) were recorded as clinical cases of FMD. Total follow-
up time for mastitis was 3683.0 cattle-months (mean 9.0, range 0.36-11.7 per animal) whereas 
for culling it was 6669.6 (mean 10.4, range 0.16-11.7). During the follow-up period, 63 cattle 
developed clinical mastitis (incidence rate 17.1 per 1000 cattle-months, 95%CI 13.4-21.9). The 
total number of animals exiting the herd during the follow up period was 166, of which 74 left 
the herd due to disease or death. The most common reason for culling was infertility (Table 
5.1). The overall incidence rate for culling was 11.1 per 1000 cattle months (95%CI 8.8-13.9). 
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Examination of Kaplan-Meier plots showed differences between FMD cases and non-cases for 
both outcomes with strong statistical evidence for a difference provided by the log rank tests 
for culling alone (Figure 5.1). For clinical mastitis, it can be seen among FMD cases that there is 
a large increase in hazard in the 1-2 months after the outbreak before appearing equivalent to 
the non-cases. The HR ultimately becomes higher among non-cases seven months after the 
outbreak started although with the confidence intervals overlapping this is unlikely to be a 
significant difference (Figure 5.1). For culling, the hazards grow progressively apart with 
animals appearing to exit in groups at 3, 5 and 9 months after the beginning of the follow-up 
period (Figure 5.2). After nine months the confidence intervals do not overlap. 
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Table 5.1. Reasons for exit and culling after a foot-and-mouth disease outbreak on Farm 1. 
Exit category n Column %  
Exit herd  166 25.8    
Not exit herd 478 74.2    
Total 644     
Reasons for exiting herd (n=166)      
Culling  52 31.3 Reasons for culling n Column % 
   Infertility 31 59.6 
   Mastitis 5 9.6 
   Lameness 5 9.6 
   Tick-borne disease 2 3.9 
   Mastitis and fertility 2 3.9 
   Poor condition 4 7.7 
   Other illness 3 5.8 
Death 22 13.3    
Low production 2 1.2    
Old age 2 1.2    
Behavioural 1 0.6    
Sold for meat 5 3.0    
Sold as breeding stock 82 49.4    
Total 166     
Note: Dairy farm is located in Nakuru County, Kenya. Follow-up period is 12 months following 
the beginning of the foot-and-mouth disease outbreak. Animals are included if present on the 
farm at some point during the outbreak period (31st August-28th September). Culling is 
defined as exiting the herd due to any disease or death. 
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Figure 5.1. Unadjusted Kaplan-Meier survival curve for FMD cases and non-cases related to 
developing clinical mastitis on Farm 1. Dairy farm was located in Nakuru County, Kenya. 
Animals were included in the analysis if present on the farm during the outbreak period (31st 
August-28th September 2012) and were followed for 12 months after the commencement of 
the outbreak. Cattle are included if over the age of 18 months at the start of outbreak, 
considered as the age when the outcome becomes a possibility. Log-rank test for equality of 
survivor function, P=0.43.  
 
Figure 5.2. Unadjusted Kaplan-Meier survival curves for FMD cases and non-cases related to 
culling on Farm 1. Animals were included in the analysis if present on the farm during the 
outbreak period (31st August-28th September 2012) and were followed for 12 months after the 
commencement of the outbreak. Culling is defined as exiting the herd due to any disease or 
death. Log-rank test for equality of survivor function, P=0.0028.  
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Previous analysis of the entire study population (n=644) indicated that older animals and those 
with a more exotic breed pedigree were at higher risk of clinical disease (Lyons et al., 2015). 
Cattle that had any disease event in the 12 months preceding the outbreak were also at 
increased risk of clinical FMD with individual associated conditions including abortion, eye 
disease, lameness, clinical mastitis, and tick borne-disease (Supplementary material 5.1). 
Conversely having diarrhoea appeared to be protective.  
Older cows in later stages of lactation had an increased rate of clinical mastitis, which was also 
the case for cows with increasing indigenous breed pedigrees (Table 5.2).  Previous lameness 
was also associated with increased mastitis incidence rate (Supplementary material 5.2). 
Similarly older cows in later stages of lactation had an increased rate of culling, which was also 
associated with dystocia, clinical mastitis and tick-borne disease in the previous 12 months 
(Table 5.3, Supplementary material 5.1). Having had any disease in the previous 12 months 
was similarly associated with likelihood of being culled. 
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Table 5.2. Clinical mastitis - characteristics of the study population (n=409) and univariable analysis for Farm 1. Continued on following page.  
Variable   FMD  Clinical mastitis   
 N  (col %) N (row %) P-value Rate per 1000 cattle-months (95% CI) HR (95% CI) P-value 
FMD        
    Yes 323 79.0 - - 18.0 (13.7, 23.7) 1.3 (0.68, 2.5) 0.43 
    No 86 21.0 -  13.8 (7.6, 24.9)   
Age (quintiles)        
    1.5-<2.0y 81 19.8 54 (66.7)  3.4 (1.1, 10.6)   
    2.0-<2.8y 82 20.1  61 (74.4)  7.5 (3.3, 16.6)   
    2.8-<3.5y 82 20.1 71 (86.6) 0.0073a 17.8 (10.3, 30.7) 1.8b (1.5, 2.2) <0.0001 
    3.5-<4.3y 83 20.3 73 (88.0)  18.1 (10.5, 31.2)   
    4.3-9.7y 81 19.3 64 (79.0)  50.8 (35.1, 73.6)   
Parity        
    0 146 35.7 107 (73.3)  1.9 (0.6, 6.0)   
    1 138 33.7 110 (79.7)  22.4 (15.3, 32.9)   
    2 77 18.8 67 (87.0) 0.042a 33.2 (21.6, 50.9) 1.7 b (1.4, 2.1) <0.0001 
    3 29 7.1 22 (75.9)  29.1 (13.1, 64.9)   
    ≥4 19 4.7 17 (89.5)  55.6 (26.5, 126.0)   
Days in milk c        
    Pre-lactating 138 33.7 102 (73.9)  1.4 (0.34, 5.4)   
    Early-lactation (<0-100d) 107 26.2 88 (82.2)  18.5 (11.5, 29.7)   
    Mid-lactation (101-250d) 85 20.8 75 (88.2) 0.027 27.7 (17.7, 43.5) 1.7 b (1.4, 2.0) <0.0001 
    Late-lactation (>250d) 44 10.8 35 (79.6)  45.2 (26.8, 76.3)   
    Dry 35 8.6 23 (65.7)  37.8 (20.9, 68.2)   
Note: Univariable analysis examines the associations with the primary risk factor (being a case of clinical FMD) and primary outcome (clinical mastitis) for 
cattle present during an outbreak of foot-and-mouth disease (FMD) on a dairy farm in Nakuru County, Kenya. Cattle are included in the analysis if over the 
age of 18 months at the start of outbreak, considered as the age when clinical mastitis becomes a possibility. HR = Hazard ratio.             
a Chi-square test for trend. b Included as linear variables based on likelihood ratio tests c Defined at the beginning of the outbreak period. 
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Table 5.2. Continued from previous page. 
Variable   FMD  Clinical mastitis   
 N  (col %) N (row %) P-value Rate per 1000 cattle-months (95% CI) HR (95% CI) P-value 
    100% Exotic breed 351 85.8 285 (81.2)  15.7 (11.9, 20.7)   
    <25% Indigenous 27 6.6 20 (74.1) 0.0046a 23.5 (10.6, 52.3) 1.3 b (1.0, 1.8) 0.053 
    25% Indigenous 19 4.7 10 (52.6)  12.8 (3.2, 51.1)   
    50% indigenous 12 2.9 8 (66.7)  54.8 (22.8, 131.6)   
Note: Univariable analysis examines the associations with the primary risk factor (being a case of clinical FMD) and primary outcome (clinical mastitis) for 
cattle present during an outbreak of foot-and-mouth disease (FMD) on a dairy farm in Nakuru County, Kenya. Cattle are included in the analysis if over the 
age of 18 months at the start of outbreak, considered as the age when clinical mastitis becomes a possibility. HR = Hazard ratio.          
a Chi-square test for trend. b Included as linear variables based on likelihood ratio tests c Defined at the beginning of the outbreak period. 
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Table 5.3. Culling - characteristics of the study population (n=644) and univariable analysis for 
Farm 1.  
Variable   Culling   
 N  (col %) Rate per 1000 cattle-
months (95% CI) 
HR (95% CI) P-value 
FMD      
    Yes 400 62.1 14.2 (11.0, 18.4) 2.3 (1.3, 3.9) 0.002 
    No 244 37.9 6.2 (3.8, 10.1)   
      
Age (quintiles) a      
    -28- <227d 128 19.9 5.0 (2.4, 10.5)   
    227-<577d 129 20.0 2.0 (0.66, 6.3)   
    577-<974d 129 20.0 11.1 (6.7, 18.4) 1.6b (1.4, 2.0) <0.0001 
    974-<1363d 129 20.0 17.1 (11.2, 25.9)   
    1364-3543d 129 20.0 23.2 (15.9, 33.8)   
      
Parity      
    0 381  59.2 4.8 (3.7, 7.4)   
    1 138  21.4 25.6 (18.1, 36.0)   
    2 77 12.0 11 (6.1, 22.4) 1.5a (1.3, 1.8) <0.0001 
    3 29 4.5 36.8 (19.2, 70.7)   
    ≥4 19 3.0 18.2 (5.9, 26.6)   
      
Days in milk      
    Pre-lactating 373 57.9 4.9 (3.1, 7.6)   
    Early-lactation (<0-100d) 107 16.6 15.2 (9.3, 24.9)   
    Mid-lactation (101-250d) 85 13.2 18.8 (11.3, 31.2) 1.6a (1.4, 1.9) <0.0001 
    Late-lactation (>250d) 44 6.8 25.4 (13.7, 47.2)   
    Dry 35 5.4 39.9 (23.1, 68.6)   
      
Breed      
    100% Exotic breed 551 85.6 5.7 (9.0, 14.6)   
    <25% Indigenous 53 8.2 10.9 (4.9, 24.4) 0.8a (0.5, 1.3) 0.30 
    25% Indigenous 28 4.4 3.7 (0.5, 26.0)   
    50% indigenous 12 1.9 8.8 (1.2, 62.7)   
Note: Univariable analysis examines putative associations with the primary outcome (culling) 
for cattle present during an outbreak of foot-and-mouth disease (FMD) on a dairy farm in 
Nakuru County, Kenya. Culling is defined as exiting the herd due to any disease or death. HR = 
Hazard ratio. a Negative values reflect animals born during the outbreak period b Included as 
linear variables based on likelihood ratio tests  
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Global Schoenfeld residual tests performed prior to backward model fitting revealed strong 
evidence of a departure from the proportional hazards assumption in both mastitis and culling 
models (Supplementary material 5.3). In the mastitis model, tests for individual variables and 
an examination of the scaled Schoenfeld residual plot showed the FMD variable to be mostly 
responsible for this deviation particularly in the 2 month period after the onset of the 
outbreak. This lack of proportionality is consistent with the Kaplan-Meier (Figure 5.1) and 
Nelson-Aalen plots. AIC tests indicated a logarithmic multiplier function to provide the best 
model fit when the FMD variable was included as a time-varying effect which led to a more 
stable scaled Schoenfeld residual plot and decreased the global test statistic. In the culling 
model, there was strong evidence that the lactation stage showed significant departure from 
the proportional hazards assumption which was similarly rectified by the inclusion of a 
logarithmic multiplier function with time based on AIC tests (Supplementary material 5.3). 
The final multivariate model for mastitis incorporating the time-varying effect of FMD was also 
adjusted for age, lactation stage, and breed (Table 5.4). There was evidence that the hazard 
ratio was significantly greater than 1.0, one month after the beginning of the outbreak with 
the effect disappearing in the subsequent follow up period as confidence intervals continually 
overlap with 1.0 (Figure 5.3). For culling, the estimate was adjusted for age, parity, and the 
presence of tick-borne disease in the previous 12 months with lactation stage as the time 
varying effect (Table 5.4). Although there was a trend for cattle affected by FMD to be culled 
sooner during the 12 month follow-up period, the statistical evidence was weak (HR=1.7, 95% 
CI 0.86-3.2, P=0.13). 
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Table 5.4. Final multivariate Cox-regression model examining the association of FMD with 
clinical mastitis and culling on Farm 1.  
Variable Clinical mastitis Culling 
 HR (95%CI) P-value  HR (95% CI) P-value 
FMD 
    Case  2.9 (0.97, 8.9) 0.057  1.7 (0.90, 3.4) 0.10 
    Non-case 
 
 Baseline -  Reference - 
Age 
a
                   Age category                                                      Age category    
 1.5-<2.0y Baseline - -28- <227d Baseline - 
 2.0-<2.8y 0.61 (0.12, 3.0) 0.54 227-<577d 0.29 (0.07, 1.2) 0.083 
 2.8-<3.5y 0.77 (0.16, 3.7) 0.75 577-<974d 0.87 (0.29, 2.6) 0.80 
 3.5-<4.3y 0.64 (0.12, 3.3) 0.60 974-<1363d 0.86 (0.24, 3.1) 0.82 
 4.3-9.7y 2.6 (0.45, 15.1) 0.29 1364-3543d 
 
1.7 (0.38, 7.4) 0.50 
       
Lactation stage 
0.46 (0.25, 0.85) 0.013 
    Non-lactating - -  
    Early lactation (<0-100d) - -  
    Mid lactation (101-250d) - -  
    Late lactation (>250d) - -  
    Dry - -  
      
Breed
b
 1.4 0.031  - - 
      
Tick borne disease (last 12 months) 
    Yes - -  3.2 (1.7, 5.9) <0.0001 
    No 
 
- -  Baseline  
      
Parity 
    0 Baseline -  Baseline  
    1 11.3 (2.5, 51.2) 0.002  2.4 (0.79, 7.4) 0.12 
    2 9.8 (1.7, 55.9) 0.010  0.58 (0.14, 2.4)  0.45 
    3 4.6 (0.65, 32.6) 0.13  2.1 (0.53, 8.6) 0.29 
    ≥4 
 
8.1 (1.2, 55.8) 0.033  0.78 (0.14, 4.4) 0.78 
Time varying interactions 
 
FMD 
 
0.43 0.016  - - 
Lactation stage 
 
- -  1.9 (1.4, 2.6) <0.0001 
Note: Animals were included in the analysis if present on the farm during the outbreak period 
(31st August-28th September 2012) and were followed for 12 months after the commencement 
of the outbreak. For the analysis of clinical mastitis, cattle are included if over the age of 18 
months at the start of outbreak, considered as the age when the outcome becomes a 
possibility. Culling is defined as exiting the herd due to any disease or death. Hazard ratios (HR) 
incorporate time varying effects with logarithmic multiplier functions to account for non-
proportional hazards. a Age categories based on quintiles. b Included as a linear effect. 
Categories are 100% exotic breed, <25% indigenous, 25% indigenous, 50% indigenous. 
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Figure 5.3. Variation in hazard ratio over time for cases of FMD developing clinical mastitis on 
Farm 1. Animals were included in the analysis if present on the farm during the outbreak 
period (31st August-28th September 2012) and were followed for 12 months after the 
commencement of the outbreak. Cattle are included if over the age of 18 months at the start 
of outbreak, considered as the age when the outcome becomes a possibility.  
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5.5 Discussion 
During this outbreak on a large-scale dairy farm in Kenya, 400/644 (62.1%) of cattle were 
affected with FMD found due to serotype SAT2. The outbreak lasted for 29 days with the index 
case identified on 31st August 2012 and the last case on the 28th September 2012. In the 12-
month follow up period commencing on the day of the index case, 74 were culled or died. For 
cattle aged 18 months or greater at the start of the outbreak, 63 developed clinical mastitis. 
Although in the univariable analysis FMD cases tended to be culled sooner after the outbreak 
onset, after adjusting for possible confounders there was weak evidence to support this 
observation. For clinical mastitis, univariable analysis showed no effect of FMD on rate of 
mastitis but after adjusting for the time varying effect of being a case there was good evidence 
of an increased rate in the first month after the onset of the outbreak. 
For correct interpretation of the Kaplan-Meier curves for clinical mastitis and culling, one must 
consider the expected timing of disease impact and farm management. The association 
between FMD and clinical mastitis is mainly related to the FMD lesions that develop on the 
teats increasing the susceptibility to secondary bacterial infection. Since this is likely to occur 
soon after the appearance of lesions, seeing non-proportional hazards in the early stages of 
the follow-up period is expected. The reason behind the increased mastitis rate in non-FMD 
cases that occurs several months after the outbreak is unknown but this difference was not 
statistically significant. Conversely the rate of cows exiting the herd due to culling appears to 
increase throughout the follow-up period. This is because FMD typically has a low mortality 
rate and farm exit will generally occur once a cow has ceased producing milk and after an 
appropriate period of time to fatten if appropriate. So the overall effect of any non-fatal 
disease on culling rate will only become apparent around a year later when cows in early 
lactation are reaching the end of their lactation, presuming they continue to lactate after 
recovering from the disease. Lactation stage has been previously shown to be associated with 
culling in a survival in a study of Holstein-Friesian cattle in Kenya with cows in later lactation 
more likely to be culled (Ojango et al., 2005). As a consequence, lactation stage at outbreak 
onset was included as a time-varying effect in the multivariable model. The decreases seen in 
the culling survival curve around 3, 5 and 9 months are likely due to management reasons 
whereby cattle are removed from the farm in groups once a decision has been made to cull.  
Despite the Kaplan-Meier curve and log-rank test revealing a trend indicating increased culling 
with cases of FMD (Figure 5.2), in the multivariate model there was only very weak evidence of 
a statistical association (Table 5.4). In this outbreak, older cows appeared at greater risk of 
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FMD and due to their advanced age, were at increased risk of culling. Therefore age was a 
strong confounder of the association between being a case of FMD and being culled. In 
contrast, the effect of FMD on clinical mastitis was strong enough that even after adjustment 
for age there was still a pronounced effect in the early follow-up period. 
Animals that had suffered from a tick-born disease (TBD) prior to the FMD outbreak were 
more likely to develop FMD and also be culled (Supplementary material 5.1). This confounder 
was present after adjusting for age which has been shown to be associated with the incidence 
of TBD (Phiri et al., 2010). Tick-borne diseases have been identified as a major cause of cow 
death and culling among smallholder dairy farms in Kenya and neighbouring Tanzania (Lyimo 
et al., 2004; Maloo et al., 2001). The major tick-borne diseases of cattle in the area are 
theileriosis (East Coast Fever, ECF), babesiosis and anaplasmosis. The farm does not 
consistently record which disease was encountered hence they were all included as one 
disease condition. In Kenya, ECF has been identified as the disease with the highest impact on 
livelihoods among pastoralists in Kenya, marginally ahead of FMD (Onono et al., 2013). The 
impact of ECF on culling has been less well characterised on large-scale dairy farms although 
an outbreak of ECF on a large-scale farm in Tanzania due to a breakdown in dipping regime led 
to severe economic losses (Msami, 2001). Additionally, acaricide dips are in wide use among 
large-scale farms in Kenya. It has been anecdotally suggested that previous exposure to other 
infectious diseases may increased the susceptibility to FMD although this is the first study to 
the authors’ knowledge that provides evidence for such an association. Although no definitive 
diagnosis of the condition was made, the clinical signs associated with these conditions are 
easily observed and commonly encountered. 
The majority of cattle present on the farm were affected with FMD despite vaccination being 
performed in all cattle approximately every 4 months. Although previous analysis indicated 
limited or no vaccine effectiveness in preventing clinical disease (Lyons et al., 2015), it cannot 
be ruled out that the vaccine provided some protection leading to an underestimate of the 
impact if the outbreak had occurred in an immunologically naive herd.  However, this study 
reflects a “real-life” impact of a FMD outbreak under field conditions. Vaccination for FMD is 
common among large-scale herds in Kenya therefore making these results very relevant to this 
population and useful when considering the impact of a vaccination programme. Similar 
estimates from outbreaks on other dairy farms with other serotypes would be useful to 
demonstrate the range of impacts obtained in the field. 
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The study was on a large-scale dairy farm which is among the minority of dairy farm types in 
Kenya so care must be taken when generalising these results to the broader dairy cow 
population although there are similarities to the local smallholder cattle population that need 
emphasising. The breeds of cattle on the study farm are predominantly exotic (mainly 
Holstein-Friesian) with some indigenous cross-breeding. Among smallholder dairy farms in 
Kenya, Holstein-Friesian is also the most common breed due to the higher milk yields (Bebe et 
al., 2000). Indeed the study farm does sell cattle to local smallholder farmers. Additionally, the 
nutritional management is often very similar particularly in organised smallholder dairy regions 
where farmers have access to concentrated feeds as is the case in the study area. Collecting 
data from surrounding affected and non-affected smallholder farms would add weight to the 
findings. The routine recording of data on various production parameters meant the data were 
easily extracted and analysed in this study. Such routine recording of data is rarely performed 
on smallholder farms making retrospective studies more challenging. Overall, it would not be 
surprising to see a similar impact among smallholder dairy cattle although the overall socio-
economic impact is likely to be different in these production systems. Experience from the 
field reveals that smallholder farmers tend to use less FMD vaccine so the impact on mastitis 
and culling may be higher. 
The statistical modelling for culling suggested that including age and parity improved model fit. 
There is strong collinearity between these two variables. Since the objective of the study is to 
look only at the impact of FMD on the primary outcomes, it was decided to include both of 
these covariates although this restricts the interpretation of their associated effect estimates 
in the final multivariate regression model.  
Survival analysis utilising a Cox proportional hazards regression model relies upon the 
fundamental assumption that the hazards for comparison groups are proportional over the 
follow-up period (Collett, 2003). If a model covariate has different effects at different time 
periods, this can violate this assumption and lead to biased statistical associations. Despite the 
importance of this assumption many published studies do not provide evidence of the 
assessment. In one review of clinical trials for human cancer, only 5/64 studies included any 
form of test for proportionality (Mathoulin-Pelissier et al., 2008). The importance of ensuring 
the validity of the assumption was particularly clear in this study as adjusting for a time varying 
effect led to a large difference in the effect of FMD on the two primary outcomes. 
In conclusion, this study is the first to utilise survival analysis methods to estimate the effect of 
FMD on subsequent clinical mastitis and culling. These results offer a detailed assessment of 
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disease impact that can inform future cost analyses that are currently over-reliant on expert 
opinion, assumptions and limited use of field data. It is only through performing such studies in 
different settings that the real impact of FMD can be estimated in endemic countries and 
inform the cost-effectiveness of national and international disease control programmes. 
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Supplementary material 5.1. Culling – univariable associations with other diseases on Farm 1. Continued on next page.  
Disease event N Col % FMD  Culling   
   N (row %) P-value Rate per 1000 cattle-months (95%CI) HR (95%CI) P-value 
b
 
Abortion        
    Yes 16 3.5 14 (87.5) 0.034 25.0 (9.4, 66.5) 2.3 (0.84, 6.3) 0.15 
    No 628 96.5 386 (61.5)  10.8 (5.8, 13.6)   
Abscess        
    Yes 6 0.9 3 (50.0) 0.54 0 (-) - - 
    No 638 99.1 397 (62.2)  11.2 (8.9, 14.1)   
Broken leg        
    Yes 1 0.2 1 (100.0) 0.99 
a
 0(-) - - 
    No 643 99.8 399 (62.1)  11.1 (8.9, 14.0)   
Dystocia        
    Yes 4 0.6 2 (50.0) 0.62 84.0 (21.0, 336.0) 7.6 (1.9, 31.2) 0.032 
    No 640 99.4 398 (62.2)  10.8 (8.6, 13.6)   
Eye disease        
    Yes 114 17.7 84 (73.7) 0.005 10.2 (5.8, 17.9) 0.9 (0.5, 1.7) 0.74 
    No 530 82.3 316 (59.6)  11.3 (8.8, 14.5)   
Lameness        
    Yes 40 6.2 32 (80.0) 0.016 9.8 (3.7, 26.1) 0.9 (0.3, 2.4) 0.78 
    No 604 93.8 368 (60.9)  11.2 (8.8, 14.1)   
Dislocated hip        
    Yes 1 0.2 1 (100.0) 0.99 
a
 0(-) - - 
    No 643 99.8 399 (62.1)  11.1 (8.9, 14.0)   
Clinical mastitis        
    Yes 35 5.4 29 (82.9) 0.009 32.9 (17.7, 61.2) 3.2 (1.6, 6.2) 0.0031 
    No 609 94.6 371 (60.9)  10.1 (7.9, 12.8)   
        
Note: Previous disease experienced in the 12 months prior to the commencement of the outbreak and the association with being a case of FMD and culling 
rate. 
a Fisher’s exact test b Likelihood ratio test 
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Supplementary material 5.1. Continued from previous page. 
Disease event N Col % FMD  Culling   
   N (row %) P-value Rate per 1000 cattle-months (95%CI) HR (95%CI) P-value 
b
 
Pneumonia        
    Yes 22 3.4 13 (59.1) 0.77 12.3 (4.0, 38.2) 1.1 (0.35, 3.5) 0.85 
    No 622 96.6 387 (62.2)  11.0 (8.8, 13.9)   
Retained foetal membranes        
    Yes 4 0.6 4 (100.0) 0.12 28.1 (4.0, 199.2) 2.4 (0.34, 17.6) 0.38 
    No 640 99.4 396 (61.9)  11.0 (8.7, 13.8)   
Diarrhoea        
    Yes 49 7.6 17 (34.7) <0.0001 5.5 (1.8, 17.1) 0.48 (0.15, 1.5) 0.17 
    No 595 92.4 383 (64.4)  11.6 (9.2, 14.6)   
Snake bite        
    Yes 1 0.2 0  (0) 0.38 
a
 0 (-) - - 
    No 643 99.8 400 (62.2)  11.1 (8.9, 14.0)   
Three-day sickness        
    Yes 3 0.5 63 (100.0) 0.18 0 (-) - - 
    No 641 99.5 397 (61.9)  11.1 (8.9, 14.0)   
Tick-borne disease        
    Yes 46 7.1 36 (78.3) 0.019 38.0 (22.9, 63.0) 3.9 (2.2, 6.9) <0.0001 
    No 596 92.9 364 (60.9)  9.4 (7.3, 12.1)   
Vulval discharge        
    Yes 8 1.2 7 (87.5) 0.14 26.5 (6.6, 106.1) 2.4 (0.59, 9.8) 0.22 
    No 636 98.8 393 (61.8)  10.9 (8.7, 13.8)   
Wound        
    Yes 17 2.6 7 (41.2) 0.071 0 (-) - - 
    No 627 97.4 393 (62.7)  11.4 (9.1, 14.3)   
Any disease        
    Yes 269 41.8 185 (68.8) 0.003 14.8 (10.8, 20.1) 1.7 (1.1, 2.7) 0.022 
    No 375 58.2 215 (57.3)  8.6 (6.1, 12.0)   
Note: Previous disease experienced in the 12 months prior to the commencement of the outbreak and the association with being a case of FMD and culling 
rate.     a Fisher’s exact test b Likelihood ratio test 
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Supplementary material 5.2. Clinical mastitis - univariable associations with other diseases on Farm 1. Continued on next page.  
Disease event N Col % FMD  Clinical mastitis   
   N (row %) P-value Rate per 1000 cattle-months (95%CI) HR (95%CI) P-value
b
 
Abortion        
    Yes 16 3.9 14 (87.5) 0.39 6.3 (0.9, 44.7) 0.37 (0.05, 2.7) 0.24 
    No 393 96.1 309 (78.6)  17.6 (13.7, 22.6)   
Abscess        
    Yes 5 1.2 2 (40.0) 0.031 0 (-) - - 
    No 404 98.8 321 (79.5)  17.4 (13.6, 22.2)   
Broken leg        
    Yes 0 0.0 - - 0 (-) - - 
    No 409 100.0 323 (79.0)  17.1 (13.4, 21.9)   
Dystocia        
    Yes 4 1.0 2 (50.0) 0.15 44.3 (6.2, 314.7) 2.1 (0.29, 15.1) 0.51 
    No 405 99.0 321 (79.3)  16.9 (13.2, 21.7)   
Eye disease        
    Yes 80 19.6 59 (73.8) 0.20 22.8 (14.0, 37.2) 1.4 (0.82, 2.6) 0.22 
    No 329 80.4 264 (80.2)  15.8 (11.8, 21.0)   
Lameness        
    Yes 31 7.6 26 (83.9) 0.49 37.6 (19.6, 72.2) 2.3 (1.1, 4.6) 0.024 
    No 378 92.4 297 (78.6)  15.7 (12.0, 20.5)   
Dislocated hip        
    Yes 1 0.2 1 (100.0) 0.61 0 (-) - - 
    No 408 99.8 322 (78.9)  17.2 (13.4, 22.0)   
Clinical mastitis        
    Yes 35 8.6 29 (82.9) 0.56 22.1 (9.9, 49.1) 1.2 (0.53, 2.9) 0.64 
    No 374 91.4 294 (78.6)  16.7 (12.9, 21.7)   
Note: Previous disease experienced in the 12 months prior to the commencement of the outbreak and the association with being a case of FMD and 
mastitis rate. a Fisher’s exact test b Likelihood ratio test 
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Supplementary material 5.2. Continued from previous page. 
Disease event N Col % FMD  Clinical mastitis   
   N (row %) P-value Rate per 1000 cattle-months (95%CI) HR (95%CI) P-value
b
 
Pneumonia        
    Yes 13 3.2 10 (76.9) 0.85 22.7 (7.3, 70.5) 1.4 (0.44, 4.4) 0.59 
    No 396 96.8 313 (79.0)  16.9 (13.1, 21.8)   
Retained foetal membranes        
    Yes 4 1.0 4 (100.0) 0.30 68.9 (17.2, 275.6) 3.9 (0.96, 16.1) 0.11 
    No 405 99.0 319 (78.8)  16.7 (13.0, 21.5)   
Diarrhoea        
    Yes 3 0.7 2 (66.7) 0.60 0 (-) - - 
    No 406 99.3 321 (79.1)  17.3 (13.5, 22.1)   
Snake bite        
    Yes 1 0.2 0 (0.0) 0.052 0 (-) - - 
    No 409 99.8 323 (79.2)  17.2 (13.4, 22.0)   
Three-day sickness        
    Yes 3 0.7 3 (100.0) 0.37 0 (-) - - 
    No 406 99.3 320 (78.8)  17.2 (13.5, 22.1)   
Tick-borne disease        
    Yes 42 10.3 35 (83.3) 0.46 29.7 (15.4, 57.0) 1.7 (0.83, 3.4) 0.18 
    No 367 89.7 288 (78.5)  16.0 (12.2, 20.9)   
Vulval discharge        
    Yes 8 2.0 7 (87.5) 0.55 31.1 (7.8, 124.3) 1.7 (0.42, 7.0) 0.49 
    No 401 98.0 316 (78.8)  16.9 (13.1, 21.7)   
Wound        
    Yes 8 2.0 5 (62.5) 0.25 11.9 (1.7, 84.6) 0.74 (0.10, 5.3) 0.75 
    No 401 98.0 318 (79.3)  17.2 (13.4, 22.1)   
Any disease        
    Yes 185 45.2 145 (78.4) 0.79 19.4 (13.7, 27.6) 1.2 (0.75, 2.0) 0.41 
    No 224 54.8 178 (79.5)  15.3 (10.8, 21.7)   
Note: Previous disease experienced in the 12 months prior to the commencement of the outbreak and the association with being a case of FMD and 
mastitis rate. a Fisher’s exact test b Likelihood ratio test 
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Supplementary material 5.3. Schoenfeld residual tests for non-proportionality of each 
indicator variable prior to model backward fitting. 
Variable Clinical mastitis Culling 
χ2 statistic P-value χ2 statistic P-value 
FMD 
 
2.0 0.16 1.6 0.20 
Age (quintiles)     
    Quintile 1 - - - - 
    Quintile 2 0.87 0.35 0.4 0.53 
    Quintile 3 3.1 0.078 2.2 0.14 
    Quintile 4 3.7 0.054 0.00 0.96 
    Quintile 5 
 
3.0 0.089 0.00 0.97 
Parity      
    0 - - - - 
    1 0.37 0.54 0.04 0.84 
    2 0.25 0.62 0.04 0.84 
    3 0.47 0.50 0.40 0.53 
    4+ 
 
0.35 0.55 0.14 0.71 
Lactation stage a   10.6 0.0011 
    Non-lactating - - 
  
    Early lactation (<0-100d) 0.53 0.46 
    Mid lactation (101-250d) 0.03 0.86 
    Late lactation (>250d) 0.07 0.79 
    Dry 
 
0.11 0.74 
Tick bone disease b 
 
- - 2.1 0.15 
Clinical mastitis b 
 
- - 2.9 0.089 
Breed 
 
1.5 0.23   
Any disease b 
 
  0.2 0.68 
Global 32.0 0.0041 39.7 0.0002 
aLRT indicated lactation stage to be categorical in the mastitis model and linear in the culling 
model. b In previous 12 months prior to commencement of outbreak 
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Chapter 6. Impact of FMD on milk yield (Research Paper 3) 
The following chapter is a research paper including the results of the milk yield analysis from 
Farm 1. This paper has been submitted to Preventive Veterinary Medicine. The supplementary 
material is included at the end of the chapter. Further details on data management are in 
Appendix C. 
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6.1 Abstract 
The economic impact of FMD has been poorly characterised particularly in endemic settings 
where such knowledge is essential for making decisions on disease control with limited 
resources. In order to address this, a study was designed using individual animal data from a 
large-scale dairy farm in Kenya to estimate the impact of an FMD outbreak due to SAT2 on milk 
yield. Daily milk yields from 218 mainly European breeds of cattle that were lactating during 
the 29-day outbreak period were considered in the analysis. At the herd level, the average 
daily yields deceased from around 20kg to 13kg per cow, recovering approximately 2 months 
after the commencement of the outbreak. Generalised estimating equations (GEE) and an 
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autoregressive correlation matrix were used to compare yields of reported clinical FMD cases 
and non-cases. No difference was found between reported clinical and non-clinical cases 
suggesting inaccurate case recording, poor sensitivity of the case definition and subclinical 
infections being present. To further investigate the impact of FMD, yields were predicted for 
each individual animal based on historic data from the same herd using a similar GEE 
approach. Comparisons were made between actual and predicted yields from the 
commencement of the outbreak for cattle lactating during the outbreak using a linear 
regression model. Animals produced significantly less than predicted if in parity 3 or greater 
and between 0 and 200 days in milk (DIM). The maximum effect was seen among animals in 
parity ≥4 being between 101 and 200 DIM at the start of the outbreak, producing on average 
547.4 kg (95%CI 295.6, 799.1) less milk than predicted for their remaining lactation. 
Generalisation of the results requires caution as the majority of Kenyan milk is produced in 
smallholder farms. However, such farms use similar genetics and feeding practices to the one 
the study is based on and such systems are increasingly important in the supply of milk 
globally. Therefore the results make an important and unique contribution to the evidence 
base on FMD impact among dairy cattle in an endemic setting.  
Keywords: foot-and-mouth disease; economics; dairy cattle; Kenya; milk yield 
6.2 Introduction 
Foot-and-mouth Disease (FMD) is caused by a highly transmissible viral infection of cloven-
hooved animals responsible for economically devastating outbreaks when introduced into 
FMD-free countries. Its impact in endemic counties is poorly characterised. Most of the world 
is endemic except for Europe, North America, Australia and New Zealand. The disease is 
characterised by lesions on the dental pad, tongue, muzzle, interdigital space and teats. These 
appear alongside initial pyrexia, dramatic reduction in milk yield and occasional abortion. 
Animals typically recover clinically within a couple of weeks after onset although secondary 
bacterial infection particularly in the feet and udder may lead to more protracted disease. It 
has been claimed that an animal will not recover to their full lactating potential for the 
remainder of the lactation (Kitching, 2002). 
Quantifying the reduction in milk output due to FMD is fundamental to understanding its 
economic impact in dairy herds and therefore resource allocation for control in endemic 
settings. This loss has been poorly documented and is often based on farm and expert opinion 
(James and Rushton, 2002; Knight-Jones and Rushton, 2013). Table 6.1 summarises all the 
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relevant available studies that could be found in the literature. Studies have estimated milk 
loss in a variety of different settings and different approaches. In an FMD free setting, a cost-
benefit evaluation in the UK estimated that the output of milk would be reduced by 25% in the 
first four years should the UK become endemic reducing to 12.5% in subsequent years (Power 
and Harris, 1973). In endemic settings, a survey of expert opinions in Turkey estimated on 
average a 22% milk yield loss per lactation in Holstein cattle if affected with FMD incurring a 
financial loss of 266USD (Şentürk and Yalçin, 2008, 2005). The estimated loss was lower for 
local breeds at 10% and 47USD respectively. Using participatory epidemiological methods, 
studies among pastoralists have estimated yield reductions of 53% and 62% during the period 
of illness in Kenya and South Sudan respectively (Barasa et al., 2008; Onono et al., 2013). Post-
outbreak surveys in Ethiopia among pastoralist farmers owning Borana cows estimated an 
average drop in milk yield of 77.3% for an average 25.5 day period representing a 7.7% 
reduction for the whole lactation (Bayissa et al., 2011). In a chronic form of the condition 
where a heat intolerance syndrome as a sequela to acute infection has been described (Catley 
et al., 2004), the loss was estimated at 78% for the lactation. In another Ethiopian post-
outbreak survey of pastoral and crop-livestock mixed farming, households reported an average 
loss of 1.8 litres/cow/day (Jemberu et al., 2014). This was based on farmer estimates prior to 
and during the outbreak and represented a 75% reduction that lasted for a mean of 23 days (7-
35) and 33.6 days (range 7-90) in the respective farming systems. In India, post outbreak 
surveys estimated FMD to cause a reduction of the national milk output of 6.5% with a 14-19% 
reduction in the annual yield of an affected animal (Saxena, 1994). 
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Table 6.1 Summary of studies reporting the impact of FMD on milk yield in cattle. 
Country Study 
period 
Farming systems Breeds Type of study Serotype Estimated loss Reference 
UK N/A
a
 UK based dairy 
farms 
Not specified Expert opinion Not 
specified 
25% in first four years nationally after incursion into 
FMD free UK; 12.5% thereafter if becomes endemic 
Power and 
Harris, 1973 
Pakistan 1976 Large-scale Sahiwal Longitudinal Not 
specified 
74.4 litres of milk lost per affected lactation Kazimi and 
Shah, 1980 
Bangladesh 1988-
1991 
Not specified Not specified Post-outbreak farm 
surveys 
Not 
specified 
66% reduction in average daily yield Chowdbury et 
al., 1993 
India 1991 Smallholders Indiginous 
and cross-
breed 
Post-outbreak farm 
surveys 
Not 
specified 
14-19% reduction in the annual yield of an affected 
animal 
Saxena, 1994 
Turkey N/A Turkish dairy 
farms 
Holstein-
Friesian 
Expert opinion Not 
specified 
22% and 10% milk yield loss in current lactation for 
Holstein Friesian and local breeds respectively 
Şentürk and 
Yalçin, 2005 
South 
Sudan 
2005 Agropastoralists Indiginous Post-outbreak 
interviews (PE
b
 
methodology) 
Not 
specified 
62% reduction while sick. Average 14 day illness. 
Mean daily loss 1.6 litres per cow compared to 
normal 2.6 litres  
Barasa et al., 
2008 
Ethiopia 2008 Large-scale Fogera Longitudinal Not 
specified 
50% of pre-outbreak level Mazengia et 
al., 2010 
Ethiopia 2008 Pastoral and agro-
pastoral 
Borana Post-outbreak farm 
surveys 
Not 
specified 
Acute phase: 1.37 litres/cow/day for average 25.5 
days (73.3% reduction while sick; 7.7% reduction per 
lactation). Chronic phase: 0.67 litres/cow/day for 3.8 
months (78% reduction per lactation)  
Bayissa et al., 
2011 
Kenya Not 
specified 
Pastoralists Indigenous Farmer surveys (PE 
methodology) 
Not 
specified 
53% reduction in a herd during outbreak period Onono et al., 
2013 
Pakistan Not 
specified 
Smallholder Not specified Longitudinal Not 
specified 
51.8% of potential during outbreak Ferrari et al., 
2013 
Ethiopia 2012-
2013 
Pastoral and 
smallholder 
Indigenous Post-outbreak farm 
surveys 
O 75% of pre-outbreak level (average loss of 1.8 
litres/cow/day) 
Jemberu et 
al., 2014 
a N/A not applicable b PE Participatory epidemiology 
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Empirical data on milk yield impact have been presented in few settings.  In Pakistan, 
examination of milk records for 77 Sahiwal cows revealed the average duration of milk loss to 
be 17.9 days with 74.4 litres of milk lost per affected lactation (Kazimi and Shah, 1980). Also in 
Pakistan, Ferrari et al (2013) performed a longitudinal study following clinically affected cows 
and buffalo2 on 50 smallholder farms. A 60-day follow-up period post disease onset was 
evaluated and included 72 milking cows and 125 milking buffalo. They estimated that cows and 
buffalo produced only 51.8% and 55.4% of their milk yield potential during this period. A study 
among Bangladesh cattle found a reduction of average daily yields of 66% but the time period 
for this reduction was not clearly specified (Chowdbury et al., 1993). An investigation into an 
outbreak at a government owned farm in Ethiopia examined the daily yields of 14 indigenous 
Fogera cows affected with clinical FMD. A comparison of the yields produced 10 days prior to 
disease with the 10 days after revealed an approximate 50% reduction between these two 
periods (Mazengia et al., 2010).  
Kenya is endemic for FMDV with serotypes A, O, SAT1 and SAT2 being present in domestic 
species (Paton et al., 2009). A nationwide serosurvey performed in 2010 revealed a 
seroprevalence of 52.5% (Kibore et al., 2013). Kenyans are among the largest consumers of 
milk in the developing world and consume four times the average for sub-Saharan Africa 
(Smallholder Dairy Project, 2004). Despite the importance of the Kenyan dairy industry, the 
impact of FMD has been poorly characterised in the country. A study among Kenyan 
pastoralists ranked FMD and East coast fever as diseases with the highest impact on 
livelihoods (Onono et al., 2013). A case-report from a large-scale farm in Kenya estimated milk 
loss to contribute 42% of the total cost of the outbreak in the 95 day period from the 
beginning of the outbreak although the exact methodology used is this calculation is not clear 
(Mulei et al., 2001).  
In August/September 2012, an outbreak of FMD due to serotype SAT2 occurred on a large-
scale dairy farm in Nakuru County as described elsewhere (Lyons et al., 2015). The regular 
recording of individual milk yields on this farm presented the opportunity to quantify 
objectively the impact of disease on milk yields. The objectives of the current study were to 
estimate the economic impact of FMD infection in commercial dairies by comparing the milk 
production between clinical FMD cases and non-cases using a linear regression approach and 
to make comparisons with predicted yields generated through analysis of historic herd data.  
                                                          
2
 Species not given but presumably Water buffalo, Bubalus bubalis 
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6.3 Materials and methods 
6.3.1 Study population 
The study farm was a 1600 hectare mixed arable/livestock enterprise located in Nakuru 
County, Kenya possessing approximately 650 cattle, 100 sheep and 300 goats. The farm 
typically milked around 200 cattle and had an all year around calving system. Cattle were kept 
in 18 different management groups, with five of these containing lactating cows. Each group 
had continuous (24 hour) surveillance by 1-2 farm staff to guard against potential predators 
and theft in addition to monitoring animal health.  
6.3.2 FMD outbreak summary 
Details of the outbreak being examined have been published elsewhere (Lyons et al., 2015). 
Briefly, all new clinical cases were reported daily by the livestock guardians to the farm’s 
livestock manager, who manually recorded the identification number and date.  One of the 
current authors interviewed farm personnel shortly after the outbreak to confirm the case 
definition. Cases were recorded as having FMD based on visible clinical signs only. Cases were 
defined as FMD if the cow was reported as having hyperptyalism during the outbreak period 
with one other clinical sign consistent with FMD. Other clinical signs were not specifically 
recorded. The index case was recorded on 31st August 2012 with the last clinical case on the 
28th September, which defines the outbreak period. Epithelium samples were taken by the 
government veterinary services and the FMDV serotype confirmed by antigen ELISA as 
Southern African Territories 2 (SAT2) by the Kenyan National FMD Laboratory, Embakasi. This 
was later confirmed at the World Reference Laboratory, Pirbright, UK. The farm uses locally 
produced quadrivalent (O, A, SAT1, SAT2) FMD vaccine (FotivaxTM, Kenya Veterinary Vaccine 
Production Institute, Embakasi, Nairobi) administered to all animals on the farm irrespective of 
age every four to six months. The vaccine had very limited or no effectiveness at preventing 
clinical disease in this outbreak (Lyons et al., 2015). 
6.3.3 Milk yield recording 
Lactating cows are kept in five groups in separate locations, three of which tend to have more 
cows in lower parities. Each group is brought to the milking parlour separately twice daily. The 
parlour is automated and mobile with a semi-fixed location depending on the location of the 
lactating cow groups. Each individual cow’s yield from every milking is weighed by farm 
personnel and recorded manually before being entered into Microsoft Excel spreadsheets. A 
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weekly mean is calculated and entered into the Interherd (InterAgri) database associated with 
the unique animal identification number. The milk yield value for each milk recording date 
therefore refers to the mean daily yield since the previous recording (approximately seven 
days). If a cow stops lactating during the week, the denominator is the number of days that 
week the cow was lactating. 
Only cows that were lactating during the outbreak period were considered in this analysis, 
defined as having at least one milk recording during this period. In order to capture the impact 
of short lactations, for all cows that were dried off before 305 days and which were either 
subsequently culled or had a dry period over the farm target of 60 days, zero yield entries 
were entered up until 305 days. Cows culled before 305 days were similarly treated. This did 
not apply for cows sold for breeding during lactation. 
6.3.4 Statistical analysis 
Data were extracted from Interherd (InterAgri) using Access (Microsoft) and imported into 
Stata 13.0 (Statacorp) for data cleaning and analysis. For comparing the yields of reported 
clinical FMD cases versus non-cases, due to the expected correlation of repeated measures of 
milk yields over time for each cow, a generalised estimating equations (GEE) model was 
utilised with a first order autoregressive correlation matrix. This method has been shown to 
produce the most appropriate model fit for bovine lactation curves (Wilson et al., 2004). Based 
on previous analysis, variables for inclusion in the model that may confound the association 
include the number of days in milk (DIM), breed of cow, parity, and calving date. Number of 
days in milk at each recording entry was considered as a linear, quadratic and cubic term as 
well as a categorical variable (50 day categories, 100 day categories, quartiles, and quintiles). 
Breeds were classified according to the proportion of the genotype ascribed to zebu breeds 
based on breeding history (100% exotic, <25% zebu, 25-49% zebu, ≥50% zebu).  Model fit was 
assessed using the “quasilikelihood under the independence model information criterion” 
(QIC) whereby the model with the smallest QICu measure is preferred (Hardin and Hilbe, 2003).  
In order to compare the actual milk production to what is predicted based on previous 
lactations by cows in the same herd, available data from all whole lactations (i.e. ≥305 days) 
prior to the FMD outbreak were extracted from Interherd and a GEE model based on that used 
by Schukken et al (2009) used for the prediction. The model used was:- 
Yield = Parity + Days in milk + Season + e       
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where Parity is grouped into 1, 2, 3 and ≥4; Days in milk was the number of days since calving 
at each recording; Season is categorised into four (January/February = 1st dry season, March-
May = Long rains, June-September= 2nd dry season, October-December= Short rains); e 
represents the error incorporating the autoregressive (AR1) variance structure. After running 
this model, an out of sample prediction was made on the dataset from cows lactating during 
the FMD outbreak. Each animal’s total cumulative yield (predicted and actual) from the 
beginning of the outbreak period to the end of the concomitant lactation was calculated 
through summing the area under the curve. The difference between the predicted and actual 
yield was used as the dependent variable in a multiple linear regression model. Parity, days in 
milk and breed were considered for inclusion in the model based on the result of univariable 
ANOVA tests, while the Akaike information criterion (AIC) was used to assess the inclusion of 
variables as linear or categorical. Heteroskedasticity was evaluated through examination of 
residual plots. 
6.4 Results 
Two hundred and seventy one cows were eligible for the study having had at least one calf 
prior to or during the FMD outbreak. Forty-two were dry during the whole outbreak period so 
were excluded. Seven were dried off on 3rd September 2012 and were excluded from the 
analysis. Two of these animals subsequently developed clinical FMD but this was not the 
reason they were dried off. One cow gave birth to a full term calf during the outbreak period 
having been a clinical FMD case four days before. This cow died two days after calving and did 
not produce any recordable milk so was excluded from the analysis. Records were absent for 
three cows leaving 218 cows included for analysis. One cow had two parities during the 
outbreak period as a management error led to the cow not being dried off at the correct time 
and she calved whilst still being milked. Each of these parities was treated separately in the 
analysis so that 219 lactations were included in the analysis. 
The study population is described in Table 6.2. At the beginning of the outbreak, the mean age 
was 4.1 years (median 3.8; range 2.4, 9.7) and the mean number of days in milk was 142.3 
(median 130; range -28, 581) with negative values reflecting cows calving during the outbreak 
period. Seventeen cows had lactations that terminated before 305 days and failed to re-calve. 
This was either due to early drying off or culling/death. Clinical FMD was recorded in 188/219 
(85.8%) of parities considered in the analysis. The demographics and FMD incidence rates for 
each management group are shown in Table 6.3.  
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Table 6.2. Description of study population for analysing the impact of FMD on milk yields on a 
large-scale dairy farm in Nakuru County, Kenya.  
Variable Category N Clinical FMD (row %) 
Age category 2-<3y 42 31 (73.8) 
 3-<4y 90 81 (90.0) 
 4-<5y 53 46 (86.8) 
 5-<6y 18 16 (88.9) 
 6-<7y 7 6 (85.7) 
 7-<8y 4 4 (100.0) 
 8-<9y 2 2 (100.0) 
 9-<10y 3 2 (66.7) 
Parity 1 98 79 (80.6) 
 2 74 69 (93.2) 
 3 28 23 (82.1) 
 4 12 11 (91.7) 
 5 4 4 (100.0) 
 6 3 2 (66.7) 
Days in milk Calved during outbreak 26 21 (80.8) 
 1-50 48 40 (83.3) 
 51-100 25 21 (84.0) 
 101-150 16 14 (87.5) 
 151-200 32 26 (81.3) 
 201-250 35 34 (97.1) 
 251-300 14 12 (85.7) 
 301-350 7 7 (100.0) 
 >350 16 13 (81.3) 
Breed 100% Exotic  183 161 (88.0) 
 <25% Zebu 12 11 (91.7) 
 25% Zebu 13 9 (69.2) 
 50% Zebu 11 7 (63.6) 
Note: Cows were included if they had at least one milk recording during the outbreak period 
(31st August 2012 to 28th September 2012). Two hundred and eighteen cows were included in 
the analysis; one cow had two parities occurring during the outbreak which were considered 
separately. 
Table 6.3. Summary of management groups containing lactating cattle for analysing the impact 
of FMD on milk yield on a large-scale dairy farm in Nakuru County, Kenya. 
Group 
ID 
Number of cows 
(range) 
Age (mean, 
range) 
Parity (mean, 
range) 
FMD incidence rate (cases per 
100 cattle days; 95%CI) 
L1 
 
29, 37 3.3 (2.6-4.3) 1.1 (0-2) 5.3 (3.7, 7.5) 
L2 
 
28, 30 3.2 (2.4-4.5) 1.1 (1-2) 3.4 (2.2, 5.2) 
L3 
 
30, 38 3.3 (2.6-5.6) 1.1  (1-3) 4.1 (2.8, 6.0) 
L4 
 
51, 58 5.0 (3.4-9.4) 2.6 (1-6) 5.5 (4.2, 7.3) 
L5 50, 57 4.7 (3.4-9.7) 2.5 (1-6) 5.0 (3.8, 6.6) 
Note: Cows were included if they had at least one milk recording during the outbreak period 
(31st August 2012 to 28th September 2012). 
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The mean daily milk yield for reported FMD cases compared with non-cases is shown in Figure 
6.1. Prior to the outbreak, the overall mean daily milk yield was around 20 litres per cow per 
day, dropping to a low of 13 litres during the outbreak period. After the outbreak, there was 
an apparent recovery of the yields rising to around 17 litres around 2 months after the 
beginning of the outbreak before another decrease in mid-December to 10 litres per day. 
There is also a clear decrease in milk yield in the week prior to observed onset of the outbreak; 
yields per group alongside the epidemic curves are shown in Supplementary material 6.1. 
Throughout the analysis period, there appears to have been no significant difference between 
reported clinical FMD cases and non-cases which is supported by the results of the GEE model 
(Table 6.4).  
 
 
Figure 6.1 Weekly calculated mean daily milk yields for cattle that were lactating during an 
outbreak of foot-and-mouth disease (FMD) on a large-scale dairy farm in Nakuru County, 
Kenya. The outbreak period was between 31st August and 28th September 2012 and is 
represented by vertical dashed lines in the figure. The graph compares reported clinical FMD 
cases and non-cases for six month periods either side of the outbreak period.  
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Table 6.4. Results of a generalised estimating equation (GEE) model comparing milk yields of 
reported clinical FMD cases and non-cases on a large-scale dairy farm in Nakuru County, 
Kenya.   
Variable Category Coefficient (95% CI) SEa P-value 
Clinical FMD Yes -0.14 (-1.1, 0.82) 0.49 0.77 
 No Reference   
     
Parity 1 Reference   
 2 0.82 (0.051, 1.6) 0.39 0.037 
 3 0.21 (-0.81, 1.2) 0.69 0.69 
 ≥4 1.1 (-0.13, 2.3) 0.63 0.080 
     
Days in milk Calved during outbreak 1.5 (0.23, 2.8) 0.39 0.037 
 0-50d Reference   
 51-100d 1.6 (0.39, 2.7) 0.60 0.009 
 101-150d 1.3 (-0.0079, 2.6) 0.67 0.051 
 151-200d 1.8 (0.78, 2.9) 0.54 0.001 
 201-250d 2.5 (1.4, 3.6) 0.55 <0.0001 
 251-300d 2.2 (0.72, 3.6) 0.75 0.003 
 301-350d 2.0 (-0.083, 4.0) 1.0 0.060 
 >350d 1.0 (-0.36, 2.5) 0.72 0.15 
     
Breed 100% Exotic breed Reference   
 <25% Zebu -1.1 (-2.5, 0.26) 0.71 0.11 
 25-49% Zebu -1.2 (-2.6, 0.22) 0.73 0.098 
 ≥50% Zebu -2.2 (-3.7, -0.75) 0.75 0.003 
     
Constant - 14.2 (13.0, 15.3) 0.57 <0.0001 
Note: An autoregressive (AR1) variance structure was used to account for the correlation of 
yields for individual animals through time. a Standard error 
 
The frequency distribution of actual yields produced from the beginning of the outbreak 
period is shown in Figure 6.2. Predictions of yields were based on 383 complete lactations 
finishing prior to the onset of FMD outbreak commencing from May 2005 onwards. A 
comparison made between predicted and actual yields from the beginning of the outbreak to 
the end of that animals lactation revealed no difference based on a paired t-test (mean yields: 
actual 2156.1 versus predicted 2010.0 litres, mean difference 56.1 litres [95%CI -31.6, 143.9]; 
P=0.21). Based on ANOVA tests, parity and days in milk at the start of the outbreak were 
associated with the difference between subsequent predicted and actual milk yields so were 
included in a multiple linear regression model (Table 6.5). The combinations of the predictors 
with confidence intervals are shown in Figure 6.3. For parity 1 and 2 animals, there was no 
effect of lactating during the outbreak on the animal’s production compared to what was 
predicted for the remainder of that animal’s lactation regardless of the stage of lactation. 
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Some animals, notably parity 1 animals at 0-100 and 201-300 DIM, produced significantly more 
than what was predicted. Parity 3 animals significantly underperformed when in the earlier 
stages of lactation (0-200 DIM) but no effect was seen for those >200 DIM. For animals in 
parity 4 or greater, all stages of lactation underperformed even those who were over 300 days 
in milk at the beginning of the outbreak period. The greatest impact was among older animals 
in parity 4 or greater at 101-200 days in milk at the beginning of the outbreak. This group 
produced on average 547.4 litres (95%CI 295.6, 799.1) less than predicted. 
 
 
Figure 6.2. Frequency distribution of actual yields produced from the beginning of the 
outbreak to the end of the animal’s lactation for all cows present during an outbreak of foot-
and-mouth disease on a large-scale dairy farm in Nakuru County, Kenya. Cows are included if 
at least one milk recording is made during the outbreak period (31st August-28th September 
2012). The average lactation length under consideration was 154.4 days (range 4-344).  
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Table 6.5. Results of a multiple linear regression model comparing the actual and predicted 
milk yields for cows lactating during an outbreak of foot-and-mouth disease on a large-scale 
dairy farm in Nakuru County, Kenya.  
Variable Category Coefficient (95% CI) SEc P-value 
Parity a - -214.1 (-304.9, -123.2) 46.1 <0.0001 
     
Days in milk b 0-100 Reference - - 
 101-200 -139.2 (-359.7, 81.2) 111.9 0.22 
 201-300 130.8 (-87.6, 349.1) 110.8 0.24 
 >300 -53.9 (-339.5, 231.8) 144.9 0.71 
     
Constant - 448.2 (256.0, 640.4) 97.5 <0.0001 
Note: The outcome in the model is the difference between actual and predicted milk yield 
from the beginning of the outbreak. Predictions are based on historic lactation data from cows 
in the same herd. Negative coefficient values reflect underperformance producing less milk 
than predicted. Predicted yields are based on historic data from the same herd. a Parity 
included as an ordered categorical variable, grouped as 1, 2, 3 and ≥4. b Includes cows calving 
during the outbreak period. c Standard error 
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Figure 6.3. Mean difference (with 95% CI) between actual and predicted milk yields for 
different combinations of predictors based on a multiple linear regression model for cows 
lactating during an outbreak of foot-and-mouth disease on a large-scale dairy farm in Nakuru 
County, Kenya. Cows were included in the analysis if they had at least one milk recording 
during the outbreak period (31st August-28th September 2012). Yields are based on the amount 
produced from the beginning of the outbreak to the end of the animal’s current lactation. 
Predictions are based on historic lactation data from cows in the same herd. X-axis categories 
represent the number of days in milk at the beginning of the outbreak (those calving during 
the outbreak are in the 0-100 category).  
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6.5 Discussion 
The study used an empirical milk yield dataset from a large-scale dairy farm to estimate the 
impact of a FMD outbreak on subsequent production. A negative effect on milk production 
was seen at the herd level with a decrease in production from an average of around 20 litres 
per cow per day decreasing to around 13 litres. On further analysis utilising a GEE model and 
adjusting for confounding variables, there was no statistical evidence that cows reportedly 
affected with FMD produced less milk than non-cases. Additionally, no effect on milk 
production was evident when comparing the actual milk production to that predicted from 
historic production data for the herd when considering all animals irrespective of reported 
FMD status. Further analysis revealed that animals in parity 3 or greater did show evidence of 
poor milk production, particularly if between 0 and 200 days in milk at the beginning of the 
outbreak period. Possible reasons for lack of difference between reported cases and non-cases 
include inaccurate case recording, poor sensitivity of the case definition, subclinical infections 
or inadequate statistical power.  
A reduction in milk yield was apparent at the herd level in the week prior to the outbreak 
being detected which may indicate a drop in yield prior to the onset of clinical signs and 
therefore may have implications for disease surveillance. The overall length of the milk yield 
depression is around two month’s duration from the beginning of the outbreak period. Despite 
this clear herd level reduction concomitant with the outbreak onset, the lack of difference 
between recorded cases and non-cases at the individual level is surprising. Possible reasons for 
this include inaccurate case recording, poor sensitivity of the case definition and subclinical 
infections. Poor recording is possible given the large number of cases affected, although each 
group was attended by herdsmen at all times and with the maximum group size of 58 cows, 
one would expect most affected cows to be detected. Additionally, all reported clinical cases of 
FMD were treated with oral sodium carbonate necessitating physical handling of the animals, 
so they could be readily identified and recorded in this context compared to merely observing 
them from a distance. Every group had clinical cases and it is therefore highly likely every 
animal was exposed to infection. The case definition for this outbreak was a cow exhibiting 
hyperptyalism during the outbreak period with any other clinical sign. Hyperptyalism is a useful 
clinical sign for recording cases of FMD because it is very commonly found, is easy to identify, 
and does not involve physical examination of the animal. In milder cases of disease, it may be 
possible for a cow to be “sick” with FMD without showing signs of hyperptyalism and therefore 
not be recorded as a case. Additionally, vaccination may have attenuated the disease impact 
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or severity although previous analysis of this outbreak revealed that the vaccine had limited or 
no effectiveness in preventing clinical disease (Lyons et al., 2015). There could also be a 
possible genetic reason with animals not showing clinical symptoms being less susceptible to 
the disease, yet obviously experiencing infection. 
Due to the lack of any difference detected between cases and non-cases despite a clear herd-
level impact during the outbreak period, the actual and predicted yields of all animals present 
during the outbreak were compared to explore this further. The results of this analysis 
revealed a significant impact among older animals of parity 3 and greater. This may be due to a 
greater degree of hardiness among younger cattle so that they recover more quickly but also 
because cows in their first and second parity tend to produce less milk over the course of 
lactation. In this herd, historic milk yield data prior to the outbreak showed parity three and 
greater cows were the highest yielders in the herd, which is consistent with observations 
elsewhere for Holstein-Friesian cows (Friggens et al., 1999). In fact, these results show first 
parity cows tended to produce more milk than predicted for reasons that are unclear but may 
reflect poor predictive ability of the method especially as milk production in the tropics can be 
so heavily influenced by seasonal differences in feed and water supply. However, the use of 
data from 2005-2012 and adjusting for the season when calving commenced should account 
for some of the variation seen. Parity one animals make up the relative majority of cows in this 
herd and so the lower impact seen among this group is a likely to contribute to the lack of 
overall effect between reported clinical cases and non-cases apparent in the analysis.  
The stage of lactation the animal was in during the outbreak also impacted subsequent 
production. The normal lactation curve for a cow typically rises to a peak early in lactation 
before decreasing at a relatively constant rate. It has been shown in Kenyan Holstein-Friesian 
cows that this peak typically occurs in the third or fourth month of lactation (Njubi et al., 
2010). It is therefore logical that the stage at which an animal is affected by disease will 
influence the impact on milk production. If a cow is affected during its period of peak yield, 
then the effect may be greater in terms of total lactation yield. This is reflected in the results of 
this study as animals between 100 and 200 days in milk had the biggest impact when 
comparing predicted and actual yields. Alternatively, if a cow is affected by a disease event 
early in lactation, then there is greater potential to recover the 305 day yield, and being 
affected in late lactation the daily milk yield may be relatively quite low and therefore the 
impact on the 305 day milk yield would be correspondingly low. The results from this study 
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indicate that animals may recover their potential lactation contrary to previously published 
anecdotal evidence (Kitching, 2002).  
In other diseases, in which higher yielding animals have been shown to be at higher disease 
risk, it has been observed previously that when higher yielding animals become sick, the 
lactation milk yield could still be comparable with that of lower yielding healthy herd mates 
(Gröhn et al., 1995). Although it cannot be said that higher yielding cows are at increased risk 
of FMD, particularly as the cows in this study population are lower yielding than typical 
European based Holstein-Friesians for which the phenomenon has been documented, this 
cannot be ruled out as a contributory factor.  
Care must be taken when generalising the study’s results to other farms in Kenya as this is only 
one example from a farm type in a particular area and with a specific serotype and strain of 
virus. However, in this part of Kenya it is common for smallholder farmers to purchase cows 
from large-scale farms, and therefore dairy cow genetics is likely to be similar among local 
smallholder farms. This combined with the common practice of purchasing supplementary 
feeds through local co-operative organisations means the difference in yields between 
smallholder and large-scale farms in this region of Kenya may not be as great as one may 
initially assume. At a global level, these types of systems are increasingly common in milk 
supply. Further studies collecting objective data on milk yields and other aspects of disease 
impact from the local smallholder dairy population is needed in order to fully appreciate the 
impact of FMD in this region of Kenya and in other parts of Africa.  
In summary, the impact of FMD is poorly characterised in endemic areas and it is important to 
publish results based on empirical data in order to contribute to the evidence base rather than 
relying on post-outbreak estimates or anecdote. The results of this study address this shortfall 
by quantifying the impact of FMD on a large-scale dairy farm in Kenya. Although there was a 
clear impact at a herd level, no difference was detectable between reported clinical cases and 
non-cases. Deeper analysis revealed that cows in parity 3 or greater particularly in the first 200 
days of lactation had a significant reduction in milk yield compared to what was predicted. The 
most severely affected group was cattle of parity 4 or greater at 101-200 days in milk at the 
start of the outbreak that produced on average 547.4 kg (95%CI 295.6, 799.1) less milk than 
predicted. 
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Supplementary material 6.1. Mean daily milk production per group on Farm 1 from one week prior to the farm index case (31/8/2012) to approximately five 
weeks after the last case (28/9/2012). Values are based on actual daily milk production rather than averaged over the week as in the main analysis in his paper.  
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Chapter 7. Farm 2 – Outbreak description and vaccine evaluation 
7.1 Introduction 
During November 2013, an outbreak of FMD was attended on another large-scale dairy farm in 
Nakuru County. At the time of the visit, the outbreak had been ongoing for approximately 
three weeks but the owners had been keeping records of cases as they occurred and were 
willing to share data for research purposes (Appendix A). The following description and 
analysis follows the same format as Chapter 4 with a discussion comparing the two outbreaks 
in Chapter 8 and a further discussion of the implications in Chapter 11. Supplementary 
materials for this outbreak are at the end of this chapter (page 163). This chapter has not been 
submitted for publication as a research paper. Further details on data management are in 
Appendix D. 
7.2 Materials and methods 
7.2.1 Farm background 
The 240 hectare farm was located in Rongai sub-county (formerly district) of Nakuru County 
near the administrative town of Kambi ya Moto. The farm primarily bred high genetic merit 
Jersey cattle for milk production and animal sales although Holstein-Friesian (HF) and various 
Jersey-HF cross-breeds were also present. The farm did not purchase cattle. In addition to the 
cattle, the farm had approximately 60 horses and numerous dogs. There were no sheep, goats 
or pigs. The farm was surrounded by a single electrified perimeter fence which was checked 
twice daily. Apart from small antelope (that may occasionally have transgressed the perimeter 
fence) there was no FMD susceptible wildlife present on the farm. Although there were other 
large-scale and smallholder farms in the area, the cattle on this farm did not graze near the 
perimeter minimising the possibility of direct contact with other livestock.  
The farm employed approximately 40 staff of whom 20 had regular contact with the livestock. 
Some of these workers lived off the farm and may have owned FMD susceptible animals. Staff 
were assigned to work with a particular management group (e.g. calves) although they assisted 
with other groups as required. 
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7.2.2 Study population 
The farm had approximately 350 cattle. Animals were managed in nine groups depending on 
their age, sex and production status (Table 7.1). Calving occurred in the close-up dry cow group 
(“C”). The dam and calf were moved to the group L1 immediately upon calving where the calf 
has the opportunity to consume colostrum from the dam. After four days, they were separated 
with the dam entering the appropriate lactating cow group (L2 if parity one, L3 if >1 parity) and 
the calves housed as part of group Y1. Male calves not retained for breeding were usually 
euthanased at this time. Calves were housed in converted stables in groups of up to three 
individuals for the next two weeks of life before being moved outside if considered strong 
enough. The movements of calves between housing and paddocks were not recorded (i.e. 
group Youngstock 1 [Y1] includes housed and non-housed calves) but all other intra-group 
stock movements were manually recorded. The exact location of groups were not recorded 
although dry cows were typically located in the centre of the farm with lactating cow groups in 
various other paddocks depending on grazing availability. Adult bulls were kept in their own 
individual paddocks separated by electric fencing although “nose-to-nose” contact was 
possible between them.  
All cattle except bull calves destined for euthanasia were individually identified with unique 
ear tag numbers and names. Calving occurred all year around with breeding through a 
combination of artificial insemination or natural service with the pedigree Jersey bulls on the 
farm. No animals with zebu genetic background were present on the farm. Cows were milked 
through an automated parlour located in the centre of the farm and all lactating cows had 
daily milk yields recorded. Prior to the FMD outbreak, the mean daily yield was approximately 
11 litres per lactating cow.  Milk was collected by a tanker every other day. All farm records 
were paper based. 
For external parasite control, all cattle were put though a spray race on the farm once a week. 
7.2.3 FMD history and current outbreak 
At the onset of the outbreak (21st October 2013), the owners suspected FMD and notified the 
local government veterinary officer. The officer later attended the outbreak but was unable to 
collect a sample suitable for diagnosis. The DVO later reported the outbreak to a EuFMD 
training course that happened to be searching for FMD demonstration cases at the time. A visit 
was undertaken on the 15th November 2013 at which time several animals were examined 
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(Appendix E) and epithelium samples from fresh lesions were taken for submission to the 
National FMD laboratory in Embakasi, Nairobi. Results of the antigen ELISA were positive for 
serotype O. At the time of writing, no sample had yet been sent to the World Reference 
Laboratory (WRL). 
All cases of FMD were recorded in a treatment book, since all affected cows were treated with 
oral sodium carbonate (“Magadi soda”) and antibiotics as appropriate. The farmer identified 
cases on the basis of hyperptyalism with a depressed appetite. Detailed clinical signs were not 
recorded.  
The farm vaccinated for FMD using a locally produced quadrivalent vaccine incorporating 
strains for the A, O, SAT1 and SAT2 serotypes. All cattle over the age of six months were 
vaccinated every four months, regardless of concurrent illness or proximity to calving. No 
second dose was given as part of the primary course. This policy had been performed for 
several years and all animals present on the farm had been exposed to the same dosing 
schedule. Vaccination was last performed prior to the outbreak on 12th July 2013. The farm 
records the batch numbers of all vaccines used, and stored vaccines in a fridge on arrival at the 
farm prior to use. Vaccines were delivered direct from the manufacturer using a courier with 
the vaccines packed on ice in sealed insulated containers. On arrival at the farm they were 
used as soon as possible, usually within a couple of days of delivery. 
The farm had experienced previous outbreaks of FMD in March 2004 and December 2010. For 
the former, serotype SAT2 was detected by the National FMD laboratory, although for the 
2010 outbreak no viral antigen could be detected. The identification of individual clinical cases 
was recorded from both of these outbreaks. The farmer recalled that the clinical signs were 
mild in the 2010 outbreak which had affected approximately 15% of the herd. The farmer also 
reported that those affected during the 2010 outbreak tended not to be affected during the 
2013 outbreak.  
In this 2013 outbreak, FMD had been present on local smallholder farms and movement of 
personnel was considered the most likely source of introduction. 
7.2.4 Data analysis 
Each animal on the farm, excluding the bull calves that were destined for euthanasia, had an 
individual record card that corresponds to the unique ear tag number and name. This card 
contained all relevant health and breeding events including abortions (Appendix D). FMD 
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recording was done separately on a treatment sheet according to the case definition given in 
the previous section (7.2.3). All relevant data were manually entered by the author into a 
Microsoft Excel spreadsheet prior to import into Stata 13.0 (Statcorp, Texas, USA) for analysis. 
A cohort study approach was utilised to describe the outbreak. The primary outcome was 
being recorded as a clinical case of FMD. The entry date into the study was the date of the 
index case. Cases exited the analysis on the date of disease onset. Non-cases were censored on 
the date of the last case or the date of exiting the herd for other reasons (e.g. death or being 
sold). To account for the correlation within groups, a mixed effects Poisson regression model 
was utilised incorporating group ID as a random effect to generate rate ratios.  
Vaccine effectiveness was calculated by the equation 1-Risk Ratio (RR). Risk ratios were 
estimated using a generalised linear model (GLM) with a binomial distribution and logarithmic 
link function. Parameters were estimated using a Fisher scoring optimisation algorithm. The 
lifetime number of doses received was included as the explanatory variable. 
7.3 Results 
7.3.1 Demography 
During the 59 day outbreak period, a total of 351 live cattle were present on the farm 
representing a total of 9,699 cattle-days at risk (Table 7.1). Thirty cows gave birth during the 
outbreak producing 14 and 15 live heifers and bulls respectively (includes one set of male 
twins). Two heifers were born dead so that a total of 31 calves were born. Twelve other 
females died during the outbreak (see details below). Of the live bull calves, two were retained 
in the herd while the remaining were euthanased between zero and five days of age (five were 
euthanased on day zero, the day of birth). Four adult bulls were present on the farm and kept 
in individual paddocks (mean age 4.7 years, range 3.9-5.5). One 18 month old bull was kept in 
the “dry cow and bulling heifers (D/B)” group whilst one four month old bull calf was in the 
Youngstock 1 (Y1) group. 
The most common breed present was purebred Jersey (236/346, 68.2%) followed by HF. A 
small number of crosses between these breeds were also present (Table 7.2). 
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Table 7.1. Descriptive data on animals present and FMD incidence by management group during the FMD outbreak on Farm 2.  
Group ID Cattle-
days 
N a Age (mean, 
range) b 
Parity (mean, 
range) 
Lifetime vaccine doses  
(mean, (median; range)) 
Incidence rate per 100 
cattle-days (95% CI) 
Date of 
onset 
Youngstock 1 (Y1) 
 
985 30 
 
21.0 (-49, 142) N/A 0.0 (-) 0.81 (0.41, 1.6) 11/11/13 
Youngstock 2 (Y2) 
 
625 19 163.8 (30, 211) N/A 0.0 (-) 1.9 (1.1, 3.4) 15/11/13 
Youngstock 3 (Y3) 
 
330 44 331.9 (154, 433) N/A 0.9 (1; 0, 2) 12.1 (8.9, 16.5) 26/10/13 
Dry cows and bulling heifers 
(D/B) 
 
1329 103 3.5 (1.2, 11.7) 1.4 (0, 7) 8.4 (4; 2, 32) 5.4 (4.3, 6.8) 21/10/13 
Close-up dry cows (C) 
 
505 57 3.2 (-0.15, 11.7) 2.4 (0, 8) 8.4 (5; 0, 32) 1.2 (0.53, 2.6) 9/11/13 
Fresh calvers and sick (L1) 
 
291 49 3.0 (-0.15, 10.4) 2.6 (0, 8) 8.0 (4; 0, 28) 0 (-) - 
Lactating – first calvers (L2) 
 
1206 42 2.8 (1.9, 3.6) 1 (-) 6.6 (6; 4, 9)  2.2 (1.5, 3.3) 2/11/13 
Lactating – others (L3) 
 
4288 111 6.6 (2.4, 11.9) 4.3 (0, 10) 17.5 (17; 5, 32) 0.98 (0.72, 1.3) 7/11/13 
Bulls (B) 
 
140 4 4.7 (3.8, 5.5) N/A 12.3 (12.5; 10, 14) 2.1 (0.69, 6.6) 16/11/13 
All groups 9699 346 1270 (-56, 4336) 1.9 (0, 10) 8.6 (6; 0, 32) 2.2 (1.9, 2.5) 21/10/13 
Note: Age and parity are based on the status at the start of outbreak (21st October). All animals were kept in freely mixing groups except Youngstock 1 that are 
housed in groups of up to three calves for the first two weeks. The five bull calves euthanased on the day of birth are excluded from the analysis. N/A = not 
applicable. a For groups, total number of individual cattle that were in the group at some stage of the outbreak. b Days for youngstock and “All groups”, years for 
other groups. Negative values reflect animals being born during the outbreak.
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7.3.2 FMD outbreak description 
The outbreak commenced on the 21st October with the last case detected on 18th December. 
The overall incidence risk was 211/346 (60.1%). The epidemic curve for the outbreak is shown 
in Figure 7.1 with individual group curves shown in Supplementary material 7.1. The index case 
was among the dry cows and bulling heifers group, located in a central farm location (Figure 
7.1). The final case was a calf born during the outbreak. This animal was 19 days old at disease 
onset which began after it left the indoor housing and entered the outdoor free-mixing 
paddock. The previous case, with onset 13 days previously, was also in the outdoor calf group. 
Both of these cases were in the sub-group of Y1 at pasture and no cases were seen among 
calves in the housed area. Clinical signs observed during the outbreak include hyperptyalism, 
milk drop, inappetence and oral, feet and teat vesicles (Appendix E). The farm reported that 
the mean daily milk yield fell as low as 8.5 litres per cow during the outbreak.  
A network of direct contacts between groups during the outbreak was elucidated with help 
from the farm staff (Figure 7.2). Approximate group locations are provided in Figure 7.3. Three 
clusters of inter-group direct contacts can be seen. The outbreak was initially among the D/B 
and Y3 groups which were in direct contact with each other but not with the other 
management groups. Group Y3 became affected five days after the onset of disease in group 
D/B, consistent with the incubation period for FMDV. A second wave of cases (Figure 7.1) 
began with group L2 and spread to all other cattle groups that were interconnected though 
likely direct contacts (Figure 7.2). The last group affected was the bulls (B) which had no direct 
contacts during the outbreak. The weighted mean group incidence rate was 2.2 (95%CI 0.84-
5.2) per 100 cattle-days, varying from 0 to 12.1 between groups. Although group L1 appears to 
have had no cases, several affected animals were present in group L1 but all had disease onset 
in other groups, either before entering this group or after departing.  
Twelve animals exited the herd during the outbreak. Four cows were culled for reasons 
unrelated to FMD and went direct to slaughter. Of the remaining eight, three died suddenly 
with no clinical signs. These animals were aged between four and five months. No post-
mortem was performed but it is possible that they died as a consequence of FMDV infection 
which is known to cause deaths among cattle of this age. The five remaining deaths were all 
ascribed to FMD according to the farmer. One was a six month old calf that died the day 
following disease onset. The remaining were all adult cows (ages 2.6, 3.5, 6.4 and 10.6 years) 
that died between seven and 19 days after FMD onset showing gradual deterioration and 
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failing to respond to supportive treatment. Excluding the cull cows, euthanased bull calves and 
stillborn, the overall mortality rate was 8/331 (2.4%). No abortions were recorded during the 
outbreak. 
Interestingly the farmer reported two cases that developed clinical lesions and then relapsed 
with fresh lesions after apparent recovery. The first was a five year old cow that showed 
clinical signs of FMD on the 12th November which then calved on the 20th November, moved 
groups as per normal farm routine, before fresh lesions were observed again on the 30th 
November. A similar course was seen in a seven month old calf that showed fresh lesions 16 
days apart although with no associated movement between groups. For the analysis, both of 
these were included as single cases on the date lesions were first recorded. 
 
 
Figure 7.1. Epidemic curve and cumulative incidence of FMD for all management groups 
combined on Farm 2. Solid arrows indicate the dates of FMD onset within each group. Dashed 
arrow represents the timing of vaccination (11th November). Denominator for cumulative 
incidence is the mean daily number of cattle present on the farm over the outbreak period 
(21st October-18th December). See Supplementary material 7.1 for individual group epidemic 
curves.  
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Figure 7.2. Schematic outline of contacts between different management groups during the 
outbreak period on Farm 2 showing three clusters of direct contacts (each circled). Contact is 
defined by animals potentially having “nose-to-nose” interactions that are represented by 
arrows. Arrow direction reflects the direction contacts may occur (i.e. the direction of animal 
movement). L2 and L3 both had “over-the-fence” contact with L1 when taken to the parlour 
for milking when a nose-to-nose interaction was possible. Group B had no direct contacts. The 
index case was in group D/B.  
D/B 
Y3 
Y1 
L1 
L2 
L3 
C 
Y2 
B 
Contact due to animal movements between paddocks 
Contact from being in neighbouring paddocks  
Contact from both animal movements and being in 
neighbouring paddocks 
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Figure 7.3. Outline of Farm 2 showing paddock and group locations during outbreak. Groups L2 
and L3 were in neighbouring paddocks not marked on map. The index case was in group D/B. 
Dashed arrow represents movement of the D/B group at the start of the outbreak as an 
attempt at isolation. Single lines represent a single fence whereas roads are represented by 
two parallel lines. “Buildings” show where the parlour was located.  
N 
Y1 = Youngstock 1 
Y2 = Youngstock 2 
Y3 = Youngstock 3 
D/B = Dry cows and Bulling heifers 
C = Close-up dry cows 
L1 = Fresh calvers and sick 
L2 = Lactating (first calvers) 
L3 = Lactating (others) 
B = Bulls 
≈ 200 metres 
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7.3.3 Farm response to FMD outbreak 
The first cases were in the dry cow and bulling heifer group (D/B) which had only had contact 
with group Y3 but was located in a central part of the farm. On seeing the cases, the farmer 
attempted to isolate the affected group by moving it to an area further away from the centre 
of the farm (represented by the dashed arrow in Figure 7.3). Cases began in group Y3 (which 
were not moved) five days later and thereafter cases began in other groups. No other 
attempts at isolation were made. All affected animals were treated with oral sodium 
carbonate and topical/parenteral antibiotics as deemed appropriate by farm staff. This was 
performed in a crush located in the middle of the farm in close proximity to the buildings 
highlighted in Figure 7.3. 
Vaccination was performed on the 11th November (day 22 of the outbreak), in line with the 
scheduled four monthly routine, not as an additional “reactive” vaccination. After discussions 
with other large-scale farmers, the decision was made to vaccinate all animals irrespective of 
age differing from their previous vaccination programme (described in section 7.2.3). The farm 
was intending to continue this practice in future due to a perceived lack of effectiveness of the 
previously used schedule. 
7.3.4 Patterns by age, sex, parity, lactation, breed and previous disease status 
The incidence was highest (over 90%) in animals aged between six and 18 months of age.  At 
older ages the incidence showed a gradual decline up to four years of age when the incidence 
plateaus at 40-50%. The incidence among animals younger than six months of age was similar 
to that among animals over four years of age (Table 7.2). After adjusting for the management 
group, the rate ratio increased to a peak in the 1-1.5 year age group and then declined to a 
plateau from ≥4 years.  
When examining the effect of parity, animals in parity two or greater had a significantly lower 
rate of disease compared to the baseline parity zero category. There was no significant 
difference between cattle in the parity zero and parity one categories (Table 7.2). 
The incidence risk was higher among female animals, but this was likely to be a function of age 
(and/or number of lifetime vaccine doses received) since most males were over four years of 
age. Indeed when adjusted for management group, there was no statistical evidence for this 
effect (Table 7.2). There was no significant effect of lactation stage or breed on the risk or rate 
of disease. 
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Of the animals present during the current outbreak, 159 were present during the December 
2010 outbreak of which 13 (8.2%) had been clinical cases. For animals present during the 2010 
outbreak, those that had clinical disease during that outbreak had an overall lower incidence in 
the 2013 outbreak although the difference was not statistically significant (Incidence in 2010 
cases = 5/13 [38.5%]; incidence in non-2010 cases = 71/146 [48.6%]; P=0.48). Nineteen animals 
present during the current outbreak had been present in March 2004 outbreak but similarly 
there was no association with those diseased then and being subsequently affected in the 
2013 outbreak (Incidence in 2004 cases = 5/12 [41.7%]; incidence in non-2004 cases = 2/7 
[28.6%]; P=0.66 [Fisher’s exact test]). 
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Table 7.2. Descriptive risk factor analysis evaluating associations with being a case of FMD on 
Farm 2.  
Variable N  FMD cases 
(row%) 
P-value
a
 Rate ratio  
(95%CI) 
P-value
b
 
Age category (n=351)      
    Born during outbreak 29 2 (6.9) 
 
0.17 (0.028, 0.97) 0.047 
    <6 months 24 12 (50.0)  0.51 (0.17, 1.5) 0.23 
    6m-<1y 27 25 (92.6)  1.46 (0.66, 3.3) 0.35 
    1-<1.5y 44 43 (97.7)  1.75 (0.94, 3.3) 0.077 
    1.5-<2y 27 22 (81.5)  0.90 (0.47, 1.7) 0.74 
    2-<3y 50 36 (72.0)  Baseline - 
    3-<4y 33 23 (69.7)  0.80 (0.45, 1.4) 0.45 
    4-<5y 22 10 (45.5) <0.0001 0.31 (0.14, 0.69) 0.004 
    5-<6y 12 3 (25.0)  0.11 (0.033, 0.39) 0.001 
    6-<7y 20 7 (35.0)  0.22 (0.088, 0.53) 0.001 
    7-<8y 27 12 (44.4)  0.26 (0.13, 0.55) <0.0001 
    8-<9y 14 7 (50.0)  0.45 (0.18, 1.1) 0.079 
    9-<10y 12 6 (50.0)  0.37 (0.15, 0.94) 0.037 
    10-<11y 5 3 (60.0)  0.45 (0.13, 1.5) 0.20 
    11-<12y 5 0 (0.0)  - - 
      
Sex (n=351)      
    Female 330 206 (62.4) 0.0005 Baseline - 
    Male 21 5 (23.8)  1.3 (0.31, 5.4) 0.72 
      
Parity (n=330)      
    0 152 118 (77.6)  Baseline - 
    1 52 36 (69.2)  0.64 (0.30, 1.3) 0.25 
    2 26 10 (38.5) <0.0001 0.14 (0.065, 0.32) <0.0001 
    3 16 9 (56.3)  0.25 (0.11, 0.55) 0.001 
    ≥4 84 33 (39.3)  0.15 (0.085, 0.26) <0.0001 
      
Lactation stage (n=182)      
    Early-lactation (<0-100d) 61 27 (44.3)  Baseline - 
    Mid-lactation (101-250d) 61 32 (52.5) 0.48 1.2 (0.73, 2.1) 0.42 
    Late-lactation (>250d) 44 23 (52.3)  1.2 (0.68, 2.1) 0.53 
    Dry 16 8 (50.0)  1.1 (0.42, 2.7) 0.89 
      
Breed (n=346)
c
      
    Holstein Friesian (HF) 80 44 (55.0)  0.78 (0.56, 1.1) 0.16 
    HF crossbreed 5 3 (60.0)  1.1 (0.35, 3.6) 0.83 
    HF x Jersey 15 6 (40.0) 0.27 0.41 (0.18, 0.92) 0.032 
    Jersey 236 151 (64.0)  Baseline - 
    Jersey crossbreed 10 7 (70.0)  0.83 (0.39, 1.8) 0.64 
Note: Rate ratios are generated from Poisson regression incorporating group ID as a random 
effect. Five bull calves euthanased at birth not included in rate ratio calculation. Animals are 
categorised based on the status at the beginning of the outbreak except lactation stage. Cows 
calving during the outbreak are included in the early-lactation category. Baseline groups are 
selected based on having the highest number of animals. a Chi-square test. Chi-square test for 
trend used for parity and lactation stage. b Wald test. c Not available for bull calves euthanased 
on day of birth 
158 
 
7.3.5 Patterns by lifetime vaccine doses received 
Figure 7.4 shows FMD incidence by numbers of vaccine doses received. The highest incidence 
of FMD was among animals that had received one dose of vaccine. A gradual decline in the 
incidence can be seen with the number of doses received, reaching a plateau at around 11 
doses. The risk of FMD was similar between animals that received no doses of vaccine (which 
according to the schedules used on this farm are mostly below the age of six months) and 
animals that received approximately nine or more doses of vaccine. The incidence among 
older animals could be confounded by exposure in previous outbreaks although there was no 
association between cows reported to have been affected and being clinically affected during 
the current outbreak. The protection seen in animals that had received no doses of vaccines is 
likely due to passive immunity from their dams. 
 
 
Figure 7.4. Incidence risk (with 95% confidence intervals) of FMD by the lifetime number of 
FMD vaccine doses given to all animals present on Farm 2 during the outbreak period  (21st 
October-18th December 2013).  Number of doses does not include the vaccination given during 
the outbreak.  
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7.3.5.1 Estimation of relative vaccine effectiveness 
Animals below the age of six months were excluded due to the effect of maternal antibody 
which from the farm’s vaccine policy removed all animals receiving zero doses of vaccine from 
this analysis. Due to the non-linear association between number of doses received and FMD 
incidence risk (Figure 7.4), the former was included as a categorical variable. The baseline 
group was animals receiving one or two doses of vaccine because the incidence risk in those 
receiving one dose was 100% prohibiting estimation of risk ratios using a GLM. Figure 7.5 
shows how the relative vaccine effectiveness varies with the number of doses received. 
Evidence of a gradual increase in protection with an increase in the number of doses can be 
seen reaching a plateau at ≥ 11 doses with a relative effectiveness of around 50-60%. Due to 
the absolute collinearity between the number of doses received and age, the latter could not 
be adjusted for in the statistical model. 
 
Figure 7.5. Relative vaccine effectiveness by the number of lifetime doses of vaccine received 
with 95% confidence intervals for Farm 2. The baseline category is animals receiving 1 or two 
doses of vaccine. Vaccine effectiveness is calculated from the equation 1-risk ratio. Risk ratios 
were estimated using a GLM with a log link and binomial distribution.  
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7.4 Discussion 
The main findings from this outbreak are the high incidence among animals up to the age of 
four years with evidence of vaccine protection only being apparent after animals had received 
several doses of vaccine. Evidence was also found of a protective effect likely due to passive 
immunity from the dam shown by the relatively low disease among animals less than six 
months of age. Neither breed nor lactation stage was associated with disease incidence. 
Females were at higher risk than males but this is likely confounded by age and the number of 
doses of vaccine received. 
The outbreak originated in a central farm location among the dry cows. This suggests that 
introduction by direct contact through the perimeter is unlikely. With no animals being 
purchased and a lack of contact between visiting people and vehicles with the livestock, the 
most likely route of introduction was indirectly through workers living off the farm. This is an 
issue that should be addressed by farm owners, who should consider implementing 
appropriate biosecurity measures for high risk workers (i.e. those that own livestock)  
particularly when FMD is known to be in the area (see further discussion on farm biosecurity in 
section 11.4.1). Once on the farm, infection initially spread between two groups that were in 
neighbouring paddocks (Figure 7.2). Infection then spread to the main cluster of groups that 
were all connected by direct contacts (Figure 7.2). This led to the second peak of cases evident 
in Figure 7.1. The last affected group was the bulls that had no direct contact with any other 
groups during the outbreak. With farm staff moving between groups and clusters without 
using adequate bio-security, indirect spread through personnel is likely to have been the main 
route of spread between the three clusters. Possible ways of limiting the spread on a farm 
once disease is detected is discussed in detail in section 11.4.1. 
The incidence among young calves was low probably due to the presence of maternal derived 
antibody (MDA). The number of doses of vaccine that lactating cows had received is relatively 
high by virtue of their age with cows on the farm typically calving for the first time between 
two and three years of age (Table 7.1). The antibody levels in calves would be expected to 
reflect this older, more heavily vaccinated population through passive acquired MDA 
consumed in colostrum until the age of around six months after which time MDA has typically 
waned (Nicholls et al., 1984). It is therefore interesting to see that the incidence among these 
older cows is very similar to that among the calves below the age of six months that had 
received no vaccine but has recently received MDA. 
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The incidence peaked between ages six and 18 months and then declined, appearing to 
plateau from the age of four years onwards. In terms of the number of doses of vaccine and 
the relative vaccine effectiveness calculation, some protection was apparent in animals 
receiving over five doses of vaccine but the best protection was seen among animals receiving 
11 or more doses. Compared to a baseline of one or two doses, the maximum vaccine 
effectiveness was around 50%.  
Although being affected in a previous outbreak was not associated with being a case in the 
study outbreak, there still could be age related effects that were not accounted for in this 
analysis. For example, some residual immunity cannot be ruled out. However the serotype in 
2004 was SAT2 and there is not thought to be any cross protection between serotypes with 
FMDV (OIE, 2009). The serotype from the 2010 outbreak is unknown but it should be borne in 
mind that animals in previous outbreaks are also older and this would confound the 
association through having a higher number of doses of vaccine. This correlation means that 
the relative vaccine effectiveness estimates are limited as they cannot be adjusted for age. As 
highlighted in section 4.5, the inability to adjust for the possible confounding effect of age in 
the model is a major limitation of the approach and highlights the difficulties in evaluating 
vaccine effectiveness on herds using a routine vaccine policy applied to all animals at the same 
time. 
The timing of vaccination during the outbreak was in keeping with the routine vaccination 
schedule the farm administers every four months rather than as part a reactive vaccination to 
limit the impact of the outbreak. As can be seen in Figure 7.1, by the time the vaccine was 
administered, six groups had already reported cases and the two remaining groups (Y2 and B) 
developed disease four and five days later respectively. This is unlikely to be enough time to 
allow the vaccination to work particularly when virus exposure is likely to have occurred so 
soon after administration. This combined with the small number of animals in these groups 
and being the first dose of vaccine received by group Y2 (and so has no appropriate 
comparison group) evaluation of the effectiveness of this strategy was not possible from this 
outbreak. 
Also of note in this outbreak is the mortality among adults. Usually FMD is associated with 
mortality in younger animals connected to myocarditis. In this study outbreak, three sudden 
deaths were seen in youngstock and one further young animal died after developing FMD 
lesions. Four further deaths were seen in adults that the farmer ascribed to FMD. Rather than 
an acute mortality as seen with myocarditis, these were related to prolonged anorexia. 
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Although unconfirmed, this report suggests that the impact of FMD is more severe among 
adults than usually thought although the overall mortality was consistent with other reports 
(for further discussion, see section 8.3).  
Further discussion of this outbreak and a comparison with the observations on Farm 1 are 
presented in Chapter 8 and Chapter 11.
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Supplementary material 7.1. Epidemic curves for each group on Farm 2. Note there is no curve presented for group L1 because no cases began in this 
group although diseased animals did pass though after disease onset. Arrow represents the date of vaccination duing the outbreak. Continued on next 
page. 
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Supplementary material 7.1. Continued from previous page. 
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Chapter 8. Discussion of the FMD outbreaks on Farm 1 and Farm 2 
Two outbreaks of FMD on large-scale dairy farms that use prophylactic vaccination have been 
described in detail in Chapter 4 and Chapter 7. There are several key similarities and 
differences between these outbreaks that give insights into FMD epidemiology and aspects of 
vaccine performance. The following is a comparison of these outbreaks and a discussion of the 
implications of the findings. Both farms used locally produced vaccine manufactured by the 
same company. Major features of the farms, the animals and the FMD outbreaks are 
summarised in Table 8.1. 
8.1 Farm backgrounds 
Both farms are located in Rongai Sub-county of Nakuru County and are approximately 14km 
apart (or 20km by road). Both are large-scale dairy farms producing milk that is sold to a dairy 
company. Both breed pedigree cattle with Farm 1 (Chapter 4, from here referred to as 
Farm1/SAT2) in particular focussing on receiving income through the sale of in-calf heifers and 
first lactation animals. Compared to Farm 2 (Chapter 7, from here referred to Farm 2/O), Farm 
1/SAT2 has more animals (including small ruminants), employs more people and also receives 
significant additional income through the sale of crops. Both calve all year around and use 
artificial insemination for breeding, although Farm 2/O also uses natural service through 
home-bred bulls.  
8.2 Farm demographics 
Due to different breeding and sales policies, the age distributions differ between the herds as 
shown in their respective population pyramids (Figure 8.1). The number of males is low in both 
herds as they are both dairy farms that usually remove males at an early age or use sexed 
semen as with Farm 1/SAT2. There are obvious differences in the age distributions, with Farm 
1/SAT2 being a younger herd and most animals tending to be between the ages of 1 and 4 
years. This reflects their policy of selling heifers or first lactation animals as an important 
source of income and tending not to retain older animals. In contrast Farm 2/O has a much 
broader age distribution. This reflects their policy of retaining cows for repeated breeding and 
milk production. 
There were some differences in the breeds on the farms, with Farm 1/SAT2 incorporating 
limited zebu genetics, but the large majority of animals were of European varieties. 
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Table 8.1. Summary of Farm 1 and Farm 2 outbreak characteristics. 
 Farm 1 (Chapter 4) Farm 2 (Chapter 7) 
Farm    
Number of susceptible cattle 644 346 
Farm size (ha) 1600 240 
Number of livestock workers 25 20 
FMD vaccine schedule All animals every 4-6 months All animals over 6 months old every 4 months 
   
Animals   
Mean yield pre-outbreak (per lactating cow per day) 17.0kg 11.0 litres 
Age at start of outbreak (days; mean, median, range) 850.5 (746.5; -28, 3543) 1270 (919.5; -56, 4336) 
Number of management groups 18 9 
Predominant breed Holstein-Friesian crossbred (248/644, 38.5%) Jersey (236/346, 68.2%) 
Small ruminants on farm Yes No 
   
Outbreak   
Dates 31st August  – 28th September 2012 21st October -18th December 2013 
Length of outbreak (days) 29 59 
Serotype SAT2 O 
Overall incidence 400/644 (62.1%) 211/346 (60.1%) 
Mortality rate 3/644 (0.47%) 8/331 (2.4%) 
Vaccine doses (mean, median, range) 5.0 (5; 0-13) 8.6 (6; 0, 32) 
Days between last vaccination and index case 99 99 
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Figure 8.1. Population pyramid and age specific incidence for Farm 1/SAT2 and Farm 2/O. Top 
graph = Farm 1/SAT2, Bottom graph = Farm 2/O) Males are represented on the left whilst 
females are on the right. The age used was the age at the beginning of the outbreak period. 
Age category “Born” means the animals were born during the outbreak. So that each age 
category is appropriately adjusted the bottom x-axis is the frequency of animals in the age 
category divided by the number of months the category contains. In farm 2 where there were 
small numbers of males that cannot be easily visualised so numbers have been inserted to 
represent the number of males in that age category. Farm 1 only has males in the “Born” 
category. On Farm 2, the five male calves that were euthanased on the day of birth are not 
included.  
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8.3 Outbreak descriptions 
The two outbreaks were caused by different serotypes: SAT2 and O for Farms 1 and 2 
respectively. The epidemic curves are similar with two main peaks of cases (Figure 8.2) 
comparable to that seen in another outbreak on a Kenyan commercial dairy farm (Figure 1.6, 
Gakuya et al. (2011)). This coincides with the onset of cases in different groups reflecting the 
spread of infection around the farms. The intervals between peaks on the farms are 10 and 12 
days for Farms 1 and 2 respectively. 
In both outbreaks, the source is likely to have involved farm workers bringing virus onto the 
farm, perhaps on clothing or other contaminated items. The reasons for this speculation are 
partly by exclusion of other possible transmission routes and particular circumstances 
surrounding the outbreaks. Both farms have a secure perimeter fence; both restrict animal 
grazing near the farm boundary; both have a policy of not buying in animals; and both allow 
limited access of visitors to the animals. In both instances, the outbreak began in a central 
farm location (i.e. not near the farm boundary) and there are a large number of livestock 
workers some of whom live off the farm and own their own FMD susceptible livestock. On 
both farms, outbreaks were also present in the surrounding area on smallholder farms with 
the same serotype detected in samples submitted to the National FMD laboratory. 
The overall incidence of FMD for both outbreaks is comparable at around 60% (Table 8.1). This 
is similar to the 95/166 (57.2%) and 123/207 (59.4%) reported on other commercial dairy 
farms in Kenya due to serotypes SAT1 and O respectively in which the routine vaccination also 
appeared ineffective (Gakuya et al., 2011; Mulei et al., 2001). The incidence was much lower 
than that reported by Kimani et al. (2005), who described an overall morbidity rate of 
2211/2430 (91%) on four large-scale dairy farms in Kenya which had not been vaccinated for 
the responsible serotype (SAT1) in the previous five years.  Closer examination of the age-
incidence patterns on the farms in this study shows some differences (Figure 8.3).  The 
incidence risk on Farm 1/SAT2 increased with age up to the 1-1.5 year age category then 
plateaued around 70-90% thereafter, with all the confidence intervals overlapping. In contrast 
on Farm 2/O, the incidence peaked in animals between the ages of six months and 1.5 years, 
being nearly 100% in the 1-1.5 year age group, and then gradually declined to a plateau of 
around 40-50%. Examination of the confidence intervals shows that the six month to 1.5 year 
old age categories were at significantly higher risk than those of four years and above. A 
similar incidence between younger (<six months old) and older animals (Figure 8.3) is 
consistent with a protective effect of maternal derived antibody (MDA) for calves less than six 
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months of age. Age-incidence patterns were not presented in the other outbreaks reported on 
Kenyan large-scale farms with the objectives of those studies being FMD economics or 
treatment effectiveness (Gakuya et al., 2011; Kimani et al., 2005; Mulei et al., 2001). 
A different pattern was seen on Farm 1/SAT2 with a comparatively low incidence in younger 
animals compared to a high incidence in their respective dams. As discussed in Chapter 4, one 
reason for this pattern on Farm 1/SAT2 could be that the particular strain of virus only caused 
mild clinical signs among younger animals in comparison to the strain on Farm 2/O that caused 
relatively severe clinical signs. Alternatively, case ascertainment among calves may have been 
poorer on Farm 1/SAT2 although a similar case definition was used by both farms. It is also 
possible that MDA could have had a protective effect on Farm 1/SAT2 if the level of antibody 
in the colostrum and thus the calf was at a higher level than their dams and therefore were 
more protected (i.e. immunity wanes quicker for the dam after vaccination than it does for 
calves that source their immunity through colostrum). With the last vaccination being over 
three months prior to the start of the outbreak, this scenario seems unlikely. 
The overall mortality rates were similar at 3/644 (0.47%, 95% CI 0.16-1.4) and 8/331 (2.4%, 
95% CI 1.2-4.7) for Farm 1/SAT2 and Farm 2/O respectively. Although deaths in adults were 
reported on both farms, the overall mortality was similar or lower than other reports in the 
literature from endemic settings. In Ethiopia, Negusssie et al. (2011) reported an overall 
mortality rate of 0.3% (19/7,127, 95% CI 0.17-0.42) among cattle from eight investigated 
outbreaks. Chowdbury et al. (1993) reported a 50.9% mortality rate among calves in 
Bangladesh, although the definition of a calf and the rate among older animals was not 
presented. Among Kenyan pastoralists, an overall mortality rate of 3% has been estimated 
(Onono et al., 2013). A study of four Kenyan large-scale dairy farms reported an overall 
mortality rate of 200/2430 (8.2%, 95%CI 7.2-9.4) (Kimani et al., 2005). These outbreaks had 
been due to serotype SAT1 for which no recent vaccination for the SAT1 serotype had been 
performed. Another report from Kenya revealed a mortality of 9/207 (4.3%, 95%CI 2.3-8.1) on 
a vaccinated herd affected with serotype O that had been vaccinated for this serotype 104 
days prior to the index case (Mulei et al., 2001). Based on the 95% confidence intervals, all 
three Kenyan large-scale farms that had an outbreak despite vaccination appear to be 
significantly lower than the outbreak that had an outbreak with no history of recent 
vaccination. This implies that the vaccine may have had some protective effect against death. 
However, these estimates are unadjusted and don’t account for baseline mortality rate on 
these farms so caution should be taken when comparing them. 
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Management systems for calves varied between Farm 1/SAT2 and Farm 2/O which may have 
affected the rate of virus transmission and levels of immunity. On Farm 1/SAT2, calves were 
immediately placed into individual hutches in a paddock up until the age of eight weeks (group 
Y1) when they were moved into free mixing groups (Y2). Exposure by direct contact in the 
hutches was unlikely with indirect routes such as through shared equipment being more likely. 
On Farm 2/O, they were housed in a converted stable until the age of two weeks in groups of 
up to three individuals per stable. Thereafter they were placed into free mixing groups (all 
included in group Y1). Therefore one would expect more effective contacts in this setting 
compared to Farm 1/SAT2.  
All calves on Farm 1/SAT2 were fed four litres of pooled colostrum by farm workers. This is 
more likely to have lead to more consistent levels of immunity among the calves compared to 
Farm 2/O that were left to suckle from their dams. Holstein-Friesians have been associated 
with producing lower quality colostrum (i.e. with lower IgG1 concentrations) compared to 
other dairy breeds (Godden, 2008). Although Farm 1/SAT2 had a greater proportion of 
Holstein-Friesian pedigree than Farm 2/O, this is unlikely to have made a significant difference 
to the colostrum quality as these cows were lower yielding than those under the European or 
North American system in which poor quality colostrum is usually associated. Moreover, Farm 
2/O had a significant Holstein-Friesian presence on the farm (Table 7.2). 
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Figure 8.2. Epidemic curves for Farm 1/SAT2 and Farm 2/O with solid arrows showing the 
onset of cases in each affected group. Dashed arrow for Farm 2/O represents the vaccination 
date. To ease comparison, the time scale has been modified for Farm 1/SAT2 compared to that 
shown in Figure 4.2.  
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Figure 8.3. Incidence of FMD by age category for Farm 1/SAT2 and Farm 2/O with 95% 
confidence intervals. 
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8.4 Vaccine use, effectiveness and schedule modification 
Both farms used the same locally available killed, aqueous-adjuvanted, non-NSP purified 
quadrivalent vaccine containing serotypes A, O, SAT1 and SAT2. The manufacturer’s 
recommendation was to vaccinate all animals on the farm at least every 6 months but 
preferably every 4 months3.  A second or third dose as part of a primary course was not 
recommended. The two farms described here employed differing vaccine schedules prior to 
the outbreaks. Farm 1/SAT2 vaccinates all animals every 4-6 months irrespective of age. Farm 
2/O vaccinates every four months but only animals over the age of six months. Although the 
former vaccinates at a younger age, the slightly less frequent vaccination and younger age 
structure on Farm 1/SAT2 means Farm 2/O is a much more heavily vaccinated population 
(Figure 8.4) reflected in the average number of vaccine doses received being 8.6 compared to 
5.0 on Farm 1/SAT2 (Table 8.1). 
Both outbreaks occurred within four months of the most recent vaccination. Estimation of the 
absolute vaccine effectiveness was not possible on either farm due to all animals being 
vaccinated at the same time and the high collinearity between the number of doses and age 
meaning there were no appropriate comparison groups. However, the incidence patterns by 
the number of doses of vaccine received provide insights into possible reasons underlying the 
poor effectiveness. On Farm 2/O, unadjusted relative vaccine effectiveness estimates were 
possible. Such an analysis was not appropriate on Farm 1/SAT2 due to the much lower 
incidence risk among younger animals meaning any risk ratios would have been over 1, with 
subsequent vaccine effectiveness estimates all being negative. 
On Farm 1/SAT2 there appears to have been no or very limited protection offered by the 
vaccine evidenced by the high incidence even among multiply vaccinated animals (Figure 8.5). 
The low incidence among animals receiving relatively low number of doses may be an age 
effect with younger animals showing less obvious clinical signs as described in Chapter 4. In 
contrast, on Farm 2/O there is some evidence of cumulative protection with the number of 
doses received with this protective effect plateauing from 11 doses. Examination of the 
confidence intervals shows animals receiving five or more doses were significantly more 
protected than those receiving one or two doses (Figure 7.5). The higher incidence among 
animals receiving 1-2 doses is likely due to an “immunity gap”, a term used to describe the 
situation in which protection from maternal antibodies has waned but insufficient doses of 
                                                          
3
 http://www.kevevapi.org/index.php?option=com_content&view=article&id=127&Itemid=123. 
Accessed 01/07/2014. 
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vaccine have been received to confer protection like that seen in animals receiving five or 
more doses. Although Farm 2/O was a more heavily vaccinated population, there were still a 
high number of animals receiving five or more doses of vaccine on Farm 1/SAT2 (Figure 8.4) 
yet the incidence was high among those animals. Indirect protection “herd immunity” effects 
on Farm 2/O from the population being more heavily vaccinated are unlikely to be so strong as 
to be responsible for the differences in effectiveness seen between the two farms. Due to the 
age and number of doses being highly collinear (Figure 8.4), age cannot be adjusted for in 
these estimates and so may be confounding this association. 
In both outbreaks, problems with the cold chain are considered unlikely due to the high 
number of vaccine doses received on multiple occasions. Farm 1/SAT2 sources vaccine through 
the local government veterinary office. Vaccine is delivered to the office directly through a 
courier when requested by the farmer. On arrival, the farmer is notified and the vaccine is 
collected, taken back to the farm and immediately refrigerated in a temperature monitored 
refrigerator up until the point of use. There are refrigerators at the local government office 
although the farmer cannot be completely sure that the cold chain has been satisfactorily 
maintained from leaving the manufacturer and arriving on the farm. Therefore on Farm 
1/SAT2, a break in the cold chain cannot be completely ruled out as contributing to the 
ineffectiveness seen although is still considered unlikely. However since the outbreak, the 
farmer now elects to collect vaccine direct from the manufacturer. In contrast, Farm 2/O 
receives vaccine directly to the farm from the manufacturer using a courier. They report that 
the vaccine is reliably delivered and is always chilled on arrival and packed with non-melted ice 
when received. Both farms order vaccine according to need, use as soon as possible after 
being delivered to the farm, and use cool boxes packed with ice when vaccinating the herd. 
After a vial is breeched it is used immediately and not kept for the following vaccination dates. 
Both farms also ensure that the vaccine has not passed the expiry date prior to use. 
Conversations with the vaccine producer in August 2014 as a consequence of the poor 
performance seen in Farm 1/SAT2 revealed that this farm hadn’t consistently order enough 
vaccine to vaccinate all animals in the herd prior to the outbreak. The farmer claims this is 
because they often had vaccine left-over from previous vaccination rounds and insists all cattle 
are routinely vaccinated at the same time. In addition, they have a refrigerator on the farm 
with a temperature monitor to ensure the temperature is kept between 2 and 8°C while 
stored. Additionally they discard broached vials after use and never use vaccine that is beyond 
the expiry date. However, the SAT2 antigen is known to be less stable than other serotypes 
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(Parida, 2009) and this could mean it has a relatively shorter shelf life even under refrigerated 
conditions. This aspect of SAT2 vaccines should be investigated (see section 11.4.5 on further 
research priorities). 
In the case of Farm 1/SAT2, it seems unlikely that changes to the vaccine schedule would have 
made any difference to the vaccine effectiveness as the incidence was so high in multiply 
vaccinated animals. The reasons behind the lack of effectiveness could be due to poor vaccine 
potency or a high disparity between the field and vaccine strains. It is possible that more 
frequent vaccination could have improved effectiveness through reducing the time between 
vaccination and exposure but this is unlikely to be acceptable to the farmer. 
In contrast, on Farm 2/O, more aggressive vaccination among younger animals may reduce the 
time between MDA waning and being able to mount a full response to the vaccine. Additional 
doses in the primary course or more frequent vaccinations up to a certain age (for example 
every 3 months) decreasing in frequency when older (for example biannually after the age of 3 
years) may improve effectiveness. Increasing number of doses among youngstock would also 
likely have indirect effects through reducing the level of exposure among older animals. 
Interestingly after this 2013 outbreak, Farm 2/O decided to change the vaccine schedule based 
upon a conversation held with another local large-scale farmer who had not had an FMD 
outbreak in recent years using a modified schedule. As a consequence, all animals on the farm 
were to be subsequently vaccinated, rather than just those over six months of age, and 
youngstock were to be given a two dose primary course, one month apart. However with an 
incidence risk still around 30-40% in multiply vaccinated animals there are likely to be other 
variables limiting the vaccine’s effectiveness. At the time of writing, no vaccine matching tests 
had been performed comparing the reactivity of sera from vaccinated animals to the field and 
virus strains. Indeed, there has been no vaccine matching performed in recent times for any 
Kenyan field strains using the current KEVEVAPI vaccine. Therefore it is likely that a 
combination of suboptimal vaccine schedule and field/vaccine strain mismatch is contributing 
to the lack of effectiveness on this farm.  
 
 
 
176 
 
 
Figure 8.4. Mean number of doses of vaccine received by age category of Farm 1/SAT2 and 
Farm 2/O with different vaccine schedules. For Farm 1/SAT2, the total number of doses 
received was not available for cattle over 8 years of age (n=9).  
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Figure 8.5. Incidence of FMD by number of doses of vaccine received for Farms 1/SAT2 and 
Farm 2/O with 95% confidence intervals. 
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Part B – 
Serology  
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Chapter 9. Literature review 2 - Decay of maternally derived antibody 
in the calf and the influence on response to FMDV vaccination 
As demonstrated in Chapter 7 and discussed in Chapter 8, there is evidence that the vaccine or 
vaccine schedule among youngstock may need modification, and that maternal immunity may 
be responsible for some of the protection seen in animals below six months of age. A 
comprehensive literature review was thus undertaken in order to establish how maternal 
immunity may interfere with vaccination. 
The specific objectives of this comprehensive literature review are: 
1) Determine the normal kinetics of declining FMD-specific maternally derived antibody 
(MDA) in calves born to vaccinated dams 
2) Appraise the evidence for the influence of MDA on the antibody response to FMD 
vaccination using commercially available vaccines in calves 
This review informs the analysis of data provided by the Kenyan Veterinary Vaccine Production 
Institute (KEVEVAPI) who produce the only available FMD vaccine in Kenya and whose product 
was used in both of the large-scale farms whose data were analysed in Part A of this thesis. 
The aim is to use the information from the literature review and analysis (Chapter 10) to 
inform vaccine schedules in youngstock among large-scale dairy farms in Kenya. 
9.1 Decline of maternally derived antibody for FMD in calves 
The newborn calf is born without antibody due to the in utero separation of the maternal and 
foetal blood preventing transplacental transfer (Godden, 2008). This is seen in all ungulate 
species and is in contrast to the situation in primates in which the haemochorial placental 
structure allows transfer of IgG antibody through the placenta (Cervenak and Kacskovics, 
2009). Therefore the newborn calf is completely reliant upon colostrum as a source of 
antibody until endogenous production begins. 
The main antibody present in colostrum is immunoglobulin G1 (IgG1) although other 
antibodies are present in low amounts in addition to other macromolecules, such as immune 
cytokines, growth factors, and maternal leukocytes. Selective accumulation of IgG1 in 
colostrum is thought to be through FcRn receptors on the mammary epithelial cells resulting in 
colostral IgG being 10-40 times the concentration of plasma, sufficient to lower the level of 
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maternal serum IgG1 in the last month of pregnancy (Cervenak and Kacskovics, 2009). 
Colostral molecules, including immunoglobulin, are able to pass through the neonatal small 
intestine through non-specific pinocytosis that occurs mainly in the first 24 hours of life before 
a process known as “gut closure” prevents further transfer. Maternal leukocytes also pass to 
the calf and traffic to neonatal lymphoid tissue. The influence these have on the neonatal 
immune system is unclear but may enhance the neonatal response to antigens to which the 
dam has previously responded (Donovan et al., 2007). 
The amount of antibody that is transferred to the calf and enters its circulation depends on 
several factors including the concentration of antibody in colostrum (often referred to as 
colostrum quality); the volume fed; timing and method of feeding; and the metabolic status of 
the calf (Godden, 2008). For some cattle vaccines, in particular to those for rotavirus, 
coronavirus and Escherichia coli, it has been shown that vaccination of the dam 3-6 weeks 
prior to calving can increase the quality of the colostrum and protect calves from clinical 
disease including under field conditions (Castrucci et al., 1987; Crouch et al., 2001; Waltner-
Toews et al., 1985). 
The half-life of IgG is considerably longer than that of other isotypes due to the presence of 
the FcRn on endothelial cells. These allow the continual uptake of IgG from serum into 
endosomes which then either transport IgG back to the serum or into the interstitial fluid. In 
cattle there is some variation in IgG half-life ranging from 10-22 days and being slightly longer 
for IgG2 compared to the other IgG isotypes (Cervenak and Kacskovics, 2009). 
For FMD specifically, several studies have looked at the decline of maternal antibodies in 
calves receiving colostrum from dams that have been vaccinated for FMD. An early study by 
Graves (1963) looked at the issue in an experimental setting. Eleven heifers were vaccinated 
with two doses of a formaldehyde inactivated serotype A (119) vaccine 30 days apart and then 
proceeded to give birth between 30 and 117 days after the second vaccination. Calves were 
left with the dams to ingest colostrum and sera were tested for FMD antibodies with a virus 
neutralising test (VNT) using a virus strain homologous to the vaccine. A single calf was blood 
sampled hourly for five hours after ingestion of colostrum which showed a rapid rise in 
neonatal antibody levels reaching a plateau five hours post vaccination. Three calves were 
sampled at “appropriate intervals” up to 90 days of age. For two calves, the half-life was 15 
days whilst in the third calf it was 19 days.  
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In a review of the subject, van Bekkum (1966) stated that according to their experiments the 
half-life varies from between 12 and 24 days and that “...antibody could usually be detected up 
to an age of 60 to 160 days in calves born from cows that had been vaccinated repeatedly 
under field conditions.” 
Figueroa et al (1973) looked at VNT titres for serotype O in 16 calves of different ages born 
from dams repeatedly vaccinated with a commercial, inactivated polyvalent FMDV vaccine. 
They found declining titres with age and detectable antibodies up to seven months of age. No 
regression coefficient or half-life was stated in the paper. 
Researchers in India took weekly blood samples from two calves beginning from one day of 
age to six weeks (Shankar and Uppal, 1981). These calves were born to dams that had received 
multiple doses of quadrivalent (A, O, C, Asia-1) vaccine. VNT titres (measured as the logarithm 
[base 10] of the reciprocal of the last dilution where antibodies were detected) to the serotype 
A and C strains revealed a mean decline from 2.75 to 1.6 and 3.0 to 1.25 respectively. 
Regression coefficients were -0.0315 and -0.0382 respectively. No half-life estimates were 
provided, but from the regression coefficients are equal to 9.6 and 7.9 days respectively.  
Nicholls et al (1984) determined the decay in VNT titres in 11 calves for strains of serotype O, A 
and C. Dams were vaccinated 4-6 months prior to the calves being born and the latter were 
blood sampled five times over a four month period (age range 7-142 days while sampled). A 
statistically significant decline in antibody levels was seen with linear regression for each strain 
(P<0.01 for each). The mean half-life for all the serotypes was 22.2 days. By 103 days of age, 
antibodies had declined to the lowest measurable levels. Two were excluded from the analysis 
as there were no detectable antibodies at the first sampling. 
As part of a study performed by Sadir et al (1988) in Argentina, three calves had samples taken 
periodically on three, five and six occasions to examine the decay in VNT titres. Sampling 
began at 1-2 weeks of age and lasted up to around six months. These calves were born 
between 60 and 70 days after dam vaccination. The average regression coefficient and half-life 
was estimated at -0.014 and 21.5 days respectively. Also in Argentina, Späth et al (1995) blood 
sampled 14 calves at five time points starting from between 42 and 66 days old up to around 
180 days of age. Liquid phase blocking ELISA (LPBE) were performed for four different strains 
of FMD virus, two of which were serotype A with the remaining being O and C. Based on 62 
observations, the half-lives ranged from 19.1 to 25 days with an overall average of 21 days 
(Table 9.1). 
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Table 9.1. Regression and correlation coefficients and associated half-lives for different strains 
of FMD virus (Adapted from Spath et al, 1995).  
FMDV Strain Regression coefficient Correlation 
coefficient 
Half life 
A79 0.014 0.78 20.8 
AB7 0.012 0.70 25 
CBS 0.016 0.80 19.1 
O1C 0.014 0.81 21.1 
Note: Estimates were based upon sampling calves at five time points between the ages of 42 
and 180 days. 
 
Dekker et al (2014) were also able to calculate the rate of MDA decay in control groups used in 
a vaccine safety trial and found an average half-life of 21 days (95% confidence interval 19-24 
days) for strains A Turkey 14/98, O Manisa and Asia-1 Shamir. These calves were born from 
dams that had been vaccinated three times with a double oil emulsion vaccine in each 
trimester of pregnancy. Similarly Bucafusco et al (2014) were able to use data from control 
groups to estimate half lives in calves having received pooled colostrum from dams receiving 
at least three vaccine doses, the last dose given within six months of calving. The vaccine used 
was an oil-adjuvanted commercially available type including strains O1/Campos, A24/Cruzeiro, 
A/Arg/01 and C3/Indaial. The estimated decay half-life ranged from 17.1 to 18.4 days. 
9.1.1 Discussion 
Table 9.2 summarises the results of the available studies examining the decline of FMD specific 
maternal antibodies in calves receiving colostrum from vaccinated dams.. The range in half-life 
estimates is 8-25 days. The predominant method of measuring the titres is through VNT, 
although one study compared serology methods (LPBE, VNT, IgG1 and IgG2 isotype ELISA) and 
the half lives ranged from 17.7 to 18.4 indicating little difference between the serology 
method used (Bucafusco et al., 2014). Although the decline of MDA to the SAT serotypes has 
never been examined, there is no reason for it to be different from MDAs to the other 
serotypes. In support of this, Dekker et al. (2014) showed that there was no statistically 
significant difference between serotypes in their study of MDAs to  serotypes A, O and Asia-1. 
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This range in half-life estimates is wider than quoted in a recent general review on the subject 
of passive immunity in cattle which gave a range of 10-22 days (Cervenak and Kacskovics, 
2009). However, the studies that included estimates outside of this range were based on very 
small number of animals. A single calf was used to predict a half-life of 25 days (Späth et al., 
1995), and similarly single calves were used to estimate half-life values of 7.9 and 9.6 days 
(Shankar and Uppal, 1981). Most studies do not provide confidence intervals around 
estimates, or present appropriate data such that a combined estimate can be calculated. 
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Table 9.2. Summary of studies examining the decline of maternal antibodies in calves receiving colostrum from dams vaccinated for FMD.  
Study/country Number of 
animals 
Serotype(s) Dam schedule (and timing of 
last dose relative to calving) 
Serology test(s) Half life estimates (days) 
Graves (1963)/USA 3 A 2 doses 30 days apart (30-117 
days) 
VNT 16.3 (range 15-19) 
Figueroa et al. 
(1973)/Chile 
16 O Repeatedly (not given) VNT Not given 
Shankar and Uppal 
(1981) India 
2 A, C Several (not given) VNT Not given (calculated as 9.6 and 7.9 for serotypes A 
and C respectively. 
Nicholls et al. 
(1984)/Uruguay,Brazil 
11 A, C, O Not given (4-6 months) VNT 22.2 
Sadir et al. 
(1988)/Argentina 
3 A Not given (60-70 days) VNT 21.5 
Späth et al. 
(1995)/Argentina 
14 A, C, O > 6 doses (5 months) LPBE 21 (range 19.1-25.0) 
Dekker et al. 
(2014)/Nethelands 
5 A, O, Asia-1 3 doses (last trimester) VNT 21 (95%CI 19-24) 
Bucafusco et al. 
(2014)/Argentina 
7 O Minimum 3 doses (within 6 
months) 
VNT, LPBE, 
IgG/IgG2 ELISA 
17.1, 17.8, 18.4, 17.6 a 
Note: All studies were longitudinal, taking repeated samples from the same animals except Figueroa et al. (1973) who correlated age and titres based on single 
samples. a Antibody half-life for LPBE, VNT, IgG1 and IgG2 ELISA respectively.  
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9.2 Influence of maternally derived antibody on the response to commercially available 
FMD vaccines in calves 
Although the transfer of maternal antibody to the neonatal calf is important to ensure 
protection from disease, it is acknowledged that this passive immunity may interfere with the 
calf’s ability to respond to vaccines through preventing access of the immune system to 
antigen. Therefore, an understanding of its impact on vaccination is important for informing 
vaccine schedules, in particular the timing of the first dose. However, in a relatively recent 
review on the subject related to all vaccines used in calves, Chase et al (2008) stated “In 
assembling this article, it is clear that many ‘‘vaccine recommendations’’ have been made but 
little research is available to indicate the true effectiveness of vaccine timing or ideal protocols 
for use in young calves.” This literature review summarises the published studies on the 
subject in relation to FMD, several of which are extensions to the studies examining the 
decline of MDA cited above. These studies are summarised in Table 9.3, and are presented in 
the context of the vaccine formation, serological assay used, and study hypothesis. 
There is a lack of consistent terminology between studies on the use of the terms “primary”, 
“booster” and “re-“ vaccination (or dose) that needs clarification. Generally a “primary course” 
or “primary series” constitutes  one or more doses that allow the “development of immunity” 
(Kroger et al., 2013). Periodic vaccination to maintain this immunity is called a “booster”. An 
example from the human vaccinology field is with Diphtheria, Pertussis and Tetanus (DPT) 
schedule, according to which infants are given the “primary course” at 2, 3 and 4 months of 
age. A booster dose is given at 3-4 years old. In this review the responses under consideration 
are in young animals and refer to the interference of MDA. Therefore it is the primary course 
that is being considered and so for consistency when comparing studies, doses shall be 
referred to simply as first, second or third doses. 
9.2.1 Early studies with formalin inactivated vaccines 
Early FMD vaccines were inactivated with formalin and used an aqueous adjuvant, either 
aluminium hydroxide alone or in combination with saponin. In the study by Graves (1963), one 
calf that had MDA was given a single dose of serotype A vaccine at 21 days of age which was 
repeated when the calf was 120 days old. No response was seen in neutralising titres to the 
first dose but an increase from 1.0 to 2.0 log10 reciprocal titre was seen with the second dose, 
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a response similar to that seen when vaccinating an immunologically naive adult. The exact 
timing of the blood sampling is not clear from the methodology presented in this study. 
Further experiments by Figueroa et al (1973) in Chile used six calves with MDA that were 
vaccinated with serotype O vaccine. Blood sampling occurred at vaccination and weekly for 
four weeks thereafter. A progressive week-on-week increase in VNT titre was detected. The 
ages at vaccination and range in MDA titres of those vaccinated was not stated, but the 
geometric mean at vaccination (1/32) and the regression line of decay in MDA suggests 
vaccination may have been at about 3.5 months. 
Uppal et al (1975) vaccinated six randomly selected 5-21 day old calves with either a full or half 
dose of a quadrivalent (A, O, C, Asia-1) vaccine born to multiply vaccinated dams. VNT titres at 
vaccination were variable ranging from 1.0 to 3.5 log10 reciprocal titres. A rise in antibody post-
vaccination was seen irrespective of the dose and whether maternal antibodies were present 
or not. A higher serological response was seen if the maternal antibody titre was lower at 
vaccination. Further studies in India by the same research group compared responses in 1-90 
day old calves born to dams in herds using regular vaccination (n=10) to those born in 
unvaccinated herds (n=8) (Shankar and Uppal, 1982). Neither herd had recorded an FMD 
outbreak in the previous 6-8 years. Calves were either given one “full” dose of a serotype A 
vaccine or two half doses, 21-days apart. VNT titres to the serotype A strain were measured.  
Significant increases in titres were observed in both groups compared to unvaccinated controls 
(P=0.05) after the first dose irrespective of MDA status although no significant difference was 
seen between the two groups. A further increase was seen after the second half dose inducing 
significantly higher titres than the single dose group, measured 50 days after the first 
vaccination. The authors stated that lower MDA titres in calves were associated with a higher 
response after vaccination although data were not presented demonstrating this effect.  They 
concluded that MDA might interfere with the vaccine response but that it does not block it 
completely and recommended a two dose schedule among calves. 
9.2.2 Aqueous versus oil adjuvanted vaccines 
Due to reports of incomplete inactivation with formalin and vaccine associated disease 
outbreaks, inactivation was later performed with the more reliable binary ethyleneimine (BEI) 
(Bahnemann, 1975)  which is still commonly used for the production of FMD vaccines. Around 
the same time, oil adjuvants also started to be used and today both aqueous and oil 
adjuvanted vaccines are commercially available. 
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Using BEI inactivated vaccines, several studies investigated the influence of adjuvant type on 
the response to vaccination, under the hypothesis that oil-based vaccines were able to 
circumvent the effect of MDA. A study in Brazil compared the response among calves with 
varying levels of MDA to oil (n=28) and aluminium hydroxide-saponin (n=31) adjuvanted 
trivalent (A, C, O) vaccines (Gomes, 1984). All dams had been vaccinated every six months with 
oil based vaccine. Calves were aged between 8 and 169 days at first vaccination and were 
blood sampled at first dose, second dose (105 days later) and seven days later. Antibody levels 
for all three serotypes were measured though the mouse protection index (MPI) 4 for which a 
cut-off of 2.0 had been shown by the same research group to be associated with clinical 
protection in cattle when intradermolingually challenged (Gomes and Astudillo, 1975). 
Increasing titres were seen with both vaccine types when given the first and second doses, 
regardless of age and serotype. However, if the MPI was greater than 2.0 a poor response was 
seen regardless of vaccine adjuvant and with both first and second doses. No statistical tests 
were performed with these data. 
Also in South America, Sadir et al (1988) made similar comparisons, following their 
observations of a poor vaccine response in calves less than 30 days old with no MDA contrary 
to reports elsewhere. Dams had received multiple doses of the oil-adjuvanted vaccine with the 
last dose given around 70 days prior to calving. When using the aqueous vaccine, the authors 
reported no increase in VNT titre even if given a second dose 60 days later and that titres were 
lower than what would be expected from usual MDA decay. A plot was presented 
demonstrating the decline of titres over time although no statistical tests were presented and 
undefined ranges around points on this graph overlap with the theoretical half life curve 
bringing this evidence into question. Additionally, the number of calves on which this aqueous-
adjuvant study was based is unclear from the description. For evaluating the oil vaccine, 26 
calves aged 1-90 days with MDA (n=15) and without MDA (n=11) were used. For calves with 
MDA, those given a first dose at 1-21 days old showed no increase in VNT titres. Although 
some increase was seen when a second dose was given 60 days later, the ranges around points 
on the graphs don’t support a significant increase. Conversely, if calves were over 30 days old 
at first vaccination, a greater response was seen together with a greater response to the 
second dose. For calves born with no MDA, a 30-60 day lag in response was seen after first 
vaccination when given at three and seven days of age although a more rapid response was 
                                                          
4
 The mouse protection test (MPT) is where comparisons are made between mice “treated” or “non-
treated” with immune serum and challenged with different titres of homologous FMD virus. The mouse 
protection index (MPI) is the log difference between the virus titres causing disease in the serum treated 
and non-treated mice. 
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seen in those vaccinated over 21 days of age. All of these calves showed a response to a 
second dose, although there were a maximum of two animals in each age category and only 
one received a second dose. No statistics are provided alongside these findings making their 
interpretation problematic. Additionally, it is difficult to compare these results with that of the 
aqueous vaccine when the neutralising antibody level appears lower with those receiving oil-
adjuvanted vaccine at first vaccination according to the figure presented in the paper. 
A group in India, compared oil and aqueous adjuvanted quadrivalent (O, A, C, Asia-1) vaccine 
(Patil et al., 2014). Calves (n=18) were aged between two and three weeks and born to 
vaccinated dams. Ten were given oil adjuvanted vaccine whilst eight were given aqueous 
vaccine. Animals were blood sampled at 0, 15, 30 and 60 days post vaccination. Similar MDA 
levels were seen in both groups at vaccination. Using the oil adjuvanted vaccine, an increase in 
VNT titre was seen peaking at the 15 day sampling for serotype O and 30 day sampling for the 
other serotypes. With the aqueous-adjuvanted vaccine, a decline of VNT titres was seen after 
vaccination. The differences in post-vaccination antibody levels between the two adjuvants 
were statistically significant throughout the study period (P<0.0001). The authors 
recommended first vaccination of animals at 8 weeks of age with the oil-adjuvanted vaccine. 
No data were presented from unvaccinated animals. 
9.2.3 Evaluation using non-VNT serology 
All the studies so far have focussed on titres as measured using VNT. Several studies have 
considered the effect on antibodies measured using alternative assays. 
Späth et al (1995) performed two experiments using a commercially available oil-adjuvanted 
vaccine for strains O1C, A79, A87, C85, by measuring liquid phase blocking ELISA (LPBE) titres. 
Dams had all received greater than six doses of the same vaccine. In the first experiment, three 
groups of 20, 30 and 40 day old calves (18 per group) were all given a single dose of vaccine 
and blood sampled at 0, 15, 30, 60, 94 and 124 days post vaccination. A control group of 14 
calves were given no vaccine, sampled 15, 30, 60, 94 and 124 days after the commencement of 
the trials (range 25-49 days old at commencement). Similar responses were seen in the 
different age groups, although the difference seen was only statistically significant at 90 and 
120 days post vaccination when comparing it to non-vaccinated calves. The authors refer to 
the “Expected Percentage of Protection” (EPP) measure (covered previously in Chapter 2, 
section 2.1) and on this basis claimed around 40-50% of calves had protective titres compared 
to 0% with the non-vaccinated calves at 120 days post vaccination. Higher initial MDA antibody 
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titres were associated with a lower response to vaccination demonstrated though linear 
regression. The slope was greater for serotype O, although no statistics supporting these 
observations were presented.  
In the second experiment by Späth et al. (1995), four groups of 14-16 animals were used and 
comparisons made between calves vaccinated at three months and four months of age. One 
three month and one four month old group received two doses (day 0, day 120) of vaccine. 
The remaining two groups received three doses (day 0, day 60, day 120). Similar titres were 
achieved with all four groups at 180 and 240 days post first vaccination (and nearly 100% 
protection based on EPP).  A statistically significant increase in titre was apparent after the 
second dose, with a greater increase seen for the serotype O strain (to which responses were 
generally higher). The increases in titre post vaccination were also inversely related to the 
MDA titre although these data were not presented.  
On the basis of their two experiments, Späth et al. (1995) concluded that vaccinating calves as 
young as 20 days generated a protective titre even in the presence of high MDA titres which 
lasted up to four months, contrary to that seen in non-vaccinated calves, and that a second 
dose given 60-days after the first ensures high antibody titres. For calves receiving vaccine at 
3-4 months old, at the “end of the colostral protection period”, protection lasted for four 
months irrespective of receiving an additional dose.  
Another assessment was performed by Bucafusco et al (2014) in Argentina. Several serological 
tests were utilised to further understand the effect of MDA on vaccination response. 
Commercial oil-based vaccines with strains O1/Campos, A24/Cruzeiro, A/Arg/01 and 
C3/Indaial were used in two experiments. Dams had received at least three vaccine doses with 
the last dose within six months of calving and calves received pooled colostrum from these 
dams. The first experiment involved three groups of four calves being vaccinated at one 
month, three months or five months of age alongside a non-vaccinated three animal control 
group. Blood sampling took place approximately every 1-2 weeks and serological tests 
included: LPBE for O1 Campos; VNT for O1 Campos; single dilution avidity ELISA; 
IgG1/IgG2/IgM isotype ELISA. When animals were vaccinated at one month of age, levels 
declined in all the serological tests although were significantly higher than the non-vaccinated 
group by 165 days post vaccination for LPBE (P<0.05). In contrast, statistically significant 
increases were seen in all tests when receiving the first dose at five months of age (P<0.05). 
Those receiving the first dose at three months had significantly increased titres in all tests 
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except the IgG1 ELISA. In this age group, responses were slower to develop and lower than the 
five month group.  
In the second experiment, two groups were selected on the basis of low (<1.3, n=13) and high 
(>2.9, n=12) MDA titres to O1 Campos measured by LPBE. Ages differed between the groups at 
165-215 days and 14-42 days respectively. Both groups were vaccinated twice, 35 days apart, 
and blood sampled at 0, 7, 21, 35, 55 and 120 days post primary dose. When MDA levels were 
low, one dose of vaccine raised titres in all tests and was sufficient to induce protective levels 
of antibody 21 days later (based on the EPP). Although IgG1 levels decayed from 55 to 120 
days post first vaccination, IgG2 levels were maintained over time. For the high MDA group, 
after the second dose titres were lower than the low MDA group and were significantly 
different for both LPBE and VNT (P<0.05). LPBE titres were significantly higher than expected 
from normal maternal decay (P<0.05) although VNT titres were not significantly different. The 
authors concluded that the presence of MDA as measured by VNT tended to interfere with the 
response to vaccination rather than the MDA measured by LPBE which measured total 
antibody levels.  
9.2.4 Evidence from the field 
Nicholls et al (1984) conducted a series of FMD vaccine studies in experimental and field 
settings. Thirty-eight calves in Uruguay born to cows vaccinated ten days to four months prior 
to calving were vaccinated with an aqueous (aluminium hydroxide and saponin) adjuvanted 
vaccine at one week of age with blood samples taken at vaccination and 21 days later. These 
were compared with six calves born in the UK that were vaccinated with the same vaccine 
batch but had no MDA. A higher VNT response to vaccine was seen in the UK based calves with 
no MDA.  Analysed through linear regression, a significantly lower response was seen when 
the MDA titres were higher (P<0.01) with similar slopes seen for each serotype. The antibody 
level was observed to decrease post vaccination in the Uruguayan calves for all three 
serotypes which the authors noted was beyond the decrease expected from normal decay. 
They speculated that the vaccination could have a depressive effect on antibody levels.  
A separate study described in the same paper, involved 59 vaccinated calves in Brazil divided 
into one, two, three and four month age groups. Blood collection occurred at vaccination and 
at 30 and 60 days later. Some animals received a second dose at the 30 day sampling point. 
They found that responses to the first and second doses both varied with the MDA levels as in 
their Uruguayan study (P<0.01), and that the maximum titres were seen after the second dose 
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although there was “considerable animal to animal variation in this response”.  The authors 
claim that low levels of MDA that were “scarcely demonstrable” appeared capable of 
interfering with responses.  
The same authors went on to conduct a field study on four large farms in Brazil where FMD 
was endemic. This study was previously described in Chapter 2 (section 2.4) of this thesis but is 
included again here due to its repeated relevance. The study compared the incidence of FMD 
among calves given two different schedules. The traditional vaccine schedule (dosed every 
four months irrespective of age) was used on half the calves on three farms and on all the 
animals on the remaining farm (n=9,056 calves). A revised schedule was used on all remaining 
animals (n=7,951 calves), delaying the first dose to 5-6 months old with a second dose given 
one month later. The clinical incidence was monitored for a 12 month period after 
implementing the change. Among calves, the incidence on the farms using the traditional 
schedule was 11.0% compared to 0.09% with the revised schedule, a difference unlikely due to 
chance (χ2= 741, P<0.01). Combined with the other findings in the paper, they recommended 
that vaccination should be delayed in calves until 5-6 months of age. Although it is encouraging 
to see field data provided to support a modification to the vaccine schedule, there are several 
limitations to this study including: a) “calves” and “adults” not being clearly defined; b) no 
explanation on the likelihood of exposure of all the groups (the authors assume “the possibility 
of an FMD outbreak was equal in all vaccination groups”); c) no comparison groups on the one 
farm which just received the traditional schedule d) numbers of cases and animals were not 
provided at the individual farm level. No vaccine effectiveness estimate was attempted by the 
authors in this study and given these methodological problems it cannot be calculated from 
the data presented.  
9.2.5 Alternative strains 
Dekker et al (2014) tested the hypothesis that if calves with MDA are vaccinated with a strain 
which is different to that given to their dams, a greater increase in neutralising titre will be 
seen after vaccination. Five groups of five calves each were used in the study, with three 
having MDA. Dams had been vaccinated as part of a vaccine safety trial with a trivalent (A 
Turkey 14/98, O Manisa, Asia-1 Shamir) double oil emulsion vaccine given once in each 
trimester of pregnancy.  Two groups of calves with MDA were vaccinated at 2-3 weeks old with 
either A Turkey 14/98 (i.e. homologous to the MDA) or A22 Iraq (i.e. heterologous to the 
MDA). As controls, two groups without MDA were similarly vaccinated and one group with 
MDA was unvaccinated. VNTs to the A Turkey 14/98 and A22 Iraq strains were performed at 
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weekly intervals for 6 weeks after vaccination and analysed with a linear mixed effects model 
accounting for repeated sampling. A significantly greater increase in titre was seen when 
calves were vaccinated with a heterologous vaccine strain compared to using a homologous 
strain (P=0.002) which led to a decline in titres in line with the normal MDA decay half-life. 
9.2.6 Reviews and unpublished data 
A series of reviews have been written on the influence of MDA on FMD vaccination including 
by those working in the pharmaceutical industry. Based at the Institute for Animal Health (now 
the Pirbright Institute, Surrey, UK), Kitching and Salt (1995) speculated on the mechanism by 
which MDA leads to poor responses with vaccination including: “Antigen blockage” from high 
MDA preventing an appropriate immune response; MDA inducing negative signals in B-cells as 
part of a negative feedback mechanism; suppression of T-helper cells; and upregulation of T 
suppressor cells. The authors described their experiences on large-scale dairy farms in the 
Middle East. They reported that animals between six and 18 months old frequently get FMD 
on these farms. Animals five to six months of age had received at least two doses of vaccines 
but appeared susceptible to clinical disease presumably due to maternal immunity interfering 
with the vaccine response. They speculated that environmental shedding from these animals 
was occasionally sufficient to overcome the immunity in older animals leading to wider 
outbreaks of disease. Studies they performed on these farms found vaccination at one day or 
one month old was ineffective at inducing an antibody response even with second dose given 
3-4 weeks later. However, they did not see suppression of antibody levels as reported by 
Nicholls et al. (1984). When these same animals received a third dose at 4-5 months old, there 
was no evidence of a priming effect with animals giving a similar response to unvaccinated 
animals of similar age from the same herd. Their conclusion from these data was that “the 
most effective vaccination program for calves of well vaccinated dams, was vaccination of all 
calves at 4, 5, and 6 months of age, to ensure that all calves had good levels of protection”. 
Details of the studies and the actual data were not published so the logic behind these 
recommendations cannot be appreciated. 
In a review by Doel (1999) based at Merial Animal Health Ltd, a major global producer of FMD 
vaccine, it was stated that “as maternal antibody wanes, there is an increasing opportunity for 
the vaccine to induce a significant titre of neutralising antibody and, in general, the population 
will respond well to vaccination after 2.5 months of age”. Additionally, “it is also the case that 
maternally derived antibodies do not always interfere with development of vaccine induced 
immunity for reasons which are not clear”. Work done in the author’s laboratory suggested 
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that the anamnestic response depends on the interval between the first and second dose with 
a two week period not inducing a strong response and suggested 3-4 weeks as an appropriate 
boosting interval. Data supporting these recommendations were not presented and it was not 
specified if this work was done in the presence of MDA. 
In a later review by the same author (Doel, 2003), the possibility was acknowledged that MDA 
might influence or prevent the development of immunological memory but no supporting data 
were provided. A pragmatic approach to vaccinating youngstock was proposed, acknowledging 
the impracticalities of withholding vaccination from calves until MDA has completely waned 
due to the prolonged “window of susceptibility” that will result. A recommendation was made 
that with vaccines containing either adjuvant type, calves from vaccinated dams should receive 
their first dose at 2.5 months of age “unless the epidemiological circumstances are very severe 
in which case 2.0 months is prescribed”. These “epidemiological circumstances” are not 
defined, but imply circumstances consistent with high risk of exposure. 
All three reviews comment on the effects of oil-based vaccines. Kitching and Salt (1995) 
speculated that the success seen with oil-adjuvant may be related to improved 
immunogenicity compared to aqueous vaccines. Doel (1999) remarked that there are several 
reports that don’t support the claim of oil-adjuvanted vaccines overcoming passive immunity, 
reiterated in the later review (Doel, 2003). 
9.2.7 Discussion 
9.2.7.1 Response to the first dose 
The results of the studies looking at the impact of MDA on response to vaccination are 
summarised in Table 9.3. It is apparent from these studies that MDA can interfere with the 
response to vaccination although this effect appears to vary between studies. Among calves 
with MDA, studies have reported an increase in titres after first vaccination to both oil and 
aqueous adjuvanted vaccines with ages ranging from a few days to five months old. Other 
studies that have reported no change or a decline in titres after first vaccination have tended 
to be in younger calves less than 3 months of age with the notable exception being the study 
by Nicholls et al. (1984) who saw decreasing titres in 1-4 month old calves given their first dose 
of an aqueous-adjuvanted vaccine. 
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It has been claimed that having an oil-adjuvant can circumvent the problem of MDA, particular 
from the study by Sadir et al. (1988) who directly compared their work to that of Nicholls et al 
(1984) in claiming the benefits of oil vaccines. They ascribe this benefit to the slow release of 
antigen from oil emulsified vaccines and therefore more persistent stimulation which has been 
reported elsewhere as a feature of vaccines containing this adjuvant (Aucouturier et al., 2001). 
This persisting effect may be responsible for the delayed response reported by Späth et al. 
(1995) who vaccinated calves less than 40 days old and only saw differences with the 
unvaccinated group at 90 and 120 days post vaccination. Based on the literature reviewed 
here, the response with oil and aqueous-adjuvanted vaccines is inconsistent as titre increases 
have been reported with both adjuvant types in the presence of MDA. Comparing the studies 
is not easy due to the different vaccine types used; lack of information on vaccine potency and 
antigen dose given; and varying MDA levels when vaccine is given. Only three studies made 
direct comparisons between these adjuvants in equivalent study populations. Gomes (1984) 
showed no difference, Sadir et al. (1988) showed a response to oil if calves were over 30 days 
of age which was not seen with an aqueous adjuvant, and Patil et al. (2014) found increased 
responses with oil adjuvants. On the evidence presented, it is not clear that oil based vaccines 
are superior to aqueous when given in the presence of detectable MDA titres. This conclusion 
is in agreement with reviews on the subject (Doel, 2003, 1999; Kitching and Salt, 1995). 
9.2.7.2 Response to repeated doses 
Several studies looked at the effects of a second dose, which was given between 21 and 120 
days after the first. In three studies both aqueous and oil adjuvanted vaccines increased titres 
with a second dose after the first failed to elicit any increased response (Graves, 1963; Nicholls 
et al., 1984; Sadir et al., 1988, Table 9.3). In three other studies, the second dose was 
ineffective at increasing the titre after an ineffective first dose, again demonstrated for both oil 
and aqueous adjuvanted vaccines (Uppal et al., 1975; Sadir et al., 1988; Bucafusco et al., 2014, 
Table 9.3). 
The second dose tended to be more effective when given at an older age, probably related to 
further MDA decay. Although the study by  Sadir et al. (1988) saw no response to a second 
dose with an aqueous-adjuvanted vaccine but did with an oil-adjuvanted equivalent in animals 
of similar ages, the number of animals receiving the aqueous booster is not made clear in the 
paper and so must be treated with caution. 
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9.2.8 Conclusion 
On the basis of this literature review, it is not possible to make general recommendations for 
the age of first dose, the necessity or possible timing of a second dose, or the relative benefits 
of using oil versus aqueous-adjuvanted vaccine. The majority of the studies are based in 
experimental settings using relatively small numbers of animals with no consideration to 
sample size. Only one study presented field evidence (Nicholls et al., 1984), but this was a poor 
study design that was inappropriately analysed so cannot be used as convincing evidence of a 
benefit of giving a second dose. Many of the studies are pre-1995 and there have likely been 
improvements in vaccine quality and potency in subsequent years. Few studies quoted the 
antigen dose used and little consideration was given to this aspect. There is also a notable 
absence of any SAT serotypes in any of the studies and none of studies are based in an African 
population. The variability in the study designs, vaccines and serological assays precludes 
combining the results, for example as a meta-analysis. There is a need for standardised 
protocols to ensure comparability of these studies. 
None of the studies considered natural immunity and the effect these colostral titres have on 
the response to vaccination, although this is likely to have been relevant in the one study 
presenting field data from an endemic area (Nicholls et al., 1984). A number of studies 
comment on the variability of titres seen in calves receiving their first dose at an equivalent 
age, and these titres will depend not only on the type of vaccine used in the dam but also with 
the FMD epidemiology and possibly the animal genetics that predominate in certain areas. 
Based on the study by Dekker et al. (2014), natural immunity is likely to have some impact on 
the response to vaccination presuming a different strain is circulating compared to the vaccine. 
These observations combined with the clear variability in results seen with vaccine types in 
different areas suggest vaccine schedule recommendations are likely to vary with the vaccine 
used and the particular FMD epidemiology though this is poorly documented in endemic 
areas. There is a need for further studies in the field in a variety of different settings using 
relevant (i.e. locally available) vaccines so that one can correctly inform optimal use in 
endemic countries. 
There are limitations to this review that should be acknowledged including the presence of 
studies in foreign journals that were either not available or not in English. Additionally it is 
acknowledged that there are many vaccine producers in the world for FMD vaccines (over 56). 
It is very likely that some, if not all, of these companies have their own data that are not 
publically available. The experiences relayed in the reviews by Doel (1999, 2003) are valuable 
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in this regard but this only represents one producer and data are not presented so are closed 
to academic rigour and informed discussion. Appraisal of the schedule recommendations of 
several large-scale producers of FMD vaccines in endemic settings (Table 9.4), it is apparent 
that there is some variation with oil based vaccines tending to not have a second dose in the 
primary course soon after the first dose. This is contrary to recommendations with the 
aqueous vaccine where a second dose 2-4 weeks is advised with the only exception being the 
Kenyan manufacturer where a second dose is not currently recommended. It is also 
noteworthy that two producers have different age recommendations depending on the 
presence of MDA (Merial/BVI and MSD Animal Health) and only two recommend vaccinating 
all ages (Brazil and Kenya).  
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Table 9.3. Summary of studies examining the antibody titre response to the first and second vaccine dose according to the age and adjuvant type used. Continued 
on next page.  
 Study/Country N Age Serotype(s) Adjuvant Titre response – first 
dose 
Titre response – second dose (dpv 
a
) 
Early studies with formalin inactivated vaccines     
Graves (1963)/USA  1 21 days A Aqueous None Increase (120) 
Figueroa et al. (1973)/Chile 6 3.5 months 
(approx.) 
O Not 
specified 
Increase N/A 
b
 
Uppal et al. (1975)/India 6 5-21 days O Aqueous Increase None (21) 
Shankar and Uppal (1982)/India 18 1-90 days A Aqueous Increase Increase (21)
 c
 
Oil versus aqueous adjuvants     
Gomes (1984)/Brazil 31 6 to 169 days A, C, O Aqueous Increase if MPT <2.0 Increase if MPT <2.0 (105) 
28 8 to 167 days Oil Increase if MPT <2.0 Increase if MPT <2.0 (105) 
Sadir et al. (1988)/Argentina - 1-90 days A Aqueous None None (30) 
 26 1-90 days  Oil None if 1-21 days old.  
Increase if >30 days old 
Increase for both age categories but greater increase if >30 
days for primary dose (30) 
Note: Increase or decrease in titre is defined relative to the titre when the dose was given. All titres measured with VNT except by Gomes (1984) (MPT) and Späth 
et al. (1995) (LPBE). Bucafusco et al. (2014) used LPBE and VNT. N/A = not applicable. “N” represents the total number of animals used in the study.     
a dpv = days post primary vaccination b N/A = Not applicable c Booster regime was half dose twice 21 days apart. Increase titre seen with both full and half dose. d 
For serotype O, higher increase than other strains with 60 day dose but decrease seen with 120 day dose. e Tests include LPBE, VNT, IgG1, IgG2, IgM, avidity ELISA 
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Table 9.3. Continued from previous page. 
Study/Country N Age Serotype(s) Adjuvant Titre response – first dose Titre response – second dose (dpv 
a
) 
Oil versus aqueous adjuvants (continued)     
Patil et al. (2014)/India 8 2-3 weeks A, C, O, 
Asia-1 
Aqueous Decrease N/A 
 10 2-3 weeks  Oil Increase N/A 
Evaluation using non-VNT methods     
Späth et al. (1995)/Argentina 68 20d, 30d, 
40d groups 
A, C, O Oil Decrease but higher than non-vaccinated controls 
at 90 and 120 dpv. No difference with age groups. 
N/A 
62 3 months 
and 4 
months 
Oil Increase Increase (60, 120 
d
) 
Bucafusco et al. (2014) 
e
/Argentina 15 1, 3, 5 
months  
O Oil Only increase with 3 and 5 month group N/A 
 13 14-42 days  Oil Decrease Decline but LPBE, IgG1, IgG2 and 
avidity assay levels were higher than 
expected than normal decay (35) 
 12 165-215 days  Oil Increase Increase (35) 
Note: Increase or decrease in titre is defined relative to the titre when the dose was given. All titres measured with VNT except by Gomes (1984) (MPT) and Späth 
et al. (1995) (LPBE). Bucafusco et al. (2014) used LPBE and VNT. N/A = not applicable. “N” represents the total number of animals used in the study.      
a dpv = days post primary vaccination b N/A = Not applicable c Booster regime was half dose twice 21 days apart. Increase titre seen with both full and half dose. d 
For serotype O, higher increase than other strains with 60 day dose but decrease seen with 120 day dose. e Tests include LPBE, VNT, IgG1, IgG2, IgM, avidity ELISA 
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Table 9.3. Continued from previous page. 
Study/Country N Age Serotype(s) Adjuvant Titre response- – first dose Titre response – second dose (dpv 
a
) 
Evidence from the field       
Nicholls et al. 
(1984)/Uruguay,Brazil 
44 1 week A, C, O Aqueous Decrease N/A 
 59 1, 2, 3, 4 
months 
 Aqueous Decrease Increase (30) 
Alternative strains       
Dekker et al. (2014)/Netherlands 25 2 weeks A Oil Increase to heterologous strain. Decrease with 
homologous strain. 
N/A 
Note: Increase or decrease in titre is defined relative to the titre when the dose was given. All titres measured with VNT except by Gomes (1984) (MPT) and Späth 
et al. (1995) (LPBE). Bucafusco et al. (2014) used LPBE and VNT. N/A = not applicable. “N” represents the total number of animals used in the study.      
a dpv = days post primary vaccination b N/A = Not applicable c Booster regime was half dose twice 21 days apart. Increase titre seen with both full and half dose. d 
For serotype O, higher increase than other strains with 60 day dose but decrease seen with 120 day dose. e Tests include LPBE, VNT, IgG1, IgG2, IgM, avidity ELISA 
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Table 9.4. Summary of a selection of commercially available FMD vaccines and suggested schedules in cattle. MDA = maternally derived antibodies. Continued on 
next page. All aqueous vaccines are adjuvanted with aluminium hydroxide and saponin.  
Manufacturer Product Adjuvant Age first dose Schedule Source 
Merial Aftovaxpur 
DOE 
Oil (double oil emulsion, 
DOE) 
2 months Primary course: 1 dose 
Booster: Every 6 months 
European medicine agency 
website 
a 
 
 Aftovax Aqueous  2 weeks (unvaccinated 
dams) 
2.5 months (vaccinated 
dams) 
Primary course: 2 doses, 3-4 weeks 
apart 
Booster: Every 4-6 months 
Botswana vaccine institute 
website 
b
 
Indian 
Immunologicals 
Raksha  Aqueous  4 months Primary course: 2 doses, 2-4 weeks 
apart 
Booster: Every 6 months 
Indian Immunologicals website 
c
 
 Raksha-Ovac Oil (double oil emulsion) 4 months Primary course: 1 dose 
Booster: 9 months, then every 12 
months 
 
ahttp://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/veterinary/002292/WC500147985.pdf (accessed 05/11/2014) 
bhttp://www.bvi.co.bw/products/AFTOVAX.html (accessed 05/11/2014) 
chttp://www.indimmune.com/livestock-vaccines.pdf (accessed 05/11/2014) 
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Table 9.4. Continued from previous page. 
Manufacturer Product Adjuvant Age first dose Schedule Source 
Bayer Bayovac® Oleosa Oil All ages Primary course: 2 doses, 90 days apart 
Booster: Every 6 months 
Bayer Brasil website 
d
 
Centro Diagnóstico Veterinaria Aftosa Oil 3 months Primary course: 2 doses, 6 months apart 
Booster: Every 12 months 
CDV website (Argentina)
e
 
MSD Animal Health Foot-and-mouth disease 
vaccine 
Oil 3 months Primary course: 3 doses at 4-6 weeks and 24 
weeks (6 months) 
Booster: Every 44-48 weeks (10-11 months) 
MSD Animal Health 
website 
f
 
 Decivac Oil (DOE) 2 weeks (no MDA) 
4 months (with MDA) 
Primary course: Single dose 
Booster: Every 6 months 
MSD Animal Health 
Website - Philippines 
h
 
Kenya Veterinary Vaccines 
Production Institute 
Fotivax Aqueous  All ages Booster: Every 4-6 months KEVEVAPI website 
g
 
dhttp://200.182.3.36/ContentAH/animproducao.nsf/Bayovac_oleosa?OpenPage (accessed 05/11/2014) 
ehttp://www.cdvsa.com.ar/vademecum-vacuna-anti-viral-aftosa-ficha.php (accessed 05/11/2014) 
fhttp://www.msd-animal-health.co.in/Products/Foot_and_Mouth_Disease_Vaccine/020_Product_Details.aspx (accessed 05/11/2014) 
ghttp://www.kevevapi.org/index.php?option=com_content&view=article&id=127&Itemid=123, accessed 01/07/2014) 
hhttp://www.msd-animal-health.ph/products/131_118551/ProductDetails_131_118625.aspx
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Chapter 10. Decline of maternal antibodies and the impact on 
vaccination response 
10.1  Introduction 
The Kenyan Veterinary Vaccine Production Institute (KEVEVAPI) is a state-owned FMD vaccine 
production company that is the sole provider of FMD vaccines in Kenya and the largest 
producer of FMD vaccine in Africa. Their vaccine (FotivaxTM) is an inactivated aqueous based 
product with aluminium hydroxide gel and saponin adjuvants. Each batch of vaccine undergoes 
potency tests conforming to OIE standards (OIE, 2009) performed by the National FMD 
laboratory which is based on the same site as the vaccine institute but is a separate 
government institution. The manufacturer’s recommended schedule is to administer vaccine 
to animals of all ages via subcutaneous injection at least every six months but four months for 
“better protection”5. It is licensed for cattle, pigs, sheep and goats. 
As part of the quality assurance (QA) at KEVEVAPI, four dairy cattle farms in different regions 
of Kenya are vaccinated every four months with free quadrivalent (O, A , SAT1, SAT2) vaccine 
in exchange for KEVAVAPI’s being able to take serum samples at vaccination and 21 days later. 
These samples are tested for FMD antibody by virus neutralisation tests (VNT). Vaccination, 
sampling and laboratory tests are all performed by the QA department at KEVEVAPI with 
appropriate measures undertaken to maintain the cold chain up until the point of vaccination. 
The primary analysis is to assess the proportion of animals that are over the 1.36 titre 
threshold which the manufacturer considers to correlate with clinical protection. The results of 
the sampling are fed back to each participating farm. At sampling, animals are classified as 
calves (<9 months old), yearlings (9-18 months old) and adults (>18 months old). 
Contact was made with one of the QA farms which was conveniently located, easily accessed, 
had individual animal records and agreed to allow access to relevant data to allow analysis of 
the VNT data. KEVEVAPI had been using this farm for QA purposes for more than 20 years with 
some data being available electronically as far back as 2006. In light of the findings on the 
large-scale farms alongside the conclusions of the preceding literature review, the objective of 
this analysis is to evaluate the effect of maternally derived antibody (MDA) on the response to 
FMD vaccine using historical data from this farm. It is hoped that the combination of this 
                                                          
5
 http://www.kevevapi.org/index.php?option=com_content&view=article&id=127&Itemid=123, 
Accessed 01/07/2014. 
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analysis with relevant epidemiological data will inform policy for vaccination in Kenya and 
other countries in East Africa. 
10.2 Methods 
10.2.1 Farm background 
The study farm was located to the west of Nairobi and had approximately 200 cattle of 
Ayrshire, Friesian, Guernsey and Jersey breeds along with various crosses between them. 
Calving took place all year around and no cattle were purchased. Each animal was individually 
identified with a unique ear tag number and name and had a unique identification card. Basic 
information was kept on the card such as the date of birth and sire/dam identification along 
with all information related to disease events and fertility (e.g. calving dates, offspring names, 
services). Electronic records were not routinely kept. 
For colostrum, calves were left with their dams for a seven day period before being transferred 
to group pens for further rearing. An outbreak of FMD was recorded on the farm in 
September/October 2009 from which SAT1 serotype antigen was detected at the National 
FMD laboratory although no virus could be detected when sent to the World Reference 
Laboratory (WRL), Pirbright, UK. No other FMD outbreaks have been recorded on the farm 
since the early 1990s. 
10.2.2 Vaccination and sampling 
All cattle over the age of three months were vaccinated at four month intervals, although 
animals could be excluded if calving is expected within two to three days of vaccination. 
Approximately 75% of animals vaccinated were blood sampled, with sampling generally not 
being performed on cows during high yielding periods due to a concern that this might 
compromise milk production and cows in late gestation so as to minimise the risk of abortion. 
The virus strains included in the vaccine (serotypes O [K77/78]; A [K5/80]; SAT1 [T155/71]; 
SAT2 [K52/84]) were the same for each vaccination although the batches varied over time 
(Table 10.1). 
10.2.3 Laboratory tests 
All VNTs were performed by KEVEVAPI using homologous virus strains. Two-fold dilutions of 
serum beginning with a 1/8 dilution were tested by their ability to neutralise the cytopathic 
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effect of FMD virus on Bovine Hamster Kidney (BHK) cells. End point titres were determined by 
a pH driven colour change that is prevented when neutralising antibodies are diluted to levels 
insufficient to prevent a viral-mediated cytopathic effect. Titres are recorded as the logarithm 
(base 10) of the reciprocal of the last dilution where a colour change was detected. If no colour 
change occurs at the lowest dilution of serum the result is referred to as <1/8 (or <0.9 as the 
reciprocal logarithm to base 10 equivalent). 
10.2.4 Data analysis 
Due to an outbreak of FMD which occurred on the farm in late September 2009, only results 
prior to this date were selected. VNT data were made available either electronically through 
KEVEVAPI or in hardcopy from the farm and manually entered. Data were entered into 
Microsoft Excel and imported into Stata 13.0 (Statacorp, Texas, USA) for analysis.  For 
analysing the decline of MDA by age, tobit regression was used to account for left censored 
VNT titres below the threshold detection limit of 1/8 (or 0.9). For the analysis of response to 
first vaccination, calves were defined as “Responders” if there was any increase in VNT titre 21 
days post-vaccination. If there was no change or titre decrease, the calf was classified as a 
“Non-responder”. MDA levels were categorised as <0.9, 0.9-1.19, 1.2-1.49, 1.5-1.79, 1.80-2.09 
and >2.1. Animals were defined as seroconverting if there was a four-fold increase in titre post 
vaccination, a cut-off that has been used previously for FMD when considering sub-clinical 
infection (Cox et al., 2010). For repeated vaccination, geometric mean titres at each dose and 
21 days later were considered and all titres <0.9 were recorded as zero and a “protective” 
threshold of 1.36 was used. 
10.3 Results 
VNT results were retrieved for all vaccination dates going back to August 2006, this being the 
first date for which electronic records were available, covering ten vaccinations (Table 10.1). 
The last of the vaccinations occurred just prior to the aforementioned outbreak and the 21-day 
follow-up testing was not performed in this instance. Date of birth records were found for 60 
calves which formed the dataset for analysis. Nine different vaccine batches were tested, two 
of which were used on two occasions. On one vaccination date two different batches were 
used although it was not recorded which animals received which batch on this occasion (Table 
10.1). 
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Table 10.1. Dates of vaccination, batch number(s) of vaccine used and the number of animals 
sampled that were being vaccinated for the first time for which farm records were available  
Vaccination date Batch number Number of animals sampled when receiving first dose 
29/08/2006 K01099 2 
28/12/2006 K01105 2 
26/04/2007 K01119 8 
06/09/2007 K01119 9 
17/01/2008 K01135 4 
22/05/2008 K01137 8 
11/09/2008 K01144/K01146 8 
15/01/2009 K01150 5 
14/05/2009 K01150 11 
10/09/2009a K01165 3 
a 21-day follow up sampling not available. 
 
Frequency distributions of titres of all the samples show a right skewed distribution with most 
animals being in the 0.9-1.19 category (Figure 10.1). The numbers of animals at first 
vaccination above the 1.36 titre which the laboratory considers consistent with protection are 
5/60 (8.3%) 3/60 (5.0%), 10/50 (20.0%) and 11/49 (22.4%) for serotypes A, O, SAT1 and SAT2 
respectively. Associations between the age at first sampling and the level of neutralising titres 
give an indication of the decay of MDA over time (Figure 10.2). For all serotypes except SAT1 
there is a decreasing trend of titre with age, although this is only statistically significant for 
serotypes O and SAT2. The half-lives for serotypes O and SAT2 are 141 (95%CI 78-687) and 158 
(95%CI 87-911) days respectively. Regression analysis indicated there was no significant 
association between the titres for the different serotypes indicating limited cross protection. 
VNT titres in respective dams were available for 22 calves from this study (Figure 10.3). The 
median titre was highest for serotype O. The distributions are broadest for serotype A, with 
the highest inter-quartile range, and SAT1 which has two outlier values (one dam had a titre of 
0.9 and one was <0.9). The mean time difference between the dam and calf being sampled 
was 69 days (standard deviation 33.7, range 8-125). 
Analysis of the response to the first dose compared to the neutralising titre of MDA showed 
that an increasing level of MDA was associated with fewer responders to first vaccination for 
serotypes A and SAT1 but there was no statistical evidence of a trend for O and SAT2 (Table 
10.2). Although for serotype O all animals with titres <0.9 responded to vaccination in contrast 
to animals with higher titres, for serotype SAT2 there was no indication at all that lower titres 
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was associated with a response. For SAT2 there even appeared to be an upward trend 
although there was no statistical evidence to support this observation (Table 10.2). No animals 
with titres above 1.5 responded to vaccination for any serotype. This analysis was supported 
by assessment of seroconversion rates, defined as a fourfold increase in VNT tires 21 days after 
vaccination (Figure 10.4). For all serotypes, very high seroconversion rates approaching 100% 
can be seen if the MDA titres are less than 0.9 except for SAT2 which is much lower at around 
20%. Based on chi-square tests for trend, for serotypes A, O and SAT1 there was very strong 
evidence of a linear trend (all P<0.0001) whereas there was no significant evidence for SAT2 
(P=0.11). 
In order to assess the effect of repeated doses, data were collected for up to five doses of 
vaccine (Table 10.3). For serotypes A and O, after receiving three doses of vaccine the mean 
titre is above the protective cut-off at the time the fourth dose of vaccine is given. This is not 
the case for the SAT serotypes for which the mean titre dropped below the protective level 
after each of the five doses indicating poor persistence of titres for these serotypes (Figure 
10.5). For serotypes A and O, after each dose of vaccine, the proportion still protected by the 
time the next four-monthly dose is given appears to be increasing with successive doses 
indicating probable increasing persistence of titres for these serotypes. This effect is less 
pronounced with the SAT serotypes which are still far below 50% protected even after the fifth 
dose of vaccine compared to 50% or greater for the A and O serotypes (Figure 10.6). 
207 
 
 
 
Figure 10.1. Frequency distribution of neutralising antibody titres for different FMDV serotypes at the time of first vaccination. Percentage of animals with 
“protective” titres:  Serotypes A 5/60 (8.3%); O 3/60 (5.0%); SAT1 10/50 (16.7%); SAT2 11/49 (18.3%). MDA = Maternally derived antibody.  
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Figure 10.2. Scatter plot of neutralising titres of calves blood sampled at the time of first vaccination versus age with regression line predicted using the 
output of a tobit regression model to account for left censoring of values below the serological threshold detection limit. Titres are measured with VNT. 
Animals are sampled (vaccinated for first time) only when over the age of three months. Regression coefficient with associated P-value and the correlation 
coefficient are shown in boxes within each graph.  
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Figure 10.3. Box plot representing the distribution of neutralising titres for 22 dams of calves in 
the study population for each serotype.  
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Table 10.2. Number of animals responding to first vaccination by the level of maternally 
derived antibody (MDA) for each serotype.  
 VNT titre at vaccination (MDA level)  
 <0.9 0.9-1.19 1.2-1.49 1.5-1.79  
Serotype Na Rb % N R % N R % N R % P-valuec 
A 
 
10 9 90.0 36 23 63.9 5 3 60.0 2 0 0.0 0.020 
O 
 
11 11 100.0 30 9 30.0 12 9 75.0 0 - - 0.29 
SAT1 
 
6 6 100.0 28 20 71.4 14 9 64.3 5 0 0.0 0.0014 
SAT2 
 
5 1 20.0 30 17 56.7 13 11 84.6 5 0 0.0 0.96 
a N = number. b R = Responder, defined by an increase in titre 21 days after vaccination. c Chi-
square test for trend. 
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Figure 10.4. Proportion of animals seroconverting to the first dose of vaccine by the level of MDA present at vaccination as measured by virus neutralisation 
test. Seroconversion is defined by a fourfold increase in titre measured 21 days after vaccination. For serotypes A, O and SAT1 there was very strong 
evidence of a linear trend based on chi-square tests for trend (all P<0.0001). For SAT2 there was no significant trend (P=0.11).MDA = Maternally derived 
antibody.  
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Table 10.3. Repeated doses of vaccine – titres at vaccination and 21 days later.  
Vaccine dose Number of 
animals 
Geometric mean titres (standard deviations) 
A O SAT1 SAT2 
D1 
 
60 0.84 (0.44) 0.86 (0.47) 0.95 (0.41) 1.0 (0.39) 
D1+21d 
 
53 1.1 (0.39) 1.1 (0.27) 1.2 (0.29) 1.1 (0.43) 
D2 
 
64a 0.99 (0.37) 0.99 (0.36) 1.1 (0.22) 0.98 (0.34) 
D2+21d 
 
50 1.4 (0.27) 1.6 (0.29) 1.4 (0.24) 1.3 (0.40) 
D3 
 
52 1.2 (0.25) 1.2 (0.29) 1.1 (0.30) 1.1 (0.34) 
D3+21d 
 
45 1.6 (0.13) 1.8 (0.30) 1.5 (0.25) 1.5 (0.38) 
D4 
 
46 1.4 (0.32) 1.4 (0.32) 1.2 (0.36) 1.2 (0.33) 
D4+21d 
 
37 1.6 (0.16) 1.8 (0.23) 1.5 (0.20) 1.6 (0.19) 
D5 
 
42 1.4 (0.27) 1.4 (0.29) 1.2 (0.37) 1.3 (0.35) 
D5+21d 
 
31 1.7 (0.18) 1.8 (0.22) 1.6 (0.18) 1.5 (0.27) 
Note: Animals are vaccinated approximately every four months. D1 represents the first dose of 
vaccine the animal receives. Samples with no detectable antibodies (i.e. <0.9) were recorded 
as zero. Data are represented graphically in Figure 10.5.                
a For some animals the first dose titre was not recorded but the second dose was hence more 
animals included at D2 than D1 
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Figure 10.5. Response to the first five doses of quadrivalent vaccine reflected by an increase in neutralising titre to the homologous virus strain. D1-5 
represents the (mean) titre at each vaccination with the D+21 representing the (mean) titre 21 days post vaccination. The horizontal line represents the 
titre considered to be protective by the manufacturer (1.36 for each). Samples with no detectable antibodies (i.e. <0.9) were recorded as zero. Data are 
tabulated in Table 10.3.  
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Figure 10.6. Proportion of animals with a “protective titre” (greater than 1.36) by the number of doses of vaccine. D1-5 represents the proportion 
“protected” at each vaccination with the D+21 representing the proportion 21 days post vaccination.  
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10.4 Discussion 
10.4.1 Maternally derived antibody 
The level of maternally derived antibody (MDA) was shown to decrease with age as expected 
due to waning levels over time associated with IgG catabolism (Cervenak and Kacskovics, 2009) 
although statistical evidence was apparent only for O and SAT2 serotypes with half-lives 
calculated as 141 (95%CI 78-687) and 158 (95%CI 87-911) days, respectively. These estimates 
are far greater than those reported in the literature and therefore cast doubt on these data. 
The total lack of an association between age and VNT level for A and SAT1 is surprising. For 
serotype A, there was a declining trend but the regression coefficient was not significantly 
different from zero (regression coefficient -0.0013; P=0.11). For SAT1, there was a slight 
upward trend and several animals had high levels of antibody (≥1.5) despite being over 150 
days of age, more than is apparent for the other serotypes, and also indicated by the higher 
proportion of animals having protective levels of antibody at the first dose (Figure 10.6). A 
similar effect is seen for SAT2 but to a lesser extent and may indicate some cross-reactivity of 
the assay although regression analysis did not indicate an association between the titres of the 
different serotypes. By 150 days of age, one would have expected the antibody levels to have 
waned to very low levels. These findings may indicate virus exposure, either of the dams 
leading to high colostrum titres that are transferred to their offspring, or more likely exposure 
of the calves leading to endogenous antibody production. The farm did not report any 
outbreaks of disease that would explain this finding although in a vaccinated population it is 
possible that clinical signs may be much reduced and transmission may be at such a level as to 
not be obvious to farm staff, particularly if older multiply vaccinated lactating cows were not 
clinically affected. 
There are likely to be several other reasons beyond possible exposure leading to inaccurate 
estimates. The absence of data in calves below the age of three months likely compromises 
the quality of the dataset and analytical capability. There are also many factors that can affect 
the quality of the colostrum, and there is likely to be variation in the initial calf titres and that 
will affect the half-life calculation. Unfortunately, maternal antibody levels were only available 
for 22 dams and few of these were close to the time of calving meaning dam levels of 
neutralising antibodies could not be usefully analysed alongside the calf data. However, titres 
in these dams were variable particularly for serotypes A and SAT1 (Figure 10.3). This variation 
may contribute to the lack of association between age and titres in their offspring for these 
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serotypes and the inaccurate half-life estimates for serotypes O and SAT2. A more reliable way 
of calculating the half-life would be to follow a cohort of individual calves with sampling 
commencing shortly after birth.  
10.4.2 Response to first dose of vaccine 
The increasing titre response to first vaccination was strongly related to the VNT levels, 
consistent with other reports in the literature, although this effect was statistically significant 
only for serotype A and SAT1. There was some indication that low MDA titres were associated 
with a greater response for serotype O but much less with SAT2, which may reflect an overall 
poor serological response to the SAT2 vaccine as seen in Figure 10.5. When considering 
seroconversion, evidence was stronger of an association with MDA. Very high seroconversion 
rates were seen for serotypes A, O and SAT1 if the MDA titre was less than 0.9 deceasing with 
higher levels. However, such evidence was not apparent from SAT2 further indicating 
problems with the SAT2 response. Although using a definition like this is likely to be an 
underestimate of seroconversion in response to vaccines when applied to settings with a high 
background immunity (Chandramohan et al., 2007), the strength of this association and the 
differences seen between SAT2 and the other serotypes is indicative of a genuine effect. 
The inconsistent association of VNT levels with age means an optimal age at first vaccination 
cannot be confidently suggested from the results of this analysis. No increase was seen for any 
serotypes when titres were over 1.5. Disregarding SAT1 results that may be unreliable due to 
possible virus exposure, the mean and median ages of calves that had titres over 1.5 at first 
vaccination were 117 and 108 days respectively. This is in contrast to a number of studies that 
showed responses to aqueous-adjuvanted vaccines in calves younger than this age (Figueroa 
et al., 1973; Shankar and Uppal, 1982; Uppal et al., 1975) but in agreement with other more 
recent studies (Nicholls et al., 1984; Patil et al., 2014; Sadir et al., 1988). Directly relating these 
findings to other studies is complicated by the use of different vaccines, different study 
populations, and variable MDA levels with age. This study was also done in a non-experimental 
setting, and utilised a quadrivalent vaccine that included SAT1 and SAT2 serotypes which has 
not been reported previously. 
10.4.3 Titre trends with repeated vaccination 
Sampling with each vaccination provided the opportunity to assess how the titres fall between 
doses, and whether protective titres are maintained. With each dose of vaccine there is a clear 
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increase in titre 21-days later which then decreased by the time the next dose is given four 
months later for all serotypes. This decrease becomes less pronounced with each dose for 
serotypes A and O but this effect is not seen to the same extent with the SAT serotypes 
indicating poor persistence of antibody even after four doses of vaccine. Indeed, the responses 
look more like a “succession of primary responses rather than a continuously maturing 
immune response” as previously observed by Doel (1996). The overall proportion of animals 
“protected” (i.e. titres ≥1.36) 21 days after vaccination reaches very high levels for serotype A 
and O being over 90% after three doses of vaccine. For the SAT serotypes, levels don’t reach 
90% even after five doses of vaccine. This indicates that although there was a response to the 
SAT serotypes at vaccination, it was less than for the other serotypes and the levels were not 
maintained. Higher antigen payload, an oil based-adjuvant, or higher frequency of doses may 
be required for the SAT serotypes although the latter will increase cost and labour and 
therefore unlikely be acceptable to the consumer given the high frequency of vaccination 
already performed. The need for a higher antigen payload for SAT2 was previously suggested 
on the basis of experience with potency tests (Parida, 2009), although similar suggestions for 
SAT1 have not been made. There is evidence that the use of an oil-based adjuvant may 
increase the duration of immunity (Gomes et al., 1980) including for SAT serotypes in field 
conditions in South Africa using equivalent antigen doses (Cloete et al., 2008). Additionally for 
SAT serotypes, higher titres have also been demonstrated post-vaccination for double oil 
emulsion vaccines compared to aqueous aluminium hydroxide/saponin equivalents (Hunter, 
1996). 
The overall levels of induced titres were generally disappointing with mean titres for each 
serotype ranging from 1.5 to 1.8 after five doses. Relating this to other studies in the literature, 
Pay and Hingley (1987) used an aqueous based vaccine for serotypes O, A and C and analysed 
how different antigen doses affected the serological response measured through serum 
neutralisation titres. They typically found titres over 2.0 with a single dose of vaccine at a 1:2 
dose dilution. Although their study was in immunologically naïve calves, similar levels should 
be attained after five doses after which time maternal antibody would have long disappeared. 
Although these antibody levels induced by the KEVEVAPI vaccine may be sufficient for clinical 
protection at 21 days post vaccination, evidenced by each batch passing a potency test, the 
lack of antibody persistence may not provide sufficient protection and higher initial titres may 
therefore be required. The antigenic dose for the KEVEVAPI vaccine is not available but clearly 
this is an aspect of vaccine production that should be addressed. 
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The results of these analyses indicate a need to address the schedules of vaccines given to 
youngstock. For serotype A and O, at least three doses are required in order to achieve 
satisfactory persistence between doses. In this study, the vaccines are given to all cattle every 
four months. Among youngstock, a second dose given at one month after the primary dose 
may allow animals to reach a higher level of protection quicker minimising the time period 
between protective MDA being present and sufficient antibody being induced by the vaccine – 
the so called “immunity gap”. Thereafter the calves may fit into the herd vaccine schedule 
receiving a booster up to four months later. The optimal age at first vaccination in repeatedly 
vaccinated herds also needs to be addressed and the results of this analysis are not able to 
suggest the optimum time. Although there are various recommendations for this age from 
other settings (Table 9.4), differences between vaccine manufacturers and the population 
being immunized mean that population-specific studies should be performed. These studies 
should consider the practical difficulties in smaller herds of ensuring calves are vaccinated at 
the correct time which is limited by the vial size and extra labour required when vaccinating 
outside of the herd schedule. 
There are uncertainties over the results presented particularly with reference to the decline in 
maternal antibodies indicating some exposure may have occurred. It also would be worthwhile 
getting external validation of the VNT results for example through the National FMD 
laboratory in Kenya or the World Reference Laboratory in Pirbright, UK. The protective titre 
assumed in this study is 1.36 for each strain which is the level used by the manufacturer. 
According to OIE guidelines “Cut-off titres for evaluating immunological protection afforded by 
vaccination have to be established from experience of potency test results with the relevant 
vaccine and target species”. No evidence from the manufacture was available publicly, but 
with all batches of vaccines undergoing potency tests, supplementary VNT information could 
be easily collected.  
The data used in this analysis were from vaccinations performed under “ideal” conditions with 
the vaccine manufacturer performing the vaccination and therefore are a “best-case scenario” 
for sero-conversion in the field. Under more realistic field conditions, the vaccine is not likely 
to perform as well with a suboptimal cold-chain, missed or inaccurate doses and deterioration 
of antigen post-manufacture. Therefore post-vaccination serological monitoring in areas of 
vaccination, performed by independent monitors or government subsidised vaccination 
campaigns would add valuable information. 
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In conclusion, the results of these analyses indicate opportunities to modify the vaccine 
schedules to achieve greater levels of protection quicker in an animal’s life. In addition, the 
antigen payload or vaccine adjuvant for the SAT serotypes needs to be addressed. Further 
validation of these results is required and the evidence for a protective titre needs to be clearly 
elucidated. 
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Chapter 11. Discussion 
This thesis has presented data relating to the epidemiology, vaccine effectiveness and disease 
impact on two large-scale farms in Kenya (Part A). The vaccine evaluations are supported by 
the analysis of serological data provided by the vaccine manufacturer (Part B). All three 
research paper publications (Chapter 4, Chapter 5 and Chapter 6) include separate discussions 
relating to their specific objectives and findings. For consistency in structure, the non-
published chapters also include separate discussion sections, including Chapter 8 comparing 
the epidemiological aspects of the two outbreaks. This final chapter provides a general 
discussion of the implications, limitations and subsequent recommendations based on the 
work as a whole. This is complemented by general observations from the field during the study 
period involving discussions with Kenyan farmers, veterinary surgeons and animal health 
assistants. 
11.1 Key findings 
Two instances of poor vaccine effectiveness on large-scale, extensively grazed dairy farms in 
Nakuru County, Kenya were investigated. Both had received the last vaccine dose 
approximately three months before the index case occurred and used a periodic vaccination 
policy whereby all eligible animals were vaccinated at the same time.  
The exact reasons for observed low effectiveness were not confirmed in this work. However, 
based on the patterns of disease and complementary analysis of the VNT data provided from 
the vaccine manufacturer, evidence was provided for three important factors:- 
1. Poor match between the field and vaccine strain (“Vaccine match”, [VM]) 
2. Waning antibody titres between vaccination rounds 
3. Sub-optimal vaccine schedules in youngstock 
Of particular concern is the vaccine for the SAT2 serotype given the high incidence of disease 
seen despite multiple doses of vaccine together with poor seroconversion rates and rapidly 
waning titres seen in the VNT analysis.  
On the farm that had the outbreak due to serotype SAT2 (Farm1/SAT2), where the vaccine 
appeared ineffective, an analysis of disease impact was performed looking at the effect of the 
outbreak on milk yield, clinical mastitis and culling. A clear impact of the disease on milk 
production was seen at a farm level decreasing from an average of 20 to around 13 kg per cow 
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per day. It took around 2 months to show some recovery before a further decline was seen. 
Despite this, no difference was found in milk yield between reported cases and non-cases. This 
may have been due to subclinical infections, poor sensitivity of the case definition or 
underreporting. Compared to predicted yields, higher impact was seen among older animals in 
peak-lactation with the greatest effect seen in cows of parity four or greater that were 
between 101 and 200 days in milk at the beginning of the outbreak. These animals produced a 
305 day milk yield which was around 550 litres less than predicted. Survival analysis showed 
recorded FMD cases were at an increased risk of clinical mastitis in the month after the 
outbreak began (HR=2.9, 95% confidence intervals [CI] 0.97-8.9, P=0.057) and weak evidence 
that they were associated with an increased culling over the 12 months after the outbreak 
began (HR=1.7, 95%CI 0.90-3.4, P=0.10).  
11.2 Implications 
11.2.1 FMD outbreaks on large-scale dairy farms in Kenya 
These studies provide useful insights into outbreaks in endemic settings that may inform 
control measures on affected farms. Both outbreaks occurred over 1-2 month periods with 
two major peaks in cases consistent with movement of virus to clusters of inter-connected 
groups. Both farms attempted isolation of clinical cases, but neither was successful in 
preventing the outbreak affecting most of the animal groups. Neither attempted any other 
forms of biosecurity. On Farm 1/SAT2, the early movement of animals in an attempt to protect 
the dairy herd is likely to be the reason the outbreak became widespread so quickly. This 
information is useful as it indicates that several measures are likely to be needed to prevent 
intra-farm spread once a farm is affected and that isolation of affected animals alone is likely 
to be insufficient.  
FMDV is well known by Kenyan farmers for its transmissibility. The author’s experience in the 
field revealed it was common for farmers to say that they would prefer an outbreak to affect 
all groups as soon as possible so as to minimise the duration of inconvenience the outbreak 
brings. This is a similar approach to the “aphthisation” described by Sutmoller et al. (2003) 
which was “common practice” globally until the 1950s. The deliberate infection of livestock 
meant farms avoided a period of uncertainty and long outbreak duration. From the author’s 
experience of visiting several large-scale farms in Kenya, it appears that most farmers are 
resigned to fate and only make half-hearted efforts at disease control once their farm is 
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affected and no sustained efforts at virus containment. When farms use vaccination it is likely 
that vaccine induced immunity is overcome by relatively high levels of exposure to virus. 
Although the risk of spread cannot be eliminated, efforts to minimise it may have some effect 
if performed appropriately. It is apparent that farms should have contingency plans designed 
to minimise spread and impact in the event of an outbreak (discussed further in section 
11.4.1). 
In particular on Farm 1/SAT2, there was a low incidence of FMD among younger animals 
(section 4.4.4). This finding is reminiscent of the disease pattern seen with a serotype O strain 
outbreak reported in the Netherlands (Bouma et al., 2004). This suggests that more proactive 
surveillance among young animals may be required to detect the presence of infection. If a 
farm is at high risk of an outbreak, individual calves may need routine close examinations to 
detect FMD. It is important to identify affected groups early so that control measures may be 
rapidly implemented. Undetected disease in youngstock may facilitate onward transmission to 
other groups on the farm, particularly if intra-group biosecurity measures have not have been 
introduced in the absence of overt disease on the farm. 
11.2.2 FMD vaccination 
These are the first studies to investigate the field effectiveness of FMD vaccination in East 
Africa and the first studies to evaluate vaccines on farms using a routine vaccination strategy. 
Field investigations are limited worldwide due to a longstanding tradition among FMD 
researchers and vaccine manufacturers towards experimental studies for evaluating vaccines. 
Such experimental studies cannot account for circumstances in the field when it comes to such 
factors as exposure, coverage, and cold chain policies. This is apparent in this study, as the 
vaccines were apparently tested and approved according to the recommended PD50 test in the 
OIE guidelines (OIE, 2009), yet did not work effectively. The poor vaccine performance was 
similar to that observed in outbreaks in Israel reported by Elnekave et al. (2013) and in 
Thailand reported by Gleeson et al. (1995) each of which occurred despite a good vaccine 
match to the field strain. This demonstrates that even a vaccine that has supposedly passed 
standardised quality control procedures may not perform as expected in the field, suggesting 
that adjustments are needed to our evaluation approach if we are to optimise effectiveness. 
As it is only through a field-based epidemiological approach that such findings are revealed, it 
is important that such studies be encouraged worldwide in similar and different settings. 
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The vaccine used in these outbreaks was a locally produced aqueous quadrivalent vaccine 
containing single strains of serotype A, O, SAT1 and SAT2 viruses. The manufacturer-
recommended schedule is a dose at least every six months but preferably every four months 
to animals of all ages (KEVEVAPI, 2014). Based on the results presented here, in particular the 
outbreak on Farm 2/O and the VNT analysis (Chapter 7 and Chapter 10), there is evidence that 
a two or three dose primary course may be needed in line with recommendations by other 
vaccine producers (Table 9.4). The high incidence among youngstock, which decreased with 
the number of doses received, suggests that more doses of vaccine need to be administered 
earlier in life to ensure sufficient levels of immunity among younger animals. Different 
schedules should be investigated by the manufacturer (see “Further research priorities”, 
section 11.4.5). 
A history of disease in a previous outbreak was not associated with protection on Farm 2/O 
suggesting that the greater protection among multiply vaccinated animals was due to 
vaccination rather than previous exposure which might have occurred in older animals. 
However, previous disease or infection cannot be ruled out entirely. Mild, unrecorded disease 
may have occurred during these known outbreak periods and it is possible that virus incursions 
could have occurred unknown to the farmer particularly as disease is endemic in the region. 
Additionally there could be other reasons that immunological protection increases with age. 
The inability to adjust for age as a confounder between the lifetime number of doses received 
and the risk of FMD is a major limitation of the analysis.  
Although there is evidence that additional doses are needed to increase protection in 
youngstock, the unacceptably high incidence among multiply vaccinated animals implies that 
schedule modification alone is unlikely to have made a substantial difference to the outcome 
on Farm 2/O (Section 7.4). Therefore schedule modification needs to be considered as part of 
a combination of measures aimed at improving effectiveness. Further investigations are 
required to establish the reason(s) behind such outbreaks.  
Although these vaccines apparently passed the OIE recommended potency tests, the rapid 
waning of titres may indicate poor vaccine quality. Figure 11.1 allows comparison between the 
incidence by the number of doses for each farm (Figure 8.5) and the neutralising titres with 
repeated doses for the respective serotype (Figure 10.5). The outbreak on both farms occurred 
coincidently 99 days after the previous dose (Table 8.1). For SAT2, lower titre increases post 
vaccination, poor persistence of titres between doses and the limited cumulative titre increase 
with each dose may explain the high incidence in multiply vaccinated animals on Farm 1/SAT2 
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at this time-point since the previous dose. For serotype O, higher post vaccination titres and 
greater cumulative increase with repeated doses could explain why this vaccine was more 
effective at this equivalent time-point since the previous dose although more vaccine had been 
used on this farm mainly due to the different age distribution. Titre kinetics for animals 
receiving further doses, preferably similar in number to what animals had received on these 
farms, would add to this interpretation. 
 
 
 
Figure 11.1. Comparison of the incidence by the number of doses for Farm 1/SAT2 and Farm 
2/O and the pattern of neutralising titres with repeated doses of vaccine for respective 
serotype. For the VNT titres (right) the response to the first five doses of vaccine is shown (see 
Figure 10.5). D1-5 represents the (mean) titre at each vaccination with the D+21 representing 
the (mean) titre 21 days post vaccination. The horizontal line represents the titre considered to 
be protective by the manufacturer (1.36 for each). 
 
The Kenyan vaccine manufacturer is currently developing a new vaccine for FMD that will be 
oil-adjuvanted and NSP purified. Oil-based vaccines have been extensively used in South 
America and experience there suggests that titres induced by such vaccines tend to be more 
persistent in cattle compared to aqueous equivalents (Sutmoller et al., 2003). More persistent 
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antibody responses with oil adjuvants have also been demonstrated under field conditions in 
Africa with SAT serotypes (Cloete et al., 2008). Advantages of oil-based vaccines have also 
been claimed in terms of improved potency as demonstrated in a study by Vianna Filho et al. 
(1993). They compared aqueous (hydroxide-saponin) and oil-based vaccines in adult (18-24 
months old) cattle by IDL challenging them with serotype O virus at 21-28 dpv and 85 dpv after 
a single dose of vaccine. At the former time point 246/271 (91%) and 300/320 (94%) were 
clinically protected with the aqueous and oil adjuvant type respectively. In contrast, at 85 dpv 
the protection was 7/15 (47%) and 14/15 (93%) respectively. The authors conclude from these 
results that the oil adjuvanted vaccines perform better than the aqueous equivalent. However, 
benefits of oil adjuvants are controversial as highlighted in Chapter 9 with reference to the 
interference with MDA consistent with published reviews on the subject (Doel, 2003; Kitching 
and Salt, 1995). In a review by Parida (2009) no clear benefit of oil based vaccines has been 
apparent from a immunological perspective since both aqueous and oil-based tend to favour 
humoral immunity and neither induces sufficient cell-mediated response which is also required 
for protection. These studies imply that oil-adjuvanted vaccines may have some advantages 
over aqueous, although field based vaccine effectiveness studies should still be a key aspect of 
their evaluation.  
11.2.3 FMD economics 
As outlined in the literature reviews to the papers in Chapter 5 and Chapter 6, there is a lack of 
field evidence on FMD impact particularly in endemic settings. This lack holds back the control 
of FMD, as governments are unable to allocate resources appropriately in national control 
strategies given that resources are scarce and competing with other areas. The importance of 
this aspect of FMD control is set out in the guidelines of the joint FAO/OIE Progressive Control 
Pathway (PCP) document, which stipulates a minimum requirement for inclusion in Stage 1 as 
having some understanding of the socio-economic impact of FMD in the country for different 
stakeholders and husbandry systems (FAO, 2011).  
Estimating the economic impact of disease is a highly complex subject due to the many direct 
and indirect effects that may occur. This combined with the lack of field data means economic 
impact assessments are often limited in their approach by either considering only direct 
effects, being based on assumptions, or using poorer quality data such as those provided by 
expert opinion (Knight-Jones and Rushton, 2013; Şentürk and Yalçin, 2008, 2005).  
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The results of the studies presented in this thesis provide objective estimates on milk yield 
(Chapter 6), clinical mastitis and culling (Chapter 5). These elements are poorly characterised 
for FMD, particularly for the latter two components that are rarely considered in economic 
impact assessments. Conducting a full cost analysis of the outbreak was not the objective of 
this thesis, and would require the development of an economic framework based on this 
Kenyan setting. However, the outputs of the studies reported here could be used to 
parameterise such economic models to estimate the overall cost of an outbreak, which could 
then be used to inform policy at the individual farm, national or regional levels. 
11.3 Strengths and limitations 
11.3.1 External validity of study results 
Great caution must be taken when extrapolating an analysis based on just two farms to the 
general population since this study population is unlikely to be representative of all farms in 
the region. This applies to the analyses of epidemiology, vaccine effectiveness and economic 
impact. Most of the dairy production in Kenya is from smallholder dairy farms, unlike the farms 
described here. 
The way in which an outbreak spreads on a farm is likely to vary depending on various 
management factors that will differ in type and extent between farms. The recognition of high 
risk exposure events on these farms may help to guide generic recommendations for these 
types of farms that may in turn be generalised to other large-scale dairy farms in Kenya and 
elsewhere in the world (see “Recommendations”, section 11.4.1). 
The FMD vaccine investigated here would probably have behaved in a similar way on other 
dairy farms in Kenya under similar exposure conditions, although the inability to find hard 
evidence for the failures limits this generalisation (e.g. other farms may have used different 
schedules or different cold chain management). A survey of vaccine management and 
vaccination policies among these different farm types would therefore be useful. Among 
smallholders in Kenya, routine vaccination is less commonly used, and farmers usually receive 
vaccines only through government-subsidised “ring” (or “reactive”) vaccination campaigns 
(described in section 1.4.2). In such circumstances, the lifetime number of vaccine doses is 
likely to be much lower than that on the large-scale farms. However, since farms are being 
“ring vaccinated” during a period of high-exposure risk, exposure may be closer in time to 
when the vaccine was given. With the problems of VNT titre persistence demonstrated in this 
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thesis (Chapter 10), it is possible that clinical protection may be greater if the time between 
vaccination and exposure is shorter. In this context, it should be stated again that the VNT data 
used in this analysis is a “best-case scenario”, as they are from quality assurance (QA) farms 
where vaccination is performed by the manufacturer under ideal conditions. Lower titres may 
be expected during field vaccination campaigns. Additionally, as smallholder populations are at 
risk of exposure to virus from farms tending to use high risk management practices (e.g. 
shared grazing, using a common dipping facility for parasite control) a higher level of 
background immunity may be present from natural exposure that may complicate the 
evaluation of ring vaccination campaigns although there are no data to support this 
supposition. 
The impact of FMD on milk yield, clinical mastitis and culling observed in this study may be 
similar to that in other large-scale farming systems. The impact of disease is likely to be 
different in areas where zebu breeds predominate and where beef ranches are more common, 
where the effects on weight gain also need to be considered. In the Nakuru County area, 
where dairy production is common, the smallholder farms often own exotic (i.e. grade or 
European) breeds of cattle due to their higher milk production. In fact cattle are often 
purchased from the large-scale farms depending on their proximity to these farms although 
the true extent of this practice is unknown (Figure 11.2). Smallholder cattle may be on a lower 
plane of nutrition compared to the large-scale farms which may affect milk yield. The author’s 
experience of working with smallholders in Nakuru County suggests that, depending on the 
area, they may have good access to high protein/energy concentrated feeds through locally 
organised co-operatives (Figure 11.3). Therefore the levels of nutrition may be comparable to 
the larger commercial farms. Given the similar genetics from purchasing cattle from the local 
large-scale farms, there is unlikely to be much difference in the rate of FMD-attributable 
clinical mastitis although decisions related to culling are likely to be different in a smallholder 
setting. At the household level, the socio-economics of disease are likely to be substantially 
different and require investigation. 
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Figure 11.2. Photograph of a smallholder farm on the outskirts of Nakuru. These cattle are zero 
grazed and fed a combination of concentrated feed and Napier grass. They were sourced from 
a nearby large-scale farm.  
 
Figure 11.3. Photograph of a Co-operative society based in Esageri, Baringo County. It is 
through co-operatives such as this that smallholder farmers can get access to concentrated 
feed that may be in part exchange for milk supplied to the co-operative society.  
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This thesis only considered cattle and none of the other FMD-susceptible species such as 
sheep, goats and pigs. The reasons for this include:  
a) In Kenya FMD vaccination is generally performed only in cattle  
b) Disease impact is considered low among small ruminants due to the tendency for 
them to have subclinical infections or mild disease 
c) The pig population is relatively small (Figure 1.4).  
Separate studies would be required for these species to evaluate the role vaccination may 
have in decreasing the transmission of FMDV and additional impacts which this might bring at 
the national level. It has been demonstrated that oil adjuvanted vaccines are more efficacious 
in pigs compared to aqueous (Anderson et al., 1971), so pig vaccination may become more 
common with the new vaccine. 
11.3.2 Vaccine effectiveness estimate 
These studies indicate low vaccine effectiveness of a particular FMD vaccine in cattle in an 
endemic setting and are the first such analyses based on data from Africa. An absolute vaccine 
effectiveness estimate was not possible from these data, and the specific reasons for the poor 
vaccine performance were not conclusively shown. As stated previously, the collinearity 
between age and lifetime number of doses received, means this important confounder cannot 
be adjusted for in effectiveness estimates. This highlights an important limitation when 
evaluating any vaccine on a farm that uses a routine whole herd vaccination strategy. 
11.3.3 Accuracy of the case definition and lack of serological data from outbreaks 
There are also concerns over the sensitivity of the case definition particularly for Farm 1/SAT2. 
NSP antibody testing can be used in vaccine effectiveness studies, increasing the sensitivity of 
the case definition. Under some circumstances this can provide a means of evaluating the 
effectiveness of the vaccine at preventing infection, as shown by Knight-Jones et al. (2014) 
among smallholders in Turkey. NSP antibody surveys were not considered appropriate in these 
outbreaks, as the vaccine was not NSP purified. The serology results would have been difficult 
to interpret due to the presence of maternal antibody in young, non-vaccinated animals and in 
the case of Farm 1/SAT2, animals being vaccinated at a young age before maternal antibody 
would have waned. There are some unpublished observations that when a non-NSP purified 
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vaccine is used a higher percentage inhibition cut-off can be used for defining those that were 
infected (for example 75% compared to the usual 50%) (C. Bartels, Personal Communication). 
Such an approach might be utilised in Kenya although validation studies would be required to 
assist interpretation under these circumstances. Although complementary laboratory testing is 
preferred in these investigations, their absence makes these studies very cheap to perform 
and the results from this thesis demonstrate that laboratory tests (for example vaccine 
matching) are not essential to begin vaccine effectiveness investigations. Field studies are 
appropriate for under-resourced endemic settings where more expensive sample submission 
can be problematic or significantly delayed. 
It could be that the failure to observe a difference in milk yield impact between reported cases 
and non-cases was due to poor recording, poor sensitivity of the case definition or subclinical 
infection. This necessitated the use of a predictive analysis which introduces greater 
uncertainty to the results. This may indicate that in a herd affected with FMD, comparisons 
between cases and non-cases in affected groups are not an appropriate form of analysis. Focus 
may be better directly towards comparing affected and non-affected groups but problems of 
comparability will arise. On this farm, all lactating groups were affected so this approach was 
not possible. Comparisons between several farms is an alternative approach although this 
would need to consider the difference in management approaches between farms that will 
affect milk yields, most importantly nutrition, fertility and genetics. 
11.3.4 Vaccine matching 
Vaccine matching (VM) data were lacking in these investigations which limited our ability to 
explain the reasons for vaccine failure. Vaccine matching is performed by a limited number of 
laboratories including the WRL in Pirbright, UK, where samples from Kenya have historically 
been sent. Although some VM results have been produced in recent years for Kenyan field 
isolates, the vaccines to which they were matched were not being used in Kenya thus limiting 
their usefulness. The WRL currently supports the processing of up to 50 FMD viruses isolated 
per country per year without charge. Financing the shipment to the WRL can be problematic 
due to limited governmental resources although funding may be sourced through research 
projects or agencies like EuFMD.  
Staff at the Kenyan National FMD Laboratory have received training on VM in recent years, 
funded through a reciprocal arrangement with EuFMD related to the Kenya based FMD 
training courses. Despite this, it is not routinely performed as more training is currently 
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needed. The process of delivering this training is ongoing, but until the laboratory becomes 
fully accustomed to this technique, there will be an ongoing need to send virus isolates to the 
WRL for VM. Even once VM has started in Kenya, there will be a continual need for external 
validation particularly in the early stages which can also be provided by the WRL.  
As detailed in the literature review in Chapter 2 (section 2.3), there are limitations to the 
inferences that can be made from VM results in isolation. However, alongside field evaluations 
they would strengthen the ability to interpret an observed level of vaccine effectiveness. At 
the time of writing, the WRL have the original strains currently used in the KEVEVAPI FMD 
vaccine with complementary BVS recently supplied by the Kenya National FMD laboratory, but 
require the currently used vaccine seed strains in order to provide reliable VM results. Through 
activities related to the research presented here, an agreement was signed in July 2014 
between KEVEVAPI and the WRL to share these strains under certain conditions respecting 
their commercial value. KEVEVAPI have also been advised to send other candidate vaccine 
seed strains and their complementary BVS so that matching to strains not currently used in 
vaccines can be similarly evaluated in case their inclusion is warranted. These samples are 
awaiting shipment, alongside some selected samples taken as part of national surveillance. 
11.3.5  “Outbreak bias” 
Clearly if the vaccine performed on all farms in Kenya like that reported in these outbreaks, 
one could not recommend its use and it is unlikely to be a cost effective control measure. 
However, a major limitation of using herds where vaccination has failed as the basis for 
evaluating a vaccine is that the approach may be biased, by focusing on farms where 
vaccination has been ineffective. This is a form of selection bias. It is possible that there are 
other farms that have not had disease despite exposure and where the vaccine has been 
successful in preventing infection or disease. Such farms are not included in the vaccine 
evaluation as no disease outbreak has been detected to alert a relevant investigation. This 
“outbreak bias” effect will tend to bias vaccine effectiveness estimates towards null. An 
assessment of the extent of outbreak bias could be performed by surveying large-scale farms 
on their experience with FMD combined with collecting information on vaccine management 
practices. Other study designs would be required to address this bias to establish whether the 
performance seen in these outbreaks is typical or atypical for other farms in Kenya (see 
“Recommendations”, section 11.4.3).  
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11.3.6 Vaccination reducing disease impact 
For the disease impact analysis on Farm 1/SAT2, the routine vaccination appears to have been 
ineffective in preventing clinical disease, but a reduction in the severity of disease due to 
vaccination cannot be ruled out. For example, vaccination may have led to less days not 
producing milk or decreased the risk of culling. Although ideally one would measure the 
impact of FMD in an unvaccinated population, based on the author’s field experience very few 
large-scale farms in Kenya do not vaccinate.   
11.3.7 Follow-up period 
An impact on clinical mastitis and culling was apparent, although the statistical evidence for 
the latter was weak. The analysis was performed one year after the outbreak started and a 12 
month follow-up period chosen as a consequence. Longer term analysis might have been more 
informative, particularly for animals that fail to get pregnant, for which a prolonged time 
period may elapse before a culling decision is made. The choice of follow-up period for culling 
will depend on the individual farm and its management policies. A shorter follow up period 
could be chosen for analysing the impact on mastitis in future studies. A 12 month follow-up 
was used in this analysis so that all available data were used.  
11.3.8 Source of VNT data 
The VNT data were supplied by the vaccine manufacturer using the QA reports that they 
provide to a commercial farm that receives free vaccine in exchange for permission to allow 
blood sampling. The precise methodology used in the VNT is unknown, and some external 
quality control would be appropriate so that the results can be validated. A protective titre of 
1.36 is used by the manufacturer although no data have been seen to support this assumption. 
The presence of subclinical infection on the farms cannot be ruled out, particularly for SAT1, 
such that cross reacting neutralising antibody may have affected the results. 
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11.4 Recommendations 
This work generates several recommendations for FMD control in Kenya related to individual 
farm outbreak management, methods of vaccine evaluation and general FMD control policy as 
outlined below. Further areas of research that should be prioritised in his area have also been 
identified. 
11.4.1 Farm contingency plans 
The epidemiological analyses suggest several areas that could be addressed on large-scale 
dairy farms to limit the spread of infection, and that individual contingency plans should be 
developed. Several high risk events were identified on these study farms that are likely to have 
led to widespread exposure and infection transmission. The experience from these outbreaks 
is that it is unlikely that isolation alone will be effective in containing an outbreak. Other 
experience, from attending outbreaks among smallholder farms in Kenya, suggests that close 
proximity does not necessarily lead to transmission. On this basis, it may be possible for large-
scale farms to contain outbreaks particularly if there is sufficient level of background immunity 
from vaccination requiring high virus exposure to initiate infection. Specific plans will vary 
depending on the individual farm. Some generic recommendations can be made on the basis 
of these findings to limit the spread between groups of animals and to prioritise the protection 
of the lactating groups among whom the impact is likely to be greatest. Due to the extensive 
sharing of equipment and personnel with lactating animals, once disease is in one of these 
groups, infection is likely to have already spread to all other lactating groups.  
Farm plans should have sections on “Preventing introduction” and on “Minimising spread and 
impact”. Recommendations are given here, in no particular order. 
Preventing introduction: 
1. Lactating groups should not be grazed in direct contact with other livestock groups or 
near the farm perimeter 
2. Farm personnel should be regularly trained on FMD recognition and the contingency 
plans 
3. If livestock personnel own their own livestock on a site off the main farm premises and 
FMD is in the area, they should notify the farm and not come to work. The farmer 
should then notify the veterinary authorities who should investigate the claim since 
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FMD is a notifiable disease. This will then act as a check that the employee’s report has 
a genuine foundation and reduce the number of false reports that may arise with such 
a policy. 
4. Separate clothing and footwear should be available for farm workers that have contact 
with livestock areas. These must never leave the farm, where they should also be 
laundered. 
5. Visitors (people, vehicles) should be denied access to animal holding areas 
6. Purchased animals should be isolated from the main herd with no direct contact for a 
minimum two week period. They should be thoroughly checked for clinical signs during 
this period. Designated staff and equipment should be assigned to this quarantine 
section or at the very least these animals should be attended to after the other groups. 
7. Small ruminants should not be co-grazed with cattle as subclinical infection is more 
common in these animals so infection may circulate unknown to the farm workers.  
8. Vehicles that work with livestock should remain within the farm and not go to other 
farms or areas that non-farm livestock may be present. If they do, they should be 
thoroughly cleaned and disinfected before being allowed back on the farm.  
Minimising spread and impact: 
1. Selection of isolation paddocks should be ad hoc depending on the location of the 
index case. Ideally no movement will be required. If it is, it should be through areas 
that other animals will not be walking through or grazing. This may necessitate the 
opening up of paddocks to avoid the use of roads.  
2. After a first case is observed in a group, the whole group should be isolated. Individual 
animals may be further isolated to reduce the exposure of non-diseased vaccinates. 
This route of isolation must be undertaken with no risk of contact with unaffected 
groups.  
3. Groups in contact with affected groups should be considered as part of an infected 
cluster and should be similarly isolated. 
4. Designated farm staff and equipment should be used for each group until two weeks 
after the onset of the last case. Such equipment should be disinfected before being 
used again after the outbreak. 
5. Separate paddocks should be created for cows that are calving to minimise their 
movements during the outbreak (i.e. movement of these animals to the main lactating 
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groups should be avoided. Hand milking may be required for these cows unless a 
portable milking unit is available). 
6. If FMD is known to be in the area, youngstock should be regularly inspected with oral 
examinations to ensure they are not affected and isolated if appropriate.  
7. Contact should be minimised between farm personnel that are working with infected 
groups and other livestock workers. A central manager on the farm who does not 
contact any animals (diseased or non-diseased) should co-ordinate activities. A 
separate office should be used by staff that are working with the affected groups.  
8. Equipment (e.g. for treatment) for the affected groups must be stored separately and 
not shared. 
9. Affected groups should be clearly indicated on farm maps but also at entry to affected 
paddocks. 
10. Paddocks where a diseased groups had been previously should not have unaffected 
groups placed into them. The length of time after which a movement may occur is not 
based on field evidence but a minimum of four weeks is suggested. 
Foot and wheel baths are often recommended for minimising the risk of FMDV transmission to 
or from a farm (Figure 11.4). Foot baths may also be recommended once an outbreak has 
begun. There are several difficulties with these biosecurity approaches that limit their 
usefulness so they are not part of the recommendations given above. The major criteria for 
effective use are: 
1. Regular, frequent changing of solution to maintain effective levels of disinfectant 
2. Removal of organic matter to allow effective disinfection 
3. Cost and availability of appropriate disinfectants 
4. Access to sufficient water with methods for distribution on the farm 
When used for preventing the introduction of virus, substantial effort (and cost) must be 
allocated to ensure the criteria above are met presuming sufficient infrastructure is already in 
place. Concerning wheel baths, for farms with large numbers of vehicles entering the 
premises, the disinfectant may become rapidly ineffective particularly in dusty environments 
as in the dry seasons in Kenya when FMDV typically circulates from increased movements of 
pastoralist herds. Although knowledge on various disinfection types is well established (DEFRA, 
2014), the data available are from laboratory measures of virus inactivation and there are few 
published studies on their effectiveness in the field (Brennan and Christley, 2012). Extended 
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contact times (for example 30 minutes) are often suggested that are simply impractical for 
field conditions and are unlikely to be used where FMD is endemic. 
A wheel bath was present on Farm 1/SAT2, but due to the large numbers of vehicles and 
required maintenance it had not been used for a number of years (Figure 11.4). With eight 
years between outbreaks on the farm in an endemic area with regularly reported outbreaks, it 
is difficult to justify continued use. After the study outbreak, the farmer did not reinstate the 
wheel bath due to the problems described above. Cost-effectiveness analyses would be useful 
but could not be performed as part of this research project and their effectiveness would be 
difficult to evaluate in the field. Similar arguments can be made for foot baths if used to 
prevent infection being introduced to the farm. Their use during an outbreak may be more 
worthwhile for individuals working with individual groups. If they are used, separate foot baths 
should be present for each affected and non-affected group.  
 
 
Figure 11.4. Photograph of wheel bath present on Farm 1/SAT2. The bath is not in use with 
only rainwater being present.  
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11.4.2 Surveillance 
Currently, all FMD outbreaks in Kenya are supposed to be notified to a local government 
veterinary officer by either a farmer, veterinary paraprofessional (for example an animal 
health assistant [AHA]) or private practitioner.  In the first instance, a government veterinary 
officer should visit the farm to see if the clinical signs are consistent with FMD and take a 
sample so that viral antigen detection tests may be performed by the National FMD 
laboratory. If FMD is suspected, a notification should be sent to the central Department of 
Veterinary Services (DVS).  
Confirmed outbreaks between 2003 and 2013 were presented in Chapter 1 (Figure 1.5). This 
graph does not include all reported outbreaks (i.e. where no virus was detected) and from 
talking to government veterinary officers in the field, it is unclear whether all outbreaks are 
consistently reported (for example if no sample could be taken or where due to being under-
resourced outbreaks were not attended) and also how an outbreak is defined. The National 
FMD laboratory is beginning to use PCR based methods for antigen detection which is likely to 
improve the sensitivity of the diagnosis for those samples being submitted. However, it is clear 
that more resources are needed in order to improve reporting of FMD outbreaks. This should 
include the regular training of field veterinarians to ensure they are aware of the systems in 
place. Many of these areas have been highlighted in the government’s national FMD control 
strategy published in 2012, although as yet no changes have been observed in the field. Part of 
this strategy is to implement an electronic notification system that may improve reporting and 
dissemination of information.  
With the plans for FMD-free zones, the government also aims to increase targeted surveillance 
through regular inspections of the free/protection zones and compulsory vaccination areas. 
Targeted surveillance should also include performing regular serosurveys, also identified in the 
national FMD control strategy, to increase the understanding of FMD epidemiology in Kenya. 
Although a Kenyan FMD serosurvey was published in 2013 (Kibore et al., 2013), this refers to 
sera collected in 2010 and there are deficiencies in the data presented complicating inference 
(see Chapter 1, section 1.4.3.2). Therefore it is suggested that a nationwide serosurvey is 
repeated by trained government epidemiologists with risk factor analysis based on NSP 
serology, possibly with guidance from the FAO. Through these activities, the implications of 
using a non-NSP purified vaccine on NSP titres may be evaluated provided accurate and 
detailed data are collected on animals sampled (i.e. age, total number of lifetime doses 
received, date since last vaccination). Large-scale farms in the first instance may be more 
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useful as they are more likely to have readily accessible data on the animals present, good 
handling facilities and the convenience of having all the animals in one location. The QA farms 
used by the vaccine company would also provide a good opportunity to meet this objective. 
11.4.3 Vaccine and impact evaluation  
When an FMD outbreak notification occurs, data on recent vaccination are usually collected on 
a standardised submission form used by the government-employed veterinary surgeon. This 
should automatically trigger notification of the vaccine manufacturer and government 
epidemiologists as a possible vaccine failure. Appropriate vaccine effectiveness evaluations 
should then be performed. This will establish an evidence base for vaccine effectiveness and 
ultimately inform resource allocation.  
The strategy of vaccine application on Kenyan farms depends on the production system. On 
large-scale farms, routine vaccination is typically used whereby all animals in the herd are 
vaccinated at the same time as on the farms described in this study. For smallholders, ring 
vaccination is more common, being used as part of government efforts to contain a confirmed 
outbreak. In the field there are also reports of private animal health assistants offering vaccine 
to smallholders although the extent of this activity is not clear. With different strategies of 
vaccination, different forms of evaluation are necessary to evaluate effectiveness. These 
investigations also provide opportunities to measure disease impact for different production 
systems.  
For large-scale farms experiencing an outbreak despite regular vaccination, it is recommended 
that individual animal data are collected in order to carry out vaccine effectiveness and disease 
impact assessments. These data include:- 
1. ID of animal affected 
2. Sex 
3. Date of birth 
4. Date affected 
5. Group ID 
6. Clinical signs 
a. Salivation 
b. Oral lesions 
c. Foot lesions (and number of feet affected) 
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d. Teat lesions 
e. Abortion 
f. Clinical mastitis 
g. Death 
7. Date (and batch number) of last vaccination 
8. Total number of vaccine doses received 
Recording clinical signs is necessary for establishing the case status using an appropriate 
definition, and also so that the impact of vaccination on disease severity may be analysed in an 
economic analysis. Most large-scale farms use individual animal identification system that 
should facilitate such data collection. Large-scale farms should be incentivised to report all 
suspect cases to the vaccine manufacturer and be given recording sheets to be used in the 
event of an outbreak. Giving regular and relevant feedback to these farms, including 
notifications of disease events in the surrounding area, is likely to improve reporting. 
For smallholder farmers, equivalent data on individual animals would ideally be collected but 
may be less readily available due to a lack of vaccination records and individual animal 
identification systems. Therefore to evaluate the effectiveness of ring vaccination in such 
settings, a different approach may be required. Where villages have been identified as having 
an outbreak and ring vaccination has occurred in the previous six months, data may be 
collected after the outbreak has finished evaluating the effectiveness of this strategy using a 
historical cohort study approach. “Cases” can be defined at the household level (i.e. did the 
household have any sick animals consistent with FMD during the recent outbreak). Vaccine 
effectiveness may therefore be defined at the household level (i.e. if a household used 
vaccination in the last six months, was this associated with the household being protected 
from disease). The number of households to interview should be based on a sample size to 
detect the minimum acceptable vaccine effectiveness estimate (e.g. 60%) and the estimated 
household coverage. Farms should be randomly selected by establishing a sampling frame 
through the use of satellite images or local knowledge of farm locations and performing a 
census. Data will also need to be collected on confounding variables that will indicate exposure 
(e.g. use of communal dip). Pilot studies among smallholders would be necessary before 
beginning such surveys to inform aspects of study design and sample size. These studies are 
not traditional vaccine effectiveness evaluations and are limited in their inference about the 
vaccine for which individual animal data are required. They may be able to indicate the 
influence of the ring vaccination campaign which is important to inform control policy. 
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Standardised approaches to investigating apparent vaccine failures will be required for 
consistency and transparency and such investigations should be performed independent of the 
vaccine company. This is particularly important when vaccines are subsidised by the 
government so that allocation of resources can be justified. 
A major problem with field evaluation of veterinary vaccines is the lack of vaccine records in 
small farms and the absence of unvaccinated controls on large farms. Also, both of the 
described investigation methods are subject to the “outbreak bias” (discussed in section 
11.3.5). The problem with evaluating any vaccine is that it is only truly tested when exposed to 
the pathogen it is meant to be protecting against. This exposure is only guaranteed on farms 
where vaccine failure is apparent and appropriate samples have been taken. A less biased 
evaluation would be to visit a series of randomly chosen large-scale farms or villages (or pre-
defined high risk sentinel populations) in endemic areas and do periodic surveys of disease 
incidence independent of an outbreak being reported. Similar investigations could be routinely 
performed to get an idea of vaccine coverage at the individual and household level. In areas 
where a non-NSP purified vaccine is used, post vaccination monitoring of herds or villages may 
be used to complement these investigations. Some insights may still be gained by doing this 
where a non-NSP purified vaccine is used if appropriately validated as described in the 
previous section. 
Alongside these investigations, attempts at virus isolation should always be made in line with 
current national policy and regular VM tests performed. However, such testing is not essential 
to begin vaccine evaluations and a lack of resources to do this should not prevent conducting 
field investigations or reported vaccine failures. If during the passive surveillance process no 
samples are taken from vaccinated populations, a subset should still always be tested for VM 
so that possible problems with matching can be identified as early as possible. 
11.4.4 National policy implications 
The FMD Control Strategy for Kenya published in January 2012 involves the establishment of 
three zones based on FMD status: an infected zone where reactive vaccination is practiced 
(similar to that described in section 1.4.2); a protection zone where there is intensive mass 
vaccination; and a FMD free zone where there is no vaccination. From the latter, the hope is to 
open up potential markets by allowing the export of meat and meat products. Vaccination is 
an important component of this strategy and therefore it is timely to recommend that Kenya 
instigates the monitoring of vaccine performance. 
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FMD is a notifiable disease in Kenya so the Government and the veterinary epidemiologists in 
their employ have a key role in its control. Currently, ring vaccination is used and is restricted 
to cattle. Large-scale farms that use routine vaccination may source their vaccine directly from 
the manufacturer although local government officials must be notified. Ring vaccination was 
not evaluated in this study, but evaluations like those recommended above should be part of 
the national control strategy. Ring vaccination campaigns take place by either farmers bringing 
their animals to a common location (for example a communal dip [Figure 11.5] or a person’s 
homestead that has appropriate handling facilities) or teams going from household to 
household offering vaccine. This typically takes place after a period of publicity such as visiting 
cattle dips, churches, schools and area chiefs, where the dates and locations of upcoming 
vaccination are advertised.  
 
 
Figure 11.5. Photograph of government-subsidised reactive vaccination campaign in Ngata, 
Nakuru County, January 2012. Vaccination is occurring at a communal dipping facility.  
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Since there may be problems with vaccine performance in the field, it is recommended that 
government vaccination teams collect routine data to assist vaccine effectiveness evaluations 
in particular data on vaccine coverage. Currently the date, number of doses of vaccine 
administered at each location and batch number is the only information recorded along with 
some relatively subjective information from the team regarding impressions on turnout and 
problems encountered. The following information should be collected and fed back to 
appropriately trained government epidemiologists: 
1. Name of owner 
2. Address (either at sub-location level or preferably referring to a map) 
3. Number of cattle vaccinated  
4. Number of cattle owned that were not vaccinated 
5. Age of animals vaccinated and non-vaccinated 
6. Batch number of vaccine 
7. Last occurrence of FMD in herd 
After a vaccination campaign, appropriately designed surveys of the area to establish the 
proportion of vaccinated households and animals are recommended. Such post vaccination 
coverage assessments are more likely to give an accurate indication of actual coverage than 
simply dividing the number of doses by the livestock census figures. Implementing a system of 
individual animal identification, as used in Europe and elsewhere, is not currently considered 
feasible in this setting. A standardised record card with vaccination details is more feasible and 
has been used to some extent already in Kenya. Figure 11.6 shows a record card used in 
regular vaccine campaigns carried out in the former Central Province organised by the Kenyan 
Veterinary Association (KVA). The KVA incentivised farmers to keep the card by charging 10 
KSH for a new card each time if they did not bring it with them to the next round of 
vaccination. A standardised card for use nationally could be developed and would help with 
studies on vaccine coverage and effectiveness.  
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Figure 11.6. Vaccination card used by the Kenyan Veterinary Association for regular campaigns 
carried out in what was the Central Province (now Nyeri County).  
 
In the course of doing field work for this research, conversations were held with many 
smallholder farmers and government employees directly involved with FMD control and 
vaccination. One problem that was reported was that vaccination often takes place in areas of 
an ongoing FMD outbreak. Some farmers will take their animals to be vaccinated at a common 
location even if disease is present in their animals either with the hope that others in the herd 
will then be protected or due to confusion over the difference between vaccination and 
treatment. This is not necessarily due to their ignorance of spreading disease as farmers 
typically know the main route of FMD transmission – animal to animal contact. Additionally 
vaccination teams may move from farm to farm with no appropriate biosecurity measures in 
place. These high risk practices may make vaccinated households at increased likelihood of 
exposure and therefore disease. This will likely result in farmers believing the vaccine is 
ineffective and thereby undermines vaccination campaign efforts. Conversations with farmers 
reveal this to be the case and vaccine evaluations are near impossible in these circumstances. 
Rigorous active surveillance occurring immediately before the vaccination campaigns is 
essential to ensure that the areas vaccinated are not already affected. Additionally a suitable 
sized buffer zone must be established within which vaccination should not occur, with 
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surveillance in this zone to ensure disease is not present. If this action is not possible due to 
limited resources, the role of ring vaccination in national policy should be questioned and even 
withdrawn from the national control strategy. 
In order to maintain the cold chain, cool boxes must be used (Figure 11.7). A survey of 
temperature monitoring in cool boxes would be worthwhile to ensure current practices are 
satisfactory. Such monitoring does not currently occur but should become routine practice.  
In order to carry out these recommendations, it is important that there are a sufficient number 
of adequately trained veterinary epidemiologists that are either employed by the government 
or alternatively employed on a consultancy basis. A national FMD consultant should also be 
appointed. This will likely require investment by the government. 
 
 
Figure 11.7. Photograph taken inside of cool box during government subsidised vaccination 
campaign in Ngata, Nakuru County, January 2013. 
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11.4.5 Further research priorities 
 Further field evaluation 
Research should be directed towards further field evaluations of vaccines in line with the 
recommendations above. A cluster-randomised trial would be the ideal choice since this study 
design will incorporate both direct and indirect protection from vaccines. Such a study has 
never been performed for evaluating FMD vaccines, and would require significant financial 
investment, so may not be feasible for Kenya at this time. 
 Assessment of different vaccination schedules 
Different schedules for youngstock need to be evaluated which in the first instance can be 
applied to the manufacturers QA farms before being assessed in the field. The ongoing VNT 
work should continue although external validation, either within or outside Kenya, is suggested 
as part of quality control. As part of this work, NSP antibody should be routinely measured so 
that the levels induced from non purified vaccines can be assessed. This will in turn inform the 
interpretation of serological surveys. 
 Assessment of SAT2 vaccine 
Assessment of the SAT2 vaccine should be addressed as a priority including the quantification 
of antigen. Given the known stability issues with SAT2 vaccines, cold chain studies analysing 
the  degradation of antigen under field conditions would also particularly worthwhile for this 
serotype.  
 Oil-based vaccines 
As the oil based, NSP-purified vaccine becomes available, it is important to evaluate the 
kinetics of antibody responses after different schedules, including long term waning of 
antibody. Vaccine match between the field and vaccine strain will still need to be monitored 
and these vaccines will still be susceptible to inactivation through insufficient maintenance of 
the cold chain. The recommendations in this thesis including the uptake of vaccine 
effectiveness evaluations are therefore still relevant with a change in vaccine adjuvant. The 
NSP-purification will also allow more informative sero-surveillance to be performed. 
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 Socioeconomic impact studies 
The need for further socio-economic impacts studies among the same and different 
stakeholders is essential to inform resource allocation. Particularly on large-scale dairy farms, 
the impact of FMD on fertility has never been fully evaluated and is worthy of investigation. 
Economic assessments are needed to inform the cost-effectiveness or cost-benefit of different 
control strategies including the use of vaccination. 
11.5 Dissemination of results 
The results of these studies have been disseminated in various ways during the course of the 
project in addition to the publications. 
A presentation was given on the disease impact work at a PCP workshop in Nakuru, August 
2014 to government representatives from Kenya and Uganda. A separate presentation was 
given during this workshop on the vaccine evaluation work to representatives from the Kenyan 
National FMD laboratory and KEVEVAPI.  Two presentations were given at the EuFMD Open 
Session in Cavtat, Croatia, in October 2014 (Appendix F).  
An interim report was provided to the Kenyan Department of Veterinary Services at their 
request in May 2013. Three copies of the final version of the thesis will be sent to the Ministry 
of Science and Higher Education in line with the research permit agreement.  
11.6 Conclusion 
This thesis presents the results from epidemiological investigations and vaccine evaluations on 
two large-scale farms in Nakuru County, Kenya, where large FMD outbreaks occurred despite 
histories of repeated vaccination. On one of these farms, the impact of FMD on milk yield, 
clinical mastitis and culling was evaluated. This work was complemented by analysis of quality 
control serological data made available from the vaccine manufacturer.  
The results provide insights into FMD epidemiology in this setting and are used to inform the 
development of farm contingency plans in the event of future outbreaks. Evidence for poor 
vaccine effectiveness was presented for O and SAT2 serotypes. Particular concerns are 
apparent over the very low effectiveness of the SAT2 vaccine supported by poor 
seroconversion rates and waning of antibody titres. Evidence was provided for limited 
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effectiveness for serotype O vaccine but only after several doses of vaccine. Modifications to 
the vaccine schedule among youngstock are suggested as is the possibility of using additional 
or alternative vaccine strains after appropriate vaccine matching studies have been performed. 
The impact analysis provides unique insights into the impact of FMD on milk yield, clinical 
mastitis and culling rates. 
Although the studies are limited in their generalisability by only including two farms and the 
specific reasons for apparent vaccine failure were not fully elucidated, the approaches used to 
evaluate the vaccine can be generalised to other circumstances. These approaches should be 
encouraged and performed alongside more conventional vaccine quality assessments the 
results of which are severely limited in their applicability and validity for field settings. With 
the control strategy for Kenya looking towards the establishment of disease free zones without 
vaccination alongside intensively vaccinated protection zones, effective vaccination is essential 
for the future of FMD control in Kenya.  
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Informed consent form for research study on Foot-and-Mouth disease 
  Informed consent form for ______________________________________________________         Farmer name 
 
Study information  We are veterinarians from the UK working in collaboration with the Department of Veterinary Services (DVS), doing research on foot-and-mouth disease (FMD) in cattle in the Rift Valley Province/Nakuru County. The purpose of the research is to understand how the disease spreads, the effectiveness of vaccination and the financial impact on farms that suffer disease.  We would like to use your farm as part of this research using data from a recent outbreak on your farm, which we previously attended with the DVS. This will involve using the data from this initial outbreak investigation alongside using individual animal and production data, and relevant maps. Where appropriate, samples already taken by the DVS may be used.   These data will be used as part of a PhD thesis performed at the London School of Hygiene and Tropical Medicine (LSHTM) and Royal Veterinary College (RVC), London, UK. Upon completion, the thesis will be published online. Additionally, articles may be published in peer-reviewed academic journals. All collected data will be securely stored and no data will be shared without your permission. In any publications you and your farm will be anonymous although if you wish to be acknowledged, then you can waive your right to anonymity by ticking the box below.    
Contact details  For any information relating to this research, call Nick Lyons on 0700126250 (Kenya) or +44(0)7976554031 (UK) or alternatively email nicholas.lyons@lshtm.ac.uk.                
267
  
Consent  Please tick the relevant boxes and sign below.  I confirm that I understand the information given in the information sheet.  I agree to sharing data on questions answered relating to the animals I own including health issues, their vaccination history and the financial income they contribute.   I understand that my participation is voluntary and am free to withdraw at any time without giving a reason.   I agree to waive my right to anonymity    Print name of consenting farmer ________________________________________________  Address of consenting farmer _______________________________________________  ________________________________________________________________________________________  ________________________________________________________________________________________   Signature of farmer ______________________________________   Date (dd/mm/yyyy) ________________________________________  
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Viale delle Terme di Caracalla, 00153 Rome, Italy Fax: +39 0657053152 Tel: +39 0657051 www.fao.org 
 
Our Ref.:       Your Ref.:       
    
 
 
 
To whom it may concern 
 
 
Nicholas Lyons is a veterinary surgeon and researcher based at the London School of Hygiene and 
Tropical Medicine (UK). He is coming to Kenya to train delegates from the European Union and Kenya in 
workshops on Foot and Mouth Disease in association with the European Union Foot and Mouth Disease 
Commission (Eu-FMD) based in United Nations agency Food and Agricultural Organization (FAO). 
 
As part of a pre-existing memorandum of understanding (MOU) between the FAO and Department 
of Veterinary Services (DVS), he will also be collecting data in collaboration with the DVS in the Rift 
Valley Province relating to foot and mouth disease for which a research permit has been granted. 
 
The workshops will take place in Nakuru between the 3rd and 7th December and 14th to 25th January. 
Between these courses he will be collecting the aforementioned data in collaboration with the DVS. 
He will leave Kenya on the 2nd March 2013. 
 
All assistance to Dr. Lyons will be very much appreciated. 
 
Faithfully 
 
 
 
  
Keith Sumption 
Secretary, European Commission 
for the Control of Foot-and-Mouth Disease 
Animal Health Service 
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Appendix C 
Data management – Farm 1/SAT2 
Routine farm data 
Each individual animal had a unique ear tag identification number associated with all recorded 
data for that individual either on paper or electronically. As events occurred, for example an 
animal being served or an animal having clinical mastitis, records were initially made on paper 
and then periodically taken to a central farm office where they were entered into InterHerd. 
The InterHerd database was backed up at the end of each day and a file stored remotely using 
Dropbox. 
Data extraction and cleaning 
InterHerd records were accessed using Microsoft Access on which the program is based. 
Appropriate links between tables were established with the assistance of people experienced 
in using the program. Specific queries were run depending on the analysis being performed. 
These results were exported into a Microsoft Excel spreadsheet and imported into Stata 12.0 
for further cleaning. A sample of animals was periodically checked to ensure consistency with 
the original Interherd database. 
All variables were recoded and labelled as appropriate. Ear tag identification numbers were 
checked to ensure they were unique. Where dates were missing or implausible, an enquiry 
was sent to the farm so that original paper records could be checked (paper records are kept 
on the farm for several years before being disposed). Occasionally dates of birth were 
mistakenly recorded under the date of registry variable in InterHerd. 
Outbreak data 
A list of all animals on the farm was printed using Interherd which formed the basis of data 
recording. As an animal became affected, the date was written alongside the respective 
animal’s  ear  tag number. Sometimes  for  convenience  the  animal’s  ID  number  was written 
down if it could not be quickly found. A single employee was responsible for this process. 
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Photographs of these records were taken and data entered into Microsoft Excel by the author 
(NL). These outbreak data were merged in Stata 12.0 with animal data from the InterHerd 
database. Entries that could not be merged for example due to inaccurate recording of the 
animal ear tag number were investigated and checked with the farm staff as necessary. For 
analysis, a separate entry was included for each animal’s  time  within  a  group  so  that group-
level incidence rates could be calculated. 
A sketch of the farm including the labelling of named bomas/paddocks was made during the 
outbreak period. A shapefile was created by drawing polygons using Google Earth, labelled 
with the name of the boma/paddock and a unique ID number. A few months after the 
outbreak had subsided, a return visit was made to the farm to establish the accuracy of this 
map. Once this was verified with the farm staff, the data were saved as a kml file and 
converted to a layer in ArcGIS 10.2 using the appropriate conversion tool in ArcToolbox. This 
was then exported as a shapefile and formed the basis of all maps produced on Farm 1/SAT2. 
Survival analysis 
All health events were extracted alongside the date they occurred (124,932 event records). 
Events were excluded if irrelevant to the analyses or the date was missing or inconsistent (for 
example if accidentally recorded in the future). Due to some inconsistency in how disease 
events were recorded in InterHerd, several variables were checked to ensure all relevant data 
were captured including the content of free text entries. 
Milk yields 
Cows were milked twice daily and the recording from each was weighed and manually 
recorded onto standardised paper sheets according to the cows ID number. Several people 
were entering weights at this stage. A single person was responsible for data entry into a 
computer in the main farm office. Each morning and afternoon weight was entered into a 
Microsoft Excel data sheet and the daily mean was calculated for each cow based on a week of 
yield data (Sunday to Saturday), using appropriate program formulae for each individual cow. 
If a cow was only lactating for part of a week, a daily mean was only based on the number of 
days that animal was lactating. These daily means were entered into InterHerd every week 
attached  to  the  cow’s  ID  number. The date for the entry corresponds to the last day of each 
week. 
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Weekly milk records began being consistently recorded from 11th April 2005 onwards. These 
71,916 entries were accessed through a specifically designed query in Microsoft Access. All 
milk records for animals calving after the outbreak period were removed. Impossible or 
extreme milk yield values were checked and recoded as missing if they could not be confirmed 
using the original milk records in Excel. 
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Appendix D 
Data management – Farm 2/O 
Routine farm data 
Apart from bull calves that were euthanased shortly after birth, each individual animal had a 
unique ear tag identification number and name which all events were associated with for that 
individual. Each animal had a record card (Figure D.1) on which health and fertility events are 
manually recorded. As events occur, for example an animal is treated for being lame, they are 
recorded in a notebook by staff working with the cows and this is given periodically to a single 
person  who  is  responsible  for  transferring  this  information  to  the  animal’s  record  card  that  are  
stored permanently in the farm office. 
Data extraction and cleaning 
On the 29th November, whilst the outbreak was ongoing, the farm was visited and the 
identities of all animals present on the farm since the date of the index case were entered into 
a Microsoft Excel spreadsheet. Using the record cards, sex, dates of birth, parity at outbreak 
onset, and current group was entered alongside the identification number of the animal. The 
dates and animal identifications relating to inter-group movements since the index case were 
also recorded. After this visit, as animals were born or died and when individuals moved 
groups, the farm manager periodically emailed these events including the date and 
identification numbers of the animals which was used to update the spreadsheet. 
Data were later imported into Stata 12.0. All variables were recoded and labelled as 
appropriate. Ear tag identification numbers were checked to ensure they were unique. Where 
dates were missing or were implausible, an enquiry was sent to the farm so that original paper 
records could be checked 
Outbreak data 
As animals became diseased, the identification number and date was recorded in a notebook. 
This was kept by the farm primarily so that a list of animals treated was kept. These data were 
inputted into the same spreadsheet described in the previous section, also supplemented by 
regular  updates  from  the  farmer.  For  analysis,  a  separate  entry  was  included  for  each  animal’s  
time within a group so that group-level incidence rates could be calculated. 
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 Figure D.1. Individual Record card used on Farm 2/O for recording animal identification, health 
and fertility events. Continued on next page. 
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 Figure D.1. Continued from previous page. 
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Appendix E  
Photographs of clinical cases from Farm 1/SAT2 and Farm 2/O 
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Farm 1/SAT2 
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 Photo 1.1. Hyperptyalism demonstrated by cow X158 on Farm 1/SAT2. This is a second parity 
cow that also developed clinical mastitis subsequent to having reported FMD and was culled as 
a consequence. 
 
Photo 1.2. Vesicles on the dorsum of the tongue in an animal with reported FMD on Farm 
1/SAT2. This cow had an epithelium sample taken confirming FMD due to serotype SAT2.  
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 Photo 1.3. Examining animals with suspected FMD on Farm 1/SAT2. 
 
 
Photo 1.4. Taking a sample of epithelium from an animal with suspected FMD on Farm 1/SAT2. 
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 Photo 1.5. Vesicles on the teats of a cow affected with suspected FMD on Farm 1/SAT2. 
 
 
Photo 1.6. Teat cannulas being used on a cow with suspected FMD on Farm 1/SAT2. The pain 
associated with the teat lesions meant the cow could not be milked normally so cannulas were 
used to allow milk let-down. 
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Farm 2/O 
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 Photo 2.1. Jersey cows with suspected FMD presented for examination on Farm 2/O. 
 
 
Photo 2.2. A Jersey cow with suspected FMD on Farm 2/O. This animal was demonstrating the 
classic “lip smacking”  sound heard in cows affected with FMD. 
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 Photo 2.3. A Jersey cow with suspected FMD on Farm 2/O demonstrating extreme 
hyperptyalism. 
 
Photo 2.4. Examining oral lesions in a cow with suspected FMD on Farm 2/O. 
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 Photo 2.5. Close-up of older suspected FMD lesions in a cow with FMD on Farm 2/O. This 
lesion was estimated to be 7-10 days old. 
 
Photo 2.6. Close up of an oral lesion consistent with FMD in a Holstein-Friesian cow on Farm 
2/O. This lesion was estimated to be 4-5 days old. 
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 Photo 2.7. A recently burst vesicle on the ventrolateral aspect of the tongue in a Jersey cow 
examined on Farm 2/O, suspected as FMD. 
 
 
Photo 2.8. A lesion consistent with FMD seen in the interdigital space of a Jersey cow. 
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 Photo 2.9. Close-up of an interdigital lesion consistent with FMD in a Jersey cow examined on 
Farm 2/O. 
 
 
Photo 2.10. Teat lesion seen in a cow on Farm 2/O with suspected FMD. 
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Appendix F 
Presentations given at the EuFMD Open Session , Cavtat, Croatia, October 2014. 
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1Impact of FMD on milk yield, mastitis, 
fertility and culling on a large-scale dairy 
farm in Kenya
Nick Lyons
London School of Hygiene and Tropical Medicine
 
2
Lack of objective field data looking at FMD impact 
particularly in endemic settings
Tendency to rely upon expert opinion and 
assumptions
More data needed to inform cost-benefit analyses 
of control measures (e.g. vaccination strategies, 
culling and compensation measures)
Need data from different people involved in the 
system as outlined in the PCP stage 1 
Background – FMD Economics
 
3
Objective: to quantify the impact of FMD on a large-
scale dairy farm in Kenya focussing on:-
• Milk yield
• Clinical Mastitis
• Culling
• Fertility
Background
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4KENYA
NAKURU COUNTY
Outbreak
 
5
Farm background
Dairy Herd: 650 mainly Holstein-Friesian
Milking around 250 cows
Calving all year around
Artificial insemination only
All cows uniquely identified
Record daily milk yields, health and fertility events, 
sales etc in InterHerd (InterAgri, School of 
Agriculture, University of Reading, UK). 
 
6
Serotype SAT2, lasting 29 days
Case definition: Hypersalivation with any other sign 
indicative of FMD: decreased milk yield, decreased feed 
intake, oral/interdigital/teat lesions,  pyrexia
Vaccine: Limited/no vaccine effect in preventing clinical 
disease. Overall Attack rate: 400/644 (62.1%) 
Outbreak – August/September 2012
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7Milk yield – overall impact
Outbreak period
 
8
Milk yield – Reported FMD cases versus non-cases
Outbreak period
 
9
Possible reasons:
1. Poor/inaccurate recording of cases
2. Insensitive case definition
3. Subclinical infection
Next approach:
Predict yield for all individuals based on historic farm 
records accounting for parity, days in milk, and season 
(GEE model with a AR1 autocorrelation matrix)
Compare production from beginning of outbreak to end 
of 305 day lactation irrespective of disease status
Milk yield – No difference?
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10
Impact dependent on parity and lactation stage when diseased
Milk yield – Actual vs Predicted
Largest 
impact
 
11
Follow up: 12 months from beginning of outbreak
Statistics: Cox proportional hazard regression
Adjusted for any non-proportional hazards by 
incorporating time varying effects
Study population: Culling - All animals
Mastitis - ≥18  months  old  
Clinical mastitis and culling – Survival analysis
 
12
Clinical mastitis
Study population restricted to animals over the age of 18 months at start of outbreak
Unadjusted
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13
Clinical mastitis
Adjusted Hazard Ratio (first month) = 
2.9, 95%CI 0.97-8.9, P=0.057
 
14
Culling
Adjusted Hazard ratio: HR=1.7, 
95% CI 0.90-3.4, P=0.10 
Culling is defined as exiting the herd for any reason associated with a adverse health event
Unadjusted
 
15
Submission rate decreased, but pregnancy rate not affected
Fertility – Submission rate, Pregnancy rate
Outbreak
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16
No obvious effect on abortion, but increased returns to service
Fertility – Abortion and Early Embryonic Death
Outbreak
 
17
• Milk yield – Depends on parity and lactation stage
• Clinical mastitis – 3 times the hazard in first month 
• Culling – 1.7 times the hazard over 12 months
• Fertility – impact on submission rate, returns to service
Data may be used in developing cost analyses
Limitations
Generalisability
(Smallholders  produce  ≈  70%  milk  output)
Lack of statistical power
Vaccination mitigating impact
Summary - overall
 
18
Great need for rigorous evaluations of disease impact
There needs to be investment in data collection on 
disease losses and costs so that we can move away 
from relying on expert opinion and assumptions
Essential to reliably quantify impact for allocating 
limited resources in animal disease control
More need for field data from different farming 
systems in different settings 
Conclusions - summary
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1Vaccine evaluation on large-scale dairy farms 
using routine prophylactic schedules for FMD
Nick Lyons
London School of Hygiene and Tropical Medicine
 
2
Vaccine effectiveness: % reduction in incidence among 
vaccinated individuals attributable to vaccination, 
measured under field conditions
Reasons for poor FMD vaccine performance in the field:
1. Poor potency
2. Lack of vaccine match
3. Break in the cold chain
4. Sub-optimal coverage
5. Interference by maternally derived antibody (MDA)
6. Incorrect schedule
Background – Vaccine effectiveness
 
3
Kenya, Nakuru County
Dairy  Herd:  ≈350  mainly  Jersey
Last known outbreaks: March 2004 (SAT2), 
December 2010 (NVR)
FMD Vaccination
Vaccinates animals every 4 months with a locally 
available quadrivalent (A, O, SAT1, SAT2) vaccine
Only vaccinates animals over 6 months old
Aqueous-adjuvanted, Non-NSP purified vaccine. 
Only  ≥6.0  PD50 vaccines are approved for use.
Farm A -Background
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4Serotype O
October-December 2013
Last dose 3 months before
Probable source:  Farm workers
Farm A - Outbreak
 
5
“Incidence risk”  versus  “Number of lifetime doses”
Farm A - Vaccine
 
6
“Incidence risk”  versus  “Number of lifetime doses”
Farm A - Vaccine
Maternal antibody? Incidence  plateau…
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7“Incidence risk”  versus  “Number of lifetime doses”
Farm A - Vaccine
Maternal antibody? Incidence  plateau…
Declining incidence implies 
some vaccine effectiveness
 
8
40% incidence in multiply vaccinated  clearly reveals a 
problem….
• Potency? 
• Match?
• Cold chain?
Suboptimal schedules as well?
Can have multiple reasons for poor VE!
Possible reasons for incidence pattern on Farm A
 
9
Kenya, Nakuru County
Dairy  Herd:  ≈650  mainly  Holstein-Friesian
Last known outbreak in 2004 (unknown serotype)
FMD vaccination
Vaccinates animals every 4-6 months with a locally available 
quadrivalent (A, O, SAT1, SAT2) vaccine
Vaccinates all animals irrespective of age
Farm B - Background
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SAT2 
August – September 2012
Last vaccination 3 months before
Probable source: Farm workers
Farm B - Outbreak
 
11
“Incidence risk”  versus  “Number of lifetime doses”
Farm B - Vaccine
 
12
“Incidence risk”  versus  “Number of lifetime doses”
Farm B - Vaccine
Lower incidence in 
youngstock…
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13
“Incidence risk”  versus  “Number of lifetime doses”
Farm B - Vaccine
Incidence plateau among 
older  animals…
Lower incidence in 
youngstock…
 
14
Possible reasons for incidence pattern on Farm B
Low incidence in youngstock – poorer reporting? 
less severe disease?, less transmission/exposure? 
(like Netherlands, 2001?)
Vaccine match? (SAT2 VP1 sequence 13% difference 
to that reported by Sangula et al, 2010)
Vaccine potency?
SAT2 – known to be less stable antigen requires 
higher antigen dose than other serotypes
Cold chain?
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Iran, Shahriar County, Tehran Province
Dairy herd: 3,500 cattle, Holstein-Friesian
Last known outbreak 4 years previously (Not Asia-1)
FMD Vaccination
Every four months with trivalent (Asia-1 Shamir, O, A).
Calves >2 months old get two doses one month apart 
as a primary course.
High potency, NSP purified vaccine.
Farm C - Background
 
310
16
Asia-1
January-March 2011
Last dose 11 weeks before
Probable source: Local semi- nomadic sheep/goat herds
Farm C - Outbreak
 
17
“Incidence risk”  versus  “Number of lifetime doses”
Farm C - Vaccine
Vaccine 
Matching
0.23
0.17
0.19
0.28
 
18
“Incidence risk”  versus  “Number of lifetime doses”
Farm C - Vaccine
Vaccine 
Matching
0.23
0.17
0.19
0.28
Maternal antibody?
Low incidence
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“Incidence risk”  versus  “Number of lifetime doses”
Farm C - Vaccine
Vaccine 
Matching
0.23
0.17
0.19
0.28
Maternal antibody?
Most disease
Another peak
Low incidence
 
20
• Does appear to be evidence of some cumulative 
protection with number of doses (Farms A and C)
• Cannot rule out other age related effects (although 
not due to exposure in these outbreaks)
• Age distribution in the herd affects coverage!
Vaccine protection and coverage
Farm B (SAT2)Farm A (O) Farm C (Asia-1)
 
21
Generalisability?
Field-based vaccine performance assessments provide 
additional information on the effectiveness of a 
control policy
Conventional laboratory-based evaluations should be 
performed alongside field evaluations
Standardised protocols for monitoring vaccine 
performance and investigating apparent low 
effectiveness are needed
Summary and conclusions
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